nv2za
As filed with
the Securities and Exchange Commission on February 6,
2012
Securities Act
Registration
No. 333-178516
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, DC 20549
Form N-2
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF
1933
Pre-Effective Amendment No.
2
Horizon Technology Finance
Corporation
(Exact name of Registrant as
specified in its charter)
312 Farmington Avenue
Farmington, Connecticut
06032
(Address of Principal Executive
Offices)
(860) 676-8654
(Registrants Telephone
Number, Including Area Code)
Robert D. Pomeroy, Jr.
Chief Executive
Officer
Horizon Technology Finance
Corporation
312 Farmington Avenue
Farmington, Connecticut
06032
(Name and Address of Agent for
Service)
Copies to:
Stephen C.
Mahon, Esq.
Toby D.
Merchant, Esq.
Squire Sanders (US)
LLP
221 East Fourth Street,
Suite 2900
Cincinnati, Ohio 45202
(513) 361-1200
(513) 361-1201
Facsimile
APPROXIMATE DATE OF PROPOSED
PUBLIC OFFERING:
From time to time after the
effective date of this Registration Statement.
If any securities being registered on this form will be offered
on a delayed or continuous basis in reliance on Rule 415
under the Securities Act of 1933, other than securities offered
in connection with a dividend reinvestment plan, check the
following
box. þ
It is proposed that this filing will become effective (check the
appropriate box)
o
When declared effective pursuant to section 8(c)
CALCULATION
OF REGISTRATION FEE UNDER THE SECURITIES ACT OF 1933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposed Maximum
|
|
|
Proposed Maximum
|
|
|
|
|
|
|
Amount Being
|
|
|
Offering Price Per
|
|
|
Aggregate Offering
|
|
|
Amount of
|
Title of Securities Being Registered
|
|
|
Registered
|
|
|
Unit
|
|
|
Price(1)
|
|
|
Registration Fee(7)
|
Primary Offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, $0.001 par value per share(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Subscription Rights(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Securities(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Primary Offering Total
|
|
|
|
|
|
|
|
|
$250,000,000
|
|
|
|
$28,650
|
|
Secondary Offering:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock, $0.001 par value per share(2)
|
|
|
1,322,669
|
|
|
$16.00(8)
|
|
|
$21,162,704
|
|
|
|
$2,426
|
|
Secondary Offering Total
|
|
|
|
|
|
|
|
|
|
|
|
|
$2,426
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
$31,076
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Estimated pursuant to Rule 457
solely for the purpose of calculating the registration fee.
Pursuant to Rule 457(o) of the rules and regulations under
the Securities Act of 1933, which permits the registration fee
to be calculated on the basis of the maximum offering price of
all the securities listed, the table does not specify by each
class information as to the amount to be registered, proposed
maximum offering price per unit or proposed maximum aggregate
offering price.
|
(2)
|
|
Subject to Note 7 below, there
is being registered hereunder an indeterminate amount of common
stock or preferred stock as may be sold, from time to time. This
includes such indeterminate number of shares of common stock as
may, from time to time, be issued upon conversion or exchange of
other securities registered hereunder, to the extent any such
securities are, by their terms, convertible or exchangeable for
common stock.
|
(3)
|
|
Subject to Note 7 below, there
is being registered hereunder an indeterminate number of
subscription rights as may be sold from time to time,
representing rights to purchase common stock.
|
(4)
|
|
Subject to Note 7 below, there
is being registered hereunder an indeterminate principal amount
of debt securities as may be sold, from time to time. If any
debt securities are issued at an original issue discount, then
the offering price shall be in such greater principal amount as
shall result in an aggregate price to investors not to exceed
$250,000,000.
|
(5)
|
|
Subject to Note 7 below, there
is being registered hereunder an indeterminate number of
warrants as may be sold, from time to time, representing rights
to purchase common stock, preferred stock or debt securities.
|
(6)
|
|
In no event will the aggregate
offering price of all securities issued from time to time
pursuant to this registration statement exceed $271,162,704.
|
|
|
|
(7)
|
|
Pursuant to Rule 457(c) of the
Securities Act of 1933, as amended, the proposed maximum
aggregate offering price and the amount of the registration fee
have been determined on the basis of the high and low market
prices of the Companys common stock reported on the NASDAQ
Global Select Market on December 12, 2011.
|
The Registrant hereby amends this Registration Statement on
such date or dates as may be necessary to delay its effective
date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall
thereafter become effective in accordance with Section 8(a)
of the Securities Act of 1933, as amended, or until this
Registration Statement shall become effective on such date as
the Securities and Exchange Commission, acting pursuant to said
Section 8(a), may determine.
The
information in this prospectus is not complete and may be
changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is
effective. This prospectus is not an offer to sell these
securities and is not soliciting an offer to buy these
securities in any state where the offer or sale is not
permitted.
|
|
|
PRELIMINARY PROSPECTUS |
Subject to Completion, dated February 6, 2012 |
$250,000,000
Horizon Technology Finance
Corporation
Common Stock
Preferred Stock
Subscription Rights
Debt Securities
Warrants
and
1,322,669 Shares of Common
Stock Offered by the Selling Stockholders
We are a non-diversified closed-end management investment
company that has elected to be regulated as a business
development company (BDC) under the Investment
Company Act of 1940 (the 1940 Act). We are
externally managed by Horizon Technology Finance Management LLC,
a registered investment adviser under the Investment Advisers
Act of 1940 (the Advisers Act). Our investment
objective is to maximize our investment portfolios return
by generating current income from the loans we make and capital
appreciation from the warrants we receive when making such
loans. We make secured loans to development-stage companies in
the technology, life science, healthcare information and
services and cleantech industries.
We may offer, from time to time, in one or more offerings or
series, together or separately, up to $250,000,000 of our common
stock, preferred stock, subscription rights, debt securities or
warrants representing rights to purchase shares of our common
stock, preferred stock or debt securities which we refer to,
collectively, as the securities. In addition,
certain of our stockholders may offer for resale, from time to
time, up to an aggregate of 1,322,669 shares of common
stock under this prospectus. We will not receive any of the
proceeds from the sale of shares of our common stock by any
selling stockholders. Sales of common stock by the selling
stockholders may negatively impact the price of our common stock.
We and/or
the selling stockholders may sell our securities through
underwriters or dealers,
at-the-market
to or through a market maker into an existing trading market or
otherwise directly to one or more purchasers or through agents
or through a combination of methods of sale. The identities of
such underwriters, dealers, market makers or agents, as the case
may be, will be described in one or more supplements to this
prospectus. The securities may be offered at prices and on terms
to be described in one or more supplements to this prospectus.
In the event we offer common stock or warrants or rights to
acquire such common stock hereunder, the offering price per
share of our common stock less any underwriting commissions or
discounts will not be less than the net asset value per share of
our common stock at the time we make the offering except
(1) in connection with the exercise of certain warrants,
options or rights whose issuance has been approved by our
stockholders at an exercise or conversion price not less than
the market value of our common stock at the date of issuance
(or, if no such market value exists, the net asset value per
share of our common stock as of such date); (2) to the
extent such an offer or sale is approved by a majority of our
stockholders and by our board of directors (our
Board); or (3) under such other circumstances
as may be permitted under the 1940 Act or by the Securities and
Exchange Commission (the SEC). We intend to seek
stockholder approval to offer our shares below net asset value
in the future. The selling stockholders will not be restricted
from selling their shares when the market price is below net
asset value.
The shares of our common stock which are offered for resale by
this prospectus are offered for the accounts of one or more of
the selling stockholders named herein, who acquired such shares
as described under Selling Stockholders. We have
agreed to bear specific expenses in connection with the
registration and sale of the common stock being offered by the
selling stockholders.
Our common stock is listed on The NASDAQ Global Select Market
(NASDAQ) under the symbol HRZN. On
February 3, 2012, the last reported sale price of a share
of our common stock on NASDAQ was $16.66. The net asset value
per share of our common stock at September 30, 2011 (the
last date prior to the date of this prospectus on which we
determined net asset value) was $17.36. Shares of our common
stock sold by the selling stockholders will generally be freely
tradable. Sales of substantial amounts of our common stock,
including by the selling stockholders, or the availability of
such common stock for sale, whether or not sold, could adversely
affect the prevailing market prices for our common stock.
Shares of closed-end investment companies, including BDCs,
frequently trade at a discount to their net asset value. If our
shares trade at a discount to net asset value, it may increase
the risk of loss for purchasers in this public offering. See
Risk Factors Risks Related to Offerings Under This
Prospectus Shares of closed-end investment companies,
including BDCs, frequently trade at a discount to their net
asset value, and we cannot assure you that the market price of
our common stock will not decline following an offering on
page 31 for more information.
This prospectus and any accompanying prospectus supplement
contain important information you should know before investing
in our securities and should be retained for future reference.
We file annual, quarterly and current reports, proxy statements
and other information about us with the SEC. We maintain a
website at www.horizontechnologyfinancecorp.com and
intend to make all of the foregoing information available, free
of charge, on or through our website. You may also obtain such
information by contacting us at 312 Farmington Avenue,
Farmington, Connecticut 06032, or by calling us at
(860) 676-8654.
The SEC maintains a website at www.sec.gov where such
information is available without charge. Information contained
on our website is not incorporated by reference into this
prospectus, and you should not consider information contained on
our website to be part of this prospectus.
Investing in our securities is highly speculative and
involves a high degree of risk, and you could lose your entire
investment if any of the risks occur. For more information
regarding these risks, please see Risk Factors
beginning on page 14. The individual securities in which we
invest will not be rated by any rating agency. If they were,
they would be rated as below investment grade or
junk. Indebtedness of below investment grade quality
has predominantly speculative characteristics with respect to
the issuers capacity to pay interest and repay
principal.
Neither the SEC nor any state securities commission has
approved or disapproved of these securities or determined if
this prospectus is truthful or complete. Any representation to
the contrary is a criminal offense.
This prospectus may not be used to consummate sales of
securities unless accompanied by a prospectus supplement.
The date of this prospectus
is ,
2012
You should rely only on the information contained in this
prospectus or any accompanying supplement to this prospectus. We
have not, and the selling stockholders have not, authorized any
other person to provide you with different information. If
anyone provides you with different or inconsistent information,
you should not rely on it. We are not, and the selling
stockholders are not, making an offer to sell these securities
in any jurisdiction where the offer or sale is not permitted.
This prospectus and any accompanying prospectus supplement do
not constitute an offer to sell or a solicitation of any offer
to buy any security other than the registered securities to
which they relate. You should assume that the information in
this prospectus is accurate only as of the date of this
prospectus. Our business, financial condition and prospects may
have changed since that date. We will update this prospectus to
reflect material changes to the information contained herein.
TABLE OF
CONTENTS
|
|
|
|
|
|
|
Page
|
|
About this Prospectus
|
|
|
1
|
|
Prospectus Summary
|
|
|
2
|
|
Offerings
|
|
|
8
|
|
Fees and Expenses
|
|
|
12
|
|
Selected Consolidated Financial and Other Data
|
|
|
14
|
|
Risk Factors
|
|
|
16
|
|
Cautionary Note Regarding Forward-Looking Statements
|
|
|
38
|
|
Use of Proceeds
|
|
|
39
|
|
Price Range of Common Stock and Distributions
|
|
|
40
|
|
Managements Discussion and Analysis of Financial Condition
and Results of Operations
|
|
|
42
|
|
Senior Securities
|
|
|
56
|
|
Business
|
|
|
57
|
|
Portfolio Companies
|
|
|
67
|
|
Management
|
|
|
73
|
|
Certain Relationships and Related Transactions
|
|
|
81
|
|
Our Advisor
|
|
|
82
|
|
Investment Management and Administration Agreements
|
|
|
83
|
|
Control Persons and Principal Stockholders
|
|
|
90
|
|
Determination of Net Asset Value
|
|
|
92
|
|
Dividend Reinvestment Plan
|
|
|
94
|
|
Description of Securities That We May Issue
|
|
|
96
|
|
Description of Common Stock That We May Issue
|
|
|
97
|
|
Description of Preferred Stock That We May Issue
|
|
|
102
|
|
Description of Subscription Rights That We May Issue
|
|
|
103
|
|
Description of Debt Securities That We May Issue
|
|
|
104
|
|
Description of Warrants That We May Issue
|
|
|
105
|
|
Shares Eligible for Future Sale
|
|
|
107
|
|
Selling Stockholders
|
|
|
108
|
|
Regulation
|
|
|
110
|
|
Brokerage Allocations and Other Practices
|
|
|
115
|
|
Plan of Distribution
|
|
|
116
|
|
Material U.S. Federal Income Tax Considerations
|
|
|
119
|
|
Custodian, Transfer Agent, Dividend Paying Agent and Registrar
|
|
|
127
|
|
Legal Matters
|
|
|
127
|
|
Independent Registered Public Accounting Firm
|
|
|
127
|
|
Where You Can Find More Information
|
|
|
127
|
|
Index to Consolidated Financial Statements
|
|
|
F-1
|
|
ABOUT
THIS PROSPECTUS
This prospectus is part of a registration statement that we have
filed with the SEC using the shelf registration
process. Under the shelf registration process, we may offer,
from time to time, up to $250,000,000 of our common stock,
preferred stock, subscription rights, debt securities, warrants
representing rights to purchase shares of our common stock,
preferred stock or debt securities on terms to be determined at
the time of the offering, and the selling stockholders may offer
for resale up to 1,322,669 shares of our common stock. This
prospectus provides you with a general description of the
securities that we
and/or one
or more of the selling stockholders may offer. Each time we
and/or one
or more of the selling stockholders use this prospectus to offer
securities, we will provide a prospectus supplement that will
contain specific information about the terms of that offering.
The prospectus supplement may also add, update or change
information contained in this prospectus. Please carefully read
this prospectus and any accompanying prospectus supplement
together with the additional information described under
Where You Can Find More Information and Risk
Factors before you make an investment decision. During an
offering, we will disclose material amendments to this
prospectus through a post-effective amendment or prospectus
supplement.
1
PROSPECTUS
SUMMARY
This summary highlights some of the information in this
prospectus. It is not complete and may not contain all of the
information that you may want to consider before investing in
our common stock. You should read the entire prospectus and any
prospectus supplement carefully, including Risk
Factors, Selected Consolidated Financial and Other
Data, Managements Discussion and Analysis of
Financial Condition and Results of Operations and the
financial statements contained elsewhere in this prospectus.
Horizon Technology Finance Corporation, a Delaware
corporation, was formed on March 16, 2010 for the purpose
of acquiring, continuing and expanding the business of its
wholly-owned subsidiary, Compass Horizon Funding Company LLC, a
Delaware limited liability company, which we refer to as
Compass Horizon, raising capital in its initial
public offering, or IPO, and operating as an externally managed
BDC under the 1940 Act. Except where the context suggests
otherwise, the terms we, us,
our and Company refer to Compass Horizon
and its consolidated subsidiary prior to our IPO and to Horizon
Technology Finance Corporation and its consolidated subsidiaries
after the IPO. In addition, we refer to Horizon Technology
Finance Management LLC, a Delaware limited liability company, as
HTFM, our Advisor or our
Administrator.
Our
Company
We are a specialty finance company that lends to and invests in
development-stage companies in the technology, life science,
healthcare information and services, and cleantech industries
(collectively, our Target Industries). Our
investment objective is to generate current income from the
loans we make and capital appreciation from the warrants we
receive when making such loans. We make secured loans
(Venture Loans) to companies backed by established
venture capital and private equity firms in our Target
Industries (Venture Lending). We also selectively
lend to publicly traded companies in our Target Industries.
Venture Lending is typically characterized by, among other
things, (i) the making of a secured loan after a venture
capital or equity investment in the portfolio company has been
made, which investment provides a source of cash to fund the
portfolio companys debt service obligations under the
Venture Loan, (ii) the senior priority of the Venture Loan
which requires repayment of the Venture Loan prior to the equity
investors realizing a return on their capital, (iii) the
relatively rapid amortization of the Venture Loan, and
(iv) the lenders receipt of warrants or other success
fees with the making of the Venture Loan.
We are an externally managed, closed-end, non-diversified
management investment company that has elected to be regulated
as a BDC under the 1940 Act. As a BDC, we are required to comply
with regulatory requirements, including limitations on our use
of debt. We are permitted to, and expect to, finance our
investments through borrowings. However, as a BDC, we are only
generally allowed to borrow amounts such that our asset
coverage, as defined in the 1940 Act, equals at least 200% after
such borrowing. The amount of leverage that we employ will
depend on our assessment of market conditions and other factors
at the time of any proposed borrowing.
We have elected to be treated for federal income tax purposes as
a regulated investment company (RIC), under
Subchapter M of the Internal Revenue Code (the
Code). As a RIC, we generally will not have to pay
corporate-level federal income taxes on any net ordinary income
or capital gains that we distribute to our stockholders if we
meet certain
source-of-income,
distribution, asset diversification and other requirements.
We are externally managed and advised by our Advisor. Our
Advisor manages our
day-to-day
operations and also provides all administrative services
necessary for us to operate.
Our
Advisor
Our investment activities are managed by our Advisor and we
expect to continue to benefit from our Advisors ability to
identify attractive investment opportunities, conduct diligence
on and value prospective investments, negotiate investments and
manage our diversified portfolio of investments. In addition to
the experience gained from the years that they have worked
together both at our Advisor and prior to the formation by our
Advisor of the Company, the members of our investment team have
broad lending backgrounds, with substantial experience at a
variety of commercial finance companies, technology banks and
private debt funds, and have developed a broad
2
network of contacts within the venture capital and private
equity community. This network of contacts provides a principal
source of investment opportunities.
Our Advisor is led by five senior managers, including its two
co-founders, Robert D. Pomeroy, Jr., our Chief Executive
Officer, and Gerald A. Michaud, our President. The other senior
managers include Christopher M. Mathieu, our Senior Vice
President and Chief Financial Officer, John C. Bombara, our
Senior Vice President, General Counsel and Chief Compliance
Officer, and Daniel S. Devorsetz, our Senior Vice President and
Chief Credit Officer.
Our
Strategy
Our investment objective is to maximize our investment
portfolios total return by generating current income from
the loans we make and capital appreciation from the warrants we
receive when making such loans. To further implement our
business strategy, our Advisor will continue to employ the
following core strategies:
|
|
|
|
|
Structured Investments in the Venture Capital and Private
Equity Markets. We make loans to
development-stage companies within our Target Industries
typically in the form of secured amortizing loans. The secured
amortizing debt structure provides a lower risk strategy, as
compared to equity investments, to participate in the emerging
technology markets because the debt structures we typically
utilize provide collateral against the downside risk of loss,
provide return of capital in a much shorter timeframe through
current pay interest and amortization of loan principal and have
a senior position in the capital structure to equity in the case
of insolvency, wind down or bankruptcy. Unlike venture capital
and private equity investments, our investment returns and
return of our capital do not require equity investment exits
such as mergers and acquisitions or initial public offerings.
Instead, we receive returns on our loans primarily through
regularly scheduled payments of principal and interest and, if
necessary, liquidation of the collateral supporting the loan.
Only the potential gains from warrants are dependent upon exits.
|
|
|
|
Enterprise Value Lending. We and
our Advisor take an enterprise value approach to the loan
structuring and underwriting process. We secure a senior or
subordinated lien position against the enterprise value of a
portfolio company.
|
|
|
|
Creative Products with Attractive Risk-Adjusted
Pricing. Each of our existing and prospective
portfolio companies has its own unique funding needs for the
capital provided from the proceeds of our Venture Loans. These
funding needs include, but are not limited to, funds for
additional development runways, funds to hire or retain sales
staff or funds to invest in research and development in order to
reach important technical milestones in advance of raising
additional equity. Our loans include current pay interest,
commitment fees, final payments, pre-payment fees and
non-utilization fees. We believe we have developed pricing
tools, structuring techniques and valuation metrics that satisfy
our portfolio companies requirements while mitigating risk
and maximizing returns on our investments.
|
|
|
|
Opportunity for Enhanced Returns. To enhance
our loan portfolio returns, in addition to interest and fees, we
obtain warrants to purchase the equity of our portfolio
companies as additional consideration for making loans. The
warrants we obtain generally include a cashless
exercise provision to allow us to exercise these rights
without requiring us to make any additional cash investment.
Obtaining warrants in our portfolio companies has allowed us to
participate in the equity appreciation of our portfolio
companies, which we expect will enable us to generate higher
returns for our investors.
|
|
|
|
Direct Origination. We originate transactions
directly with technology, life science, healthcare information
and services and cleantech companies. These transactions are
referred to our Advisor from a number of sources, including
referrals from, or direct solicitation of, venture capital and
private equity firms, portfolio company management teams, legal
firms, accounting firms, investment banks and other lenders that
represent companies within our Target Industries. Our Advisor
has been the sole or lead originator in substantially all
transactions in which the funds it manages have invested.
|
|
|
|
Disciplined and Balanced Underwriting and Portfolio
Management. We use a disciplined underwriting
process that includes obtaining information validation from
multiple sources, extensive knowledge of our Target Industries,
comparable industry valuation metrics and sophisticated
financial analysis related to
|
3
|
|
|
|
|
development-stage companies. Our Advisors due diligence on
investment prospects includes obtaining and evaluating
information on the prospective portfolio companys
technology, market opportunity, management team, fund raising
history, investor support, valuation considerations, financial
condition and projections. We seek to balance our investment
portfolio to reduce the risk of down market cycles associated
with any particular industry or sector, development-stage or
geographic area. Our Advisor employs a hands on
approach to portfolio management requiring private portfolio
companies to provide monthly financial information and to
participate in regular updates on performance and future plans.
|
|
|
|
|
|
Use of Leverage. We currently use leverage to
increase returns on equity through revolving credit facilities
provided by WestLB AG (the WestLB Facility) and
Wells Fargo Capital Finance, LLC (the Wells Facility
and collectively with the WestLB Facility, the Credit
Facilities). See Managements Discussion and
Analysis of Financial Condition and Results of
Operations Liquidity and Capital Resources for
additional information about the Credit Facilities. In addition,
we may issue debt securities in one or more series or preferred
stock in the future. The specific terms of each series of debt
securities we publicly offer will be described in the particular
prospectus supplement relating to that series and the particular
terms of any preferred stock we offer will be described in the
prospectus supplement relating to such preferred stock shares.
See Description of Debt Securities that We May Issue
and Description of Preferred Stock that We May Issue
for additional information about the debt securities or
preferred stock we may issue.
|
Market
Opportunity
We focus our investments primarily in four key industries of the
emerging technology market: technology, life science, healthcare
information and services and cleantech. The technology sectors
we focus on include communications, networking, wireless
communications, data storage, software, cloud computing,
semiconductor, internet and media and consumer-related
technologies. The life science sectors we focus on include
biotechnology, drug delivery, bioinformatics and medical
devices. The healthcare information and services sectors we
focus on include diagnostics, medical record services and
software and other healthcare related services and technologies
that improve efficiency and quality of administered healthcare.
The cleantech sectors we focus on include alternative energy,
water purification, energy efficiency, green building materials
and waste recycling.
We believe that Venture Lending has the potential to achieve
enhanced returns that are attractive notwithstanding the high
degree of risk associated with lending to development-stage
companies. Potential benefits include:
|
|
|
|
|
interest rates that typically exceed rates that would be
available to portfolio companies if they could borrow in
traditional commercial financing transactions;
|
|
|
|
the loan support provided by cash proceeds from equity capital
invested by venture capital and private equity firms;
|
|
|
|
relatively rapid amortization of loans;
|
|
|
|
senior ranking to equity and collateralization of loans to
minimize potential loss of capital; and
|
|
|
|
potential equity appreciation through warrants.
|
We believe that Venture Lending also provides an attractive
financing source for portfolio companies, their management teams
and their equity capital investors, as it:
|
|
|
|
|
is typically less dilutive to the equity holders than additional
equity financing;
|
|
|
|
extends the time period during which a portfolio company can
operate before seeking additional equity capital or pursuing a
sale transaction or other liquidity event; and
|
|
|
|
allows portfolio companies to better match cash sources with
uses.
|
4
Competitive
Strengths
We believe that we, together with our Advisor, possess
significant competitive strengths, which include the following:
|
|
|
|
|
Consistently Execute Commitments and Close
Transactions. Our Advisor and its senior
management and investment professionals have an extensive track
record of originating, underwriting and closing Venture Loans.
Our Advisor has directly originated, underwritten and managed
more than 130 Venture Loans with an aggregate original principal
amount over $800 million since it commenced operations in
2004. In our experience, prospective portfolio companies prefer
lenders that have demonstrated their ability to deliver on their
commitments.
|
|
|
|
Robust Direct Origination Capabilities. Our
Advisors managing directors each have significant
experience originating Venture Loans in our Target Industries.
This experience has given each managing director a deep
knowledge of our Target Industries and an extensive base of
transaction sources and references. Our Advisors brand
name recognition in our market has resulted in a steady flow of
high quality investment opportunities that are consistent with
the strategic vision and expectations of our Advisors
senior management.
|
|
|
|
Highly Experienced and Cohesive Management
Team. Our Advisor has had the same senior
management team of experienced professionals since its
inception. This consistency allows companies, their management
teams and their investors to rely on consistent and predictable
service, loan products and terms and underwriting standards.
|
|
|
|
Relationships with Venture Capital and Private Equity
Investors. Our Advisor has developed strong relationships
with venture capital and private equity firms and their
partners. The strength and breadth of our Advisors venture
capital and private equity relationships would take considerable
time and expense to develop.
|
|
|
|
Well-Known Brand Name. Our Advisor has
originated Venture Loans to more than 130 companies in our
Target Industries under the Horizon Technology
Finance brand. Each of these companies is backed by one or
more venture capital or private equity firms. We believe that
the Horizon Technology Finance brand, as a
competent, knowledgeable and active participant in the Venture
Lending marketplace, will continue to result in a significant
number of referrals and prospective investment opportunities in
our Target Industries.
|
Our
Portfolio
Since our inception and through September 30, 2011, we have
funded 65 portfolio companies and have invested
$337.9 million in loans (including 28 loans that have been
repaid). As of September 30, 2011, our total investment
portfolio consisted of 37 loans which totaled
$174.4 million and our net assets were $132.4 million.
Our existing loans are secured by all or a portion of the
tangible and intangible assets of the applicable portfolio
company. The loans in our loan portfolio generally are not rated
by any rating agency. If the individual loans in our portfolio
companies were rated, they would be rated below
investment grade because they are subject to
many risks, including volatility, intense competition, shortened
product life cycles and periodic downturns.
For the nine months ended September 30, 2011, our loan
portfolio had a dollar-weighted average annualized yield of
approximately 14.6% (excluding any yield from warrants). As of
September 30, 2011, our loan portfolio had a
dollar-weighted average term of approximately 38 months
from inception and a dollar-weighted average remaining term of
approximately 28 months. In addition, we held warrants to
purchase either common stock or preferred stock in 48 portfolio
companies. As of September 30, 2011, our loans had an
original committed principal amount of between $1 million
and $12 million, repayment terms of between 30 and
48 months and bore current pay interest at annual interest
rates of between 10% and 14%.
5
Risk
Factors
The values of our assets, as well as the market price of our
shares, fluctuate. Our investments may be risky, and you may
lose all or part of your investment in us. Investing in us
involves other risks, including the following:
|
|
|
|
|
We have a limited operating history and may not be able to
achieve our investment objective or generate sufficient revenue
to make or sustain distributions to our stockholders and your
investment in us could decline substantially;
|
|
|
|
|
|
We and our Advisor have limited experience operating under the
constraints imposed on a BDC or managing an investment company,
which may affect our ability to manage our business and impair
your ability to assess our prospects;
|
|
|
|
|
|
We are dependent upon key personnel of our Advisor and our
Advisors ability to hire and retain qualified personnel;
|
|
|
|
We operate in a highly competitive market for investment
opportunities, and if we are not able to compete effectively,
our business, results of operations and financial condition may
be adversely affected and the value of your investment in us
could decline;
|
|
|
|
If we are unable to satisfy the requirements under the Code for
qualification as a RIC, we will be subject to corporate-level
federal income tax;
|
|
|
|
Regulations governing our operation as a BDC affect our ability
to, and the way in which we, raise additional capital, which may
expose us to additional risks;
|
|
|
|
We have not yet identified many of the potential investment
opportunities for our portfolio that we will invest in with the
proceeds of an offering under this registration statement;
|
|
|
|
If our investments do not meet our performance expectations, you
may not receive distributions;
|
|
|
|
Most of our portfolio companies will need additional capital,
which may not be readily available;
|
|
|
|
Economic recessions or downturns could adversely affect our
business and that of our portfolio companies which may have an
adverse effect on our business, results of operations and
financial condition;
|
|
|
|
|
|
Our investment strategy focuses on investments in
development-stage companies in our Target Industries, which are
subject to many risks, including volatility, intense
competition, shortened product life cycles and periodic
downturns, and would be rated below investment grade;
|
|
|
|
|
|
We cannot assure you that the market price of shares of our
common stock will not decline following an offering;
|
|
|
|
|
|
Subsequent sales in the public market of substantial amounts of
our common stock by the selling stockholders may have an adverse
effect on the market price of our common stock and the
registration of a substantial amount of insider shares, whether
or not actually sold, may have a negative impact on the market
price of our common stock;
|
|
|
|
|
|
Our common stock price may be volatile and may decrease
substantially;
|
|
|
|
We may allocate the net proceeds from an offering in ways with
which you may not agree;
|
|
|
|
Your interest in us may be diluted if you do not fully exercise
subscription rights in any rights offering. In addition, if the
subscription price is less than our net asset value per share,
then you will experience an immediate dilution of the aggregate
net asset value of your shares;
|
|
|
|
Investors in offerings of our common stock may incur immediate
dilution upon the closing of such offering;
|
|
|
|
If we sell common stock at a discount to our net asset value per
share, stockholders who do not participate in such sale will
experience immediate dilution in an amount that may be material;
|
|
|
|
|
|
There is a risk that investors in our equity securities may not
receive dividends or that our dividends may not grow over time,
and that a portion of distributions paid to you may be a return
of capital;
|
6
|
|
|
|
|
Shares of closed-end investment companies, including BDCs,
frequently trade at a discount to their net asset value, and we
cannot assure you that the market price of our common stock will
not decline following an offering;
|
|
|
|
Stockholders will experience dilution in their ownership
percentage if they do not participate in our dividend
reinvestment plan;
|
|
|
|
The trading market or market value of publicly issued debt
securities that we may issue may fluctuate;
|
|
|
|
|
|
The securities in which we invest generally will have no market
price and we value them based on estimates. Our valuations are
inherently uncertain and may differ materially from the values
that would be assessed if a ready market for these securities
existed.
|
|
|
|
|
|
Terms relating to redemption may materially adversely affect
return on any debt securities that we may issue; and
|
|
|
|
|
|
Credit ratings provided by third party credit rating agencies
may not reflect all risks of an investment in any debt
securities that we may issue.
|
|
|
|
|
|
Shares of our common stock sold by the selling stockholders will
generally be freely tradable. Sales of substantial amounts of
our common stock, including by the selling stockholders, or the
availability of such common stock for sale, whether or not sold,
could adversely affect the prevailing market prices for our
common stock.
|
See Risk Factors beginning on page 14 and the
other information included in this prospectus for a more
detailed discussion of the material risks you should carefully
consider before deciding to invest in our securities.
Company
Information
Our administrative and executive offices and those of our
Advisor are located at 312 Farmington Avenue, Farmington,
Connecticut 06032, and our telephone number is
(860) 676-8654.
Our corporate website is located at
www.horizontechnologyfinancecorp.com. Information
contained on our website is not incorporated by reference into
this prospectus, and you should not consider information
contained on our website to be part of this prospectus.
7
OFFERINGS
We may offer, from time to time, up to $250,000,000 of our
common stock, preferred stock, subscription rights, debt
securities
and/or
warrants representing rights to purchase shares of our common
stock, preferred stock or debt securities on terms to be
determined at the time of the offering. Any debt securities,
preferred stock, warrants and subscription rights offered by
means of this prospectus may be convertible or exchangeable into
shares of our common stock, on terms to be determined at the
time of the offering. We will offer our securities at prices and
on terms to be set forth in one or more supplements to this
prospectus. The selling stockholders may offer, from time to
time, up to 1,322,669 shares of our common stock for resale
at prices and on terms to be set forth in one or more
supplements to this prospectus.
We and/or
one or more of the selling stockholders may offer our securities
directly to one or more purchasers, including existing
stockholders in a rights offering, through agents that we
designate from time to time or to or through underwriters or
dealers. The prospectus supplement relating to each offering
will identify any agents or underwriters involved in the sale of
our securities and will set forth any applicable purchase price,
fee, commission or discount arrangement between us and our
agents or underwriters or among our underwriters or the basis
upon which such amount may be calculated. See Plan of
Distribution. We
and/or the
selling stockholders may not sell any of our securities through
agents, underwriters or dealers without delivery of a prospectus
supplement describing the method and terms of the offering of
our securities.
Set forth below is additional information regarding offerings of
our securities:
|
|
|
Use of proceeds |
|
We intend to use the net proceeds from selling our securities to
make new investments in portfolio companies in accordance with
our investment objective and strategies as described in this
prospectus and for working capital and general corporate
purposes. We will not receive any proceeds from the sale of our
common stock by the selling stockholders. |
|
Listing |
|
Our common stock is traded on NASDAQ under the symbol
HRZN. |
|
|
|
Dividends and Distributions |
|
We pay quarterly dividends to our stockholders out of assets
legally available for distribution. Our dividends, if any, will
be determined by our Board. Our ability to declare dividends
depends on our earnings, our overall financial condition
(including our liquidity position), maintenance of RIC status
and such other factors as our Board may deem relevant from time
to time.
|
|
|
|
To the extent our taxable earnings fall below the total amount
of our distributions for any given fiscal year, a portion of
those distributions may be deemed to be a return of capital to
our common stockholders for U.S. federal income tax
purposes. Thus, the source of a distribution to our stockholders
may be the original capital invested by the stockholder rather
than our income or gains. Stockholders should read any written
disclosure accompanying a dividend payment carefully and should
not assume that the source of any distribution is our ordinary
income or gains. |
|
|
|
Taxation |
|
We have elected to be treated as a RIC. Accordingly, we
generally will not pay corporate-level federal income taxes on
any net ordinary income or capital gains that we distribute to
our stockholders as dividends. To maintain RIC tax treatment, we
must meet specified
source-of-income
and asset diversification requirements and distribute annually
at least 90% of our net ordinary income and realized net
short-term capital gains in excess of realized net long-term
capital losses, if any. |
|
Leverage |
|
We borrow funds to make additional investments. We use this
practice, which is known as leverage, to attempt to
increase returns to our |
8
|
|
|
|
|
stockholders, but it involves significant risks. See Risk
Factors. With certain limited exceptions, we are only
allowed to borrow amounts such that our asset coverage, as
defined in the 1940 Act, equals at least 200% after such
borrowing. |
|
Trading at a Discount |
|
Shares of closed-end investment companies frequently trade at a
discount to their net asset value. This risk is separate and
distinct from the risk that our net asset value per share may
decline. We cannot predict whether our common stock will trade
above, at or below net asset value. |
|
Dividend Reinvestment Plan |
|
We have a dividend reinvestment plan for our stockholders. The
dividend reinvestment plan is an opt out dividend
reinvestment plan. As a result, if we declare a dividend, then
stockholders cash dividends will be automatically
reinvested in additional shares of our common stock, unless they
specifically opt out of the dividend reinvestment plan so as to
receive cash dividends. Stockholders who receive distributions
in the form of stock will be subject to the same federal, state
and local tax consequences as stockholders who elect to receive
their distributions in cash. See Dividend Reinvestment
Plan. |
|
|
|
Sales of Common Stock Below Net Asset Value |
|
In the event we offer common stock or warrants or rights to
acquire such common stock, the offering price per share of our
common stock less any underwriting commissions or discounts will
not be less than the net asset value per share of our common
stock at the time we make the offering except (1) in
connection with the exercise of certain warrants, options or
rights whose issuance has been approved by our stockholders at
an exercise or conversion price not less than the market value
of our common stock at the date of issuance (or, if no such
market value exists, the net asset value per share of our common
stock as of such date); (2) to the extent such an offer or
sale is approved by a majority of our stockholders and our
Board; or (3) under such other circumstances as may be
permitted under the 1940 Act or by the SEC. For purposes of
(2) above, a majority of outstanding securities
is defined in the 1940 Act as (i) 67% or more of the voting
securities present at a stockholders meeting if the
holders of more than 50% of the outstanding voting securities of
the Company are present or represented by proxy; or
(ii) 50% of the outstanding voting securities of the
Company, whichever is less. Restrictions on selling below net
asset value are not applicable to the selling stockholders. |
|
|
|
Selling Stockholders |
|
The selling stockholders are Compass Horizon Partners LP and
HTF-CHF Holdings LLC. HTF-CHF Holdings LLC is substantially
owned by the Companys officers, as described under the
sections entitled Control Persons and Principal
Stockholders and Selling Stockholders. Prior
to completion of our IPO, the owners of membership interests in
Compass Horizon exchanged their membership interests for shares
of our common stock and we entered into a registration rights
agreement with respect to those shares. Pursuant to the terms of
the registration rights agreement, we have agreed to bear
specific expenses of the selling stockholders in connection with
the registration and sale of such shares. HTF-CHF Holdings LLC
does not currently intend to sell its shares within a year of
the effective date of this Registration Statement. All
contractual lock-ups and other restrictions applicable to sales
by insiders have expired. |
9
|
|
|
|
|
Once the shares of the selling stockholders are sold under this
registration statement, the shares will be freely tradable in
the hands of persons other than our affiliates. See
Certain Relationships and Related Transactions and
Shares Eligible for Future Sale. |
|
|
|
Certain Anti-Takeover Provisions |
|
Our certificate of incorporation and bylaws, as well as certain
statutory and regulatory requirements, contain certain
provisions that may have the effect of discouraging a third
party from making an acquisition proposal for us. These
anti-takeover provisions may inhibit a change in control in
circumstances that could give the holders of our common stock
the opportunity to realize a premium over the market price for
our common stock. See Description of Common Stock That We
May Issue. |
|
Investment Management Agreement |
|
We have entered into an investment management agreement (the
Investment Management Agreement) with our Advisor,
under which our Advisor, subject to the overall supervision of
our Board, manages our
day-to-day
operations and provides investment advisory services to us. For
providing these services, our Advisor receives a base management
fee from us, paid monthly in arrears, at an annual rate of 2% of
our gross assets, including any assets acquired with the
proceeds of leverage. The Investment Management Agreement also
provides that our Advisor or its affiliates may be entitled to
an incentive fee under certain circumstances. The incentive fee
has two parts, which are independent of each other, with the
result that one part may be payable even if the other is not.
Under the first part, we will pay our Advisor each quarter 20%
of the amount by which our accrued net income for the quarter
after expenses and excluding the effect of any realized capital
gains and losses and any unrealized appreciation and
depreciation for the quarter exceeds 1.75% (which is 7%
annualized) of our average net assets at the end of the
immediately preceding calendar quarter, subject to a
catch-up
feature. Under the second part of the incentive fee, we will pay
our Advisor at the end of each calendar year 20% of our realized
capital gains from inception through the end of that year,
computed net of all realized capital losses and all unrealized
depreciation on a cumulative basis, less the aggregate amount of
any previously paid capital gain incentive fees. The second part
of the incentive fee is not subject to any minimum return to
stockholders. The Investment Management Agreement may be
terminated by either party without penalty by delivering written
notice to the other party upon not more than 60 days
written notice. See Investment Management and
Administration Agreements Investment Management
Agreement. |
|
Administration Agreement |
|
We reimburse our Administrator for the allocable portion of
overhead and other expenses incurred by our Administrator in
performing its obligations under an administration agreement
(the Administration Agreement), including furnishing
rent, the fees and expenses associated with performing
compliance functions and our allocable portion of the costs of
compensation and related expenses of our chief compliance
officer and chief financial officer and their respective staffs.
See Investment Management and Administration
Agreements Administration Agreement. |
|
Available Information |
|
We are required to file periodic reports, current reports, proxy
statements and other information with the SEC. This information
is available on the SECs website at www.sec.gov.
You can also inspect any |
10
|
|
|
|
|
materials we file with the SEC, without charge, at the
SECs Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at
1-800-SEC-0330
for further information on the Public Reference Room. You may
also obtain such information by contacting us at 312 Farmington
Avenue, Farmington, Connecticut 06032 or by calling us at
(860) 676-8654.
We intend to provide much of the same information on our website
at www.horizontechnologyfinancecorp.com. Information
contained on our website is not part of this prospectus or any
prospectus supplement and should not be relied upon as such. |
11
FEES AND
EXPENSES
The following table is intended to assist you in understanding
the costs and expenses that an investor will bear directly or
indirectly. However, we caution you that some of the percentages
indicated in the table below are estimates and may vary. The
following table and example should not be considered a
representation of our future expenses. Actual expenses may be
greater or less than shown. Except where the context suggests
otherwise, whenever this prospectus contains a reference to fees
or expenses paid by you or us or that
we will pay fees or expenses, stockholders will
indirectly bear such fees or expenses as investors in the
Company.
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholder Transaction Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales Load (as a percentage of offering price)
|
|
|
|
%(1)
|
|
|
|
|
|
|
|
|
Offering Expenses (as a percentage of offering price)
|
|
|
|
%(2)
|
|
|
|
|
|
|
|
|
Dividend Reinvestment Plan Fees
|
|
|
None
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Stockholder Transaction Expenses (as a percentage of
offering price)
|
|
|
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Expenses (as a Percentage of Net Assets Attributable
to Common
Stock)(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
Base Management Fee
|
|
|
3.30
|
%(5)
|
|
|
|
|
|
|
|
|
Incentive Fees Payable Under the Investment Management Agreement
|
|
|
2.15
|
%(6)
|
|
|
|
|
|
|
|
|
Interest Payments on Borrowed Funds
|
|
|
3.58
|
%(7)
|
|
|
|
|
|
|
|
|
Other Expenses (estimated for the current fiscal year)
|
|
|
1.81
|
%(8)
|
|
|
|
|
|
|
|
|
Acquired Fund Fees and Expenses
|
|
|
0.03
|
%(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Annual Expenses (estimated)
|
|
|
10.83
|
%(5)(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
In the event that securities to
which this prospectus relates are sold to or through
underwriters or agents, a corresponding prospectus supplement
will disclose the applicable sales load.
|
(2)
|
|
In the event that we conduct an
offering of any of our securities, a corresponding prospectus
supplement will disclose the estimated offering expenses because
they will be ultimately borne by the Company.
|
(3)
|
|
The expenses of the dividend
reinvestment plan are included in Other Expenses in
the table. See Dividend Reinvestment Plan.
|
(4)
|
|
Net Assets Attributable to Common
Stock equals estimated average net assets for the current fiscal
year and is based on our net assets at September 30, 2011.
|
(5)
|
|
Our base management fee under the
Investment Management Agreement is based on our gross assets,
which includes assets acquired using leverage, and is payable
monthly in arrears. The management fee referenced in the table
above is based on our average gross assets of $218 million
for the three months ended September 30, 2011 and includes
assets estimated to be acquired in the current fiscal year using
leverage. See Investment Management and Administration
Agreements Investment Management Agreement.
|
(6)
|
|
Our incentive fee payable under the
Investment Management Agreement consists of two parts:
|
|
|
|
The first part, which is payable
quarterly in arrears, equals 20% of the excess, if any, of our
Pre-Incentive Fee Net Investment Income over a 1.75%
quarterly (7% annualized) hurdle rate and a
catch-up
provision measured as of the end of each calendar quarter. Under
this provision, in any calendar quarter, our Advisor receives no
incentive fee until our net investment income equals the hurdle
rate of 1.75% but then receives, as a
catch-up,
100% of our Pre-Incentive Fee Net Investment Income with respect
to that portion of such Pre-Incentive Fee Net Investment Income,
if any, that exceeds the hurdle rate but is less than 2.1875%.
The effect of this provision is that, if Pre-Incentive Fee Net
Investment Income exceeds 2.1875% in any calendar quarter, our
Advisor will receive 20% of our Pre-Incentive Fee Net Investment
Income as if a hurdle rate did not apply. The first part of the
incentive fee is computed and paid on income that may include
interest that is accrued but not yet received in cash.
|
|
|
|
The second part of the incentive
fee equals 20% of our Incentive Fee Capital Gains,
if any, which will equal our realized capital gains on a
cumulative basis from inception through the end of each calendar
year, computed net of all realized capital losses and unrealized
capital depreciation on a cumulative basis, less the aggregate
amount of any previously paid capital gain incentive fees. The
second part of the incentive fee is payable, in arrears, at the
end of each calendar year (or upon termination of the Investment
Management Agreement, as of the termination date). For a more
detailed discussion of the calculation of this fee, see
Investment Management and Administration
Agreements Investment Management Agreement.
|
|
|
|
The incentive fee payable to our
Advisor is based on the actual amount incurred under the first
part of the Investment Management Agreement during the three
months ended September 30, 2011, annualized for a full
year. As we cannot predict the occurrence of any capital gains
from the portfolio, we have assumed no Incentive Fee Capital
Gains.
|
(7)
|
|
We will continue to borrow funds
from time to time to make investments to the extent we determine
that the economic situation is conducive to doing so. The costs
associated with our outstanding borrowings are indirectly borne
by our investors. For purposes of this
|
12
|
|
|
|
|
section, we have computed the
interest expense using the balance outstanding at
September 30, 2011 which represents an estimate of our
interest expense for the current fiscal year. We used the LIBOR
rate on September 30, 2011 and the interest rates on the
Credit Facilities. We have also included the estimated
amortization of fees incurred in establishing the Credit
Facilities. At September 30, 2011, we had approximately
$66 million outstanding under the WestLB Facility and
approximately $16 million outstanding under the Wells
Facility. We also assumed that we increased outstanding
borrowings by $25 million at a fixed rate of 7.25% plus
0.45% for the estimated amortization of fees incurred in
establishing this additional borrowing. We may also issue
preferred stock, subject to our compliance with applicable
requirements under the 1940 Act, however, we have no current
intention to do so during the year following the effective date
of this registration statement.
|
|
|
|
(8)
|
|
Includes our overhead expenses,
including payments under the Administration Agreement, based on
our allocable portion of overhead and other expenses incurred by
the Administrator in performing its obligations under the
Administration Agreement. See Investment Management and
Administration Agreements Administration
Agreement. Other Expenses are based on
estimated amounts to be incurred on an annual basis.
|
(9)
|
|
Amount reflects our estimated
expenses of the temporary investment of offering proceeds in
money market funds pending our investment of such proceeds in
portfolio companies in accordance with the investment objective
and strategies described in this prospectus.
|
(10)
|
|
Total Annual Expenses
as a percentage of consolidated net assets attributable to
common stock are higher than the total annual expenses
percentage would be for a company that is not leveraged. We
borrow money to leverage our net assets and increase our total
assets. The SEC requires that the Total Annual
Expenses percentage be calculated as a percentage of net
assets (defined as total assets less indebtedness and after
taking into account any incentive fees payable during the
period), rather than the total assets, including assets that
have been funded with borrowed monies.
|
Example
The following example demonstrates the projected dollar amount
of total cumulative expenses that would be incurred over various
periods with respect to a hypothetical investment in our common
stock. This example and the expenses in the table above should
not be considered a representation of our future expenses, and
actual expenses (including the cost of debt, if any, and other
expenses) may be greater or less than those shown. In
calculating the following expense amounts, we have assumed that
our annual operating expenses remain at the levels set forth in
the table above. In the event that shares to which this
prospectus relates are sold to or through underwriters or
agents, a corresponding prospectus supplement will restate this
example to reflect the applicable sales load.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 Year
|
|
3 Years
|
|
5 Years
|
|
10 Years
|
|
You would pay the following expenses on a $1,000 investment,
assuming a 5% annual return
|
|
$
|
87
|
|
|
$
|
250
|
|
|
$
|
400
|
|
|
$
|
724
|
|
The example and the expenses in the tables above should not
be considered a representation of our future expenses, and
actual expenses may be greater or lesser than those shown.
While the example assumes, as required by the applicable rules
of the SEC, a 5% annual return, our performance will vary and
may result in a return greater or less than 5%. The incentive
fee under the Investment Management Agreement is unlikely to be
significant assuming a 5% annual return and is not included in
the example. If we achieve sufficient returns on our
investments, including through the realization of capital gains,
to trigger an incentive fee of a material amount, our
distributions to our common stockholders and our expenses would
likely be higher. See Investment Management and
Administration Agreements Examples of Incentive Fee
Calculation for additional information regarding the
calculation of incentive fees. In addition, while the example
assumes reinvestment of all dividends and other distributions at
net asset value, participants in our dividend reinvestment plan
receive a number of shares of our common stock determined by
dividing the total dollar amount of the distribution payable to
a participant by the market price per share of our common stock
at the close of trading on the valuation date for the
distribution. This price may be at, above or below net asset
value. See Dividend Reinvestment Plan for additional
information regarding our dividend reinvestment plan.
13
SELECTED
CONSOLIDATED FINANCIAL AND OTHER DATA
The selected historical financial and other data below reflects
our consolidated operations. The selected financial data for the
period from October 29, 2010 to December 31, 2010, the
period from January 1, 2010 to October 28, 2010, the
year ended December 31, 2009 and the period from
March 4, 2008 to December 31, 2008 have been derived
from our consolidated financial statements that have been
audited by McGladrey & Pullen, LLP, an independent
registered public accounting firm. Interim financial information
for the nine months ended September 30, 2011 and 2010 is
derived from our unaudited consolidated financial statements,
and in the opinion of management, reflects all adjustments
(consisting only of normal recurring adjustments) that are
necessary to present fairly the results of such interim period.
Results for the year ended December 31, 2010 and the nine
months ended September 30, 2011 are not necessarily
indicative of the results that may be expected for the current
year. You should read this selected consolidated financial and
other data in conjunction with our Managements
Discussion and Analysis of Financial Condition and Results of
Operations and the consolidated financial statements and
notes thereto.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-IPO Prior
|
|
|
|
|
|
|
|
|
|
|
Post-IPO as a
|
|
to becoming a
|
|
Post-IPO as a
|
|
|
|
|
|
|
|
|
Business
|
|
Business
|
|
Business
|
|
|
|
|
|
|
|
|
Development
|
|
Development
|
|
Development
|
|
|
|
|
|
March 4,
|
|
|
Company
|
|
Company
|
|
Company
|
|
|
|
|
|
2008
|
|
|
Nine Months
|
|
Nine Months
|
|
October 29,
|
|
January 1,
|
|
|
|
(Inception)
|
|
|
Ended
|
|
Ended
|
|
2010 to
|
|
2010 to
|
|
Year Ended
|
|
through
|
|
|
September 30,
|
|
September 30,
|
|
December 31,
|
|
October 28,
|
|
December 31,
|
|
December 31,
|
|
|
2011
|
|
2010
|
|
2010
|
|
2010
|
|
2009
|
|
2008
|
|
|
(Dollar amounts in thousands, except per share data)
|
|
Total investment income
|
|
$
|
17,871
|
|
|
$
|
13,250
|
|
|
$
|
3,251
|
|
|
$
|
14,956
|
|
|
$
|
15,326
|
|
|
$
|
7,021
|
|
Total expenses
|
|
|
10,670
|
|
|
|
5,372
|
|
|
|
1,892
|
|
|
|
5,931
|
|
|
|
6,769
|
|
|
|
4,031
|
|
Net investment income
|
|
|
7,201
|
|
|
|
7,878
|
|
|
|
1,359
|
|
|
|
9,025
|
|
|
|
8,557
|
|
|
|
2,990
|
|
Credit (provision) for loan losses
|
|
|
|
|
|
|
739
|
|
|
|
|
|
|
|
739
|
|
|
|
(274
|
)
|
|
|
(1,650
|
)
|
Net realized gain (loss) on investments
|
|
|
5,544
|
|
|
|
(2
|
)
|
|
|
611
|
|
|
|
69
|
|
|
|
138
|
|
|
|
22
|
|
Net unrealized (depreciation) appreciation on investments
|
|
|
(2,535
|
)
|
|
|
1,549
|
|
|
|
1,449
|
|
|
|
1,481
|
|
|
|
892
|
|
|
|
(73
|
)
|
Net increase in net assets resulting from operations
|
|
$
|
10,210
|
|
|
$
|
10,164
|
|
|
$
|
3,419
|
|
|
$
|
11,314
|
|
|
$
|
9,313
|
|
|
$
|
1,289
|
|
Net investment income per common share
|
|
$
|
0.95
|
|
|
|
N/A
|
|
|
$
|
0.18
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Net increase in net assets per common share
|
|
$
|
1.34
|
|
|
|
N/A
|
|
|
$
|
0.45
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Per share dividend declared
|
|
$
|
0.73
|
|
|
|
N/A
|
|
|
$
|
0.22
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Dollar amount of dividends declared
|
|
$
|
5,551
|
|
|
|
N/A
|
|
|
$
|
1,662
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Weighted average common shares
|
|
|
7,604,345
|
|
|
|
N/A
|
|
|
|
7,555,722
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30,
|
|
September 30,
|
|
December 31,
|
|
December 31,
|
|
December 31,
|
|
|
2011
|
|
2010
|
|
2010
|
|
2009
|
|
2008
|
|
|
(Dollar amounts in thousands, except per share data)
|
|
Balance sheet data at period end:
|
Investments
|
|
$
|
180,186
|
|
|
$
|
137,818
|
|
|
$
|
136,810
|
|
|
$
|
111,954
|
|
|
$
|
92,174
|
|
Other assets
|
|
|
36,685
|
|
|
|
22,118
|
|
|
|
79,395
|
|
|
|
12,914
|
|
|
|
23,041
|
|
Total assets
|
|
|
216,871
|
|
|
|
159,936
|
|
|
|
216,205
|
|
|
|
124,868
|
|
|
|
115,215
|
|
Total liabilities
|
|
|
84,492
|
|
|
|
89,870
|
|
|
|
89,010
|
|
|
|
65,375
|
|
|
|
65,430
|
|
Total net assets
|
|
|
132,379
|
|
|
|
70,065
|
|
|
|
127,195
|
|
|
|
59,493
|
|
|
|
49,785
|
|
14
SELECTED
QUARTERLY FINANCIAL DATA (Unaudited)
The following tables set forth certain quarterly financial
information for each of the eleven quarters ending with the
quarter ended September 30, 2011. This information was
derived from our unaudited consolidated financial statements.
Results for any quarter are not necessarily indicative of
results for the past fiscal year or for any future quarter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2011
|
|
|
Q3
|
|
Q2
|
|
Q1
|
|
|
(Dollar amounts in thousands, except per share data)
|
|
Total investment income
|
|
$
|
6,441
|
|
|
$
|
5,970
|
|
|
$
|
5,460
|
|
Net investment income
|
|
$
|
2,993
|
|
|
$
|
1,980
|
|
|
$
|
2,228
|
|
Net realized and unrealized (loss) gain
|
|
$
|
(234
|
)
|
|
$
|
1,843
|
|
|
$
|
1,400
|
|
Net increase in net assets resulting from operations
|
|
$
|
2,759
|
|
|
$
|
3,823
|
|
|
$
|
3,628
|
|
Earnings per
share(1)
|
|
$
|
0.39
|
|
|
$
|
0.26
|
|
|
$
|
0.29
|
|
Net asset value per share at the end of the
quarter(2)
|
|
$
|
17.36
|
|
|
$
|
17.40
|
|
|
$
|
17.23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
Q4
|
|
Q3
|
|
Q2
|
|
Q1
|
|
|
(Dollar amounts in thousands, except per share data)
|
|
Total investment income
|
|
$
|
4,956
|
|
|
$
|
5,189
|
|
|
$
|
4,270
|
|
|
$
|
3,793
|
|
Net investment income
|
|
$
|
2,507
|
|
|
$
|
3,257
|
|
|
$
|
2,509
|
|
|
$
|
2,113
|
|
Net realized and unrealized gain (loss)
|
|
$
|
2,063
|
|
|
$
|
1,711
|
|
|
$
|
(366
|
)
|
|
$
|
202
|
|
Net increase in net assets resulting from operations
|
|
$
|
4,570
|
|
|
$
|
5,288
|
|
|
$
|
2,259
|
|
|
$
|
2,618
|
|
Earnings per
share(3)
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
Net asset value per share at the end of the
quarter(2)(3)
|
|
$
|
16.75
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
Q4
|
|
Q3
|
|
Q2
|
|
Q1
|
|
|
(Dollar amounts in thousands, except per share data)
|
|
Total investment income
|
|
$
|
4,155
|
|
|
$
|
4,169
|
|
|
$
|
3,746
|
|
|
$
|
3,256
|
|
Net investment income
|
|
$
|
2,492
|
|
|
$
|
2,393
|
|
|
$
|
1,998
|
|
|
$
|
1,673
|
|
Net realized and unrealized gain (loss)
|
|
$
|
498
|
|
|
$
|
(55
|
)
|
|
$
|
143
|
|
|
$
|
445
|
|
Net increase in net assets resulting from operations
|
|
$
|
3,343
|
|
|
$
|
2,004
|
|
|
$
|
1,884
|
|
|
$
|
2,083
|
|
Earnings per
share(3)
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
Net asset value per share at the end of the
quarter(3)
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
$
|
N/A
|
|
|
|
|
(1)
|
|
Based on the weighted average
shares outstanding for the respective period.
|
(2)
|
|
Based on shares outstanding at the
end of the respective period.
|
(3)
|
|
For periods prior to
October 29, 2010, the Company did not have common shares
outstanding or an equivalent and, therefore, cannot calculate
earnings per share and net asset value per share.
|
15
RISK
FACTORS
Investing in our securities involves a high degree of risk.
Before you invest in our securities, you should be aware of
various risks, including those described below. You should
carefully consider these risk factors, together with all of the
other information included in this prospectus and any
accompanying prospectus supplement, before you decide whether to
make an investment in our securities. The risks set forth below
are not the only risks we face. If any of the following events
occur, our business, financial condition and results of
operations could be materially adversely affected. In such case,
our net asset value and the trading price of our securities
could decline, and you may lose all or part of your
investment.
Risks
Relating to Our Business and Structure
We
have a limited operating history and may not be able to achieve
our investment objective or generate sufficient revenue to make
or sustain distributions to our stockholders and your investment
in us could decline substantially.
We commenced operations in March 2008 and became a public
company on October 28, 2010. As a result of our limited
operating history, we are subject to certain business risks and
uncertainties associated with any recently formed business
enterprise, including the risk that we will not achieve our
investment objective and that the value of your investment in us
could decline substantially. As a public company, we are subject
to the regulatory requirements of the SEC, in addition to the
specific regulatory requirements applicable to BDCs under the
1940 Act and RICs under the Code. Our management and our Advisor
have limited experience operating under this regulatory
framework, and we may incur substantial additional costs, and
expend significant time or other resources, to do so. From time
to time our Advisor may pursue investment opportunities, like
equity investments, in which our Advisor has more limited
experience. In addition, we may be unable to generate sufficient
revenue from our operations to make or sustain distributions to
our stockholders.
We and
our Advisor have limited experience operating under the
constraints imposed on a BDC or managing an investment company,
which may affect our ability to manage our business and impair
your ability to assess our prospects.
Prior to becoming a public company in October 2010, we did not
operate as a BDC or manage an investment company under the 1940
Act. As a result, we have limited operating results under this
regulatory framework that can demonstrate to you either its
effect on our business or our ability to manage our business
within this framework. The 1940 Act imposes numerous constraints
on the operations of BDCs. For example, BDCs are required to
invest at least 70% of their total assets in specified types of
securities, primarily securities of eligible portfolio
companies (as defined in the 1940 Act), cash, cash
equivalents, U.S. government securities and other high
quality debt investments that mature in one year or less. See
Regulation. Our Advisors lack of experience in
managing a portfolio of assets under these constraints may
hinder our ability to take advantage of attractive investment
opportunities and, as a result, could impair our ability to
achieve our investment objective. Furthermore, if we are unable
to comply with the requirements imposed on BDCs by the 1940 Act,
the SEC could bring an enforcement action against us
and/or we
could be exposed to claims of private litigants. In addition, we
could be regulated as a closed-end management investment company
under the 1940 Act, which could further decrease our operating
flexibility and may prevent us from operating our business,
either of which could have a material adverse effect on our
business, results of operations or financial condition.
We are
dependent upon key personnel of our Advisor and our
Advisors ability to hire and retain qualified
personnel.
We depend on the members of our Advisors senior
management, particularly Mr. Pomeroy, our Chairman and
Chief Executive Officer, and Mr. Michaud, our President, as
well as other key personnel for the identification, evaluation,
final selection, structuring, closing and monitoring of our
investments. These employees have critical industry experience
and relationships that we rely on to implement our business plan
to originate Venture Loans in our Target Industries. Our future
success depends on the continued service of Mr. Pomeroy and
Mr. Michaud as well as the other senior members of our
Advisors management team. If our Advisor were to lose the
services of either
16
Mr. Pomeroy or Mr. Michaud or any of the other senior
members of our Advisors management team, we may not be
able to operate our business as we expect, and our ability to
compete could be harmed, either of which could cause our
business, results of operations or financial condition to
suffer. In addition, if either of Mr. Pomeroy or
Mr. Michaud cease to be employed by us, WestLB AG
(WestLB) could, absent a waiver or cure, demand
repayment of any outstanding obligations under the WestLB
Facility and, if more than one of Mr. Pomeroy,
Mr. Michaud or Mr. Mathieu, our Chief Financial
Officer, shall cease to be actively involved in the Company or
our Advisor, and are not replaced by individuals satisfactory to
Wells Fargo Capital Finance, LLC (Wells) within
ninety days, Wells could, absent a waiver or cure, demand
repayment of any outstanding obligations under the Wells
Facility. Our future success also depends, in part, on our
Advisors ability to identify, attract and retain
sufficient numbers of highly skilled employees. Absent exemptive
or other relief granted by the SEC and for so long as we remain
externally managed, the 1940 Act prevents us from granting
options to our employees and adopting a profit sharing plan,
which may make it more difficult for us to attract and retain
highly skilled employees. If we are not successful in
identifying, attracting and retaining these employees, we may
not be able to operate our business as we expect. Moreover, we
cannot assure you that our Advisor will remain our investment
advisor or that we will continue to have access to our
Advisors investment professionals or its relationships.
For example, our Advisor may in the future manage investment
funds with investment objectives similar to ours thereby
diverting the time and attention of its investment professionals
that we rely on to implement our business plan.
We
operate in a highly competitive market for investment
opportunities, and if we are not able to compete effectively,
our business, results of operations and financial condition may
be adversely affected and the value of your investment in us
could decline.
We compete for investments with a number of investment funds and
other BDCs, as well as traditional financial services companies
such as commercial banks and other financing sources. Some of
our competitors are larger and have greater financial,
technical, marketing and other resources than we have. For
example, some competitors may have a lower cost of funds and
access to funding sources that are not available to us. This may
enable these competitors to make commercial loans with interest
rates that are comparable to, or lower than, the rates we
typically offer. We may lose prospective portfolio companies if
we do not match our competitors pricing, terms and
structure. If we do match our competitors pricing, terms
or structure, we may experience decreased net interest income
and increased risk of credit losses. In addition, some of our
competitors may have higher risk tolerances or different risk
assessments, which could allow them to consider a wider variety
of investments, establish more relationships than us and build
their market shares. Furthermore, many of our competitors are
not subject to the regulatory restrictions that the 1940 Act
imposes on us as a BDC or that the Code imposes on us as a RIC.
If we are not able to compete effectively, we may not be able to
take advantage of attractive investment opportunities that we
identify and may not be able to fully invest our available
capital. If this occurs, our business, financial condition and
results of operations could be materially adversely affected.
We
borrow money, which magnifies the potential for gain or loss on
amounts invested and may increase the risk of investing in
us.
Leverage is generally considered a speculative investment
technique, and we intend to continue to borrow money as part of
our business plan. The use of leverage magnifies the potential
for gain or loss on amounts invested and, therefore, increases
the risks associated with investing in us. We borrow from and
issue senior debt securities to banks and other lenders. Such
senior debt securities include those under the Credit
Facilities. See Managements Discussion and Analysis
of Financial Condition and Results of Operations
Liquidity and Capital Resources. Lenders of senior debt
securities have fixed dollar claims on our assets that are
superior to the claims of our common stockholders. If the value
of our assets increases, then leveraging would cause the net
asset value attributable to our common stock to increase more
sharply than it would have had we not leveraged. However, any
decrease in our income would cause net income to decline more
sharply than it would have had we not leveraged. This decline
could adversely affect our ability to make common stock dividend
payments. In addition, because our investments may be illiquid,
we may be unable to dispose of them, or unable to do so at a
favorable price in the event we need to do so, if we are unable
to refinance any indebtedness upon maturity, and, as a result,
we may suffer losses.
17
Our ability to service any debt that we incur depends largely on
our financial performance and is subject to prevailing economic
conditions and competitive pressures. Moreover, as our
Advisors management fee is payable to our Advisor based on
our gross assets, including those assets acquired through the
use of leverage, our Advisor may have a financial incentive to
incur leverage which may not be consistent with our
stockholders interests. In addition, holders of our common
stock bear the burden of any increase in our expenses as a
result of leverage, including any increase in the management fee
payable to our Advisor.
Illustration: The following table illustrates the effect
of leverage on returns from an investment in our common stock
assuming various annual returns, net of expenses. The
calculations are hypothetical and actual returns may be higher
or lower than those appearing in the table below:
|
|
|
|
|
|
|
|
|
|
|
|
|
Assumed Return on Our Portfolio
|
|
|
(Net of Expenses)
|
|
|
−10%
|
|
−5%
|
|
0%
|
|
5%
|
|
10%
|
|
Corresponding return to
stockholder(1)
|
|
−18.50%
|
|
−10.28%
|
|
−2.06%
|
|
6.16%
|
|
14.38%
|
|
|
|
(1)
|
|
Assumes $217 million in total
assets, $82 million in debt outstanding, $132 million
in stockholders equity, and an average cost of funds of
3.32%. Assumptions are based on our financial condition and our
average costs of funds at September 30, 2011. Actual
interest payments may be different.
|
Based on our outstanding indebtedness of $82 million as of
September 30, 2011 and the effective annual interest rate
of 3.32% as of that date, our investment portfolio would have
been required to experience an annual return of at least 1.52%
to cover annual interest payments on the outstanding debt.
If we
are unable to comply with the covenants or restrictions in our
Credit Facilities or make payments when due thereunder, our
business could be materially adversely affected.
Our Credit Facilities are secured by a lien on the assets of our
wholly owned subsidiaries, Horizon Credit I LLC
(Credit I) and Horizon Credit II LLC
(Credit II), which hold substantially all of
our assets. The breach of certain of the covenants or
restrictions or our failure to make payments when due under the
Credit Facilities, unless cured within the applicable grace
period, would result in a default under the Credit Facilities
that would permit the lenders to declare all amounts outstanding
to be due and payable. In such an event, we may not have
sufficient assets to repay such indebtedness and the lenders may
exercise rights available to them, including, without
limitation, to the extent permitted under applicable law, the
seizure of such assets without adjudication.
The Credit Facilities include covenants that, among other
things, restrict the ability of Credit I and Credit II to
(i) make loans to, or investments in, third parties (other
than Venture Loans and warrants or other equity participation
rights), (ii) pay dividends and distributions,
(iii) incur additional indebtedness, (iv) engage in
mergers or consolidations, (v) create liens on the
collateral securing the Credit Facilities, (vi) permit
additional negative pledges on such collateral,
(vii) change the business currently conducted by them, and
(viii) to have a change of control.
The Credit Facilities also require Credit I, Credit II
and our Advisor to comply with various financial covenants,
including, among other covenants, maintenance by our Advisor of
a minimum tangible net worth and limitations on the value of,
and modifications to, the loan collateral that secures the
Credit Facilities. Complying with these restrictions may prevent
us from taking actions that we believe would help us to grow our
business or are otherwise consistent with our investment
objective. These restrictions could also limit our ability to
plan for or react to market conditions, meet extraordinary
capital needs or otherwise restrict corporate activities, and
could result in our failing to qualify as a RIC resulting in
our becoming subject to corporate-level income tax. See
Managements Discussion and Analysis of Financial
Condition and Results of Operations Liquidity and
Capital Resources for additional information regarding our
credit arrangements.
An event of default or acceleration under the Credit Facilities
could also cause a cross-default or cross-acceleration of
another debt instrument or contractual obligation, which would
adversely impact our liquidity. We may not be granted waivers or
amendments to the Credit Facilities if for any reason we are
unable to comply with it, and we may not be able to refinance
the Credit Facilities on terms acceptable to us, or at all.
18
The
impact of recent financial reform legislation on us is
uncertain.
In light of current conditions in the U.S. and global
financial markets and the U.S. and global economy,
legislators, the presidential administration and regulators have
increased their focus on the regulation of the financial
services industry. The Dodd-Frank Wall Street Reform and
Consumer Protection Act institutes a wide range of reforms that
will have an impact on all financial institutions. Many of these
provisions are subject to rule making procedures and studies
that will be conducted in the future. Accordingly, we cannot
predict the effect it or its implementing regulations will have
on our business, results of operations or financial condition.
Because
we distribute all or substantially all of our income and any
realized net short-term capital gains over realized net
long-term capital losses to our stockholders, we will need
additional capital to finance our growth, if any. If additional
funds are unavailable or not available on favorable terms, our
ability to grow will be impaired.
To satisfy the requirements applicable to a RIC, to avoid
payment of excise taxes and to minimize or avoid payment of
corporate-level federal income taxes, we intend to distribute to
our stockholders all or substantially all of our net ordinary
income and realized net short-term capital gains over realized
net long-term capital losses except that we may retain certain
net long-term capital gains, pay applicable income taxes with
respect thereto, and elect to treat such retained capital gains
as deemed distributions to our stockholders. As a BDC, we
generally are required to meet a coverage ratio of total assets
to total senior securities, which includes all of our borrowings
and any preferred stock we may issue in the future, of at least
200%. This requirement limits the amount that we may borrow.
Because we continue to need capital to grow our loan and
investment portfolio, this limitation may prevent us from
incurring debt and require us to raise additional equity at a
time when it may be disadvantageous to do so. We cannot assure
you that debt and equity financing will be available to us on
favorable terms, or at all, and debt financings may be
restricted by the terms of any of our outstanding borrowings. In
addition, as a BDC, we are limited in our ability to issue
equity securities priced below net asset value. If additional
funds are not available to us, we could be forced to curtail or
cease new lending and investment activities, and our net asset
value could decline.
If we
are unable to obtain additional debt financing, our business
could be materially adversely affected.
We may want to obtain additional debt financing, or need to do
so upon maturity of the Credit Facilities, in order to obtain
funds which may be made available for investments. We currently
may not request new advances under the WestLB Facility and we
must repay the outstanding advances under the WestLB Facility at
such times and in such amounts as are necessary to maintain
compliance with the terms and conditions of the WestLB Facility.
All outstanding amounts under the WestLB Facility are due and
payable on March 4, 2015. We may borrow under the Wells
Facility until July 14, 2014, and, after such date, we must
repay the outstanding advances under the Wells Facility in
accordance with its terms and conditions. All outstanding
advances under the Wells Facility are due and payable on
July 14, 2017, unless such date is extended in accordance
with its terms. If we are unable to increase, renew or replace
any such facility and enter into a new debt financing facility
on commercially reasonable terms, our liquidity may be reduced
significantly. In addition, if we are unable to repay amounts
outstanding under any such facilities and are declared in
default or are unable to renew or refinance these facilities, we
may not be able to make new investments or operate our business
in the normal course. These situations may arise due to
circumstances that we may be unable to control, such as lack of
access to the credit markets, a severe decline in the value of
the U.S. dollar, a further economic downturn or an
operational problem that affects third parties or us, and could
materially damage our business. Moreover, we have withdrawn our
application to the Small Business Administration
(SBA) for a license to operate as a small business
investment company (SBIC), which was originally
filed on December 6, 2010, and, though we may in the future
submit a new application, we have no present intention to do so
and, therefore, do not expect to be able to access liquidity by
issuing SBA-guaranteed debentures.
Changes
in interest rates may affect our cost of capital and net
investment income.
Because we currently incur indebtedness to fund our investments,
a portion of our income depends upon the difference between the
interest rate at which we borrow funds and the interest rate at
which we invest these funds. Most of our investments have fixed
interest rates, while our borrowings have floating interest
rates. As a result, a significant change in interest rates could
have a material adverse effect on our net investment income. In
periods of
19
rising interest rates, our cost of funds could increase, which
would reduce our net investment income. We may hedge against
interest rate fluctuations by using hedging instruments such as
swaps, futures, options and forward contracts, subject to
applicable legal requirements, including, without limitation,
all necessary registrations (or exemptions from registration)
with the Commodity Futures Trading Commission. These activities
may limit our ability to benefit from lower interest rates with
respect to the hedged portfolio. Adverse developments resulting
from changes in interest rates or hedging transactions or any
adverse developments from our use of hedging instruments could
have a material adverse effect on our business, financial
condition and results of operations. In addition, we may be
unable to enter into appropriate hedging transactions when
desired and any hedging transactions we enter into may not be
effective.
Because
many of our investments typically are not and will not be in
publicly traded securities, the value of our investments may not
be readily determinable, which could adversely affect the
determination of our net asset value.
Our investments consist, and we expect our future investments to
consist, primarily of loans or securities issued by privately
held companies. The fair value of these investments that are not
publicly traded may not be readily determinable. In addition, we
are not permitted to maintain a general reserve for anticipated
loan losses. Instead, we are required by the 1940 Act to
specifically value each investment and record an unrealized gain
or loss for any asset that we believe has increased or decreased
in value. We value these investments on a quarterly basis, or
more frequently as circumstances require, in accordance with our
valuation policy consistent with generally accepted accounting
principles. Our Board employs an independent third-party
valuation firm to assist them in arriving at the fair value of
our investments. Our Board discusses valuations and determines
the fair value in good faith based on the input of our Advisor
and the third-party valuation firm. The factors that may be
considered in fair value pricing our investments include the
nature and realizable value of any collateral, the portfolio
companys earnings and its ability to make payments on its
indebtedness, the markets in which the portfolio company does
business, comparisons to publicly traded companies, discounted
cash flow and other relevant factors. Because such valuations
are inherently uncertain and may be based on estimates, our
determinations of fair value may differ materially from the
values that would be assessed if a ready market for these
securities existed. Our net asset value could be adversely
affected if our determinations regarding the fair value of our
investments are materially higher than the values that we
ultimately realize upon the disposal of these investments.
Disruption
in the capital markets and the credit markets could adversely
affect our business.
Without sufficient access to the capital markets or credit
markets, we may be forced to curtail our business operations or
we may not be able to pursue new investment opportunities. The
global capital markets are in a period of disruption and extreme
volatility and, accordingly, there has been and will continue to
be uncertainty in the financial markets in general. Ongoing
disruptive conditions in the financial industry could restrict
our business operations and could adversely impact our results
of operations and financial condition. We are unable to predict
when economic and market conditions may become more favorable.
Even if these conditions improve significantly over the long
term, adverse conditions in particular sectors of the financial
markets could adversely impact our business.
We may
not realize gains from our equity investments.
We may make non-control, equity co-investments in companies in
conjunction with private equity sponsors. The equity interests
we receive may not appreciate in value and, in fact, may decline
in value. Accordingly, we may not be able to realize gains from
our equity interests, and any gains we do realize on the
disposition of any equity interests may not be sufficient to
offset any other losses we experience. We also may be unable to
realize any value if a portfolio company does not have a
liquidity event, such as a sale of the business, refinancing or
public offering, which would allow us to sell the underlying
equity interests. In addition, our Advisors significant
experience in Venture Lending may not result in returns on our
equity investments.
From time to time we may also acquire equity participation
rights in connection with an investment which will allow us, at
our option, to participate in future rounds of equity financing
through direct capital investments in our portfolio companies.
Our Advisor determines whether to exercise any of these rights.
Accordingly, you will have no
20
control over whether or to what extent these rights are
exercised, if at all. If we exercise these rights, we will be
making an additional investment completely in the form of equity
which will subject us to significantly more risk than our
Venture Loans and we may not receive the returns that are
anticipated with respect to these investments.
We may
not realize expected returns on warrants received in connection
with our debt investments.
As discussed above, we generally receive warrants in connection
with our debt investments. If we do not receive the returns that
are anticipated on the warrants, our investment returns on our
portfolio companies, and the value of your investment in us, may
be lower than expected.
Regulations
governing our operation as a BDC affect our ability to, and the
way in which, we raise additional capital, which may expose us
to additional risks.
Our business plan contemplates a need for a substantial amount
of capital in addition to our current amount of capital. We may
obtain additional capital through the issuance of debt
securities or preferred stock, and we may borrow money from
banks or other financial institutions, which we refer to
collectively as senior securities, up to the maximum
amount permitted by the 1940 Act. If we issue senior securities,
we would be exposed to typical risks associated with leverage,
including an increased risk of loss. In addition, if we issue
preferred stock, it would rank senior to common stock in our
capital structure and preferred stockholders would have separate
voting rights and may have rights, preferences or privileges
more favorable than those of holders of our common stock. We do
not presently intend to issue preferred stock within one year of
the effective date of this registration statement.
The 1940 Act permits us to issue senior securities in amounts
such that our asset coverage ratio, as defined in the 1940 Act,
equals at least 200% after each issuance of senior securities.
If our asset coverage ratio is not at least 200%, we are not
permitted to pay dividends or issue additional senior
securities. If the value of our assets declines, we may be
unable to satisfy this asset coverage test. If that happens, we
may be required to liquidate a portion of our investments and
repay a portion of our indebtedness at a time when we may be
unable to do so or unable to do so on favorable terms. See
Note 6 to Consolidated Financial Statements for additional
information regarding borrowings.
As a BDC, we generally are not able to issue our common stock at
a price below net asset value without first obtaining the
approval of our stockholders and our independent directors, and
we intend to seek such approval to sell our common stock below
net asset value in the future. This requirement does not apply
to stock issued upon the exercise of options, warrants or rights
that we may issue from time to time. If we raise additional
funds by issuing more common stock or senior securities
convertible into, or exchangeable for, our common stock, the
percentage ownership of our stockholders at that time would
decrease, and you may experience dilution.
If we
are unable to satisfy the requirements under the Code for
qualification as a RIC, we will be subject to corporate-level
federal income tax.
To qualify as a RIC under the Code, we must meet certain
source-of-income,
diversification and other requirements contained in Subchapter M
of the Code and maintain our election to be regulated as a BDC
under the 1940 Act. We must also meet the Annual Distribution
Requirement, as defined in Material U.S. Federal Income
Tax Considerations to avoid corporate-level federal income
tax in that year on all of our taxable income, regardless of
whether we make any distributions to our stockholders.
The
source-of-income
requirement is satisfied if we derive in each taxable year at
least 90% of our gross income from dividends, interest
(including tax-exempt interest), payments with respect to
certain securities loans, gains from the sale or other
disposition of stock, securities or foreign currencies, other
income (including but not limited to gain from options, futures
or forward contracts) derived with respect to our business of
investing in stock, securities or currencies, or net income
derived from an interest in a qualified publicly traded
partnership. The status of certain forms of income we
receive could be subject to different interpretations under the
Code and might be characterized as non-qualifying income that
could cause us to fail to qualify as a RIC, assuming we do not
qualify for or take advantage of certain remedial provisions,
and, thus, may cause us to be subject to corporate-level federal
income taxes.
21
The Annual Distribution Requirement for a RIC is satisfied if we
distribute to our stockholders on an annual basis an amount
equal to at least 90% of our net ordinary income and realized
net short-term capital gains in excess of realized net long-term
capital losses, if any. If we borrow money, we may be subject to
certain asset coverage ratio requirements under the 1940 Act and
loan covenants that could, under certain circumstances, restrict
us from making distributions necessary to qualify as a RIC. If
we are unable to obtain cash from other sources, we may fail to
qualify as a RIC, assuming we do not qualify for or take
advantage of certain remedial provisions, and, thus, may be
subject to corporate-level income tax.
To qualify as a RIC, we must also meet certain asset
diversification requirements at the end of each calendar
quarter. Failure to meet these tests may result in our having to
(i) dispose of certain investments quickly; (ii) raise
additional capital to prevent the loss of RIC status; or
(iii) engage in certain remedial actions that may entail
the disposition of certain investments at disadvantageous prices
that could result in substantial losses, and the payment of
penalties, if we qualify to take such actions. Because most of
our investments are and will be in development-stage companies
within our Target Industries, any such dispositions could be
made at disadvantageous prices and may result in substantial
losses. If we raise additional capital to satisfy the asset
diversification requirements, it could take a longer time to
invest such capital. During this period, we will invest in
temporary investments, such as cash and cash equivalents, which
we expect will earn yields substantially lower than the interest
income that we anticipate receiving in respect of our
investments in secured and amortizing loans.
If we were to fail to qualify for the federal income tax
benefits allowable to RICs for any reason and become subject to
a corporate-level federal income tax, the resulting taxes could
substantially reduce our net assets, the amount of income
available for distribution to our stockholders and the actual
amount of our distributions. Such a failure would have a
material adverse effect on us, the net asset value of our common
stock and the total return, if any, obtainable from your
investment in our common stock. In addition, we could be
required to recognize unrealized gains, pay substantial taxes
and interest and make substantial distributions before
requalifying as a RIC. See Regulation.
We may
have difficulty paying our required distributions if we
recognize taxable income before or without receiving
cash.
We may be required to recognize taxable income in circumstances
in which we do not receive cash. For example, if we hold debt
instruments that are treated under applicable tax rules as
having original issue discount (such as debt instruments with
payment-in-kind
interest or, in certain cases, increasing interest rates or
issued with warrants), we must include in taxable income each
year a portion of the original issue discount that accrues over
the life of the debt instrument, regardless of whether cash
representing such income is received by us in the same taxable
year. We do not have a policy limiting our ability to invest in
original issue discount instruments, including payment-in-kind
loans. Because in certain cases we may recognize taxable income
before or without receiving cash representing such income, we
may have difficulty meeting the requirement that we distribute
an amount equal to at least 90% of our net ordinary income and
realized net short-term capital gains in excess of realized
long-term capital losses, if any.
Accordingly, we may need to sell some of our assets at times
that we would not consider advantageous, raise additional debt
or equity capital or forego new investment opportunities or
otherwise take actions that are disadvantageous to our business
(or be unable to take actions that we believe are necessary or
advantageous to our business) in order to satisfy the Annual
Distribution Requirement. If we are unable to obtain cash from
other sources to satisfy the Annual Distribution Requirement, we
may fail to qualify for the federal income tax benefits
allowable to RICs and, thus, become subject to a corporate-level
federal income tax on all our income. The proportion of our
income, consisting of net investment income and our realized
gains and losses, that resulted from the portion of original
issue discount not received in cash for the years ended
December 31, 2009 and 2010 and the nine months ended
September 30, 2011 was 8.7%, 9.1% and 7.0%, respectively.
22
If we
do not invest a sufficient portion of our assets in qualifying
assets, we could fail to qualify as a BDC or be precluded from
investing according to our current business
strategy.
As a BDC, we are prohibited from acquiring any assets other than
qualifying assets unless, at the time of and after
giving effect to such acquisition, at least 70% of our total
assets are qualifying assets. Substantially all of our assets
are qualifying assets and we expect that substantially all
assets that we may acquire in the future will be qualifying
assets, although we may decide to make other investments that
are not qualifying assets to the extent permitted by the 1940
Act. If we acquire debt or equity securities from an issuer that
has outstanding marginable securities at the time we make an
investment, these acquired assets may not be treated as
qualifying assets. This result is dictated by the definition of
eligible portfolio company under the 1940 Act, which
in part looks to whether a company has outstanding marginable
securities. See Regulation Qualifying
Assets. If we do not invest a sufficient portion of our
assets in qualifying assets, we could lose our status as a BDC,
which would have a material adverse effect on our business,
financial condition and results of operations.
Changes
in laws or regulations governing our business could adversely
affect our business, results of operations and financial
condition.
Changes in the laws or regulations or the interpretations of the
laws and regulations that govern BDCs, RICs or non-depository
commercial lenders could significantly affect our operations,
our cost of doing business and our investment strategy. We are
subject to federal, state and local laws and regulations and
judicial and administrative decisions that affect our
operations, including our loan originations, maximum interest
rates, fees and other charges, disclosures to portfolio
companies, the terms of secured transactions, collection and
foreclosure procedures, portfolio composition and other trade
practices. If these laws, regulations or decisions change, or if
we expand our business into jurisdictions that have adopted more
stringent requirements, we may incur significant expenses to
comply with these laws, regulations or decisions or we might
have to restrict our operations or alter our investment
strategy. In addition, if we do not comply with applicable laws,
regulations and decisions, we may lose licenses needed for the
conduct of our business and be subject to civil fines and
criminal penalties, any of which could have a material adverse
effect upon our business, results of operations or financial
condition.
Our
Advisor has significant potential conflicts of interest with us
and our stockholders.
As a result of our arrangements with our Advisor, there may be
times when our Advisor has interests that differ from those of
our stockholders, giving rise to a potential conflict of
interest. Our executive officers and directors, as well as the
current and future executives and employees of our Advisor,
serve or may serve as officers, directors or principals of
entities that operate in the same or a related line of business
as we do. Accordingly, they may have obligations to investors in
those entities, the fulfillment of which might not be in the
best interests of our stockholders. In addition, our Advisor may
manage other funds in the future that may have investment
objectives that are similar, in whole or in part, to ours. Our
Advisor may determine that an investment is appropriate for us
and for one or more of those other funds. In such an event,
depending on the availability of the investment and other
appropriate factors, our Advisor will endeavor to allocate
investment opportunities in a fair and equitable manner and act
in accordance with its written conflicts of interest policy to
address and, if necessary, resolve any conflicts of interest. It
is also possible that we may not be given the opportunity to
participate in these other investment opportunities.
We pay management and incentive fees to our Advisor and
reimburse our Advisor for certain expenses it incurs. As a
result, investors in our common stock invest on a
gross basis and receive distributions on a
net basis after expenses, resulting in a lower rate
of return than an investor might achieve through direct
investments. Also, the incentive fee payable by us to our
Advisor may create an incentive for our Advisor to pursue
investments on our behalf that are riskier or more speculative
than would be the case in the absence of such compensation
arrangements.
We have entered into a license agreement with Horizon Technology
Finance, LLC, pursuant to which it has agreed to grant us a
non-exclusive, royalty-free right and license to use the service
mark Horizon Technology Finance. Under this
agreement, we have a right to use the Horizon Technology
Finance service mark for so long as the Investment
Management Agreement is in effect between us and our Advisor. In
addition, we pay our Advisor our allocable portion of overhead
and other expenses incurred by our Advisor in performing its
obligations under
23
the Administration Agreement, including rent, the fees and
expenses associated with performing compliance functions, and
our allocable portion of the compensation of our chief financial
officer and any administrative support staff. Any potential
conflict of interest arising as a result of our arrangements
with our Advisor could have a material adverse effect on our
business, results of operations and financial condition.
Our
incentive fee may impact our Advisors structuring of our
investments, including by causing our Advisor to pursue
speculative investments.
The incentive fee payable by us to our Advisor may create an
incentive for our Advisor to pursue investments on our behalf
that are riskier or more speculative than would be the case in
the absence of such compensation arrangement. The incentive fee
payable to our Advisor is calculated based on a percentage of
our return on invested capital. This may encourage our Advisor
to use leverage to increase the return on our investments. Under
certain circumstances, the use of leverage may increase the
likelihood of default, which would impair the value of our
common stock. In addition, our Advisor receives the incentive
fee based, in part, upon net capital gains realized on our
investments. Unlike that portion of the incentive fee based on
income, there is no hurdle rate applicable to the portion of the
incentive fee based on net capital gains. As a result, our
Advisor may have a tendency to invest more capital in
investments that are likely to result in capital gains as
compared to income-producing securities. Such a practice could
result in our investing in more speculative investments than
would otherwise be the case, which could result in higher
investment losses, particularly during economic downturns. In
addition, the incentive fee may encourage our Advisor to pursue
different types of investments or structure investments in ways
that are more likely to result in warrant gains or gains on
equity investments, including upon exercise of equity
participation rights, which are inconsistent with our investment
strategy and disciplined underwriting process.
The incentive fee payable by us to our Advisor may also induce
our Advisor to pursue investments on our behalf that have a
deferred interest feature, even if such deferred payments would
not provide cash necessary to enable us to pay current
distributions to our stockholders. Under these investments, we
would accrue interest over the life of the investment but would
not receive the cash income from the investment until the end of
the term. Our net investment income used to calculate the income
portion of our investment fee, however, includes accrued
interest. Thus, a portion of this incentive fee would be based
on income that we have not yet received in cash. In addition,
the
catch-up
portion of the incentive fee may encourage our Advisor to
accelerate or defer interest payable by portfolio companies from
one calendar quarter to another, potentially resulting in
fluctuations in the timing and amounts of dividends. Our
governing documents do not limit the number of loans we may make
with deferred interest features or the proportion of our income
we derive from such loans.
Our
Advisors liability is limited, and we have agreed to
indemnify our Advisor against certain liabilities, which may
lead our Advisor to act in a riskier manner on our behalf than
it would when acting for its own account.
Under the Investment Management Agreement, our Advisor does not
assume any responsibility to us other than to render the
services called for under that agreement, and it is not
responsible for any action of our Board in following or
declining to follow our Advisors advice or
recommendations. Under the terms of the Investment Management
Agreement, our Advisor, its officers, members, personnel and any
person controlling or controlled by our Advisor is not liable to
us, any subsidiary of ours, our directors, our stockholders or
any subsidiarys stockholders or partners for acts or
omissions performed in accordance with and pursuant to the
Investment Management Agreement, except those resulting from
acts constituting gross negligence, willful misconduct, bad
faith or reckless disregard of our Advisors duties under
the Investment Management Agreement. In addition, we have agreed
to indemnify our Advisor and each of its officers, directors,
members, managers and employees from and against any claims or
liabilities, including reasonable legal fees and other expenses
reasonably incurred, arising out of or in connection with our
business and operations or any action taken or omitted on our
behalf pursuant to authority granted by the Investment
Management Agreement, except where attributable to gross
negligence, willful misconduct, bad faith or reckless disregard
of such persons duties under the Investment Management
Agreement. These protections may lead our Advisor to act in a
riskier manner when acting on our behalf than it would when
acting for its own account.
24
If we
are unable to manage our future growth effectively, we may be
unable to achieve our investment objective, which could
adversely affect our business, results of operations and
financial condition and cause the value of your investment in us
to decline.
Our ability to achieve our investment objective depends on our
ability to achieve and sustain growth, which depends, in turn,
on our Advisors direct origination capabilities and
disciplined underwriting process in identifying, evaluating,
financing, investing in and monitoring suitable companies that
meet our investment criteria. Accomplishing this result on a
cost-effective basis is largely a function of our Advisors
marketing capabilities, management of the investment process,
ability to provide efficient services and access to financing
sources on acceptable terms. In addition to monitoring the
performance of our existing investments, our Advisor may also be
called upon to provide managerial assistance to our portfolio
companies. These demands on their time may distract them or slow
the rate of investment. If we fail to manage our future growth
effectively, our business, results of operations and financial
condition could be materially adversely affected and the value
of your investment in us could decrease.
Our
Board may change our operating policies and strategies,
including our investment objective, without prior notice or
stockholder approval, the effects of which may adversely affect
our business.
Our Board may modify or waive our current operating policies and
strategies, including our investment objective, without prior
notice and without stockholder approval (provided that no such
modification or waiver may change the nature of our business so
as to cease to be, or withdraw our election as, a BDC as
provided by the 1940 Act without stockholder approval at a
special meeting called upon written notice of not less than ten
or more than sixty days before the date of such meeting). We
cannot predict the effect any changes to our current operating
policies and strategies would have on our business, results of
operations or financial condition or on the value of our stock.
However, the effects of any changes might adversely affect our
business, any or all of which could negatively impact our
ability to pay dividends or cause you to lose all or part of
your investment in us.
Our
quarterly and annual operating results may fluctuate due to the
nature of our business.
We could experience fluctuations in our quarterly and annual
operating results due to a number of factors, some of which are
beyond our control, including: our ability to make investments
in companies that meet our investment criteria; the interest
rate payable on our loans; the default rate on these
investments; the level of our expenses, variations in, and the
timing of, the recognition of realized and unrealized gains or
losses; and the degree to which we encounter competition in our
markets and general economic conditions. For example, we have
historically experienced greater investment activity during the
second and fourth quarters relative to other periods. As a
result of these factors, you should not rely on the results for
any prior period as being indicative of our performance in
future periods.
Our
business plan and growth strategy depends to a significant
extent upon our Advisors referral relationships. If our
Advisor is unable to develop new or maintain existing
relationships, or if these relationships fail to generate
investment opportunities, our business could be materially
adversely affected.
We have historically depended on our Advisors referral
relationships to generate investment opportunities. For us to
achieve our future business objectives, members of our Advisor
need to maintain these relationships with venture capital and
private equity firms and management teams and legal firms,
accounting firms, investment banks and other lenders, and we
rely to a significant extent upon these relationships to provide
us with investment opportunities. If they fail to maintain their
existing relationships or develop new relationships with other
firms or sources of investment opportunities, we may not be able
to grow our investment portfolio. In addition, persons with whom
our Advisor has relationships are not obligated to provide us
with investment opportunities, and, therefore, there is no
assurance that such relationships will lead to the origination
of debt or other investments.
Our
Advisor can resign on 60 days notice and we may not
be able to find a suitable replacement within that time,
resulting in a disruption in our operations that could adversely
affect our business, results of operations or financial
condition.
Under the Investment Management Agreement, our Advisor has the
right to resign at any time, including during the first two
years following the Investment Management Agreements
effective date, upon not more than 60 days written
notice, whether we have found a replacement or not. If our
Advisor resigns, we may not be able to
25
find a new investment advisor or hire internal management with
similar expertise and ability to provide the same or equivalent
services on acceptable terms within 60 days, or at all. If
we are unable to do so, our operations are likely to be
disrupted, our business, results of operations and financial
condition and our ability to pay distributions may be adversely
affected and the market price of our shares may decline. In
addition, the coordination of our internal management and
investment activities is likely to suffer if we are unable to
identify and reach an agreement with a single institution or
group of executives having the expertise possessed by our
Advisor and its affiliates. Even if we are able to retain
comparable management, whether internal or external, the
integration of new management and their lack of familiarity with
our investment objective may result in additional costs and time
delays that may adversely affect our business, results of
operations or financial condition.
Our
ability to enter into transactions with our affiliates is
restricted.
As a BDC, we are prohibited under the 1940 Act from
participating in certain transactions with our affiliates
without the prior approval of our independent directors and, in
some cases, the SEC. Any person that owns, directly or
indirectly, 5% or more of our outstanding voting securities is
considered our affiliate for purposes of the 1940 Act. We are
generally prohibited from buying or selling any security from or
to an affiliate, absent the prior approval of our independent
directors. The 1940 Act also prohibits certain joint
transactions with an affiliate, which could include investments
in the same portfolio company (whether at the same or different
times), without prior approval of our independent directors. If
a person acquires more than 25% of our voting securities, we are
prohibited from buying or selling any security from or to that
person or certain of that persons affiliates, or entering
into prohibited joint transactions with those persons, absent
the prior approval of the SEC. Similar restrictions limit our
ability to transact business with our officers or directors or
their affiliates. These restrictions could limit or prohibit us
from making certain attractive investments that we might
otherwise make absent such restrictions.
While we have no current intention to enter into any principal
transactions or joint arrangements with any affiliates, we have
considered and evaluated, and will continue to consider and
evaluate, the potential advantages and disadvantages of doing
so. If we decide to enter into any such transactions in the
future we will not do so until we have requested and received
the requisite exemptive relief under Section 57 of the 1940
Act, the filing of which our Board has previously authorized.
We
incur significant costs as a result of being a publicly traded
company.
As a publicly traded company, we incur legal, accounting and
other expenses, including costs associated with the periodic
reporting requirements applicable to a company whose securities
are registered under the Securities Exchange Act of 1934, as
amended (the Exchange Act), as well as additional
corporate governance requirements, including requirements under
the Sarbanes-Oxley Act of 2002 (the Sarbanes Oxley
Act), and other rules implemented by the SEC.
Efforts
to comply with Section 404 of the Sarbanes-Oxley Act may
involve significant expenditures, and non-compliance with
Section 404 of the Sarbanes-Oxley Act may adversely affect
us and the market price of our common stock.
Under current SEC rules, we are required to report on our
internal control over financial reporting pursuant to
Section 404 of the Sarbanes-Oxley Act and related rules and
regulations of the SEC. As a result, we incur additional
expenses that may negatively impact our financial performance
and our ability to make distributions. This process also results
in a diversion of managements time and attention. We
cannot be certain as to the timing of completion of our
evaluation, testing and remediation actions or the impact of the
same on our operations, and we may not be able to ensure that
the process is effective or that our internal control over
financial reporting is or will be effective in a timely manner.
In the event that we are unable to maintain or achieve
compliance with Section 404 of the Sarbanes-Oxley Act and
related rules, we and the market price of our securities may be
adversely affected.
26
Terrorist
attacks and other catastrophic events may disrupt the businesses
in which we invest and harm our operations and our
profitability.
Terrorist attacks and threats, escalation of military activity
or acts of war may significantly harm our results of operations
and your investment. We cannot assure you that there will not be
further terrorist attacks against the United States or United
States businesses. Such attacks or armed conflicts in the United
States or elsewhere may impact the businesses in which we invest
directly or indirectly, by undermining economic conditions in
the United States or elsewhere. In addition, because many of our
portfolio companies operate and rely on network infrastructure
and enterprise applications and internal technology systems for
development, marketing, operational, support and other business
activities, a disruption or failure of any or all of these
systems in the event of a major telecommunications failure,
cyber-attack, fire, earthquake, severe weather conditions or
other catastrophic event could cause system interruptions,
delays in product development and loss of critical data and
could otherwise disrupt their business operations. Losses
resulting from terrorist attacks are generally uninsurable.
Risks
Related to our Investments
We
have not yet identified many of the potential investment
opportunities for our portfolio.
We have not yet identified many of the potential investment
opportunities for our portfolio. Our future investments will be
selected by our Advisor, subject to the approval of its
investment committee. Our stockholders do not have input into
our Advisors investment decisions. As a result, our
stockholders are unable to evaluate any of our future portfolio
company investments. These factors increase the uncertainty, and
thus the risk, of investing in our securities.
We are
a non-diversified investment company within the meaning of the
1940 Act, and therefore we generally are not limited with
respect to the proportion of our assets that may be invested in
securities of a single issuer.
We are classified as a non-diversified investment company within
the meaning of the 1940 Act, which means that we are not limited
by the 1940 Act with respect to the proportion of our assets
that we may invest in securities of a single issuer, excluding
limitations on stake holdings in investment companies. To the
extent that we assume large positions in the securities of a
small number of issuers, our net asset value may fluctuate to a
greater extent than that of a diversified investment company as
a result of changes in the financial condition or the
markets assessment of the issuer. We may also be more
susceptible to any single economic or regulatory occurrence than
a diversified investment company. Beyond our income tax
diversification requirements, we do not have fixed guidelines
for diversification, and our investments could be concentrated
in relatively few portfolio companies.
If our
investments do not meet our performance expectations, you may
not receive distributions.
We intend to make distributions of income on a quarterly basis
to our stockholders. We may not be able to achieve operating
results that will allow us to make distributions at a specific
level or increase the amount of these distributions from time to
time. In addition, due to the asset coverage test applicable to
us as a BDC, we may be limited in our ability to make
distributions. See Regulation. Also, restrictions
and provisions in any existing or future credit facilities may
limit our ability to make distributions. If we do not distribute
a certain percentage of our income annually, we will suffer
adverse tax consequences, including failure to obtain, or
possible loss of, the federal income tax benefits allowable to
RICs.
Most
of our portfolio companies will need additional capital, which
may not be readily available.
Our portfolio companies typically require substantial additional
financing to satisfy their continuing working capital and other
capital requirements and service the interest and principal
payments on our investments. We cannot predict the circumstances
or market conditions under which our portfolio companies will
seek additional capital. Each round of institutional equity
financing is typically intended to provide a company with only
enough capital to reach the next stage of development. It is
possible that one or more of our portfolio companies will not be
able to raise additional financing or may be able to do so only
at a price or on terms that are unfavorable to the portfolio
company, either of which would negatively impact our investment
returns. Some of these companies may
27
be unable to obtain sufficient financing from private investors,
public capital markets or lenders, thereby requiring these
companies to cease or curtail business operations. Accordingly,
investing in these types of companies generally entails a higher
risk of loss than investing in companies that do not have
significant incremental capital raising requirements.
Economic
recessions or downturns could adversely affect our business and
that of our portfolio companies which may have an adverse effect
on our business, results of operations and financial
condition.
General economic conditions may affect our activities and the
operation and value of our portfolio companies. Economic
slowdowns or recessions may result in a decrease of
institutional equity investment, which would limit our lending
opportunities. Furthermore, many of our portfolio companies may
be susceptible to economic slowdowns or recessions and may be
unable to repay our loans during these periods. Therefore, our
non-performing assets are likely to increase and the value of
our portfolio is likely to decrease during these periods.
Adverse economic conditions may also decrease the value of
collateral securing some of our loans and the value of our
equity investments. Economic slowdowns or recessions could lead
to financial losses in our portfolio and a decrease in revenues,
net income and assets. Unfavorable economic conditions could
also increase our funding costs, limit our access to the capital
markets or result in a decision by lenders not to extend credit
to us.
A portfolio companys failure to satisfy financial or
operating covenants imposed by us or other lenders could lead to
defaults and, potentially, termination of its loans and
foreclosure on its secured assets, which could trigger
cross-defaults under other agreements and jeopardize the
portfolio companys ability to meet its obligations under
the loans that we hold. We may incur expenses to the extent
necessary to recover our investment upon default or to negotiate
new terms with a defaulting portfolio company. These events
could harm our financial condition and operating results.
Our
investment strategy focuses on investments in development-stage
companies in our Target Industries, which are subject to many
risks, including volatility, intense competition, shortened
product life cycles and periodic downturns, and would be rated
below investment grade.
We intend to invest, under normal circumstances, most of the
value of our total assets (including the amount of any
borrowings for investment purposes) in development-stage
companies, which may have relatively limited operating
histories, in our Target Industries. Many of these companies may
have narrow product lines and small market shares, compared to
larger established publicly-owned firms, which tend to render
them more vulnerable to competitors actions and market
conditions, as well as general economic downturns. The revenues,
income (or losses) and valuations of development-stage companies
in our Target Industries can and often do fluctuate suddenly and
dramatically. For these reasons, investments in our portfolio
companies, if rated by one or more ratings agency, would
typically be rated below investment grade, which
refers to securities rated by ratings agencies below the four
highest rating categories. These companies may also have more
limited access to capital and higher funding costs. In addition,
development-stage technology markets are generally characterized
by abrupt business cycles and intense competition, and the
competitive environment can change abruptly due to rapidly
evolving technology. Therefore, our portfolio companies may face
considerably more risk than companies in other industry sectors.
Accordingly, these factors could impair their cash flow or
result in other events, such as bankruptcy, which could limit
their ability to repay their obligations to us and may
materially adversely affect the return on, or the recovery of,
our investments in these businesses.
Because of rapid technological change, the average selling
prices of products and some services provided by
development-stage companies in our Target Industries have
historically decreased over their productive lives. These
decreases could adversely affect their operating results and
cash flow, their ability to meet obligations under their debt
securities and the value of their equity securities. This could,
in turn, materially adversely affect our business, financial
condition and results of operations.
Any
unrealized depreciation we experience on our loan portfolio may
be an indication of future realized losses, which could reduce
our income available for distribution.
As a BDC, we are required to carry our investments at fair value
which shall be the market value of our investments or, if no
market value is ascertainable, at the fair value as determined
in good faith pursuant to
28
procedures approved by our Board in accordance with our
valuation policy. We are not permitted to maintain a reserve for
loan losses. Decreases in the fair values of our investments are
recorded as unrealized depreciation. Any unrealized depreciation
in our loan portfolio could be an indication of a portfolio
companys inability to meet its repayment obligations to us
with respect to the affected loans. This could result in
realized losses in the future and ultimately reduces our income
available for distribution in future periods.
If the
assets securing the loans we make decrease in value, we may not
have sufficient collateral to cover losses and may experience
losses upon foreclosure.
We believe our portfolio companies generally are and will be
able to repay our loans from their available capital, from
future capital-raising transactions or from cash flow from
operations. However, to mitigate our credit risks, we typically
take a security interest in all or a portion of the assets of
our portfolio companies, including the equity interests of their
subsidiaries. There is a risk that the collateral securing our
loans may decrease in value over time, may be difficult to
appraise or sell in a timely manner and may fluctuate in value
based upon the business and market conditions, including as a
result of the inability of a portfolio company to raise
additional capital, and, in some circumstances, our lien could
be subordinated to claims of other creditors. In addition,
deterioration of a portfolio companys financial condition
and prospects, including its inability to raise additional
capital, may be accompanied by deterioration of the value of the
collateral for the loan. Consequently, although such loan is
secured, we may not receive principal and interest payments
according to the loans terms and the value of the
collateral may not be sufficient to recover our investment
should we be forced to enforce our remedies.
In addition, because we invest in development-stage companies in
our Target Industries, a substantial portion of the assets
securing our investment may be in the form of intellectual
property, if any, inventory, equipment, cash and accounts
receivables. Intellectual property, if any, which secures a
loan, could lose value if the companys rights to the
intellectual property are challenged or if the companys
license to the intellectual property is revoked or expires. In
addition, in lieu of a security interest in a portfolio
companys intellectual property, we may sometimes obtain a
security interest in all assets of the portfolio company other
than intellectual property and also obtain a commitment by the
portfolio company not to grant liens to any other creditor on
the companys intellectual property. In these cases, we may
have additional difficulty recovering our principal in the event
of a foreclosure. Similarly, any equipment securing our loan may
not provide us with the anticipated security if there are
changes in technology or advances in new equipment that render
the particular equipment obsolete or of limited value or if the
company fails to adequately maintain or repair the equipment.
Any one or more of the preceding factors could materially impair
our ability to recover principal in a foreclosure.
We may
choose to waive or defer enforcement of covenants in the debt
securities held in our portfolio, which may cause us to lose all
or part of our investment in these companies.
We structure the debt investments in our portfolio companies to
include business and financial covenants placing affirmative and
negative obligations on the operation of the companys
business and its financial condition. However, from time to time
we may elect to waive breaches of these covenants, including our
right to payment, or waive or defer enforcement of remedies,
such as acceleration of obligations or foreclosure on
collateral, depending upon the financial condition and prospects
of the particular portfolio company. These actions may reduce
the likelihood of our receiving the full amount of future
payments of interest or principal and be accompanied by a
deterioration in the value of the underlying collateral as many
of these companies may have limited financial resources, may be
unable to meet future obligations and may go bankrupt. These
events could harm our financial condition and operating results.
The
lack of liquidity in our investments may adversely affect our
business, and if we need to sell any of our investments, we may
not be able to do so at a favorable price. As a result, we may
suffer losses.
We plan to generally invest in loans with terms of up to four
years and hold such investments until maturity, unless earlier
prepaid, and we do not expect that our related holdings of
equity securities will provide us with liquidity opportunities
in the near-term. We expect to primarily invest in companies
whose securities are not publicly-traded, and whose securities
are subject to legal and other restrictions on resale or are
otherwise less liquid than publicly-traded securities. The
illiquidity of these investments may make it difficult for us to
sell these investments when desired. We may also face other
restrictions on our ability to liquidate an investment in a
public portfolio company to
29
the extent that we possess material non-public information
regarding the portfolio company. In addition, if we are required
to liquidate all or a portion of our portfolio quickly, we may
realize significantly less than the value at which we had
previously recorded these investments. As a result, we do not
expect to dispose of our investments in the near term. However,
we may be required to do so in order to maintain our
qualification as a BDC and as a RIC if we do not satisfy one or
more of the applicable criteria under the respective regulatory
frameworks. Because most of our investments are illiquid, we may
be unable to dispose of them, in which case we could fail to
qualify as a RIC
and/or BDC,
or we may not be able to dispose of them at favorable prices,
and as a result, we may suffer losses.
Our
portfolio companies may incur debt that ranks equally with, or
senior to, our investments in such companies.
We plan to invest primarily in loans issued by our portfolio
companies. Some of our portfolio companies are permitted to have
other debt that ranks equally with, or senior to, our loans in
the portfolio company. By their terms, these debt instruments
may provide that the holders thereof are entitled to receive
payment of interest or principal on or before the dates on which
we are entitled to receive payments in respect of our loans.
These debt instruments may prohibit the portfolio companies from
paying interest on or repaying our investments in the event of,
and during, the continuance of a default under the debt
instruments. In addition, in the event of insolvency,
liquidation, dissolution, reorganization or bankruptcy of a
portfolio company, holders of debt instruments ranking senior to
our investment in that portfolio company would typically be
entitled to receive payment in full before we receive any
payment in respect of our investment. After repaying senior
creditors, a portfolio company may not have any remaining assets
to use for repaying its obligation to us. In the case of debt
ranking equally with our loans, we would have to share on an
equal basis any distributions with other creditors holding such
debt in the event of an insolvency, liquidation, dissolution,
reorganization or bankruptcy.
There
may be circumstances where our loans could be subordinated to
claims of other creditors or we could be subject to lender
liability claims.
Even though certain of our investments are structured as senior
loans, if one of our portfolio companies were to go bankrupt,
depending on the facts and circumstances, including the extent
to which we actually provided managerial assistance to that
portfolio company, a bankruptcy court might recharacterize our
debt investment and subordinate all or a portion of our claim to
that of other creditors. We may also be subject to lender
liability claims for actions taken by us with respect to a
portfolio companys business, including in rendering
significant managerial assistance, or instances where we
exercise control over the portfolio company.
An
investment strategy focused primarily on privately held
companies presents certain challenges, including the lack of
available information about these companies, a dependence on the
talents and efforts of only a few key portfolio company
personnel and a greater vulnerability to economic
downturns.
We currently invest, and plan to invest, primarily in privately
held companies. Generally, very little public information exists
about these companies, and we are required to rely on the
ability of our Advisor to obtain adequate information to
evaluate the potential returns from investing in these
companies. If we are unable to uncover all material information
about these companies, we may not make a fully informed
investment decision, and we may lose money on our investments.
Also, privately held companies frequently have less diverse
product lines and a smaller market presence than larger
competitors. Thus, they are generally more vulnerable to
economic downturns and may experience substantial variations in
operating results. These factors could affect our investment
returns.
In addition, our success depends, in large part, upon the
abilities of the key management personnel of our portfolio
companies, who are responsible for the
day-to-day
operations of our portfolio companies. Competition for qualified
personnel is intense at any stage of a companys
development. The loss of one or more key managers can hinder or
delay a companys implementation of its business plan and
harm its financial condition. Our portfolio companies may not be
able to attract and retain qualified managers and personnel. Any
inability to do so may negatively affect our investment returns.
30
Prepayments
of our debt investments by our portfolio companies could
adversely impact our results of operations and reduce our return
on equity.
We are subject to the risk that the investments we make in our
portfolio companies may be repaid prior to maturity. For
example, most of our debt investments have historically been
repaid prior to maturity by our portfolio companies. At the time
of a liquidity event, such as a sale of the business,
refinancing or public offering, many of our portfolio companies
have availed themselves of the opportunity to repay our loans
prior to maturity. Our investments generally allow for repayment
at any time subject to certain penalties. When this occurs, we
generally reinvest these proceeds in temporary investments,
pending their future investment in new portfolio companies.
These temporary investments have substantially lower yields than
the debt being prepaid, and we could experience significant
delays in reinvesting these amounts. Any future investment in a
new portfolio company may also be at lower yields than the debt
that was repaid. As a result, our results of operations could be
materially adversely affected if one or more of our portfolio
companies elects to prepay amounts owed to us. Additionally,
prepayments could negatively impact our return on equity, which
could result in a decline in the market price of our common
stock.
Our
business and growth strategy could be adversely affected if
government regulations, priorities and resources impacting the
industries in which our portfolio companies operate
change.
Some of our portfolio companies operate in industries that are
highly regulated by federal, state
and/or local
agencies. Changes in existing laws, rules or regulations, or
judicial or administrative interpretations thereof, or new laws,
rules or regulations could have an adverse impact on the
business and industries of our portfolio companies. In addition,
changes in government priorities or limitations on government
resources could also adversely impact our portfolio companies.
We are unable to predict whether any such changes in laws, rules
or regulations will occur and, if they do occur, the impact of
these changes on our portfolio companies and our investment
returns.
Our
portfolio companies operating in the life science industry are
subject to extensive government regulation and certain other
risks particular to that industry.
As part of our investment strategy, we have invested, and plan
to invest in the future, in companies in the life science
industry that are subject to extensive regulation by the Food
and Drug Administration and to a lesser extent, other federal
and state agencies. If any of these portfolio companies fail to
comply with applicable regulations, they could be subject to
significant penalties and claims that could materially and
adversely affect their operations. Portfolio companies that
produce medical devices or drugs are subject to the expense,
delay and uncertainty of the regulatory approval process for
their products and, even if approved, these products may not be
accepted in the marketplace. In addition, new laws, regulations
or judicial interpretations of existing laws and regulations
might adversely affect a portfolio company in this industry.
Portfolio companies in the life science industry may also have a
limited number of suppliers of necessary components or a limited
number of manufacturers for their products, and therefore face a
risk of disruption to their manufacturing process if they are
unable to find alternative suppliers when needed. Any of these
factors could materially and adversely affect the operations of
a portfolio company in this industry and, in turn, impair our
ability to timely collect principal and interest payments owed
to us.
If our
portfolio companies are unable to commercialize their
technologies, products, business concepts or services, the
returns on our investments could be adversely
affected.
The value of our investments in our portfolio companies may
decline if our portfolio companies are not able to commercialize
their technology, products, business concepts or services.
Additionally, although some of our portfolio companies may
already have a commercially successful product or product line
at the time of our investment, technology-related products and
services often have a more limited market or life span than
products in other industries. Thus, the ultimate success of
these companies often depends on their ability to continually
innovate in increasingly competitive markets. If they are unable
to do so, our investment returns could be adversely affected and
their ability to service their debt obligations to us over the
life of the loan could be impaired. Our portfolio companies may
be unable to successfully acquire or develop any new
technologies and the intellectual property they currently hold
may not remain viable. Even if our portfolio companies are able
to develop commercially viable products, the market for new
products and services is highly competitive and rapidly
changing. Neither our portfolio
31
companies nor we have any control over the pace of technology
development. Commercial success is difficult to predict, and the
marketing efforts of our portfolio companies may not be
successful.
If our
portfolio companies are unable to protect their intellectual
property rights, our business and prospects could be harmed, and
if portfolio companies are required to devote significant
resources to protecting their intellectual property rights, the
value of our investment could be reduced.
Our future success and competitive position depends in part upon
the ability of our portfolio companies to obtain, maintain and
protect proprietary technology used in their products and
services. The intellectual property held by our portfolio
companies often represents a substantial portion of the
collateral securing our investments
and/or
constitutes a significant portion of the portfolio
companies value that may be available in a downside
scenario to repay our loans. Our portfolio companies rely, in
part, on patent, trade secret and trademark law to protect that
technology, but competitors may misappropriate their
intellectual property, and disputes as to ownership of
intellectual property may arise. Portfolio companies may, from
time to time, be required to institute litigation to enforce
their patents, copyrights or other intellectual property rights,
protect their trade secrets, determine the validity and scope of
the proprietary rights of others or defend against claims of
infringement. Such litigation could result in substantial costs
and diversion of resources. Similarly, if a portfolio company is
found to infringe or misappropriate a third partys patent
or other proprietary rights, it could be required to pay damages
to the third party, alter its products or processes, obtain a
license from the third party
and/or cease
activities utilizing the proprietary rights, including making or
selling products utilizing the proprietary rights. Any of the
foregoing events could negatively affect both the portfolio
companys ability to service our debt investment and the
value of any related debt and equity securities that we own, as
well as the value of any collateral securing our investment.
We do
not expect to control any of our portfolio
companies.
We do not control, or expect to control in the future, any of
our portfolio companies, even though our debt agreements may
contain certain restrictive covenants that limit the business
and operations of our portfolio companies. We also do not
maintain, or intend to maintain in the future, a control
position to the extent we own equity interests in any portfolio
company. As a result, we are subject to the risk that a
portfolio company in which we invest may make business decisions
with which we disagree and the management of such company, as
representatives of the holders of their common equity, may take
risks or otherwise act in ways that do not serve our interests
as debt investors. Due to the lack of liquidity of the
investments that we typically hold in our portfolio companies,
we may not be able to dispose of our investments in the event we
disagree with the actions of a portfolio company and we may
therefore, suffer a decrease in the value of our investments.
Risks
Related to Offerings Under This Prospectus
There
is a risk that investors in our equity securities may not
receive dividends or that our dividends may not grow over time
and, a portion of distributions paid to you may be a return of
capital.
We intend to make distributions on a quarterly basis to our
stockholders out of assets legally available for distribution.
We cannot assure you that we will achieve investment results
that will allow us to make a specified level of cash
distributions or
year-to-year
increases in cash distributions. Our ability to pay dividends
might be adversely affected by, among other things, the impact
of one or more risk factors described herein. In addition, due
to the asset coverage test applicable to us as a BDC, we may be
limited in our ability to make distributions. All distributions
will be paid at the discretion of our Board and will depend on
our earnings, our financial condition, maintenance of our RIC
status, compliance with BDC regulation and such other factors as
our Board may deem relevant from time to time. We cannot assure
you that we will pay distributions to our stockholders in the
future. Further, if we invest a greater amount of assets in
equity securities that do not pay current dividends, it could
reduce the amount available for distribution. See Price
Range of Common Stock and Distributions.
On an annual basis, we will be required to determine the extent
to which any distributions we made were paid out of current or
accumulated earnings, recognized capital gains or capital. To
the extent there is a return of capital, investors will be
required to reduce their basis in our stock for
U.S. federal income tax purposes, which will result in
higher tax liability when the shares are sold, even if they have
not increased in value or have lost value. In addition,
32
any return of capital will be net of any sales load and
offering expenses associated with sales of shares of our common
stock. In the future, our distributions may include a return of
capital.
We
cannot assure you that the market price of shares of our common
stock will not decline.
Prior to our IPO, there was no public trading market for our
common stock. We cannot predict the prices at which our common
stock will trade. Shares of closed-end management investment
companies have in the past frequently traded at discounts to
their net asset values and our common stock has been and may
continue to be discounted in the market. This characteristic of
closed-end management investment companies is separate and
distinct from the risk that our net asset value per share may
decline. We cannot predict whether shares of our common stock
will trade above, at or below our net asset value. If our common
stock trades below its net asset value, we will generally not be
able to sell additional shares of our common stock to the public
at its market price without first obtaining the approval of our
stockholders (including our unaffiliated stockholders) and our
independent directors.
Our
common stock price may be volatile and may decrease
substantially.
The trading price of our common stock may fluctuate
substantially and the liquidity of our common stock may be
limited, in each case depending on many factors, some of which
are beyond our control and may not be directly related to our
operating performance. These factors include the following:
|
|
|
|
|
price and volume fluctuations in the overall stock market or in
the market for BDCs from time to time;
|
|
|
|
investor demand for our shares of common stock;
|
|
|
|
significant volatility in the market price and trading volume of
securities of registered closed-end management investment
companies, BDCs or other financial services companies;
|
|
|
|
our inability to raise capital, borrow money or deploy or invest
our capital;
|
|
|
|
fluctuations in interest rates;
|
|
|
|
any shortfall in revenue or net income or any increase in losses
from levels expected by investors or securities analysts;
|
|
|
|
operating performance of companies comparable to us;
|
|
|
|
changes in regulatory policies or tax guidelines with respect to
RICs or BDCs;
|
|
|
|
losing RIC status;
|
|
|
|
actual or anticipated changes in our earnings or fluctuations in
our operating results;
|
|
|
|
changes in the value of our portfolio of investments;
|
|
|
|
general economic conditions, trends and other external factors;
|
|
|
|
departures of key personnel; or
|
|
|
|
loss of a major source of funding.
|
In the past, following periods of volatility in the market price
of a companys securities, securities class action
litigation has often been brought against that company. Due to
the potential volatility of our stock price, we may therefore be
the target of securities litigation in the future. Securities
litigation could result in substantial costs and divert
managements attention and resources from our business.
Shares
of closed-end investment companies, including BDCs, frequently
trade at a discount to their net asset value, and we cannot
assure you that the market price of our common stock will not
decline following an offering.
We cannot predict the price at which our common stock will
trade. Shares of closed-end investment companies frequently
trade at a discount to their net asset value and our stock may
also be discounted in the market. This characteristic of
closed-end investment companies is separate and distinct from
the risk that our net asset value per
33
share may decline. We cannot predict whether shares of our
common stock will trade above, at or below our net asset value.
In addition, if our common stock trades below its net asset
value, we will generally not be able to issue additional shares
of our common stock at its market price without first obtaining
the approval of our stockholders and our independent directors.
We
currently invest a portion of our capital in high-quality
short-term investments, which generate lower rates of return
than those expected from investments made in accordance with our
investment objective.
We currently invest a portion of the net proceeds of our capital
in cash, cash equivalents, U.S. government securities and
other high-quality short-term investments. These securities may
earn yields substantially lower than the income that we
anticipate receiving once these proceeds are fully invested in
accordance with our investment objective.
Investing
in shares of our common stock may involve an above average
degree of risk.
The investments we make in accordance with our investment
objective may result in a higher amount of risk, volatility or
loss of principal than alternative investment options. Our
investments in portfolio companies may be highly speculative and
aggressive, and therefore, an investment in our common stock may
not be suitable for investors with lower risk tolerance.
We may
allocate the net proceeds from an offering in ways with which
you may not agree.
We have significant flexibility in investing the net proceeds of
an offering and may use the net proceeds from an offering in
ways with which you may not agree or for purposes other than
those contemplated at the time of the offering.
We estimate that it will take up to 6 months for us to
substantially invest the net proceeds of any offering made
pursuant to this prospectus, depending on the availability of
attractive opportunities and market conditions. However, we can
offer no assurances that we will be able to achieve this goal.
Pending such use, we will invest the remaining net proceeds of
this offering primarily in cash, cash equivalents,
U.S. Government securities and high-quality debt
investments that mature in one year or less from the date of
investment. These temporary investments may have lower yields
than our other investments and, may result in lower
distributions, if any, during such period. See
Regulation Temporary Investments for
additional information about temporary investments we may make
while waiting to make longer-term investments in pursuit of our
investment objective.
Anti-takeover
provisions in our charter documents and other agreements and
certain provisions of the DGCL could deter takeover attempts and
have an adverse impact on the price of our common
stock.
The Delaware General Corporation Law (the DGCL), our
certificate of incorporation and our bylaws contain provisions
that may have the effect of discouraging a third party from
making an acquisition proposal for us. Among other things, our
certificate of incorporation and bylaws:
|
|
|
|
|
provide for a classified board of directors, which may delay the
ability of our stockholders to change the membership of a
majority of our Board;
|
|
|
|
authorize the issuance of blank check preferred
stock that could be issued by our Board to thwart a takeover
attempt;
|
|
|
|
do not provide for cumulative voting;
|
|
|
|
provide that vacancies on our Board, including newly created
directorships, may be filled only by a majority vote of
directors then in office;
|
|
|
|
limit the calling of special meetings of stockholders;
|
|
|
|
provide that our directors may be removed only for cause;
|
|
|
|
require supermajority voting to effect certain amendments to our
certificate of incorporation and our bylaws; and
|
34
|
|
|
|
|
require stockholders to provide advance notice of new business
proposals and director nominations under specific procedures.
|
These anti-takeover provisions may inhibit a change in control
in circumstances that could give the holders of our common stock
the opportunity to realize a premium over the market price of
our common stock. Our WestLB Facility also contains a covenant
that prohibits us from merging or consolidating with any other
person or selling all or substantially all of our assets without
the prior written consent of WestLB. If we were to engage in
such a transaction without such consent, WestLB could accelerate
our repayment obligations under,
and/or
terminate, our WestLB Facility. In addition, it is a default
under our Wells Facility if (i) a person or group of
persons (within the meaning of the Exchange Act) acquires
beneficial ownership of 20% or more of our issued and
outstanding stock or (ii) during any twelve month period
individuals who at the beginning of such period constituted our
Board cease for any reason, other than death or disability, to
constitute a majority of the directors in office. If either
event were to occur, Wells could accelerate our repayment
obligations under,
and/or
terminate, our Wells Facility.
If we
elect to issue preferred stock, holders of any such preferred
stock will have the right to elect members of our Board and have
class voting rights on certain matters.
The 1940 Act requires that holders of shares of preferred stock
must be entitled as a class to elect two directors at all times
and to elect a majority of the directors if dividends on such
preferred stock are in arrears by two years or more, until such
arrearage is eliminated. In addition, certain matters under the
1940 Act require the separate vote of the holders of any issued
and outstanding preferred stock, including changes in
fundamental investment restrictions and conversion to open-end
status and, accordingly, preferred stockholders could veto any
such changes. Restrictions imposed on the declarations and
payment of dividends or other distributions to the holders of
our common stock and preferred stock, both by the 1940 Act and
by requirements imposed by rating agencies, might impair our
ability to maintain our qualification as a RIC for
U.S. federal income tax purposes.
Your
interest in us may be diluted if you do not fully exercise your
subscription rights in any rights offering. In addition, if the
subscription price is less than our net asset value per share,
then you will experience an immediate dilution of the aggregate
net asset value of your shares.
In the event we issue subscription rights, stockholders who do
not fully exercise their rights should expect that they will, at
the completion of a rights offering pursuant to this prospectus,
own a smaller proportional interest in us than would otherwise
be the case if they fully exercised their rights. Such dilution
is not currently determinable because it is not known what
proportion of the shares will be purchased as a result of such
rights offering. Any such dilution will disproportionately
affect nonexercising stockholders. If the subscription price per
share is substantially less than the current net asset value per
share, this dilution could be substantial.
In addition, if the subscription price is less than our net
asset value per share, our stockholders would experience an
immediate dilution of the aggregate net asset value of their
shares as a result of such rights offering. The amount of any
decrease in net asset value is not predictable because it is not
known at this time what the subscription price and net asset
value per share will be on the expiration date of the rights
offering or what proportion of the shares will be purchased as a
result of such rights offering. Such dilution could be
substantial.
Investors
in offerings of our common stock may incur immediate dilution
upon the closing of such offering.
If the public offering price for any offering of shares of our
common stock is higher than the book value per share of our
outstanding common stock, investors purchasing shares of common
stock in any such offering pursuant to this prospectus will pay
a price per share that exceeds the tangible book value per share
after such offering.
If we
sell common stock at a discount to our net asset value per
share, stockholders who do not participate in such sale will
experience immediate dilution in an amount that may be
material.
The issuance or sale by us of shares of our common stock at a
discount to net asset value poses a risk of dilution to our
stockholders. In particular, stockholders who do not purchase
additional shares at or below the discounted price in proportion
to their current ownership will experience an immediate decrease
in net asset value per share (as
35
well as in the aggregate net asset value of their shares if they
do not participate at all). These stockholders will also
experience a disproportionately greater decrease in their
participation in our earnings and assets and their voting power
than the increase we experience in our assets, potential earning
power and voting interests from such issuance or sale. In
addition, such sales may adversely affect the price at which our
common stock trades. See Sales of Common Stock Below Net
Asset Value.
Stockholders
will experience dilution in their ownership percentage if they
do not participate in our dividend reinvestment
plan.
All dividends payable to stockholders that are participants in
our dividend reinvestment plan are automatically reinvested in
shares of our common stock. As a result, stockholders that do
not participate in the dividend reinvestment plan will
experience dilution over time.
The
trading market or market value of our publicly issued debt
securities that we may issue may fluctuate.
Upon issuance, any publicly issued debt securities that we may
issue will not have an established trading market. We cannot
assure you that a trading market for our publicly issued debt
securities will ever develop or, if developed, will be
maintained. In addition to our creditworthiness, many factors
may materially adversely affect the trading market for, and
market value of, our publicly issued debt securities. These
factors include:
|
|
|
|
|
the time remaining to the maturity of these debt securities;
|
|
|
|
the outstanding principal amount of debt securities with terms
identical to these debt securities;
|
|
|
|
the supply of debt securities trading in the secondary market,
if any;
|
|
|
|
the redemption or repayment features, if any, of these debt
securities;
|
|
|
|
the level, direction and volatility of market interest rates
generally; and
|
|
|
|
market rates of interest higher or lower than rates borne by the
debt securities.
|
You should also be aware that there may be a limited number of
buyers when you decide to sell your debt securities. This too
may materially adversely affect the market value of the debt
securities or the trading market for the debt securities.
Terms
relating to redemption may materially adversely affect your
return on the debt securities that we may issue.
If we issue debt securities that are redeemable at our option,
we may choose to redeem the debt securities at times when
prevailing interest rates are lower than the interest rate paid
on the debt securities. In addition, if such debt securities are
subject to mandatory redemption, we may be required to redeem
the debt securities at times when prevailing interest rates are
lower than the interest rate paid on the debt securities. In
this circumstance, you may not be able to reinvest the
redemption proceeds in a comparable security at an effective
interest rate as high as your debt securities being redeemed.
Credit
ratings provided by third party credit rating agencies may not
reflect all risks of an investment in debt securities that we
may issue.
Credit ratings provided by third party credit rating agencies
are an assessment by third parties of our ability to pay our
obligations. Consequently, real or anticipated changes in our
credit ratings will generally affect the market value of debt
securities that we may issue. Credit ratings provided by third
party credit rating agencies, however, may not reflect the
potential impact of risks related to market conditions generally
or other factors discussed above on the market value of or
trading market for any publicly issued debt securities that we
may issue.
36
Subsequent
sales in the public market of substantial amounts of our common
stock by the selling stockholders may have an adverse effect on
the market price of our common stock and the registration of a
substantial amount of insider shares, whether or not actually
sold, may have a negative impact on the market price of our
common stock.
Shares of our common stock sold by the selling stockholders will
generally be freely tradeable. Sales of substantial amounts of
our common stock, or the availability of such common stock for
sale, whether or not actually sold, including those registered
pursuant to this Registration Statement, could adversely affect
the prevailing market price of our common stock. If this occurs
and continues, it could impair our ability to raise additional
capital through the sale of equity securities should we desire
to do so. In addition, because shares owned by HTF-CHF Holdings
LLC, an entity that is primarily owned by certain of our
officers, are being registered for resale, a negative perception
could be created in the market about the Companys
prospects by such registration.
37
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
In addition to factors previously identified elsewhere in this
prospectus, including the Risk Factors section of
this prospectus, the following factors, among others, could
cause actual results to differ materially from forward-looking
statements or historical performance:
|
|
|
|
|
our future operating results, including the performance of our
existing loans and warrants;
|
|
|
|
the introduction, withdrawal, success and timing of business
initiatives and strategies;
|
|
|
|
changes in political, economic or industry conditions, the
interest rate environment or financial and capital markets,
which could result in changes in the value of our assets;
|
|
|
|
the relative and absolute investment performance and operations
of our Advisor;
|
|
|
|
the impact of increased competition;
|
|
|
|
the impact of investments we intend to make and future
acquisitions and divestitures;
|
|
|
|
the unfavorable resolution of legal proceedings;
|
|
|
|
our business prospects and the prospects of our portfolio
companies;
|
|
|
|
the projected performance of other funds managed by our Advisor;
|
|
|
|
the impact, extent and timing of technological changes and the
adequacy of intellectual property protection;
|
|
|
|
our regulatory structure and tax status;
|
|
|
|
the adequacy of our cash resources and working capital;
|
|
|
|
the timing of cash flows, if any, from the operations of our
portfolio companies;
|
|
|
|
the impact of interest rate volatility on our results,
particularly because we use leverage as part of our investment
strategy;
|
|
|
|
the ability of our portfolio companies to achieve their
objectives;
|
|
|
|
our ability to cause a subsidiary to become a licensed SBIC;
|
|
|
|
the impact of legislative and regulatory actions and reforms and
regulatory, supervisory or enforcement actions of government
agencies relating to us or our Advisor;
|
|
|
|
our contractual arrangements and relationships with third
parties;
|
|
|
|
our ability to access capital and any future financings by us;
|
|
|
|
the ability of our Advisor to attract and retain highly talented
professionals; and
|
|
|
|
the impact of changes to tax legislation and, generally, our tax
position.
|
This prospectus, and other statements that we may make, may
contain forward-looking statements with respect to future
financial or business performance, strategies or expectations.
Forward-looking statements are typically identified by words or
phrases such as trend, opportunity,
pipeline, believe,
comfortable, expect,
anticipate, current,
intention, estimate,
position, assume, plan,
potential, project, outlook,
continue, remain, maintain,
sustain, seek, achieve and
similar expressions, or future or conditional verbs such as
will, would, should,
could, may or similar expressions.
Forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and we
assume no duty to and do not undertake to update forward-looking
statements. These forward-looking statements do not meet the
safe harbor for forward-looking statements pursuant to
Section 27A of the Securities Act or Section 21E of
the Exchange Act. Actual results could differ materially from
those anticipated in forward-looking statements and future
results could differ materially from historical performance.
38
USE OF
PROCEEDS
Unless otherwise specified in any prospectus supplement
accompanying this prospectus, we intend to use the net proceeds
from the sale of our securities for investment in portfolio
companies in accordance with our investment objective and
strategies as described in this prospectus and for working
capital and general corporate purposes. The supplement to this
prospectus relating to an offering will more fully identify the
use of proceeds from such offering. We estimate that it will
take up to 6 months for us to substantially invest the net
proceeds of any offering made pursuant to this prospectus,
depending on the availability of attractive opportunities and
market conditions. However, we can offer no assurances that we
will be able to achieve this goal. Pending such use, we will
invest the remaining net proceeds of this offering primarily in
cash, cash equivalents, U.S. Government securities and
high-quality debt investments that mature in one year or less
from the date of investment. These temporary investments may
have lower yields than our other investments and, accordingly,
may result in lower distributions, if any, during such period.
See Regulation Temporary Investments for
additional information about temporary investments we may make
while waiting to make longer-term investments in pursuit of our
investment objective. We will not receive any proceeds from the
resale of our common stock by the selling stockholders.
39
PRICE
RANGE OF COMMON STOCK AND DISTRIBUTIONS
Our common stock is traded on NASDAQ, under the symbol
HRZN. The following table sets forth, for each
fiscal quarter since our IPO, the range of high and low sales
prices of our common stock as reported on NASDAQ, the sales
price as a percentage of our net asset value and the
distributions declared by us for each fiscal quarter.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Premium/
|
|
Premium/
|
|
|
|
|
|
|
|
|
discount of
|
|
Discount of
|
|
|
|
|
|
|
|
|
High Sales
|
|
Low Sales
|
|
|
|
|
|
|
|
|
Price to
|
|
Price to
|
|
Cash
|
|
|
Net Asset
|
|
|
|
Net Asset
|
|
Net Asset
|
|
Distributions
|
|
|
Value(1)
|
|
Closing Sales Price
|
|
Value(2)
|
|
Value(2)
|
|
per
Share(3)
|
|
|
|
|
High
|
|
Low
|
|
|
|
|
|
|
|
Year ended December 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First
Quarter(4)
|
|
$
|
*
|
|
|
$
|
16.89
|
|
|
$
|
15.79
|
|
|
|
*
|
%
|
|
|
*
|
%
|
|
$
|
*
|
|
Year ended December 31, 2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
*
|
|
|
$
|
16.32
|
|
|
$
|
14.40
|
|
|
|
*
|
%
|
|
|
*
|
%
|
|
$
|
*
|
|
Third Quarter
|
|
$
|
17.36
|
|
|
$
|
16.25
|
|
|
$
|
13.88
|
|
|
|
94
|
%
|
|
|
80
|
%
|
|
$
|
0.45
|
|
Second Quarter
|
|
$
|
17.40
|
|
|
$
|
16.17
|
|
|
$
|
15.21
|
|
|
|
93
|
%
|
|
|
87
|
%
|
|
$
|
0.40
|
|
First Quarter
|
|
$
|
17.23
|
|
|
$
|
16.25
|
|
|
$
|
14.90
|
|
|
|
94
|
%
|
|
|
86
|
%
|
|
$
|
0.33
|
|
Year ended December 31, 2010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth
Quarter(5)
|
|
$
|
16.75
|
|
|
$
|
15.59
|
|
|
$
|
13.83
|
|
|
|
93
|
%
|
|
|
83
|
%
|
|
$
|
0.22
|
|
|
|
|
(1)
|
|
Net asset value per share is
determined as of the last day in the relevant quarter and
therefore may not reflect the net asset value per share on the
date of the high and low sales prices. The net asset values
shown are based on outstanding shares at the end of each period.
|
|
(2)
|
|
Calculated as the respective high
or low sales price divided by net asset value.
|
|
(3)
|
|
Represents the distribution
declared for the specified quarter. We have adopted an opt
out dividend reinvestment plan for our common
stockholders. As a result, if we declare a distribution, then
stockholders cash distributions are automatically
reinvested in additional shares of our common stock, unless they
specifically opt out of the dividend reinvestment plan so as to
receive cash distributions. See Dividend Reinvestment
Plan.
|
|
|
|
(4)
|
|
From January 1, 2012 to
February 3, 2012.
|
|
|
|
(5)
|
|
From October 29, 2010 (initial
public offering) to December 31, 2010.
|
|
|
|
*
|
|
Not yet determined at the time of
filing.
|
The last reported price for our common stock on February 3,
2012 was $16.66 per share. As of February 3, 2012, we had
four stockholders of record, which does not include stockholders
for whom shares are held in nominee or street name.
Shares of BDCs may trade at a market price that is less than the
net asset value that is attributable to those shares. The
possibility that our shares of common stock will trade at a
discount from net asset value or at a premium that is
unsustainable over the long term is separate and distinct from
the risk that our net asset value will decrease. It is not
possible to predict whether our shares will trade at, above or
below net asset value in the future.
We intend to continue making quarterly distributions to our
stockholders. The timing and amount of our quarterly
distributions, if any, is determined by our Board. Any
distributions to our stockholders are declared out of assets
legally available for distribution. We monitor available net
investment income to determine if a tax return of capital may
occur for the fiscal year. To the extent our taxable earnings
fall below the total amount of our distributions for any given
fiscal year, a portion of those distributions may be deemed to
be a return of capital to our common stockholders for
U.S. federal income tax purposes. Thus, the source of a
distribution to our stockholders may be the original capital
invested by the stockholder rather than our income or gains.
Stockholders should read any written disclosure accompanying a
dividend payment carefully and should not assume that the source
of any distribution is our ordinary income or gains.
To maintain RIC status, we must, among other things, meet the
Annual Distribution Requirement. Depending on the level of
taxable income earned in a tax year, we may choose to carry
forward taxable income in excess of
40
current year distributions into the next tax year and pay a 4%
excise tax on such income. Distributions of any such carryover
taxable income must be made through a dividend declared prior to
filing the final tax return related to the year in which such
taxable income was generated in order to count towards the
satisfaction of the Annual Distribution Requirement in the year
in which such income was generated. We may, in the future, make
actual distributions to our stockholders of our net capital
gains. We can offer no assurance that we will achieve results
that will permit the payment of any cash distributions and, if
we issue senior securities, we may be prohibited from making
distributions if doing so causes us to fail to maintain the
asset coverage ratios stipulated by the 1940 Act or if
distributions are limited by the terms of any of our borrowings.
See Material U.S. Federal Income Tax Considerations.
In January 2010, the Internal Revenue Service (the
IRS) extended a revenue procedure that temporarily
allows a RIC to distribute its own stock as a dividend for the
purpose of fulfilling its distribution requirements. Pursuant to
this revenue procedure, a RIC may treat a distribution of its
own stock as a dividend if (1) the stock is publicly traded
on an established securities market, (2) the distribution
is declared on or before December 31, 2012 with respect to
a taxable year ending on or before December 31, 2011 and
(3) each stockholder may elect to receive his or her entire
distribution in either cash or stock of the RIC subject to a
limitation on the aggregate amount of cash to be distributed to
all stockholders, which must be at least 10% of the aggregate
declared distribution. If too many stockholders elect to receive
cash, each stockholder electing to receive cash will receive a
pro rata amount of cash (with the balance of the distribution
paid in stock). In no event will any stockholder electing to
receive cash receive less than 10% of his or her entire
distribution in cash. We have not elected to distribute stock as
a dividend but reserve the right to do so.
In order to qualify as a RIC and to avoid corporate level tax on
the income we distribute to our stockholders, we are required
under the Code to distribute at least 90% of our net ordinary
income and net short-term capital gains in excess of net
long-term capital losses, if any, to our stockholders on an
annual basis. Additionally, we must distribute at least 98% of
our ordinary income and 98% (or, for our taxable years beginning
in 2011, 98.2%) of our capital gain net income on an annual
basis and any net ordinary income and net capital gains for
preceding years that were not distributed during such years and
on which we previously paid no U.S. federal income tax to
avoid a U.S. federal excise tax. If we do not distribute a
certain percentage of our income annually, we will suffer
adverse tax consequences, including the possible loss of our
qualification as a RIC. We cannot assure stockholders that they
will receive any distributions.
We have adopted an opt out dividend reinvestment
plan for our common stockholders. As a result, if we declare a
distribution, then stockholders cash distributions are
automatically reinvested in additional shares of our common
stock unless a stockholder specifically opts out of our dividend
reinvestment plan. If a stockholder opts out, that stockholder
receives cash distributions. Although distributions paid in the
form of additional shares of our common stock are generally
subject to U.S. federal, state and local taxes in the same
manner as cash distributions, stockholders participating in our
dividend reinvestment plan do not receive any corresponding cash
distributions with which to pay any such applicable taxes.
41
MANAGEMENTS
DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
In this section, except where the context suggests otherwise,
the terms we, us, our and
Horizon Technology Finance refer to Horizon
Technology Finance Corporation and its consolidated
subsidiaries. The information contained in this section should
be read in conjunction with our consolidated financial
statements and related notes thereto appearing elsewhere in this
registration statement on
Form N-2.
For periods prior to October 28, 2010, the consolidated
financial statements and related footnotes reflect the
performance of our predecessor, Compass Horizon, and its
wholly-owned subsidiary, Horizon Credit I LLC, both of which
were formed in January 2008 and commenced operations in March
2008. Amounts are stated in thousands, except shares and per
share data and where otherwise noted. Our actual results could
differ materially from those anticipated by forward-looking
information due to factors discussed under Risk
Factors and Cautionary Note Regarding
Forward-Looking Statements appearing elsewhere herein.
Overview
We are a specialty finance company that lends to and invests in
development-stage companies in the technology, life science,
healthcare information and services and cleantech industries.
Our investment objective is to generate current income from the
loans we make and capital appreciation from the warrants we
receive when making such loans. We make Venture Loans to
companies backed by established venture capital and private
equity firms in our Target Industries. We also selectively lend
to publicly traded companies in our Target Industries.
We are an externally managed, closed-end, non-diversified
management investment company that has elected to be regulated
as a BDC under the 1940 Act. As a BDC, we are required to comply
with regulatory requirements, including limitations on our use
of debt. We are permitted to, and expect to, finance our
investments through borrowings. However, as a BDC, we are only
generally allowed to borrow amounts such that our asset
coverage, as defined in the 1940 Act, equals at least 200% after
such borrowing.
Compass Horizon, our predecessor company, commenced operation in
March 2008. We were formed in March 2010 for the purpose of
acquiring Compass Horizon and continuing its business as a
public entity.
Portfolio
Composition and Investment Activity
The following table shows our portfolio by asset class as of
September 30, 2011 and December 31, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
|
|
|
|
|
|
|
% of
|
|
|
|
|
|
|
|
|
% of
|
|
|
|
# of
|
|
|
Fair
|
|
|
Total
|
|
|
# of
|
|
|
Fair
|
|
|
Total
|
|
|
|
Investments
|
|
|
Value
|
|
|
Portfolio
|
|
|
Investments
|
|
|
Value
|
|
|
Portfolio
|
|
|
|
($ in thousands)
|
|
|
Term loans
|
|
|
35
|
|
|
$
|
170,187
|
|
|
|
94.5
|
%
|
|
|
31
|
|
|
$
|
127,949
|
|
|
|
93.5
|
%
|
Revolving loans
|
|
|
1
|
|
|
|
2,933
|
|
|
|
1.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
Equipment loans
|
|
|
1
|
|
|
|
1,282
|
|
|
|
0.7
|
%
|
|
|
1
|
|
|
|
2,285
|
|
|
|
1.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total loans
|
|
|
37
|
|
|
|
174,402
|
|
|
|
96.8
|
%
|
|
|
32
|
|
|
|
130,234
|
|
|
|
95.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants
|
|
|
48
|
|
|
|
5,091
|
|
|
|
2.8
|
%
|
|
|
43
|
|
|
|
6,225
|
|
|
|
4.6
|
%
|
Equity
|
|
|
2
|
|
|
|
693
|
|
|
|
0.4
|
%
|
|
|
2
|
|
|
|
351
|
|
|
|
0.3
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
|
|
|
$
|
180,186
|
|
|
|
100.0
|
%
|
|
|
|
|
|
$
|
136,810
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42
Total portfolio investment activity for the three and nine month
periods ended September 30, 2011 and 2010 was as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
For the Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2011
|
|
|
2010
|
|
|
2011
|
|
|
2010
|
|
|
|
|
|
|
($ in thousands)
|
|
|
|
|
|
Beginning portfolio
|
|
$
|
186,029
|
|
|
$
|
143,008
|
|
|
$
|
136,810
|
|
|
$
|
113,878
|
|
New loan funding
|
|
|
7,000
|
|
|
|
15,000
|
|
|
|
86,833
|
|
|
|
75,517
|
|
Less refinanced balances
|
|
|
|
|
|
|
|
|
|
|
(8,677
|
)
|
|
|
(10,909
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net new loan funding
|
|
|
7,000
|
|
|
|
15,000
|
|
|
|
78,156
|
|
|
|
64,608
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal and stock payments received on investments
|
|
|
(8,559
|
)
|
|
|
(11,278
|
)
|
|
|
(22,666
|
)
|
|
|
(28,104
|
)
|
Early pay-offs
|
|
|
(4,315
|
)
|
|
|
(9,777
|
)
|
|
|
(9,908
|
)
|
|
|
(13,231
|
)
|
Accretion of loan fees
|
|
|
527
|
|
|
|
451
|
|
|
|
1,356
|
|
|
|
934
|
|
New loan fees
|
|
|
(40
|
)
|
|
|
(134
|
)
|
|
|
(967
|
)
|
|
|
(651
|
)
|
New equity investments
|
|
|
|
|
|
|
79
|
|
|
|
577
|
|
|
|
79
|
|
Net depreciation on investments
|
|
|
(456
|
)
|
|
|
1,654
|
|
|
|
(3,172
|
)
|
|
|
1,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending portfolio
|
|
$
|
180,186
|
|
|
$
|
139,003
|
|
|
$
|
180,186
|
|
|
$
|
139,003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We receive payments in our loan portfolio based on scheduled
amortization of the outstanding balances. In addition, we
receive repayments of some of our loans prior to their scheduled
maturity date. The frequency or volume of these repayments may
fluctuate significantly from period to period.
The following table shows our debt investments by industry
sector as of September 30, 2011 and December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
|
Loans at
|
|
|
Percentage
|
|
|
Loans at
|
|
|
Percentage
|
|
|
|
Fair
|
|
|
of Total
|
|
|
Fair
|
|
|
of Total
|
|
|
|
Value
|
|
|
Portfolio
|
|
|
Value
|
|
|
Portfolio
|
|
|
|
|
|
|
($ in thousands)
|
|
|
|
|
|
Life Science
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$
|
28,118
|
|
|
|
16.1
|
%
|
|
$
|
30,470
|
|
|
|
23.4
|
%
|
Medical Device
|
|
|
26,499
|
|
|
|
15.2
|
%
|
|
|
19,572
|
|
|
|
15.0
|
%
|
Technology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer-related Technologies
|
|
|
2,574
|
|
|
|
1.5
|
%
|
|
|
4,460
|
|
|
|
3.4
|
%
|
Networking
|
|
|
1,282
|
|
|
|
0.7
|
%
|
|
|
2,285
|
|
|
|
1.8
|
%
|
Semiconductors
|
|
|
9,739
|
|
|
|
5.6
|
%
|
|
|
|
|
|
|
0.0
|
%
|
Software
|
|
|
23,719
|
|
|
|
13.6
|
%
|
|
|
8,745
|
|
|
|
6.7
|
%
|
Data Storage
|
|
|
4,929
|
|
|
|
2.8
|
%
|
|
|
7,912
|
|
|
|
6.1
|
%
|
Communications
|
|
|
5,648
|
|
|
|
3.2
|
%
|
|
|
7,591
|
|
|
|
5.9
|
%
|
Cleantech
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Energy Efficiency
|
|
|
25,479
|
|
|
|
14.6
|
%
|
|
|
16,570
|
|
|
|
12.7
|
%
|
Waste Recycling
|
|
|
4,889
|
|
|
|
2.8
|
%
|
|
|
2,363
|
|
|
|
1.8
|
%
|
Healthcare Information and Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
22,584
|
|
|
|
13.0
|
%
|
|
|
20,472
|
|
|
|
15.7
|
%
|
Other Healthcare Related Services and Technologies
|
|
|
18,942
|
|
|
|
10.9
|
%
|
|
|
9,794
|
|
|
|
7.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
174,402
|
|
|
|
100.0
|
%
|
|
$
|
130,234
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
43
The largest loans may vary from year to year as new loans are
recorded and repaid. Our five largest loans represented
approximately 27% and 31% of total loans outstanding as of
September 30, 2011 and December 31, 2010,
respectively. No single loan represented more than 10% of our
total loans as of September 30, 2011 and December 31,
2010.
As of September 30, 2011 and December 31, 2010,
interest receivable was $2.5 million and $1.9 million,
respectively, which represents one month of accrued interest
income on loans. The increase in 2011 was due to a larger loan
portfolio relative to 2010.
Loan
Portfolio Asset Quality
We use a credit rating system which rates each loan on a scale
of 4 to 1, with 4 being the highest credit quality rating and 3
being the rating for a standard level of risk. A rating of 2 or
1 represents a deteriorating credit quality and increased risk.
The following table shows the classification of our loan
portfolio by credit rating as of September 30, 2011 and
December 31, 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
|
Loans at
|
|
|
Percentage
|
|
|
Loans at
|
|
|
Percentage
|
|
|
|
Fair
|
|
|
of Loan
|
|
|
Fair
|
|
|
of Loan
|
|
|
|
Value
|
|
|
Portfolio
|
|
|
Value
|
|
|
Portfolio
|
|
|
|
($ in thousands)
|
|
|
Credit Rating
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
|
|
$
|
34,161
|
|
|
|
19.6
|
%
|
|
$
|
29,054
|
|
|
|
22.3
|
%
|
3
|
|
|
126,168
|
|
|
|
72.3
|
%
|
|
|
94,200
|
|
|
|
72.3
|
%
|
2
|
|
|
14,073
|
|
|
|
8.1
|
%
|
|
|
6,980
|
|
|
|
5.4
|
%
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
174,402
|
|
|
|
100.0
|
%
|
|
$
|
130,234
|
|
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of September 30, 2011 and December 31, 2010, our
loan portfolio had a weighted average credit rating of 3.2.
As of September 30, 2011 and December 31, 2010, no
investments were on non-accrual status.
Results
of Operations
The consolidated results of operations set forth below include
historical financial information of our predecessor, Compass
Horizon, prior to our election to become a BDC and our election
to be treated as a RIC. As a BDC and a RIC for U.S. federal
income tax purposes, we are also subject to certain constraints
on our operations, including limitations imposed by the 1940 Act
and the Code. Also, the management fee that we pay to our
Advisor under the Investment Management Agreement is determined
by reference to a formula that differs materially from the
management fee paid by Compass Horizon in prior periods. For
these and other reasons set forth below, the results of
operations described below may not be indicative of the results
we report in future periods.
44
Consolidated
Results of Operations for the Three Months Ended
September 30, 2011 and 2010
Consolidated operating results for the three months ended
September 30, 2011 and 2010 are as follows:
|
|
|
|
|
|
|
|
|
|
|
For the Three Months
|
|
|
|
Ended September 30,
|
|
|
|
2011
|
|
|
2010
|
|
|
|
($ in thousands)
|
|
|
Total investment income
|
|
$
|
6,441
|
|
|
$
|
5,189
|
|
Total expenses
|
|
|
3,448
|
|
|
|
1,932
|
|
|
|
|
|
|
|
|
|
|
Net investment income
|
|
|
2,993
|
|
|
|
3,257
|
|
Net realized loss on investments
|
|
|
(17
|
)
|
|
|
|
|
Net unrealized (depreciation) appreciation on investments
|
|
|
(217
|
)
|
|
|
1,711
|
|
Credit for loan losses
|
|
|
|
|
|
|
320
|
|
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
2,759
|
|
|
$
|
5,288
|
|
|
|
|
|
|
|
|
|
|
Average debt investments, at fair value
|
|
$
|
180,951
|
|
|
$
|
137,867
|
|
|
|
|
|
|
|
|
|
|
Average borrowings outstanding
|
|
$
|
80,871
|
|
|
$
|
91,640
|
|
|
|
|
|
|
|
|
|
|
Net investment income for the three months ended
September 30, 2011 was $3.0 million or $0.39 per
share. Excluding the impact of the reduction in the second part
of the incentive fee expense of $0.2 million, net
investment income totaled $2.8 million or $0.37 per share.
Investment
Income
Investment income increased by $1.3 million, or 24.1%, for
the three months ended September 30, 2011 as compared to
the three months ended September 30, 2010. For the three
months ended September 30, 2011, total investment income
consisted primarily of $6.1 million in interest income from
investments, which included $0.5 million in income from the
amortization of discounts and origination fees on investments.
Interest income on investments and other investment income
increased primarily due to the increased average size of the
loan portfolio. Fee income on investments was primarily
comprised of prepayment fees collected from our portfolio
companies. For the three months ended September 30, 2010,
total investment income consisted primarily of $5.0 million
in interest income from investments, which included
$0.5 million in income from the amortization of discounts
and origination fees on investments. For the three months ended
September 30, 2011 and 2010, our dollar-weighted average
annualized yield on average loans was approximately 14.2% and
15.0%, respectively.
Investment income, consisting of interest income and fees on
loans, can fluctuate significantly upon repayment of large
loans. Interest income from the five largest loans accounted for
approximately 27% and 31% of investment income for the three
months ended September 30, 2011 and 2010, respectively.
Expenses
Total expenses increased by $1.5 million, or 78.5%, to
$3.4 million for the three months ended September 30,
2011 as compared to the three months ended September 30,
2010. Total operating expenses for each period consisted
principally of management fees, incentive and administrative
fees and interest expense and, to a lesser degree, professional
fees and general and administrative expenses. Interest expense,
which includes the amortization of debt issuance costs,
decreased for the three months ended September 30, 2011
compared to the three months ended September 30, 2010
primarily due to the end of our WestLB Facilitys revolving
term and the scheduled amortization of the remaining balance.
Effective with the completion of our IPO in October 2010, we pay
management and incentive fees under the Investment Management
Agreement, which provides a higher management fee base as
compared to amounts previously paid by Compass Horizon. Base
management fee expense for the three months ended
September 30, 2011 increased by approximately
$0.4 million compared to the three months ended
September 30, 2010 primarily due to the higher management
fee base. Incentive fees for the three months ended
September 30, 2011 totaled
45
approximately $0.6 million compared to no incentive fees
for the three months ended September 30, 2010. The
incentive fees for the three months ended September 30,
2011 consisted of approximately $0.7 million for part one
of the incentive fee offset by a reduction of previously accrued
part two incentive fees. In connection with the Administration
Agreement, we incurred $0.4 million of administrative
expenses for the three months ended September 30, 2011. We
did not pay an administrative servicing fee for the three months
ended September 30, 2010.
Professional fees and general and administrative expenses
include legal and audit fees, insurance premiums, and
miscellaneous other expenses. These expenses for the three
months ended September 30, 2011 increased by approximately
$0.6 million compared to the three months ended
September 30, 2010 primarily due to the increased cost of
being a public company and the expensing of $0.2 million of
previously capitalized costs related to our efforts to obtain a
license to operate a SBIC.
Net
Realized Gain (Loss) and Net Unrealized Appreciation
(Depreciation)
Realized gains or losses are measured by the difference between
the net proceeds from the repayment or sale and the cost basis
of our investments without regard to unrealized appreciation or
depreciation previously recognized, and includes investments
charged off during the period, net of recoveries. The net change
in unrealized appreciation or depreciation primarily reflects
the change in portfolio investment fair values during the
reporting period, including the reversal of previously recorded
unrealized appreciation or depreciation when gains or losses are
realized.
Consolidated
Results of Operations for the Nine Months Ended
September 30, 2011 and 2010
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months
|
|
|
|
Ended September 30,
|
|
|
|
2011
|
|
|
2010
|
|
|
|
($ in thousands)
|
|
|
Total investment income
|
|
$
|
17,871
|
|
|
$
|
13,250
|
|
Total expenses
|
|
|
10,670
|
|
|
|
5,372
|
|
|
|
|
|
|
|
|
|
|
Net investment income
|
|
|
7,201
|
|
|
|
7,878
|
|
Net realized gain (loss) on investments
|
|
|
5,544
|
|
|
|
(2
|
)
|
Net unrealized (depreciation) appreciation on investments
|
|
|
(2,535
|
)
|
|
|
1,549
|
|
Credit for loan losses
|
|
|
|
|
|
|
739
|
|
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
10,210
|
|
|
$
|
10,164
|
|
|
|
|
|
|
|
|
|
|
Average debt investments, at fair value
|
|
$
|
162,623
|
|
|
$
|
123,298
|
|
|
|
|
|
|
|
|
|
|
Average borrowings outstanding
|
|
$
|
82,606
|
|
|
$
|
78,195
|
|
|
|
|
|
|
|
|
|
|
Net investment income for the nine months ended
September 30, 2011 was $7.2 million or $0.95 per
share. Excluding the impact of the capital gains incentive fee
expense of $0.7 million, net investment income totaled
$7.9 million or $1.04 per share.
Investment
Income
Investment income increased by $4.6 million, or 34.9%, for
the nine months ended September 30, 2011 as compared to the
nine months ended September 30, 2010. For the nine months
ended September 30, 2011, total investment income consisted
primarily of $16.9 million in interest income from
investments, which included $1.3 million in income from the
amortization of discounts and origination fees on investments.
Interest income on investments and other investment income
increased primarily due to the increased average size of the
loan portfolio. Fee income on investments was primarily
comprised of a one-time success fee received upon the completion
of an acquisition of one of our portfolio companies and from
prepayment fees collected from our portfolio companies. For the
nine months ended September 30, 2010, total investment
income consisted primarily of $12.9 million in interest
income from investments, which included $0.9 million in
income from the amortization of discounts and
46
origination fees on investments. For the nine months ended
September 30, 2011 and 2010, our dollar-weighted average
annualized yield on average loans was approximately 14.6% and
14.3%, respectively.
Investment income, consisting of interest income and fees on
loans, can fluctuate significantly upon repayment of large
loans. Interest income from the five largest loans accounted for
approximately 25% and 19% of investment income for the nine
months ended September 30, 2011 and 2010, respectively.
Expenses
Total expenses increased by $5.3 million, or 98.6%, to
$10.6 million for the nine months ended September 30,
2011 as compared to the nine months ended September 30,
2010. Total operating expenses for each period consisted
principally of management fees, incentive and administrative
fees, interest expense and, to a lesser degree, professional
fees and general and administrative expenses. Interest expense,
which includes the amortization of debt issuance costs,
decreased for the nine months ended September 30, 2011
compared to the nine months ended September 30, 2010
primarily due to the expiration of our WestLB Facilitys
revolving term and the amortization of the remaining balance.
Effective with the completion of our IPO in October 2010, we pay
management and incentive fees under the Investment Management
Agreement, which provides a higher management fee base as
compared to amounts previously paid by Compass Horizon. Base
management fee expense for the nine months ended
September 30, 2011 increased by approximately
$1.4 million compared to the nine months ended
September 30, 2010 primarily due to the higher management
fee base. Incentive fees for the nine months ended
September 30, 2011 totaled approximately $2.7 million
compared to no incentive fees for the nine months ended
September 30, 2010. The incentive fees for the nine months
ended September 30, 2011 consisted of approximately
$2.0 million and $0.7 million for part one and part
two of the incentive fee, respectively. In connection with the
Administration Agreement, we incurred $0.9 million of
administrative expenses for the nine months ended
September 30, 2011. We did not pay an administrative
servicing fee for the nine months ended September 30, 2010.
Professional fees and general and administrative expenses
include legal and audit fees, insurance premiums and
miscellaneous other expenses. These expenses for the nine months
ended September 30, 2011 increased by approximately
$1.5 million compared to the nine months ended
September 30, 2010 primarily due to the increased cost of
being a public company and the expensing of previously
capitalized costs related to our efforts to obtain a license to
operate a SBIC.
Net
Realized Gain (Loss) and Net Unrealized Appreciation
(Depreciation)
Realized gains or losses are measured by the difference between
the net proceeds from the repayment or sale and the cost basis
of our investments without regard to unrealized appreciation or
depreciation previously recognized, and includes investments
charged off during the period, net of recoveries. Net change in
unrealized appreciation or depreciation primarily reflects the
change in portfolio investment fair values during the reporting
period, including the reversal of previously recorded unrealized
appreciation or depreciation when gains or losses are realized.
During the nine months ended September 30, 2011, we had
$5.5 million in net realized gain on investments. Net
realized gain on investments resulted primarily from the sale of
stock through the exercise of warrants in portfolio companies.
Credit
for Loan Losses
For the three and nine months ended September 30, 2010, the
credit for loan losses was $0.3 million and
$0.7 million, respectively. The loan portfolio had a
weighted average credit rating of 3.1 as of September 30,
2010. See Loan Portfolio Asset Quality.
As of October 28, 2010, the date of our election to be
treated as a BDC, we no longer record a credit or provision for
loan losses. We record each individual loan and investment on a
quarterly basis at fair value. Changes in fair value are
recorded through our statement of operations.
47
Consolidated
Results of Operations for the Years Ended December 31, 2010
and 2009, and the Period from March 4, 2008 (Inception) to
December 31, 2008
Compass Horizon, our predecessor for accounting purposes, was
formed as a Delaware limited liability company in January 2008
and had limited operations through March 3, 2008. As a
result, there is no period with which to compare our results of
operations for the period from January 1, 2008 through
March 3, 2008 or for the period from March 4, 2008
through December 31, 2008.
Consolidated operating results for the years ended
December 31, 2010 and 2009, and the period from
March 4, 2008 (inception) to December 31, 2008 are as
follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
|
($ in thousands)
|
|
|
Total investment income
|
|
$
|
18,207
|
|
|
$
|
15,326
|
|
|
$
|
7,021
|
|
Total expenses
|
|
|
7,823
|
|
|
|
6,769
|
|
|
|
4,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment income
|
|
|
10,384
|
|
|
|
8,557
|
|
|
|
2,990
|
|
Net realized gains
|
|
|
680
|
|
|
|
138
|
|
|
|
22
|
|
Net unrealized appreciation (depreciation) on investments
|
|
|
2,930
|
|
|
|
892
|
|
|
|
(73
|
)
|
Credit (provision) for loan losses
|
|
|
739
|
|
|
|
(274
|
)
|
|
|
(1,650
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
14,733
|
|
|
$
|
9,313
|
|
|
$
|
1,289
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average debt investments, at fair value
|
|
$
|
124,027
|
|
|
$
|
109,561
|
|
|
$
|
63,111
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Average borrowings outstanding
|
|
$
|
77,174
|
|
|
$
|
70,582
|
|
|
$
|
37,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income can vary substantially from period to period for
various reasons, including the recognition of realized gains and
losses and unrealized appreciation and depreciation. As a
result, annual comparisons of net income may not be meaningful.
Investment
Income
Investment income increased by $2.9 million, or 19.0%, for
the year ended December 31, 2010 as compared to the year
ended December 31, 2009. For the year ended
December 31, 2010, total investment income consisted
primarily of $17.4 million in interest income from
investments, which included $1.4 million in income from the
amortization of discounts and origination fees on investments.
Interest income on investments and other investment income
increased primarily due to the increased average size of the
loan portfolio. Other investment income was primarily comprised
of loan prepayment fees collected from our portfolio companies
and increased primarily due to a higher number of prepayments in
2010.
Investment income increased by $8.3 million, or 118.3%, for
the year ended December 31, 2009 as compared to the period
from March 4, 2008 (inception) to December 31, 2008.
For the year ended December 31, 2009, total investment
income consisted primarily of $14.9 million in interest
income from investments, which included $1.0 million in
income from the amortization of discounts and origination fees
on investments. Interest income on investments and other
investment income increased primarily due to (i) the
increased average size of the loan portfolio and (ii) there
being a full 12 months of income in 2009 compared to only
10 months in 2008 in light of when we commenced operations.
Other investment income was primarily comprised of loan
prepayment fees collected from our portfolio companies.
For the years ended December 31, 2010, December 31,
2009 and the ten month period ended December 31, 2008, our
dollar-weighted average annualized yield on average loans was
approximately 14.6%, 13.9% and 12.7%, respectively. We compute
the yield on average loans as (i) total investment interest
and other investment income divided by (b) average gross
loans receivable. We used month end loan balances during the
period to compute average loans receivable. Since we commenced
operations in March 2008, the results for the period ended
December 31, 2008 were annualized.
48
Investment income, consisting of interest income and fees on
loans, can fluctuate significantly upon repayment of large
loans. Interest income from the five largest loans accounted for
approximately 22%, 23% and 21% of investment income for the
years ended December 31, 2010, December 31, 2009 and
the period from March 4, 2008 (inception) to
December 31, 2008, respectively.
Expenses
Total expenses increased by $1.1 million, or 15.6%, to
$7.8 million for the year ended December 31, 2010 as
compared to the year ended December 31, 2009. Total
expenses increased by $2.7 million, or 67.9%, to
$6.8 million for the year ended December 31, 2009 as
compared to the period from March 4, 2008 to
December 31, 2008.
Total operating expenses for each period consisted principally
of management fees and interest expense and, to a lesser degree,
professional fees and general and administrative expenses.
Interest expense, which includes the amortization of debt
issuance costs, increased in 2010 from 2009 primarily from
higher average outstanding debt balances on the WestLB Facility.
Interest expense increased in 2009 from the ten months ended
December 31, 2008 primarily due to higher average
outstanding debt balances on the WestLB Facility, partially
offset by lower rates charged on the WestLB Facility due to a
lower level of the WestLB Facilitys index rate, one-month
LIBOR.
Effective with the completion of our IPO in October 2010, we now
pay management and incentive fees under the Investment
Management Agreement which provides a higher management fee base
as compared to amounts previously paid by Compass Horizon.
Management fee expense in 2010 increased compared to 2009
primarily due to an increase in the average loan portfolio in
2010 from 2009 and increased in 2009 compared to the ten months
ended December 31, 2008 due to a full twelve months of
expense in 2009 compared to only ten months in 2008. Incentive
fees for the period since our IPO totaled approximately $414,000
compared to no incentives fees prior to the IPO.
In connection with the Administrative Agreement, we have
incurred $88,000 for the period since our IPO through
December 31, 2010. We did not pay an administrative
servicing fee prior to our IPO.
Professional fees and general and administrative expenses
include legal, accounting fees, insurance premiums and
miscellaneous other expenses. These expenses increased in 2010
from 2009 primarily from the increased cost as a public company.
These expenses increased in 2009 from the ten months ended
December 31, 2008 primarily because of the longer period in
2009.
Net
Realized Gains and Net Unrealized Appreciation and
Depreciation
During the years ended December 31, 2010 and 2009, we had
$0.7 million and $0.1 million in net realized gains on
investments, respectively. During the same periods, we had
$2.9 million and $0.9 million in unrealized
appreciation on investments, respectively. Net realized gain on
warrants resulted from the sale of stock through the exercise of
warrants in portfolio companies. For these periods, the net
increase in unrealized appreciation on investments was primarily
from our warrant investments. Net unrealized appreciation on
warrants is the difference between the net changes in warrant
fair values from the prior determination date and the reversal
of previously recorded unrealized appreciation or depreciation
when gains or losses are realized. The increase in net
unrealized appreciation on warrants in 2010 and 2009 is
primarily due to an increase in the enterprise value of a number
of private companies for which we hold warrants. In addition,
the increased net appreciation on warrants is due to the
increase in the share value of the public company warrants held.
Credit
or Provision for Loan Losses
For the period from January 1, 2010 through
October 28, 2010 the credit for loan losses was
$0.7 million and for the year ended December 31, 2009
and the period from March 4, 2008 to December 31, 2008
the provision for loan losses was $0.3 million and
$1.6 million, respectively. The credit rose from
December 31, 2009 through October 28, 2010 primarily
due to improved portfolio asset quality during 2010 across all
Credit Ratings within the loan portfolio. The loan portfolio had
a weighted average credit rating of 3.1 and 2.9 as of
October 28, 2010 and December 31, 2009, respectively.
See Loan Portfolio Asset Quality. The
decrease in the provision for loan losses in 2009 compared to
2008 was due to less significant loan growth in 2009. As of our
election to be treated as a BDC, we no longer record a credit or
provision for loan losses. We record each individual loan and
investment on a quarterly basis at fair value. Changes in fair
value are recorded through our statement of operations.
49
Liquidity
and Capital Resources
As of September 30, 2011 and December 31, 2010, we had
cash and cash equivalents of $32.6 million and
$76.8 million, respectively. Cash and cash equivalents are
available to fund new investments, reduce borrowings under the
Credit Facilities, pay operating expenses and pay dividends. To
date, our primary sources of capital have been from our IPO, use
of the Credit Facilities and the private placement for
$50 million of equity capital completed on March 4,
2008.
The WestLB Facility had a three year initial revolving term and
on March 3, 2011 the revolving term ended. The balance as
of September 30, 2011 of $66 million will be amortized
based on loan investment payments received through March 3,
2015.
As of September 30, 2011, we had available borrowing
capacity of approximately $59.2 million under our Wells
Facility, subject to existing terms and advance rates.
Our operating activities used cash of $32.4 million for the
nine months ended September 30, 2011, and our financing
activities used cash of $11.8 million for the same period.
Our operating activities used cash primarily for investing in
portfolio companies. Such cash was provided primarily from
proceeds from our IPO and draws under the Credit Facilities.
Our operating activities used cash of $15.5 million for the
nine months ended September 30, 2010, and our financing
activities provided net cash proceeds of $24.8 million for
the same period. Our operating activities used cash primarily
for investing in portfolio companies that was provided primarily
from our availability under our WestLB Facility.
Our operating activities used cash of $8 million for the
year ended December 31, 2010 and our financing activities
provided net cash proceeds of $75 million for the same
period. Our operating activities used cash primarily for
investing in portfolio companies. Such cash was provided
primarily from proceeds from our IPO and draws under the WestLB
Facility.
Our operating activities used cash of $11 million for the
year ended December 31, 2009 and our financing activities
provided net cash proceeds of $0.5 million for the same
period. Our operating activities used cash primarily for
investing in portfolio companies that was provided primarily
from our availability on our WestLB Facility.
Our operating activities used cash of $90 million for the
10 month period ended December 31, 2008 and our
financing activities provided net cash proceeds of
$110 million for the same period. Our operating activities
used cash primarily for investing in portfolio companies that
was provided primarily from proceeds from an equity private
placement and draws under the WestLB Facility.
Our primary use of available funds is investments in portfolio
companies and cash distributions to holders of our common stock.
We seek to opportunistically raise additional capital as needed,
and subject to market conditions, to support our future growth
through future equity offerings, issuances of senior securities
and/or
future borrowings, to the extent permitted by the 1940 Act.
In order to satisfy the Code requirements applicable to a RIC,
we intend to distribute to our stockholders all or substantially
all of our income except for certain net capital gains. In
addition, as a BDC, we generally are required to meet an asset
coverage ratio of 200%. This requirement limits the amount that
we may borrow.
Distributions
In order to qualify as a RIC and to avoid corporate level tax on
the income we distribute to our stockholders, we are required
under the Code to distribute at least 90% of our net ordinary
income and net short-term capital gains in excess of net
long-term capital losses, if any, to our stockholders on an
annual basis. Additionally, we must distribute at least 98% of
our ordinary income and 98% (or, for our taxable years beginning
in 2011, 98.2%) of our capital gain net income on an annual
basis and any net ordinary income and net capital gains for
preceding years that were not distributed during such years and
on which we previously paid no U.S. federal income tax to
avoid a U.S. federal excise tax. We intend to distribute
quarterly dividends to our stockholders as determined by our
Board.
50
We may not be able to achieve operating results that will allow
us to make distributions at a specific level or to increase the
amount of our distributions from time to time. In addition, we
may be limited in our ability to make distributions due to the
asset coverage requirements applicable to us as a BDC under the
1940 Act. If we do not distribute a certain percentage of our
income annually, we will suffer adverse tax consequences,
including the possible loss of our qualification as a RIC. We
cannot assure stockholders that they will receive any
distributions.
To the extent our taxable earnings fall below the total amount
of our distributions for that fiscal year, a portion of those
distributions may be deemed a return of capital to our
stockholders for U.S. federal income tax purposes. Thus,
the source of a distribution to our stockholders may be the
original capital invested by the stockholder rather than our
income or gains. Stockholders should read any written disclosure
accompanying a dividend payment carefully and should not assume
that the source of any distribution is our ordinary income or
gains.
We have adopted an opt out dividend reinvestment
plan for our common stockholders. As a result, if we declare a
distribution, then stockholders cash distributions will be
automatically reinvested in additional shares of our common
stock unless a stockholder specifically opts out of our dividend
reinvestment plan. If a stockholder opts out, that stockholder
will receive cash distributions. Although distributions paid in
the form of additional shares of our common stock will generally
be subject to U.S. federal, state and local taxes in the
same manner as cash distributions, stockholders participating in
our dividend reinvestment plan will not receive any
corresponding cash distributions with which to pay any such
applicable taxes.
Current
Borrowings
We, through our wholly-owned subsidiary, Credit I, entered
into the WestLB Facility. Per this agreement, base rate
borrowings bear interest at one-month LIBOR (0.24% as of
September 30, 2011 and 0.26% as of December 31,
2010) plus 2.50%. The rates were 2.74% and 2.76% as of
September 30, 2011 and December 31, 2010,
respectively. We were able to request advances under the WestLB
Facility through March 4, 2011. We may not request new
advances and we must repay the outstanding advances under the
WestLB Facility as of such date and at such times and in such
amounts as are necessary to maintain compliance with the terms
and conditions of the WestLB Facility, particularly the
condition that the principal balance of the WestLB Facility does
not exceed 75% of the aggregate principal balance of our
eligible loans to our portfolio companies. All outstanding
advances under the WestLB Facility are due and payable on
March 4, 2015.
The WestLB Facility is collateralized by all loans and warrants
held by Credit I and permits an advance rate of up to 75% of
eligible loans held by Credit I. The WestLB Facility contains
covenants that, among other things, require the Company to
maintain a minimum net worth and to restrict the loans securing
the WestLB Facility to certain criteria for qualified loans, and
includes portfolio company concentration limits as defined in
the related loan agreement.
We, through our wholly-owned subsidiary, Credit II, entered
into the Wells Facility. Per this agreement, the interest rate
is based upon the one-month LIBOR plus a spread of 4%, with a
LIBOR floor of 1%. The rate was 5% as of September 30, 2011.
We may request advances under the Wells Facility through
July 14, 2014 (the Revolving Period). After the
Revolving Period, we may not request new advances and we must
repay the outstanding advances under the Wells Facility as of
such date, at such times and in such amounts as are necessary to
maintain compliance with the terms and conditions of the Wells
Facility. All outstanding advances under the Wells Facility are
due and payable on July 14, 2017.
The Wells Facility is collateralized by loans held by
Credit II and permits an advance rate of up to 50% of
eligible loans and warrants held by Credit II. The Wells
Facility contains covenants that, among other things, require
the Company to maintain a minimum net worth, to restrict the
loans securing the Wells Facility to certain criteria for
qualified loans and to comply with portfolio company
concentration limits as defined in the related loan agreement.
Interest
Rate Swaps and Hedging Activities
In 2008, we entered into two interest rate swap agreements with
WestLB, fixing the rate of $10 million at 3.58% and
$15 million at 3.2% on the first advances of a like amount
of variable rate WestLB Facility borrowings.
51
As of September 30, 2011, only the $10 million
interest rate swap was still outstanding, which expired in
October 2011.
Contractual
Obligations and Off-Balance Sheet Arrangements
A summary of our significant contractual payment obligations as
of September 30, 2011 is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments due by period
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
More
|
|
|
|
|
|
|
Less than
|
|
|
|
|
|
|
|
|
than 5
|
|
Contractual Obligations
|
|
Total
|
|
|
1 year
|
|
|
1 - 3 years
|
|
|
3 - 5 years
|
|
|
years
|
|
|
Borrowings
|
|
$
|
81,885
|
|
|
$
|
36,278
|
|
|
$
|
45,607
|
|
|
$
|
|
|
|
$
|
|
|
Unfunded commitments
|
|
|
18,667
|
|
|
|
9,834
|
|
|
|
8,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total contractual obligations
|
|
$
|
100,552
|
|
|
$
|
46,112
|
|
|
$
|
54,440
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the normal course of business, we are party to financial
instruments with off-balance sheet risk. These consist primarily
of unfunded commitments to extend credit, in the form of loans,
to our portfolio companies. Unfunded commitments to provide
funds to portfolio companies are not reflected on our balance
sheet. Our unfunded commitments may be significant from time to
time. As of September 30, 2011, we had unfunded commitments
of approximately $18.7 million. These commitments are
subject to the same underwriting and ongoing portfolio
maintenance as are the balance sheet financial instruments that
we hold. Since these commitments may expire without being drawn
upon, the total commitment amount does not necessarily represent
future cash requirements.
In addition to the Credit Facilities, we have certain
commitments pursuant to the Investment Management Agreement
entered into with our Advisor. We have agreed to pay a fee for
investment advisory and management services consisting of two
components a base management fee and an incentive
fee. Payments under the Investment Management Agreement are
equal to (1) a base management fee equal to a percentage of
the value of our average gross assets and (2) a two-part
incentive fee. We have also entered into a contract with our
Advisor to serve as our administrator. Payments under the
Administration Agreement are equal to an amount based upon our
allocable portion of our Advisors overhead in performing
its obligation under the agreement, including rent, fees and
other expenses inclusive of our allocable portion of the
compensation of our chief financial officer and any
administrative staff. See Note 3 to Consolidated Financial
Statements for additional information regarding the Investment
Management Agreement and the Administration Agreement.
Critical
Accounting Policies
The discussion of our financial condition and results of
operation is based upon our financial statements, which have
been prepared in accordance with GAAP. The preparation of these
consolidated financial statements requires management to make
estimates and assumptions that affect the reported amounts of
assets, liabilities, revenues and expenses. Changes in the
economic environment, financial markets and any other parameters
used in determining such estimates could cause actual results to
differ. In addition to the discussion below, we describe our
significant accounting policies in the notes to our consolidated
financial statements.
We have identified the following items as critical accounting
policies.
Valuation
of Investments
Investments are recorded at fair value. Our Board determines the
fair value of our portfolio investments. Prior to our election
to become a BDC, loan investments were stated at current unpaid
principal balances adjusted for the allowance for loan losses,
unearned income and any unamortized deferred fees or costs.
We apply fair value to substantially all of our investments in
accordance with relevant GAAP, which establishes a framework
used to measure fair value and requires disclosures for fair
value measurements. We have categorized our investments carried
at fair value, based on the priority of the valuation technique,
into a three-level fair value hierarchy. Fair value is a
market-based measure considered from the perspective of the
market
52
participant who holds the financial instrument rather than an
entity-specific measure. Therefore, when market assumptions are
not readily available, our own assumptions are set to reflect
those that management believes market participants would use in
pricing the financial instrument at the measurement date.
The availability of observable inputs can vary depending on the
financial instrument and is affected by a wide variety of
factors, including, for example, the type of product, whether
the product is new, whether the product is traded on an active
exchange or in the secondary market and the current market
conditions. To the extent that the valuation is based on models
or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment.
The three categories within the hierarchy are as follows:
|
|
|
|
Level 1
|
Quoted prices in active markets for identical assets and
liabilities.
|
|
|
Level 2
|
Observable inputs other than Level 1 prices such as quoted
prices for similar assets or liabilities in active markets,
quoted prices in markets that are not active and model-based
valuation techniques for which all significant inputs are
observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
|
|
|
Level 3
|
Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the
assets or liabilities. Level 3 assets and liabilities include
financial instruments whose value is determined using pricing
models, discounted cash flow methodologies or similar
techniques, as well as instruments for which the determination
of fair value requires significant management judgment or
estimation.
|
See Note 5 to Consolidated Financial Statements for further
information regarding fair value.
Income
Recognition
Interest on loan investments is accrued and included in income
based on contractual rates applied to principal amounts
outstanding. Interest income is determined using a method that
results in a level rate of return on principal amounts
outstanding. When a loan becomes 90 days or more past due,
or if we otherwise do not expect to receive interest and
principal repayments, the loan is placed on non-accrual status
and the recognition of interest income is discontinued. Interest
payments received on loans that are on non-accrual status are
treated as reductions of principal until the principal is repaid.
We receive a variety of fees from borrowers in the ordinary
course of conducting our business, including advisory fees,
commitment fees, amendment fees, non-utilization fees and
prepayment fees. In a limited number of cases, we may also
receive a non-refundable deposit earned upon the termination of
a transaction. Loan origination fees, net of certain direct
origination costs, are deferred, and along with unearned income,
are amortized as a level yield adjustment over the respective
term of the loan. Fees for counterparty loan commitments with
multiple loans are allocated to each loan based upon each
loans relative fair value. When a loan is placed on
non-accrual status, the amortization of the related fees and
unearned income is discontinued until the loan is returned to
accrual status.
Certain loan agreements also require the borrower to make an
end-of-term
payment that is accrued into income over the life of the loan to
the extent such amounts are expected to be collected. We
generally cease accruing the income if there is insufficient
value to support the accrual or if we do not expect the borrower
to be able to pay all principal and interest due.
In connection with substantially all lending arrangements, we
receive warrants to purchase shares of stock from the borrower.
The warrants are recorded as assets at estimated fair value on
the grant date using the Black-Scholes valuation model. The
warrants are considered loan fees and are also recorded as
unearned loan income on the grant date. The unearned income is
recognized as interest income over the contractual life of the
related loan in accordance with our income recognition policy.
Subsequent to loan origination, the warrants are also measured
at fair value using the Black-Scholes valuation model. Any
adjustment to fair value is recorded through earnings as net
unrealized gain or loss on warrants. Gains from the disposition
of the warrants or stock acquired from the exercise of warrants
are recognized as realized gains on warrants.
53
Allowance
for Loan Losses
Prior to our election to become a BDC, the allowance for loan
losses represented managements estimate of probable loan
losses inherent in the loan portfolio as of the balance sheet
date. The estimation of the allowance was based on a variety of
factors, including past loan loss experience, the current credit
profile of our borrowers, adverse situations that had occurred
that may affect individual borrowers ability to repay, the
estimated value of underlying collateral and general economic
conditions. The loan portfolio is comprised of large balance
loans that are evaluated individually for impairment and are
risk-rated based upon a borrowers individual situation,
current economic conditions, collateral and industry-specific
information that management believes is relevant in determining
the potential occurrence of a loss event and in measuring
impairment. The allowance for loan losses was sensitive to the
risk rating assigned to each of the loans and to corresponding
qualitative loss factors that we used to estimate the allowance.
Those factors were applied to the outstanding loan balances in
estimating the allowance for loan losses. If necessary, based on
performance factors related to specific loans, specific
allowances for loan losses were established for individual
impaired loans. Increases or decreases to the allowance for loan
losses were charged or credited to current period earnings
through the provision (credit) for loan losses. Amounts
determined to be uncollectible were charged against the
allowance for loan losses, while amounts recovered on previously
charged-off loans increased the allowance for loan losses.
A loan was considered impaired when, based on current
information and events, it was probable that we were unable to
collect the scheduled payments of principal or interest when due
according to the contractual terms of the loan agreement.
Factors considered by management in determining impairment
included payment status, collateral value and the probability of
collecting scheduled principal and interest payments when due.
Loans that experienced insignificant payment delays and payment
shortfalls generally were not classified as impaired. Management
determined the significance of payment delays and payment
shortfalls on a
case-by-case
basis, taking into consideration all of the circumstances
surrounding the loan and the borrower, including the length of
the delay, the reasons for the delay, the borrowers prior
payment record and the amount of the shortfall in relation to
the principal and interest owed. Impairment was measured on a
loan by loan basis by either the present value of expected
future cash flows discounted at the loans effective
interest rate, the loans observable market price or the
fair value of the collateral, if the loan was collateral
dependent.
Impaired loans also included loans modified in troubled debt
restructurings where concessions had been granted to borrowers
experiencing financial difficulties. These concessions could
include a reduction in the interest rate on the loan, payment
extensions, forgiveness of principal, forbearance or other
actions intended to maximize collection.
Income
taxes
We have elected to be treated as a RIC under subchapter M of the
Code and to operate in a manner so as to qualify for the tax
treatment applicable to RICs. In order to qualify as a RIC,
among other things, we are required to meet certain source of
income and asset diversification requirements and we must timely
distribute to our stockholders at least 90% of investment
company taxable income, as defined by the Code, for each year.
We, among other things, have made and intend to continue to make
the requisite distributions to our stockholders, which generally
relieves us from U.S. federal income taxes.
Depending on the level of taxable income earned in a tax year,
we may choose to carry forward taxable income in excess of
current year dividend distributions into the next tax year and
pay a 4% excise tax on such income, as required. To the extent
that we determine our estimated current year annual taxable
income will be in excess of estimated current year dividend
distributions, we will accrue excise tax, if any, on estimated
excess taxable income as taxable income is earned. For the nine
months ended September 30, 2011, no amount was recorded for
U.S. federal excise tax.
We evaluate tax positions taken in the course of preparing our
tax returns to determine whether the tax positions are
more-likely-than-not to be sustained by the
applicable tax authority. Tax benefits of positions not deemed
to meet the more-likely-than-not threshold, or uncertain tax
positions, would be recorded as a tax expense in the current
year. It is our policy to recognize accrued interest and
penalties related to uncertain tax benefits in income tax
expense. There were no material uncertain tax positions at
September 30, 2011 and December 31, 2010.
54
Prior to our election to become a BDC, we were a limited
liability company treated as a partnership for U.S. federal
income tax purposes and, as a result, all items of income and
expense were passed through to, and are generally reportable on,
the tax returns of the respective members of the limited
liability company. Therefore, no federal or state income tax
provision has been recorded for the nine months ended
September 30, 2010.
Quantitative
and Qualitative Disclosures about Market Risk
We are subject to financial market risks, including changes in
interest rates. During the periods covered by our financial
statements, the interest rates on the loans within our portfolio
were all at fixed rates and we expect that our loans in the
future will also have primarily fixed interest rates. The
initial commitments to lend to our portfolio companies are
usually based on a floating LIBOR index and typically have
interest rates that are fixed at the time of the loan funding
and remain fixed for the term of the loan.
Assuming that the balance sheet as of September 30, 2011
was to remain constant and no actions were taken to alter the
existing interest rate sensitivity, a hypothetical immediate 1%
change in interest rates may affect net income by more than 1%
over a one-year horizon. Although management believes that this
measure is indicative of our sensitivity to interest rate
changes, it does not adjust for potential changes in the credit
market, credit quality, size and composition of the assets on
the balance sheet and other business developments that could
affect net increase in net assets resulting from operations, or
net income. Accordingly, no assurances can be given that actual
results would not differ materially from the statement above.
The Credit Facilities have floating interest rate provisions
based on a LIBOR index which resets daily, and we expect that
any other credit facilities into which we enter in the future
may have floating interest rate provisions. We have used hedging
instruments in the past to protect us against interest rate
fluctuations and we may use them in the future. Such instruments
may include swaps, futures, options and forward contracts. While
hedging activities may insulate us against adverse changes in
interest rates, they may also limit our ability to participate
in the benefits of lower interest rates with respect to the
investments in our portfolio with fixed interest rates.
Because we currently fund, and will continue to fund, our
investments with borrowings, our net income is dependent upon
the difference between the rate at which we borrow funds and the
rate at which we invest the funds borrowed. Accordingly, there
can be no assurance that a significant change in market interest
rates will not have a material adverse effect on our net income.
In periods of rising interest rates, our cost of funds would
increase, which could reduce our net investment income if there
is not a corresponding increase in interest income generated by
floating rate assets in our investment portfolio.
55
SENIOR
SECURITIES
Information about our senior securities is shown in the
following table as of September 30, 2011, December 31,
2010, December 31, 2009 and December 31, 2008. The
information contained in the table for the years ended
December 31, 2010 and 2009 and the period from
March 4, 2008 (inception) to December 31, 2008 has
been derived from our audited financial statements and the
information contained in the table in respect of
September 30, 2011 has been derived from unaudited
financial data. See Managements Discussion and
Analysis of Financial Condition and Results of
Operations Liquidity and Capital
Resources Current Borrowings for more detailed
information regarding the senior securities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Amount
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding
|
|
|
|
|
|
Involuntary
|
|
|
Average
|
|
|
|
Exclusive of
|
|
|
Asset
|
|
|
Liquidation
|
|
|
Market
|
|
|
|
Treasury
|
|
|
Coverage
|
|
|
Preference
|
|
|
Value
|
|
Class and Year
|
|
Securities(1)
|
|
|
per
Unit(2)
|
|
|
per
Unit(3)
|
|
|
per
Unit(4)
|
|
|
|
(dollar amounts
|
|
|
|
|
|
|
|
|
|
|
|
|
in millions)
|
|
|
|
|
|
|
|
|
|
|
|
Credit Facilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2011 (as of September 30, 2011)
|
|
$
|
81.9
|
|
|
$
|
2,617
|
|
|
|
|
|
|
|
N/A
|
|
2010
|
|
$
|
87.4
|
|
|
$
|
2,455
|
|
|
|
|
|
|
|
N/A
|
|
2009
|
|
$
|
64.2
|
|
|
$
|
1,927
|
|
|
|
|
|
|
|
N/A
|
|
2008
|
|
$
|
63.7
|
|
|
$
|
1,782
|
|
|
|
|
|
|
|
N/A
|
|
|
|
|
(1)
|
|
Total amount of senior securities
outstanding at the end of the period presented.
|
|
(2)
|
|
Asset coverage per unit is the
ratio of the total carrying value of our total consolidated
assets, less all liabilities and indebtedness not represented by
senior securities, to the aggregate amount of senior securities
representing indebtedness. Asset coverage per unit is expressed
in terms of dollar amounts per $1,000 of indebtedness.
|
|
(3)
|
|
The amount of which such class of
senior security would be entitled upon the voluntary liquidation
of the issuer in preference to any security junior to it. The
in this column indicates that the SEC
expressly does not require this information to be disclosed for
certain types of securities.
|
|
(4)
|
|
Not applicable because senior
securities are not registered for public trading.
|
56
BUSINESS
General
We are a specialty finance company that lends to and invests in
development-stage companies in the technology, life science,
healthcare information and services and cleantech industries. We
were formed on March 16, 2010 as a Delaware corporation for
the purpose of acquiring, continuing and expanding the business
of our wholly-owned subsidiary, Compass Horizon and operating as
an externally managed BDC under the 1940 Act. Our investment
objective is to generate current income from the loans we make
and capital appreciation from the warrants we receive when
making such loans. We make secured loans to companies backed by
established venture capital and private equity firms in our
Target Industries. We also selectively lend to publicly-traded
companies in our Target Industries. Venture Lending is typically
characterized by, among other things, (i) the making of a
secured loan after a venture capital or equity investment in the
portfolio company has been made, which investment provides a
source of cash to fund the portfolio companys debt service
obligations under the Venture Loan, (ii) the senior
priority of the Venture Loan which requires repayment of the
Venture Loan prior to the equity investors realizing a return on
their capital, (iii) the relatively rapid amortization of
the Venture Loan, and (iv) the lenders receipt of
warrants or other success fees with the making of the Venture
Loan.
We are an externally managed, closed-end, non-diversified
management investment company that has elected to be regulated
as a BDC under the 1940 Act. As a BDC, we are required to comply
with regulatory requirements, including limitations on our use
of debt. We are permitted to, and expect to, finance our
investments through borrowings. However, as a BDC, we are only
generally allowed to borrow amounts such that our asset
coverage, as defined in the 1940 Act, equals at least 200% after
such borrowing. The amount of leverage that we employ depends on
our assessment of market conditions and other factors at the
time of any proposed borrowing.
We have elected to be treated for federal income tax purposes as
a RIC under Subchapter M of the Code. As a RIC, we generally do
not have to pay corporate-level federal income taxes on any net
ordinary income or capital gains that we distribute to our
stockholders if we meet certain
source-of-income,
distribution, asset diversification and other requirements.
We are externally managed and advised by our Advisor. Our
Advisor manages our
day-to-day
operations and also provides all administrative services
necessary for us to operate.
Our
Portfolio
Since our inception and through September 30, 2011, we have
funded 65 portfolio companies and have invested
$337.9 million in loans (including 28 loans that have been
repaid). As of September 30, 2011, our total investment
portfolio consisted of 37 loans which totaled
$174.4 million and our net assets were $132.4 million.
Our existing loans are secured by all or a portion of the
tangible and intangible assets of the applicable portfolio
company. The loans in our loan portfolio generally are not rated
by any rating agency. For the nine months ended
September 30, 2011, our loan portfolio had a
dollar-weighted average annualized yield of approximately 14.6%
(excluding any yield from warrants). As of September 30,
2011, our loan portfolio had a dollar-weighted average term of
approximately 38 months from inception and a
dollar-weighted average remaining term of approximately
28 months. In addition, we held warrants to purchase either
common stock or preferred stock in 48 portfolio companies. As of
September 30, 2011, our loans had an original committed
principal amount of between $1 million and
$12 million, had repayment terms of between 30 and
48 months and bore current pay interest at annual interest
rates of between 10% and 14%.
Our
Advisor
Our investment activities are managed by our Advisor and we
expect to continue to benefit from our Advisors ability to
identify attractive investment opportunities, conduct diligence
on and value prospective investments, negotiate investments and
manage our diversified portfolio of investments. In addition to
the experience gained from the years that they have worked
together both at our Advisor and prior to the formation by our
Advisor of the Company, the members of our investment team have
broad lending backgrounds, with substantial experience at a
variety of commercial finance companies, technology banks and
private debt funds, and have developed a broad
57
network of contacts within the venture capital and private
equity community. This network of contacts provides a principal
source of investment opportunities.
Our Advisor is led by five senior managers, including its two
co-founders, Robert D. Pomeroy, Jr., our Chief Executive
Officer, and Gerald A. Michaud, our President. The other senior
managers include Christopher M. Mathieu, our Senior Vice
President and Chief Financial Officer, John C. Bombara, our
Senior Vice President, General Counsel and Chief Compliance
Officer, and Daniel S. Devorsetz, our Senior Vice President and
Chief Credit Officer.
Our
Strategy
Our investment objective is to maximize our investment
portfolios total return by generating current income from
the loans we make and capital appreciation from the warrants we
receive when making such loans. To further implement our
business strategy, our Advisor employs the following core
strategies:
|
|
|
|
|
Structured Investments in the Venture Capital and Private
Equity Markets. We make loans to
development-stage companies within our Target Industries
typically in the form of secured amortizing loans. The secured
amortizing debt structure provides a lower risk strategy, as
compared to equity investments, to participate in the emerging
technology markets because the debt structures we typically
utilize provide collateral against the downside risk of loss,
provide return of capital in a much shorter timeframe through
current pay interest and amortization of loan principal and have
a senior position in the capital structure to equity in the case
of insolvency, wind down or bankruptcy. Unlike venture capital
and private equity-backed investments, our investment returns
and return of our capital do not require equity investment exits
such as mergers and acquisitions or initial public offerings.
Instead, we receive returns on our loans primarily through
regularly scheduled payments of principal and interest and, if
necessary, liquidation of the collateral supporting the loan.
Only the potential gains from warrants are dependent upon exits.
|
|
|
|
Enterprise Value Lending. We and our Advisor
take an enterprise value approach to the loan structuring and
underwriting process. We secure a senior or subordinated lien
position against the enterprise value of a portfolio company and
generally our exposure is less than 25% of the enterprise value
and we obtain pricing enhancements in the form of warrants and
other success-based fees that build long-term asset
appreciation in our portfolio. These methods reduce the downside
risk of Venture Lending. Enterprise value lending requires an
in-depth understanding of the companies and markets served. We
believe that this in-depth understanding of how venture capital
and private equity-backed companies in our Target Industries
grow in value, finance that growth over time and various
business cycles can be carefully analyzed by Venture Lenders who
have substantial experience, relationships and knowledge within
the markets they serve. We believe the experience that our
Advisor possesses gives us enhanced capabilities in making these
qualitative enterprise value evaluations, which we believe can
produce a high quality Venture Loan portfolio with enhanced
returns for our stockholders.
|
|
|
|
Creative Products with Attractive Risk-Adjusted
Pricing. Each of our existing and prospective
portfolio companies has its own unique funding needs for the
capital provided from the proceeds of our Venture Loans. These
funding needs include, but are not limited to, funds for
additional development runways, funds to hire or retain sales
staff or funds to invest in research and development in order to
reach important technical milestones in advance of raising
additional equity. Our loans include current pay interest,
commitment fees, pre-payment fees and non-utilization fees. We
believe we have developed pricing tools, structuring techniques
and valuation metrics that satisfy our portfolio companies
requirements while mitigating risk and maximizing returns on our
investments.
|
|
|
|
Opportunity for Enhanced Returns. To enhance
our loan portfolio returns, in addition to interest and fees, we
obtain warrants to purchase the equity of our portfolio
companies as additional consideration for making loans. The
warrants we obtain generally include a cashless
exercise provision to allow us to exercise these rights
without requiring us to make any additional cash investment.
Obtaining warrants in our portfolio companies has allowed us to
participate in the equity appreciation of our portfolio
companies which we expect will enable us to generate higher
returns for our investors.
|
58
|
|
|
|
|
Direct Origination. We originate transactions
directly with technology, life science, healthcare information
and services and cleantech companies. These transactions are
referred to our Advisor from a number of sources, including
referrals from, or direct solicitation of, venture capital and
private equity firms, portfolio company management teams, legal
firms, accounting firms, investment banks and other lenders that
represent companies within our Target Industries. Our Advisor
has been the sole or lead originator in substantially all
transactions in which the funds it manages have invested.
|
|
|
|
Disciplined and Balanced Underwriting and Portfolio
Management. We use a disciplined underwriting
process that includes obtaining information validation from
multiple sources, extensive knowledge of our Target Industries,
comparable industry valuation metrics and sophisticated
financial analysis related to development-stage companies. Our
Advisors due diligence on investment prospects includes
obtaining and evaluating information on the prospective
portfolio companys technology, market opportunity,
management team, fund raising history, investor support,
valuation considerations, financial condition and projections.
We seek to balance our investment portfolio to reduce the risk
of down market cycles associated with any particular industry or
sector, development stage or geographic area. Our Advisor
employs a hands on approach to portfolio management
requiring private portfolio companies to provide monthly
financial information and to participate in regular updates on
performance and future plans.
|
|
|
|
|
|
Use of Leverage. We currently use leverage to
increase returns on equity through revolving credit facilities
provided by WestLB and Wells. See Managements
Discussion and Analysis of Financial Condition and Results of
Operations Liquidity and Capital Resources. In
addition, we may issue debt securities in one or more series or
preferred stock in the future. The specific terms of each series
of debt securities we publicly offer will be described in the
particular prospectus supplement relating to that series and the
particular terms of any preferred stock we offer will be
described in the prospectus supplement relating to such
preferred shares. See Description of Debt Securities that
We May Issue and Description of Preferred Stock that
We May Issue for additional information about the debt
securities and preferred stock we may issue.
|
|
|
|
|
|
Customized Loan Documentation Process. Our
Advisor employs an internally managed documentation process that
assures that each loan transaction is documented using our
enterprise value loan documents specifically
tailored to each transaction. Our Advisor uses experienced
in-house senior legal counsel to oversee the documentation and
negotiation of each of our transactions.
|
|
|
|
Active Portfolio Management. Because many of
our portfolio companies are privately held, development-stage
companies in our Target Industries, our Advisor employs a
hands on approach to its portfolio management
processes and procedures. Our Advisor requires the private
portfolio companies to provide monthly financial information,
and our Advisor participates in quarterly discussions with the
management and investors of our portfolio companies. Our Advisor
prepares monthly management reporting and internally rates each
portfolio company.
|
|
|
|
Portfolio Composition. Monitoring the
composition of the portfolio is an important component of the
overall growth and portfolio management strategy. Our Advisor
monitors the portfolio regularly to avoid undue focus in any
sub-industry,
stage of development or geographic area. By regularly monitoring
the portfolio for these factors we attempt to reduce the risk of
down market cycles associated with any particular industry,
development stage or geographic area.
|
Market
Opportunity
We focus our investments primarily in four key industries of the
emerging technology market: technology, life science, healthcare
information and services and cleantech. The technology sectors
we focus on include communications, networking, wireless
communications, data storage, software, cloud computing,
semiconductor, internet and media and consumer-related
technologies. The life science sectors we focus on include
biotechnology, drug delivery, bioinformatics and medical
devices. The healthcare information and services sectors we
focus on include diagnostics, medical record services and
software and other healthcare related services and technologies
that improve efficiency and quality of administered healthcare.
The cleantech sectors we focus on include alternative energy,
water purification, energy efficiency, green building materials
and waste recycling.
59
We believe that Venture Lending has the potential to achieve
enhanced returns that are attractive notwithstanding the high
degree of risk associated with lending to development-stage
companies. Potential benefits include:
|
|
|
|
|
Higher Interest Rates. Venture Loans typically
bear interest at rates that exceed the rates that would be
available to portfolio companies if they could borrow in
traditional commercial financing transactions. We believe these
rates provide a risk-adjusted return to lenders compared with
other types of debt investing and provide a significantly less
expensive alternative to equity financing for development-stage
companies.
|
|
|
|
Loan Support Provided by Cash Proceeds from Equity Capital
Provided by Venture Capital and Private Equity
Firms. In many cases, a Venture Lender makes a
Venture Loan to a portfolio company in conjunction with, or
immediately after, a substantial venture capital or private
equity investment in the portfolio company. This equity capital
investment supports the loan by initially providing a source of
cash to fund the portfolio companys debt service
obligations. In addition, because the loan ranks senior in
priority of payment to the equity capital investment, the
portfolio company must repay that debt before the equity capital
investors realize a return on their investment. If the portfolio
company subsequently becomes distressed, its venture capital and
private equity investors will likely have an incentive to assist
it in avoiding a payment default, which could lead to
foreclosure on the secured assets. We believe that the support
of venture capital and private equity investors increases the
likelihood that a Venture Loan will be repaid.
|
|
|
|
Relatively Rapid Amortization of
Loans. Venture Loans typically require that
interest payments begin within one month of closing, and
principal payments begin within twelve months of closing,
thereby returning capital to the lender and reducing the capital
at risk with respect to the investment. Because Venture Loans
are typically made at the time of, or soon after, a portfolio
company completes a significant venture capital or private
equity financing, the portfolio company usually has sufficient
funds to begin making scheduled principal and interest payments
even if it is not then generating revenue
and/or
positive cash flow. If a portfolio company is able to increase
its enterprise value during the term of the loan
(which is typically between 24 and 48 months), the lender
may also benefit from a reduced
loan-to-value
ratio, which reduces the risk of the loan.
|
|
|
|
Senior Ranking to Equity and
Collateralization. A Venture Loan is typically
secured by some or all of the portfolio companys assets,
thus making the loan senior in priority to the equity invested
in the portfolio company. In many cases, if a portfolio company
defaults on its loan, the value of this collateral will provide
the lender with an opportunity to recover all or a portion of
its investment. Because holders of equity interests in a
portfolio company will generally lose their investments before
the Venture Lender experiences losses, we believe that the
likelihood of losing all of our invested capital in a Venture
Loan is lower than would be the case with an equity investment.
|
|
|
|
Potential Equity Appreciation Through
Warrants. Venture Lenders are typically granted
warrants in portfolio companies as additional consideration for
making Venture Loans. The warrants permit the Venture Lender to
purchase equity securities of the portfolio companies at the
same price paid by the portfolio companys investors for
such preferred stock in the most recent or next equity round of
the portfolio companys financing. Historically, warrants
granted to Venture Lenders have generally had a term of ten
years and been in dollar amounts equal to between 5% and 20% of
the principal loan amount. Warrants provide Venture Lenders with
an opportunity to participate in the potential growth in value
of the portfolio company, thereby increasing the potential
return on investment.
|
We believe that Venture Lending also provides an attractive
financing source for portfolio companies, their management teams
and their equity capital investors, because of the following:
|
|
|
|
|
Venture Loans are Typically Less Dilutive than Venture
Capital and Private Equity Financing. Venture
Loans allow a company to access the cash necessary to implement
its business plan without diluting the existing investors in the
company. Typically, the warrants or other equity securities
issued as part of a Venture Lending transaction result in only
minimal dilution to existing investors as compared to the
potential dilution of a new equity round of financing.
|
60
|
|
|
|
|
Venture Loans Extend the Time Period During Which a Portfolio
Company Can Operate Before Seeking Additional Equity
Financing. By using a Venture Loan,
development-stage companies can postpone the need for their next
round of equity financing, thereby extending their cash
available to fund operations. This delay can provide portfolio
companies with additional time to improve technology, achieve
development milestones and, potentially, increase the
companys valuation before seeking more equity investments.
|
|
|
|
Venture Loans Allow Portfolio Companies to Better Match Cash
Sources with Uses. Debt is often used to fund
infrastructure costs, including office space and laboratory
equipment. The use of debt to fund infrastructure costs allows a
portfolio company to spread these costs over time, thereby
conserving cash at a stage when its revenues may not be
sufficient to cover expenses. Similarly, working capital
financing may be used to fund selling and administrative
expenses ahead of anticipated corresponding revenue. In both
instances, equity capital is preserved for research and
development expenses or future expansion.
|
Competitive
Strengths
We believe that we, together with our Advisor, possess
significant competitive strengths, including:
|
|
|
|
|
Consistently Execute Commitments and Close
Transactions. Our Advisor and its senior
management and investment professionals have an extensive track
record of originating, underwriting and closing Venture Loans.
Our Advisor has directly originated, underwritten and managed
more than 130 Venture Loans with an aggregate original principal
amount over $800 million since it commenced operations in
2004. In our experience, prospective portfolio companies prefer
lenders that have demonstrated their ability to deliver on their
commitments.
|
|
|
|
Robust Direct Origination Capabilities. Our
Advisors managing directors each have significant
experience originating Venture Loans in our Target Industries.
This experience has given each managing director a deep
knowledge of our Target Industries and an extensive base of
transaction sources and references. Our Advisors brand
name recognition in our market has resulted in a steady flow of
high quality investment opportunities that are consistent with
the strategic vision and expectations of our Advisors
senior management.
|
|
|
|
Highly Experienced and Cohesive Management
Team. Our Advisor has had the same senior
management team of experienced professionals since its
inception. This consistency allows companies, their management
teams and their investors to rely on consistent and predictable
service, loan products and terms and underwriting standards.
|
|
|
|
Relationships with Venture Capital and Private Equity
Investors. Our Advisor has developed strong
relationships with venture capital and private equity firms and
their partners. The strength and breadth of our Advisors
venture capital and private equity relationships would take
considerable time and expense to develop.
|
|
|
|
Well-Known Brand Name. Our Advisor has
originated Venture Loans to more than 130 companies in our
Target Industries under the Horizon Technology
Finance brand. Each of these companies is backed by one or
more venture capital or private equity firms. We believe that
the Horizon Technology Finance brand, as a
competent, knowledgeable and active participant in the Venture
Lending marketplace, will continue to result in a significant
number of referrals and prospective investment opportunities in
our Target Industries.
|
61
Stages of
Development of Venture Capital and Private Equity-backed
Companies
Below is a typical development curve for a company in our Target
Industries and the various milestones along the development
curve where we believe a Venture Loan may be a preferred
financing solution:
Investment
Criteria
We make investments in companies that are diversified by their
stage of development, their Target Industries and sectors of
Target Industries and their geographical location, as well as by
the venture capital and private equity sponsors that support our
portfolio companies. While we invest in companies at various
stages of development, we require that prospective portfolio
companies be beyond the seed stage of development and have
received at least their first round of venture capital or
private equity financing. We expect a prospective portfolio
company to demonstrate its ability to advance technology and
increase its value over time.
We have identified several criteria that we believe have proven,
and will prove, important in achieving our investment objective.
These criteria provide general guidelines for our investment
decisions. However, we caution you that not all of these
criteria are met by each portfolio company in which we choose to
invest.
Management. Our portfolio companies are
generally led by experienced management that has in-market
expertise in the Target Industry in which the company operates,
as well as extensive experience with development-stage
companies. The adequacy and completeness of the management team
is assessed relative to the stage of development and the
challenges facing the potential portfolio company.
Continuing Support from One or More Venture Capital and
Private Equity Investors. We typically invest in
companies in which one or more established venture capital and
private equity investors have previously invested and continue
to make a contribution to the management of the business. We
believe that established venture capital and private equity
investors can serve as a committed partner and will assist their
portfolio companies and their management teams in creating
value. We take into consideration the total amount raised by the
company, the valuation history, investor reserves for future
investment and the expected timing and milestones to the next
equity round financing.
Operating Plan and Cash Resources. We
generally require that a prospective portfolio company, in
addition to having sufficient access to capital to support
leverage, demonstrate an operating plan capable of generating
cash flows or the ability to raise the additional capital
necessary to cover its operating expenses and service its debt.
Our
62
review of the operating plan will take into consideration
existing cash, cash burn, cash runway and the milestones
necessary for the company to achieve cash flow positive
operations or to access additional equity from the investors.
Enterprise and Technology Value. We expect
that the enterprise value of a prospective portfolio company
should substantially exceed the principal balance of debt
borrowed by the company. Enterprise value includes the implied
valuation based upon recent equity capital invested as well as
the intrinsic value of the companys unique technology,
service or customer base.
Market Opportunity and Exit Strategy. We seek
portfolio companies that are addressing large market
opportunities that capitalize on their competitive advantages.
Competitive advantages may include unique technology, protected
intellectual property, superior clinical results or significant
market traction. As part of our investment analysis, we will
consider potential realization of our warrants through merger,
acquisition or initial public offering based upon comparable
exits in the companys Target Industry.
Investment
Process
Our Advisor has created an integrated approach to the loan
origination, underwriting, approval and documentation process
that effectively combines all of the skills of our
Advisors professionals. This process allows our Advisor to
achieve an efficient and timely closing of an investment from
the initial contact with a prospective portfolio company through
the investment decision, close of documentation and funding of
the investment, while ensuring that our Advisors rigorous
underwriting standards are consistently maintained. Our Board
has delegated authority for all investment decisions to our
Advisor. We believe that the high level of involvement by our
Advisors staff in the various phases of the investment
process allows us to minimize the credit risk while delivering
superior service to our portfolio companies.
Origination. Our Advisors loan
origination process begins with its industry-focused regional
managing directors who are responsible for identifying,
contacting and screening prospects. The managing directors meet
with key decision makers and deal referral sources such as
venture capital and private equity firms and management teams,
legal firms, accounting firms, investment banks and other
lenders to source prospective portfolio companies. We believe
our brand name and management team are well known within the
Venture Lending community, as well as by many repeat
entrepreneurs and board members of prospective portfolio
companies. These broad relationships, which reach across the
Venture Lending industry, give rise to a significant portion of
our Advisors deal origination.
The responsible managing director of our Advisor obtains review
materials from the prospective portfolio company and from those
materials, as well as other available information, determines
whether it is appropriate for our Advisor to issue a non-binding
term sheet. The managing director bases this decision to proceed
on his or her experience, the competitive environment and the
prospective portfolio companys needs and also seeks the
counsel of our Advisors senior management and investment
team.
Term Sheet. If the managing director
determines, after review and consultation with senior
management, that the potential transaction meets our
Advisors initial credit standards, our Advisor will issue
a non-binding term sheet to the prospective portfolio company.
The terms of the transaction are tailored to a prospective
portfolio companys specific funding needs while taking
into consideration market dynamics, the quality of the
management team, the venture capital and private equity
investors involved and applicable credit criteria, which may
include the prospective portfolio companys existing cash
resources, the development of its technology and the anticipated
timing for the next round of equity financing.
Underwriting. Once the term sheet has been
negotiated and executed and the prospective portfolio company
has remitted a good faith deposit, we request additional due
diligence materials from the prospective portfolio company and
arrange for a due diligence visit.
Due Diligence. The due diligence process
includes a formal visit to the prospective portfolio
companys location and interviews with the prospective
portfolio companys senior management team including its
Chief Executive Officer, Chief Financial Officer, Chief
Scientific or Technology Officer, principal marketing or sales
professional and other key managers. The process includes
contact with key analysts that affect the prospective
63
portfolio companys business, including analysts that
follow the technology market, through leaders in our Target
Industries and important customers or partners, if any. Outside
sources of information are reviewed, including industry
publications, scientific and market articles, Internet
publications, publicly available information on competitors or
competing technologies and information known to our
Advisors investment team from their experience in the
technology markets.
A key element of the due diligence process is interviewing key
existing investors in the prospective portfolio company, who are
often also members of the prospective portfolio companys
board of directors. While these board members
and/or
investors are not independent sources of information, their
support for management and willingness to support the
prospective portfolio companys further development are
critical elements of our decision making process.
Investment Memorandum. Upon completion of the
due diligence process and review and analysis of all of the
information provided by the prospective portfolio company and
obtained externally, our Advisors assigned credit officer
prepares an investment memorandum for review and approval. The
investment memorandum is reviewed by our Advisors Chief
Credit Officer and submitted to our Advisors investment
committee for approval.
Investment Committee. Our Board delegates
authority for all investment decisions to our Advisors
investment committee.
Our Advisors investment committee is responsible for
overall credit policy, portfolio management, approval of all
investments, portfolio monitoring and reporting and managing of
problem accounts. The committee interacts with the entire staff
of our Advisor to review potential transactions and deal flow.
This interaction of cross-functional members of our
Advisors staff assures efficient transaction sourcing,
negotiating and underwriting throughout the transaction process.
Portfolio performance and current market conditions are reviewed
and discussed by the investment committee on a regular basis to
assure that transaction structures and terms are consistent and
current.
Loan Closing and Funding. Approved investments
are documented and closed by our Advisors in-house legal
and loan administration staff. Loan documentation is based upon
standard templates created by our Advisor and is customized for
each transaction to reflect the specific deal terms. The
transaction documents typically include a loan and security
agreement, warrant agreement and applicable perfection
documents, including Uniform Commercial Code financing
statements, and, as applicable, may also include a landlord
agreement, patent and trademark security grants, a subordination
agreement and other standard agreements for commercial loans in
the Venture Lending industry. Funding requires final approval by
our Advisors General Counsel, Chief Executive Officer or
President, Chief Financial Officer and Chief Credit Officer.
Portfolio Management and Reporting. Our
Advisor maintains a hands on approach to maintain
communication with our portfolio companies. At least quarterly,
our Advisor contacts our portfolio companies for operational and
financial updates by phone and performs reviews on an annual
basis. Our Advisor may contact portfolio companies deemed to
have greater credit risk on a monthly basis. Our Advisor
requires all private companies to provide financial statements
on a monthly basis. For public companies, our Advisor typically
relies on publicly reported quarterly financials. Our Advisor
also typically receives copies of bank and security statements,
as well as any other information required to verify reported
financial information. Among other things, this allows our
Advisor to identify any unexpected developments in the financial
performance or condition of the portfolio company.
Our Advisor has developed a proprietary credit rating system to
analyze the quality of our loans. Using this system, our Advisor
analyzes and then rates the credit risk within the portfolio on
a monthly basis. Each portfolio company is rated on a 1 through
4 scale, with 3 representing the rating for a standard level of
risk. A rating of 4 represents an improved and better credit
quality. A rating of 2 or 1 represents a deteriorating credit
quality and increasing risk. Newly funded investments are
typically assigned a rating of 3, unless extraordinary
circumstances require otherwise. These investment ratings are
generated internally by our Advisor, and we cannot guarantee
that others would assign the same ratings to our portfolio
investments or similar portfolio investments.
Our Advisor closely monitors portfolio companies rated a 1 or 2
for adverse developments. In addition, our Advisor has regular
contact with the management, board of directors and major equity
holders of these portfolio
64
companies in order to discuss strategic initiatives to correct
the deterioration of the portfolio company (e.g., cost
reductions, new equity issuance or strategic sale of the
business).
The table below describes each rating level:
|
|
|
Rating
|
|
|
|
4
|
|
The portfolio company has performed in excess of our
expectations at underwriting as demonstrated by exceeding
revenue milestones, clinical milestones or other operating
metrics or as a result of raising capital well in excess of our
underwriting assumptions. Generally the portfolio company
displays one or more of the following: its enterprise value
greatly exceeds our loan balance; it has achieved cash flow
positive operations or has sufficient cash resources to cover
the remaining balance of the loan; there is strong potential for
warrant gains from our warrants; and there is a high likelihood
that the borrower will receive favorable future financing to
support operations. Loans rated 4 are the lowest risk profile in
our portfolio and there is no expected risk of principal loss.
|
3
|
|
The portfolio company has performed to our expectations at
underwriting as demonstrated by hitting revenue milestones,
clinical milestones or other operating metrics. It has raised,
or is expected to raise, capital consistent with our
underwriting assumptions. Generally the portfolio company
displays one or more of the following: its enterprise value
comfortably exceeds our loan balance; it has sufficient cash
resources to operate per its plan; it is expected to raise
additional capital as needed; and there continues to be
potential for warrant gains from our warrants. All new loans are
rated 3 when approved and thereafter 3 rated loans represent a
standard risk profile, with no loss currently expected.
|
2
|
|
The portfolio company has performed below our expectations at
underwriting as demonstrated by missing revenue milestones,
delayed clinical progress or otherwise failing to meet projected
operating metrics. It may have raised capital in support of the
poorer performance but generally on less favorable terms than
originally contemplated at the time of underwriting. Generally
the portfolio company displays one or more of the following: its
enterprise value exceeds our loan balance but at a lower
multiple than originally expected; it has sufficient cash to
operate per its plan but liquidity may be tight; and it is
planning to raise additional capital but there is uncertainty
and the potential for warrant gains from our warrants are
possible, but unlikely. Loans rated 2 represent an increased
level of risk. While no loss is currently anticipated for a 2
rated loan, there is potential for future loss of principal.
|
1
|
|
The portfolio company has performed well below plan as
demonstrated by materially missing revenue milestones, delayed
or failed clinical progress or otherwise failing to meet
operating metrics. The portfolio company has not raised
sufficient capital to operate effectively or retire its debt
obligation to us. Generally the portfolio company displays one
or more of the following: its enterprise value may not exceed
our loan balance; it has insufficient cash to operate per its
plan and liquidity may be tight; and there are uncertain plans
to raise additional capital or the portfolio company is being
sold under distressed conditions. There is no potential for
warrant gains from our warrants. Loans rated 1 are generally put
on non-accrual and represent a high degree of risk of loss. The
fair value of 1 rated loans is reduced to the amount that is
expected to be recovered from liquidation of the collateral.
|
For a discussion of the ratings of our existing portfolio, see
Managements Discussion and Analysis of Financial
Condition and Results of Operations Loan Portfolio
Asset Quality.
Managerial
Assistance
As a BDC, we offer, through our Advisor, and must provide upon
request, managerial assistance to certain of our portfolio
companies. This assistance may involve, among other things,
monitoring the operations of the portfolio companies,
participating in board of directors and management meetings,
consulting with and advising officers of portfolio companies and
providing other organizational and financial guidance.
We may receive fees for these services, though we may reimburse
our Advisor for its expenses related to providing such services
on our behalf.
65
Competition
We compete for investments with a number of investment funds and
other BDCs, as well as traditional financial services companies
such as commercial banks and other financing sources. Some of
our competitors are larger and have greater financial and other
resources than we do. We believe we compete effectively with
these entities primarily on the basis of the experience,
industry knowledge and contacts of our Advisors investment
professionals, its responsiveness and efficient investment
analysis and decision-making processes, its creative financing
products and its customized investment terms. We do not intend
to compete primarily on the interest rates we offer and believe
that some competitors make loans with rates that are comparable
or lower than our rates. For additional information concerning
the competitive risks see Risk Factors Risks
Related to Our Business and Structure We operate in
a highly competitive market for investment opportunities, and if
we are not able to compete effectively, our business, results of
operations and financial condition may be adversely affected and
the value of your investment in us could decline.
Employees
We do not have any employees. Each of our executive officers
described under Management is an employee of our
Advisor. The
day-to-day
investment operations are managed by our Advisor. As of
September 30, 2011, our Advisor had 16 employees,
including investment and portfolio management professionals,
operations and accounting professionals, legal counsel and
administrative staff. In addition, we reimburse our Advisor for
our allocable portion of expenses incurred by it in performing
its obligations under the Administration Agreement, including
our allocable portion of the cost of our Chief Financial Officer
and Chief Compliance Officer and their respective staffs.
Properties
We do not own any real estate or other physical properties
materially important to our operation. Our headquarters and our
Advisors headquarters are currently located at 312
Farmington Avenue, Farmington, Connecticut 06032. We believe
that our office facilities are suitable and adequate to our
business.
Legal
Proceedings
Neither we nor our Advisor are currently subject to any material
legal proceedings.
66
PORTFOLIO
COMPANIES
The following table sets forth certain information as of
September 30, 2011 for each portfolio company in which we
had a debt or equity investment. Other than these investments,
our only relationships with our portfolio companies involve the
managerial assistance we may separately provide to our portfolio
companies, such services being ancillary to our investments, and
the board observer or participation rights we may receive in
connection with our investment. We do not control
and are not an affiliate of any of our portfolio
companies, each as defined in the 1940 Act. In general, under
the 1940 Act, we would control a portfolio company
if we owned more than 25% of its voting securities and would be
an affiliate of a portfolio company if we owned 5%
or more of its voting securities.
The following table sets forth certain information for each
portfolio company in which we had an investment as of
September 30, 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
Debt Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Life Science
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACT Biotech Corporation
717 Market Street, Suite 650
San Francisco, CA 94103
|
|
Biotechnology
|
|
Term Loan(1)
Term
Loan(1)
Term
Loan(1)
|
|
13.10%
13.01%
13.01%
|
|
$
|
12/1/2013
12/1/2013
12/1/2013
|
|
|
$
|
913
913
1,410
|
|
|
$
|
905
905
1,371
|
|
|
|
905
905
1,371
|
|
Ambit Biosciences Corporation
4215 Sorrento Valley Blvd.
San Diego, CA 92121
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
12.25%
|
|
|
10/1/2013
|
|
|
|
5,123
|
|
|
|
5,066
|
|
|
|
5,066
|
|
Anacor Pharmaceuticals,
Inc.(5)
1020 East Meadow Circle
Palo Alto, CA 94303
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
9.41%
|
|
|
4/1/2015
|
|
|
|
3,333
|
|
|
|
3,206
|
|
|
|
3,206
|
|
GenturaDx, Inc.
24590 Clawiter Road
Hayward, CA 94545
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
11.25%
|
|
|
4/1/2014
|
|
|
|
2,000
|
|
|
|
1,903
|
|
|
|
1,903
|
|
N30 Pharmaceuticals, LLC
3122 Sterling Circle, Suite 200
Boulder, CO 80301
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
11.25%
|
|
|
9/1/2014
|
|
|
|
2,500
|
|
|
|
2,412
|
|
|
|
2,412
|
|
Pharmasset,
Inc.(5)
303-A
College Road East
Princeton, NJ 08540
|
|
Biotechnology
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.00%
12.50%
|
|
|
1/1/2012
10/1/2012
|
|
|
|
380
1,459
|
|
|
|
379
1,453
|
|
|
|
379
1,453
|
|
Revance Therapeutics, Inc.
7555 Gateway Blvd.
Newark, CA 94560
|
|
Biotechnology
|
|
Convertible
Note(1)
|
|
8.00%
|
|
|
2/10/2013
|
|
|
|
62
|
|
|
|
62
|
|
|
|
62
|
|
Supernus Pharmaceuticals, Inc.
1550 East Gude Drive
Rockville, MD 20850
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
11.00%
|
|
|
8/1/2014
|
|
|
|
3,000
|
|
|
|
2,947
|
|
|
|
2,947
|
|
Tranzyme,
Inc.(5)
4819 Emperor Blvd., Suite 400
Durham, NC 27703
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
10.75%
|
|
|
1/1/2014
|
|
|
|
4,558
|
|
|
|
4,538
|
|
|
|
4,538
|
|
Xcovery Holding Company, LLC
505 S. Flagler Drive, Suite 1330
West Palm Beach, FL 33401
|
|
Biotechnology
|
|
Term Loan(2)
Term
Loan(2)
|
|
12.00%
12.00%
|
|
|
10/1/2013
7/1/2014
|
|
|
|
1,500
1,500
|
|
|
|
1,494
1,477
|
|
|
|
1,494
1,477
|
|
Concentric Medical, Inc.
301 East Evelyn Avenue
Mountain View, CA 94041
|
|
Medical Device
|
|
Term
Loan(1)
|
|
12.04%
|
|
|
9/1/2013
|
|
|
|
6,741
|
|
|
|
6,676
|
|
|
|
6,676
|
|
OraMetrix, Inc.
2350 Campbell Creek Blvd., Suite 400
Richardson, TX 75082
|
|
Medical Device
|
|
Term
Loan(1)
|
|
11.50%
|
|
|
4/1/2014
|
|
|
|
4,740
|
|
|
|
4,669
|
|
|
|
4,669
|
|
PixelOptics, Inc.
5241 Valleypark Drive
Roanoke, VA 24019
|
|
Medical Device
|
|
Term
Loan(2)
|
|
10.75%
|
|
|
11/1/2014
|
|
|
|
10,000
|
|
|
|
9,910
|
|
|
|
9,910
|
|
Tengion,
Inc.(5)
2900 Potshop Lane, Suite 100
East Norriton, PA 19403
|
|
Medical Device
|
|
Term
Loan(2)
|
|
11.75%
|
|
|
1/1/2014
|
|
|
|
5,000
|
|
|
|
4,948
|
|
|
|
4,588
|
|
ViOptix, Inc.
47224 Misson Fall Ct.
Fremont, CA 94539
|
|
Medical Device
|
|
Term
Loan(1)
|
|
13.55%
|
|
|
11/1/2011
|
|
|
|
657
|
|
|
|
656
|
|
|
|
656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Life Science
|
|
|
55,789
|
|
|
|
54,977
|
|
|
|
54,617
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
Debt Investments Technology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OpenPeak, Inc.
1750 Clint Moore Road
Boca Raton, FL 33487
|
|
Communications
|
|
Term
Loan(1)
|
|
11.86%
|
|
$
|
12/1/2013
|
|
|
$
|
6,085
|
|
|
$
|
6,016
|
|
|
|
5,647
|
|
Starcite, Inc.
1600 Market Street, 27th Floor
Philadelphia, PA 19103
|
|
Consumer-related
Technologies
|
|
Term
Loan(1)
|
|
12.05%
|
|
|
9/1/2012
|
|
|
|
1,609
|
|
|
|
1,604
|
|
|
|
1,604
|
|
Tagged, Inc.
840 Battery Street, 2nd Floor
San Francisco, CA 94111
|
|
Consumer-related
Technologies
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.78%
11.46%
|
|
|
5/1/2012
8/1/2012
|
|
|
|
672
300
|
|
|
|
671
300
|
|
|
|
671
300
|
|
Xtera Communications, Inc.
500 W. Bethany Drive, Suite 100
Allen, TX 75013
|
|
Semiconductors
|
|
Term
Loan(2)
|
|
11.50%
|
|
|
12/1/2014
|
|
|
|
10,000
|
|
|
|
9,739
|
|
|
|
9,739
|
|
Vette Corp.
14 Manchester Square, Suite 210
Portsmouth, NH 03801
|
|
Data Storage
|
|
Term
Loan(1)
|
|
11.75%
|
|
|
7/1/2014
|
|
|
|
5,000
|
|
|
|
4,928
|
|
|
|
4,928
|
|
IntelePeer, Inc.
2855 Campus Drive, Suite 200
San Mateo, CA 94403
|
|
Networking
|
|
Term Loan(1)
Term
Loan(1)
Term
Loan(1)
|
|
12.43%
12.33%
12.33%
|
|
|
4/1/2012
6/1/2012
10/1/2012
|
|
|
|
240
316
733
|
|
|
|
238
315
729
|
|
|
|
238
315
729
|
|
Construction Software Technologies, Inc.
4500 Lake Forest Drive, Suite 502
Cincinnati, OH 45202
|
|
Software
|
|
Term Loan(2)
Term Loan
|
|
11.75%
11.75%
|
|
|
12/1/2014
6/1/2014
|
|
|
|
4,000
2,000
|
|
|
|
3,940
1,969
|
|
|
|
3,940
1,969
|
|
Courion Corporation
1900 West Park Drive, 1st Floor
Westborough, MA 01581
|
|
Software
|
|
Term
Loan(1)
|
|
11.45%
|
|
|
9/1/2014
|
|
|
|
7,000
|
|
|
|
6,889
|
|
|
|
6,889
|
|
Recondo Technology, Inc.
6312 South Fiddlers Green Cir.,
Suite 600 East
Greenwood Village, CO 80111
|
|
Software
|
|
Term Loan
|
|
11.50%
|
|
|
4/1/2015
|
|
|
|
2,000
|
|
|
|
1,923
|
|
|
|
1,923
|
|
Seapass Solutions, Inc.
90 Park Avenue, Suite 1720
New York, NY 10016
|
|
Software
|
|
Term
Loan(2)
|
|
11.75%
|
|
|
11/1/2014
|
|
|
|
5,000
|
|
|
|
4,924
|
|
|
|
4,924
|
|
StreamBase Systems, Inc.
181 Spring Street
Lexington, MA 02421
|
|
Software
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.51%
12.50%
|
|
|
11/1/2013
6/1/2014
|
|
|
|
3,152
974
|
|
|
|
3,115
960
|
|
|
|
3,115
960
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Technology
|
|
|
49,081
|
|
|
|
48,260
|
|
|
|
47,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Cleantech
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(5)
300 North Continental Blvd., Suite 100
El Segundo, CA 90245
|
|
Waste Recycling
Waste Recycling
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.00%
12.00%
|
|
|
4/1/2014
6/1/2014
|
|
|
|
2,500
2,500
|
|
|
|
2,448
2,441
|
|
|
|
2,448
2,441
|
|
Enphase Energy, Inc.
201 1st Street, Suite 300
Petaluma, CA 94952
|
|
Energy Efficiency
|
|
Term Loan(1)
Term Loan
Term Loan
|
|
12.60%
10.75%
10.75%
|
|
|
10/1/2013
4/1/2015
4/1/2015
|
|
|
|
5,770
2,000
3,000
|
|
|
|
5,697
1,968
2,938
|
|
|
|
5,697
1,968
2,938
|
|
Satcon Technology
Corporation(5)
27 Drydock Avenue
Boston, MA 02210
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
12.58%
|
|
|
1/1/2014
|
|
|
|
8,697
|
|
|
|
8,521
|
|
|
|
8,521
|
|
Tigo Energy, Inc.
420 Blossom Hill Road
Los Gatos, CA 95032
|
|
Energy Efficiency
|
|
Term Loan(1)
Revolver(2)
|
|
11.00%
10.75%
(Prime + 7.50)%
|
|
|
8/1/2014
1/1/2014
|
|
|
|
3,500
3,000
|
|
|
|
3,422
2,933
|
|
|
|
3,422
2,933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Cleantech
|
|
|
30,967
|
|
|
|
30,368
|
|
|
|
30,368
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Healthcare information and
services
|
BioScale, Inc.
4 Maguire Road
Lexington, MA 02421
|
|
Diagnostics
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.00%
11.51%
|
|
|
8/1/2012
1/1/2014
|
|
|
|
1,354
5,000
|
|
|
|
1,351
4,941
|
|
|
|
1,351
4,941
|
|
Precision Therapeutics, Inc.
2516 Jane Street
Pittsburgh, PA 15203
|
|
Diagnostics
|
|
Term Loan
|
|
10.25%
|
|
|
12/1/2014
|
|
|
|
7,000
|
|
|
|
6,952
|
|
|
|
6,952
|
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
Radisphere National Radiology Group, Inc.
23625 Commerce Park, Suite 204
Beachwood, OH 44122
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
12.75%
|
|
$
|
1/1/2014
|
|
|
$
|
9,427
|
|
|
$
|
9,340
|
|
|
|
9,340
|
|
Aperio Technologies, Inc.
1360 Park Center Drive
Vista, CA 92081
|
|
Other Healthcare
|
|
Term Loan
|
|
9.64%
|
|
|
5/1/2015
|
|
|
|
5,000
|
|
|
|
4,929
|
|
|
|
4,929
|
|
Patientkeeper, Inc.
880 Winter Street, Suite 300
Waltham, MA 02451
|
|
Other Healthcare
|
|
Term Loan
|
|
10.50%
|
|
|
12/1/2014
|
|
|
|
5,500
|
|
|
|
5,222
|
|
|
|
5,222
|
|
Singulex, Inc.
1650 Harbor Bay Parkway, Suite 200
Alameda, CA 94502
|
|
Other Healthcare
|
|
Term Loan(1)
Term
Loan(1)
|
|
11.00%
11.00%
|
|
|
3/1/2014
3/1/2014
|
|
|
|
3,000
2,000
|
|
|
|
2,968
1,978
|
|
|
|
2,968
1,978
|
|
Talyst, Inc.
11100 NE 8th Street, Suite 600
Bellevue, WA 98004
|
|
Other Healthcare
|
|
Term Loan(1)
Term
Loan(1)
|
|
12.10%
12.05%
|
|
|
12/1/2013
12/1/2013
|
|
|
|
1,957
1,957
|
|
|
|
1,924
1,921
|
|
|
|
1,924
1,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investment Healthcare information and
services
|
|
|
42,195
|
|
|
|
41,526
|
|
|
|
41,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments
|
|
|
178,032
|
|
|
|
175,131
|
|
|
|
174,402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Life Science
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ACT Biotech Corporation
717 Market Street, Suite 650
San Francisco, CA 94103
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
58
|
|
|
|
67
|
|
Ambit Biosciences, Inc.
4215 Sorrento Valley Blvd.
San Diego, CA 92121
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
143
|
|
|
|
98
|
|
Anacor Pharmaceuticals,
Inc.(5)
1020 East Meadow Circle
Palo Alto, CA 94303
|
|
Biotechnology
|
|
Common Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
22
|
|
Anesiva,
Inc.(5)
650 Gateway Boulevard
South San Francisco, CA 94080
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
GenturaDx, Inc.
24590 Clawiter Road
Hayward, CA 94545
|
|
Biotechnology
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
63
|
|
|
|
60
|
|
N30 Pharmaceuticals, LLC
3122 Sterling Circle, Suite 200
Boulder, CO 80301
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
59
|
|
|
|
46
|
|
Novalar Pharmaceuticals, Inc.
12555 High Bluff Drive, Suite 300
San Diego, CA 92130
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
|
|
Revance Therapeutics, Inc.
7555 Gateway Blvd.
Newark, CA 94560
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
224
|
|
|
|
489
|
|
Supernus Pharmaceuticals, Inc.
1550 East Gude Drive
Rockville, MD 20850
|
|
Biotechnology
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
15
|
|
Tranzyme,
Inc.(5)
4819 Emperor Blvd., Suite 400
Durham, NC 27703
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
Concentric Medical, Inc.
301 East Evelyn Avenue
Mountain View, CA 94041
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
84
|
|
|
|
875
|
|
EnteroMedics,
Inc.(5)
2800 Patton Road
Saint Paul, MN 55113
|
|
Medical Device
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
347
|
|
|
|
2
|
|
OraMetrix, Inc.
2350 Campbell Creek Blvd., Suite 400
Richardson, TX 75082
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
78
|
|
|
|
67
|
|
69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
PixelOptics, Inc.
5241 Valleypark Drive
Roanoke, VA 24019
|
|
Medical Device
|
|
Preferred Stock
Warrants(2)
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
96
|
|
|
|
46
|
|
Tengion,
Inc.(5)
2900 Potshop Lane, Suite 100
East Norriton, PA 19403
|
|
Medical Device
|
|
Common Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
62
|
|
|
|
|
|
ViOptix, Inc.
47224 Misson Fall Ct.
Fremont, CA 94539
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Life Science
|
|
|
|
|
|
|
1,373
|
|
|
|
1,787
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Technology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OpenPeak, Inc.
1750 Clint Moore Road
Boca Raton, FL 33487
|
|
Communications
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
89
|
|
|
|
|
|
Everyday Health, Inc.
45 Main Street
Brooklyn, NY 11201
|
|
Consumer-related
technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
116
|
|
SnagAJob.com, Inc.
4880 Cox Road, Suite 200
Glenn Allen, VA 23060
|
|
Consumer-related
technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
270
|
|
Starcite, Inc.
1600 Market Street, 27th Floor
Philadelphia, PA 19103
|
|
Consumer-related
technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
27
|
|
Tagged, Inc.
840 Battery Street, 2nd Floor
San Francisco, CA 94111
|
|
Consumer-related
technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
27
|
|
Xtera Communications, Inc.
500 W. Bethany Drive, Suite 100
Allen, TX 75013
|
|
Semiconductors
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
206
|
|
|
|
242
|
|
Vette Corp.
14 Manchester Square, Suite 210
Portsmouth, NH 03801
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
75
|
|
|
|
48
|
|
XIOtech, Inc.
6455 Flying Cloud Drive
Eden Prairie, MN 55344
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
80
|
|
Cartera Commerce, Inc.
One Cranberry Hill, Suite 203
Lexington, MA 02421
|
|
Internet and media
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
30
|
|
Grab Networks, Inc.
21000 Atlantic Boulevard
Dulles, VA 20166
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
IntelePeer, Inc.
2855 Campus Drive, Suite 200
San Mateo, CA 94403
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
524
|
|
Motion Computing, Inc.
8601 RR 2222, Building II
Austin, TX 78730
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
334
|
|
Impinj, Inc.
701 N. 34th Street, Suite 300
Seattle, WA 98103
|
|
Semi-conductor
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
Clarabridge, Inc.
11400 Commerce Park Drive, Suite 500
Reston, VA 20191
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
24
|
|
Construction Software Technologies, Inc.
4500 Lake Forest Drive, Suite 502
Cincinnati, OH 45202
|
|
Software
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
45
|
|
|
|
44
|
|
Courion Corporation
1900 West Park Drive, 1st Floor
Westborough, MA 01581
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
85
|
|
|
|
100
|
|
70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
DriveCam, Inc.
8911 Balboa Ave.
San Diego, CA 92123
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
20
|
|
|
|
7
|
|
Netuitive, Inc.
12700 Sunrise Valley Drive
Reston, VA 20191
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
21
|
|
Recondo Technology, Inc.
6312 South Fiddlers Green Cr.,
Suite 600 East
Greenwood Village, CO 80111
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
47
|
|
|
|
47
|
|
Seapass Solutions, Inc.
90 Park Avenue, Suite 1720
New York, NY 10016
|
|
Software
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
43
|
|
|
|
42
|
|
StreamBase Systems, Inc.
181 Spring Street
Lexington, MA 02421
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
67
|
|
|
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Technology
|
|
|
|
|
|
|
1,029
|
|
|
|
2,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Cleantech
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(5)
300 North Continental Blvd., Suite 100
El Segundo, CA 90245
|
|
Waste Recycling
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
112
|
|
|
|
28
|
|
Enphase Energy, Inc.
201 1st Street, Suite 300
Petaluma, CA 94952
|
|
Energy Efficiency
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
175
|
|
|
|
136
|
|
Satcon Technology
Corporation(5)
27 Drydock Avenue
Boston, MA 02210
|
|
Energy Efficiency
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
285
|
|
|
|
5
|
|
Tigo Energy, Inc.
420 Blossom Hill Road
Los Gatos, CA 95032
|
|
Energy Efficiency
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
101
|
|
|
|
79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Cleantech
|
|
|
|
|
|
|
673
|
|
|
|
248
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Healthcare information and services
|
BioScale, Inc.
4 Maguire Road
Lexington, MA 02421
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
54
|
|
|
|
62
|
|
Precision Therapeutics, Inc.
2516 Jane Street
Pittsburgh, PA 15203
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
73
|
|
|
|
158
|
|
Radisphere National Radiology Group, Inc.
23625 Commerce Park, Suite 204
Beachwood, OH 44122
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
167
|
|
|
|
372
|
|
Aperio Technologies, Inc.
1360 Park Center Drive
Vista, CA 92081
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
35
|
|
|
|
34
|
|
Patientkeeper, Inc.
880 Winter Street, Suite 300
Waltham, MA 02451
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
269
|
|
|
|
266
|
|
Singulex, Inc.
1650 Harbor Bay Parkway, Suite 200
Alameda, CA 94502
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
40
|
|
|
|
31
|
|
Talyst, Inc.
11100 NE 8th Street, Suite 600
Bellevue, WA 98004
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Healthcare information and services
|
|
|
|
|
|
|
738
|
|
|
|
1,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
|
|
|
|
3,813
|
|
|
|
5,091
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Insmed
Incorporated(5)
4851 Lake Brook Drive
Glen Allen, VA 23058
|
|
Biotechnology
|
|
Common
Stock(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
227
|
|
|
|
169
|
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
|
|
|
|
Interest
|
|
|
|
Principal
|
|
Cost of
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)(7)
|
|
Rate(4)
|
|
Maturity
|
|
Amount
|
|
Investment(6)
|
|
Fair Value
|
|
Overture Networks Inc.
507 Aiport Blvd., Building 111
Morrisville, NC 27650
|
|
Communications
|
|
Preferred
Stock(1)
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
480
|
|
|
|
524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Equity
|
|
|
|
|
|
|
707
|
|
|
|
693
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Investment Assets
|
|
|
|
|
|
$
|
179,651
|
|
|
$
|
180,186
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short Term Investments Money Market Funds
|
|
|
|
|
|
|
|
|
|
|
|
|
Blackrock Liquid Fed Funds Institutional (Fund #30)
|
|
|
|
|
|
|
19,951
|
|
|
|
19,951
|
|
First American Prime Obligations Fund (Class D)
|
|
|
|
|
|
|
8,166
|
|
|
|
8,166
|
|
Fidelity Prime Money Market (Class I Fund #690)
|
|
|
|
|
|
|
691
|
|
|
|
691
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Short Term Investments Money Market
Funds
|
|
|
|
|
|
$
|
28,808
|
|
|
$
|
28,808
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Agreement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WestLB, AG
|
|
Interest rate swap pay
fixed/receive floating, Notional
Amount $10 million
|
|
3.58%
|
|
|
10/14/2011
|
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Investment Liabilities
|
|
|
|
|
|
$
|
|
|
|
$
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Has been pledged as collateral
under the WestLB Facility.
|
(2)
|
|
Has been pledged as collateral
under the Wells Facility.
|
(3)
|
|
All investments are less than 5%
ownership of the class and ownership of the portfolio company.
|
(4)
|
|
All interest is payable in cash due
monthly in arrears, unless otherwise indicated and applies only
to the Companys debt investments. Amount is the annual
interest rate on the debt investment and does not include any
additional fees related to the investment, such as deferred
interest, commitment fees or prepayment fees. The majority of
the debt investments are at fixed rates for the term of the
loan. For each debt investment, we have provided the current
interest rate in effect as of September 30, 2011.
|
(5)
|
|
Portfolio company is a public
company.
|
(6)
|
|
For debt investments, represents
principal balance less unearned income.
|
|
|
|
(7)
|
|
Preferred and common stock warrants
and equity interests are non-income producing.
|
72
MANAGEMENT
Our business and affairs are managed under the direction of our
Board. Our Board consists of seven members, four of whom are not
interested persons of our Company or of our Advisor
as defined in Section 2(a)(19) of the 1940 Act and are
independent as determined by our Board, consistent
with the rules of NASDAQ. We refer to these individuals as our
independent directors. Our Board elects our
officers, who serve at the discretion of our Board.
Board of
Directors and Executive Officers
Our directors are divided into three classes. Each class of
directors holds office for a three-year term. However, the
initial members of the three classes have initial terms of one,
two and three years, respectively. At each annual meeting of our
stockholders, the successors to the class of directors whose
terms expire at such meeting will be elected to hold office for
a term expiring at the annual meeting of stockholders held in
the third year following the year of their election. This
classification of our Board may have the effect of delaying or
preventing a change in control of our management. Each director
will hold office for the term to which he or she is elected and
until his or her successor is duly elected and qualified. Our
Board may elect directors to fill vacancies that are created
either through an increase in the number of directors or due to
the resignation, removal or death of any director.
Directors
Information regarding our Board is set forth below. We have
divided the directors into two groups independent
directors and interested directors. Interested directors are
interested persons of the company as defined in
Section 2(a)(19) of the 1940 Act.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Expiration of
|
|
Interested Director
Name
|
|
Age
|
|
|
Position
|
|
Since
|
|
|
Current Term
|
|
|
Robert D. Pomeroy,
Jr.(1)
|
|
|
60
|
|
|
Chief Executive Officer and Chairman of the Board
|
|
|
2010
|
|
|
|
2013
|
|
Gerald A.
Michaud(1)
|
|
|
59
|
|
|
President and Director
|
|
|
2010
|
|
|
|
2012
|
|
David P.
Swanson(2)
|
|
|
38
|
|
|
Director
|
|
|
2010
|
|
|
|
2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director
|
|
|
Expiration of
|
|
Independent Director
Name
|
|
Age
|
|
|
Position
|
|
Since
|
|
|
Current Term
|
|
|
James J. Bottiglieri
|
|
|
55
|
|
|
Director
|
|
|
2010
|
|
|
|
2014
|
|
Edmund V. Mahoney
|
|
|
60
|
|
|
Director
|
|
|
2010
|
|
|
|
2012
|
|
Brett N. Silvers
|
|
|
56
|
|
|
Director
|
|
|
2010
|
|
|
|
2012
|
|
Christopher B. Woodward
|
|
|
62
|
|
|
Lead Independent Director
|
|
|
2010
|
|
|
|
2013
|
|
|
|
|
(1)
|
|
Interested person of the Company
due to his position as an officer of the Company.
|
(2)
|
|
Interested person of the Company
due to his indirect ownership in the Advisor.
|
The address for each of Mr. Pomeroy and Mr. Michaud
and each of the independent directors is c/o Horizon Technology
Finance Corporation, 312 Farmington Avenue, Farmington,
Connecticut 06032. The address for Mr. Swanson is Compass
Group Management LLC, 61 Wilton Road, 2nd Floor, Westport,
Connecticut 06880.
73
Executive
Officers Who Are Not Directors
Information regarding our executive officers who are not
directors is as follows:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Position
|
|
Christopher M. Mathieu
|
|
|
46
|
|
|
Senior Vice President, Chief Financial Officer and Treasurer
|
John C. Bombara
|
|
|
47
|
|
|
Senior Vice President, General Counsel, Chief Compliance
Officer
and Secretary
|
Daniel S. Devorsetz
|
|
|
41
|
|
|
Senior Vice President and Chief Credit Officer
|
The address for each executive officer is
c/o Horizon
Technology Finance Corporation, 312 Farmington Avenue,
Farmington, Connecticut 06032.
Biographical
Information
Interested
Directors
Robert D. Pomeroy, Jr., Chief Executive Officer and
Chairman of the Board of
Directors. Mr. Pomeroy co-founded our
Advisor in May 2003 and has been a managing member of our
Advisor and its Chief Executive Officer since its inception.
Mr. Pomeroy was President of GATX Ventures, Inc. (a
subsidiary of GATX Corporation engaged in the venture lending
business) from July 2000 to April 2003, with full profit and
loss responsibility including managing a staff of 39 and
chairing the investment committee with credit authority. GATX
Ventures, Inc. had total assets of over $270 million.
Before joining GATX Ventures in July 2000, Mr. Pomeroy was
Executive Vice President of Transamerica Business Credit (a
subsidiary of Transamerica Corporation engaged in the venture
lending business) and a co-founder of its Transamerica
Technology Finance division. Mr. Pomeroy was the general
manager of Transamerica Technology Finance from September 1996
to July 2000, with full profit and loss responsibility, credit
authority and responsibility for a staff of 50 and over
$480 million in assets. Prior to co-founding Transamerica
Technology Finance in September 1996, Mr. Pomeroy served
from January 1989 to August 1996 as Senior Vice President and
chaired the investment committee of Financing for Science
International, Inc., a publicly traded venture financing and
healthcare leasing company that was acquired by Finova Capital
Corporation in August 1996. Mr. Pomeroy started his career
with Crocker Bank in 1974 and has over 35 years of
diversified lending and leasing experience. Mr. Pomeroy
earned both a Master of Business Administration and a Bachelor
of Science degree from the University of California at Berkeley.
Gerald A. Michaud, President and
Director. Mr. Michaud co-founded our Advisor
in May 2003 and has been a managing member of our Advisor and
its President since its inception. From July 2000 to May 2003,
Mr. Michaud was Senior Vice President of GATX Ventures,
Inc. and its senior business development executive. From
September 1996 to July 2000, Mr. Michaud was Senior Vice
President of Transamerica Business Credit and a co-founder of
its Transamerica Technology Finance division. Mr. Michaud
was the senior business development executive for Transamerica
Technology Finance with oversight of more than $700 million
in loans funded. From May 1993 to September 1996,
Mr. Michaud served as a Vice President of Financing for
Science International, Inc. Prior to 1993, Mr. Michaud
founded and served as President of Venture Leasing and Capital.
Mr. Michaud attended Northeastern University, Rutgers
University and the University of Phoenix, completed a commercial
credit training program with Shawmut Bank and has taken
executive courses at Harvard Business School.
David P. Swanson, Director. Mr. Swanson
has been a partner in The Compass Group since December 2005 and
has been with The Compass Group and its affiliates since August
2001, serving as a Vice President from August 2001 to December
2003 and a Principal from December 2003 to December 2005. He is
a member of the board of directors of AFM Holding Corporation,
Liberty Safe Holding Corporation and CamelBak Acquisition Corp.
From August 1996 to July 1998, Mr. Swanson was with Goldman
Sachs in the Financial Institutions and Distressed Debt
practices. Mr. Swanson earned a Master of Business
Administration from the Harvard Business School MBA program and
a Bachelor of Arts degree in Economics from the University of
Chicago, where he was elected Phi Beta Kappa.
74
Independent
Directors
James J. Bottiglieri,
Director. Mr. Bottiglieri has served as a
director of Compass Diversified Holdings, Inc.
(CODI) since December 2005, as well as its chief
financial officer since its inception in November 2005.
Mr. Bottiglieri has also been an executive vice president
of CODIs external manager since 2005. Previously,
Mr. Bottiglieri was the senior vice president/controller of
WebMD Corporation. Prior to that, Mr. Bottiglieri was with
Star Gas Corporation and a predecessor firm to KPMG LLP.
Mr. Bottiglieri is a graduate of Pace University.
Mr. Bottiglieri serves as a director for a majority of
CODIs subsidiary companies.
Edmund V. Mahoney, Director. Mr. Mahoney
is Vice President, Investments (Chief Investment Officer) of
Vantis Life Insurance Company (Vantis Life) and is
responsible for all of its investment and portfolio management
activities. Prior to joining Vantis Life in 2009,
Mr. Mahoney was Senior Vice President, Compliance of
Hartford Investment Management Company from 1994 through 2009,
an investment adviser registered with the SEC with nearly
$150 billion of assets under management. From 1986 through
1994, Mr. Mahoney was Assistant Vice President and
Assistant Treasurer of Aetna Life and Casualty Company,
responsible for international finance, foreign exchange risk
management, cash management and leasing activities. From 1979
through 1984, Mr. Mahoney was assistant treasurer of Urban
Investment and Development Company, a real estate development
and management company located in Chicago, Illinois, responsible
for the companys risk management, commercial paper and
construction loan programs. Mr. Mahoney earned a Bachelor
of Arts degree from Colby College, a Master of Business
Administration (with distinction) from Babson College and
attended real estate finance related post graduate courses at
The Wharton School of the University of Pennsylvania.
Brett N. Silvers, Director. Mr. Silvers
has been the President and Chief Executive Officer of
WorldBusiness Capital, Inc. since he founded it in 2003. He was
previously the Chairman and Chief Executive Officer of First
International Bancorp, Inc. (NASDAQ: FNCE) for 13 years,
during which time he led the banks expansion, successful
initial public offering and sale to a Fortune 100 Company.
Mr. Silvers currently serves on the Industry Trade Advisory
Committee on Small and Minority Business of the
U.S. Department of Commerce/Office of the U.S. Trade
Representative. He has also served on the Board of Regents of
the University of Hartford, the Board of Directors of the
Private Export Funding Corporation, the New England Advisory
Council of the Federal Reserve Bank of Boston and the Advisory
Committee of the Export-Import Bank of the United States.
Mr. Silvers received his Bachelor of Arts in Political
Science from Yale University and Master of Arts in Law and
Diplomacy from The Fletcher School, Tufts University.
Christopher B. Woodward, Lead Independent
Director. Mr. Woodward is a private investor
and corporate finance business advisor. He has previously held
several domestic and global management positions as a Director,
Deputy Chief Executive Officer and acting Chief Financial
Officer with Canterbury of New Zealand from 2000 through 2009,
as Vice President-Corporate Finance with Montgomery Securities
and its predecessors from 1983 through 1987 and as a senior
finance and management executive with various other large and
small public and private enterprises. Mr. Woodward began
his career with Coopers & Lybrand (a predecessor firm
to PricewaterhouseCoopers) where he was a Certified Public
Accountant engaged in providing audit, tax and financial
advisory services to various sized public and private companies
across a number of industries from 1973 through 1980. During
such time, he was involved in that firms early Silicon
Valley practice as it assisted emerging, venture-backed growth
companies. Mr. Woodward earned both Bachelor of Science and
Master in Business Administration degrees from the Haas School
at the University of California, Berkeley.
Executive
Officers who are not Directors
Christopher M. Mathieu, Senior Vice President, Chief
Financial Officer and Treasurer. Mr. Mathieu
is an original member of the team that founded our Advisor in
May 2003 and its Chief Financial Officer since inception.
Mr. Mathieu has been involved in the accounting, finance
and venture debt industries for more than 22 years. From
July 2000 to May 2003, Mr. Mathieu was Vice
President Life Sciences of GATX Ventures, Inc. and
the primary business development officer for the life science
sector. From September 1996 to July 2000, Mr. Mathieu was
Vice President Life Sciences of Transamerica
Business Credits Technology Finance division where, in
addition to co-developing and implementing the business plan
used to form the division, he was the primary business
development officer responsible for the life science sector and
was directly responsible for more than $200 million
75
in loan originations. From March 1993 to September 1996,
Mr. Mathieu was a Vice President, Finance at Financing for
Science International, Inc. Prior to March 1993,
Mr. Mathieu was a manager with the financial services group
of KPMG working with both public and private banks and
commercial finance companies. Mr. Mathieu graduated with
honors from Western New England College with a Bachelor of
Science in Business Administration degree in accounting and is a
Certified Public Accountant, chartered in the State of
Connecticut.
John C. Bombara, Senior Vice President, General Counsel,
Chief Compliance Officer and Secretary. Mr. Bombara is an
original member of the team that founded our Advisor in May 2003
and has been its Senior Vice President, General Counsel and
Chief Compliance Officer since our Advisors inception.
Mr. Bombara handles all legal functions for our Advisor,
including overseeing the negotiation and documentation of its
investments. Mr. Bombara has more than 20 years of
experience providing legal services to financial institutions
and other entities and individuals. Prior to joining our
company, Mr. Bombara served as in-house counsel for GATX
Ventures, Inc. from December 2000 to May 2003 where he directed
the legal operations of the GATX Ventures east coast
office in closing and managing its portfolio of debt and equity
investments in technology and life science companies throughout
the United States. Mr. Bombara also represented GATX
Corporations other venture lending units in Canada and
Europe. In addition, Mr. Bombara was responsible for
assisting and advising senior management, credit analysts and
marketing directors with respect to appropriate deal structures,
market trends, risk management and compliance with corporate
policies and worked with co-participants business
personnel and counsel in facilitating and coordinating joint
investments. Prior to joining GATX, Mr. Bombara was a
partner at the business law firm of Pepe & Hazard,
LLP. Mr. Bombara received his Bachelor of Arts degree from
Colgate University and his Juris Doctor degree from Cornell Law
School.
Daniel S. Devorsetz, Senior Vice President and Chief Credit
Officer. Mr. Devorsetz joined our Advisor in
October 2004 and has been its Senior Vice President and the
Chief Credit Officer since such time. He is responsible for
underwriting and portfolio management. Mr. Devorsetz has
more than 15 years of financial services and lending
experience, including spending the past 10 years in the venture
lending industry. Prior to joining the team, from May 2003 to
October 2004, Mr. Devorsetz was a Vice President in General
Electric Capital Corporations Life Science Finance Group,
where he was primarily responsible for the underwriting and
portfolio management of debt and equity investments to venture
capital-backed life science companies. Prior to that, from
December 2000 to May 2003, Mr. Devorsetz was a Credit
Manager at GATX Ventures, Inc. concentrating on the high tech
and software industries. He was also a member of GATXs
international credit committee. From July 1999 to December 2000,
Mr. Devorsetz was a Vice President and Director of Analysis
for Student Loans with Citigroup. Mr. Devorsetzs
previous experience includes tenures in private placement
investment banking and securitizations at Advest, Inc. and
Ironwood Capital. Mr. Devorsetz received his Bachelor of
Science degree from Cornell University.
Committees
of the Board of Directors
Our Board has the following board committees:
Audit Committee. The members of the audit
committee are James J. Bottiglieri, Brett N. Silvers and
Christopher B. Woodward, each of whom are independent for
purposes of the 1940 Act and NASDAQ corporate governance listing
standards. James J. Bottiglieri serves as the chairman of the
audit committee and is an audit committee financial
expert as defined under the SEC rules. The audit committee
operates pursuant to a written charter approved by our Board
that sets forth the responsibilities of the audit committee. The
audit committee is responsible for selecting our independent
accountants, reviewing the plans, scope and results of the audit
engagement with our independent accountants, approving
professional services provided by our independent accountants,
reviewing the independence of our independent accountants and
reviewing the adequacy of our internal accounting controls. For
the year ended December 31, 2010, the audit committee met
one time.
Nominating and Corporate Governance
Committee. The members of the nominating and
corporate governance committee are James J. Bottiglieri, Brett
N. Silvers and Edmund V. Mahoney, each of whom are independent
for purposes of the 1940 Act and the NASDAQ corporate governance
listing standards. Edmund V. Mahoney serves as the chairman of
the nominating and corporate governance committee. The
nominating and corporate governance committee operates pursuant
to a written charter approved by our Board. The nominating and
corporate governance committee is responsible for identifying,
researching and nominating directors for election by
76
our stockholders, selecting nominees to fill vacancies on our
Board or a committee of our Board, developing and recommending
to our Board a set of corporate governance principles and
overseeing the evaluation of our Board and our management. Our
procedures for stockholder nominees for director are described
under Description of Common Stock That We May
Issue Anti-takeover Effects of Provisions of Our
Certificate of Incorporation, Bylaws, the DGCL and Other
Arrangements. For the year ended December 31, 2010, the
nominating and corporate governance committee met one time.
Compensation Committee. We do not have a
compensation committee because our executive officers do not
receive any direct compensation from us. Decisions regarding
executive compensation, to the extent they arise, will be made
by the independent directors on our Board.
Compensation
of Directors
The following table sets forth compensation received by our
directors during the period from January 1, 2011 to
December 31, 2011.
|
|
|
|
|
|
|
|
|
|
|
Fees Earned
|
|
|
|
|
or Paid in
|
|
|
Name
|
|
Cash(1)(2)
|
|
Total
|
|
Interested Directors
|
|
|
|
|
|
|
|
|
Robert D. Pomeroy, Jr.
|
|
|
None
|
|
|
|
None
|
|
Gerald A. Michaud
|
|
|
None
|
|
|
|
None
|
|
David P. Swanson
|
|
|
None
|
|
|
|
None
|
|
|
|
|
|
|
|
|
|
|
Independent Directors
|
|
|
|
|
|
|
|
|
James J. Bottiglieri
|
|
$
|
57,500
|
|
|
$
|
57,500
|
|
Edmund V. Mahoney
|
|
$
|
47,500
|
|
|
$
|
47,500
|
|
Brett N. Silvers
|
|
$
|
47,500
|
|
|
$
|
47,500
|
|
Christopher B. Woodward
|
|
$
|
52,500
|
|
|
$
|
52,500
|
|
|
|
|
(1)
|
|
For a discussion of the independent
directors compensation, see below.
|
(2)
|
|
We do not maintain a stock or
option plan, non-equity incentive plan or pension plan for our
directors.
|
As compensation for serving on our Board, each of our
independent directors receives an annual fee of $35,000. Each
member of the audit committee is paid an annual fee of $7,500
and each member of each other committee is paid an annual fee of
$5,000. In addition, the chairman of the audit committee
receives an additional annual fee of $10,000 and each chairman
of any other committee receives an additional annual fee of
$7,500 for their additional services, if any, in these
capacities. Our lead independent director is also paid an annual
fee of $10,000. We reimburse all our directors for their
reasonable
out-of-pocket
expenses incurred in attending our Board and committee meetings.
No compensation is, or is expected to be, paid to directors who
are interested persons of the Company, as such term
is defined in the 1940 Act.
Leadership
Structure of the Board of Directors and its Role in Risk
Oversight
Our Chief Executive Officer, Robert D. Pomeroy, Jr., is
Chairman of our Board and an interested person under
Section 2(a)(19) of the 1940 Act. Christopher B. Woodward
is our lead independent director and presides over executive
sessions of independent directors. Under our bylaws, our Board
is not required to have an independent chairman. Many
significant corporate governance duties of our Board are
executed by committees of independent directors, each of which
has an independent chairman. We believe that it is in the best
interests of our stockholders for Mr. Pomeroy to lead our
Board because of his broad experience. See
Biographical Information
Interested Directors for a description of
Mr. Pomeroys experience. As a co-founder of our
Advisor, Mr. Pomeroy has demonstrated a track record of
achievement on strategic and operating aspects of our business.
While our Board regularly evaluates alternative structures, we
believe that, as a BDC, it is appropriate for one of our
co-founders, Chief Executive Officer and a member of our
Advisors investment committee to perform the functions of
Chairman of the Board, including leading discussions of
strategic issues we expect to face. We
77
believe the current structure of our Board provides appropriate
guidance and oversight while also enabling ample opportunity for
direct communication and interaction between management and our
Board.
There are a number of significant risks facing us which are
described under the heading Risk Factors. Our Board
uses its judgment to create and maintain policies and practices
designed to limit or manage the risks we face, including:
(1) the establishment of board-approved policies and
procedures designed to serve our interests, (2) the
application of these policies uniformly to directors, management
and third-party service providers, (3) the establishment of
independent board committees with clearly defined risk oversight
functions and (4) review and analysis by the Board of
reports by management and certain third-party service providers.
Accordingly, our Board has approved a code of ethics to promote
ethical conduct and prohibit certain transactions that could
pose significant risks to us. Our Board has established a
related party transaction review policy, under which it monitors
the risks related to certain transactions that present a
conflict of interest on a quarterly basis. Our Board has also
established and approved an investment valuation process to
manage risks relating to the valuations of our investments and
to ensure that our financial statements appropriately reflect
the performance of our portfolio of assets. Additionally,
through the delegated authority of our Board, the audit
committee has primary oversight over risks relating to our
internal controls over financial reporting and audit-related
risks, while the nominating and corporate governance committee
has primary oversight over risks relating to corporate
governance and oversees the evaluation of our Board and our
management. Under this oversight structure, our management team
manages the risks facing us in our
day-to-day
operations. We caution you, however, that although our Board
believes it has established an effective system of oversight, no
risk management system can eliminate risks or ensure that
particular events do not adversely affect our business.
Directors
Qualifications and Review of Director Nominees
Our nominating and corporate governance committee of our Board
makes recommendations to our Board regarding the size and
composition of our Board. The nominating and corporate
governance committee annually reviews with our Board the
composition of our Board, as a whole, and recommends, if
necessary, measures to be taken so that our Board reflects the
appropriate balance of knowledge, experience, skills, expertise
and diversity required for our Board, as a whole, and contains
at least the minimum number of independent directors required by
applicable laws and regulations. The nominating and corporate
governance committee is responsible for ensuring that the
composition of the members of our Board accurately reflects the
needs of our business and, in furtherance of this goal,
proposing the addition of members and the necessary resignation
of members for purposes of obtaining the appropriate members and
skills. Our directors should possess such attributes and
experience as are necessary to provide a broad range of personal
characteristics including diversity, management skills,
financial skills and technological and business experience. Our
directors should also be able to commit the requisite time for
preparation and attendance at regularly scheduled Board and
committee meetings, as well as be able to participate in other
matters necessary to ensure good corporate governance is
practiced.
In evaluating a director candidate, the nominating and corporate
governance committee considers factors that are in our best
interests and our stockholders best interests, including
the knowledge, experience, integrity and judgment of each
candidate; the potential contribution of each candidate to the
diversity of backgrounds, experience and competencies which our
Board desires to have represented; each candidates ability
to devote sufficient time and effort to his or her duties as a
director; independence and willingness to consider all strategic
proposals; any other criteria established by our Board and any
core competencies or technical expertise necessary to staff our
Boards committees. In addition, the nominating and
corporate governance committee assesses whether a candidate
possesses the integrity, judgment, knowledge, experience, skills
and expertise that are likely to enhance our Boards
ability to manage and direct our affairs and business,
including, when applicable, to enhance the ability of committees
of our Board to fulfill their duties. In addition, the
nominating and corporate governance committee may consider
self-and peer-evaluations provided by each current director to
determine, among other things, that the directors work well
together and operate together effectively.
In addition to fulfilling the above criteria, four of the seven
directors named above are considered independent under NASDAQ
rules (Mr. Pomeroy, Mr. Michaud and Mr. Swanson
being the exception as Mr. Pomeroy and Mr. Michaud are
employees of our Advisor and Mr. Swanson is an indirect
owner of the Advisor), and the nominating and corporate
governance committee believes that all seven nominees are
independent of the influence
78
of any particular stockholder or group of stockholders whose
interests may diverge from the interests of our stockholders as
a whole.
Each director brings a strong and unique background and set of
skills to our Board, giving our Board, as a whole, competence
and experience in a wide variety of areas, including corporate
governance and board service, executive management, finance,
private equity, workout and turnaround situations, manufacturing
and marketing. Set forth below are our conclusions with regard
to our directors.
Mr. Pomeroy has more than 35 years of experience in
diversified lending and leasing, including positions in sales,
marketing, and senior management. He has held the positions as
chief executive officer or general manager of each organization
which he has led since 1996. His responsibilities have included:
accountability for the overall profit and loss of the
organization, credit authority and credit committee oversight,
strategic planning, human resource oversight including hiring,
termination and compensation, reporting compliance for his
business unit, investor relations, fund raising and all aspects
of corporate governance. Mr. Pomeroy founded and has
operated our Advisor, a Venture Lending management company.
Prior to founding our Advisor, Mr. Pomeroy was the Senior
Vice President of Financing for Science International, Inc.,
Executive Vice President of Transamerica Business Credit and the
General Manager of its Technology Finance Division and President
of GATX Ventures, Inc. This experience has provided him with the
extensive judgment, experience, skills and knowledge to make a
significant contribution as Chairman of our Board and supporting
its ability to govern our affairs and business.
Mr. Michaud has been President of our Advisor since its
formation. He has extensive knowledge and expertise in venture
lending and has developed, implemented and executed on marketing
strategies and products targeted at the venture backed
technology and life science markets for a period of over
20 years. In addition, he has extensive knowledge in the
formation of compensation plans for key employees involved in
the marketing of venture loans. He is a member of our
Advisors Credit Committee responsible for approving all
investments made by us and oversight of our portfolio. He has
held senior management positions with several venture lending
organizations within public companies, including Transamerica
Business Credit and GATX Ventures, Inc. As senior vice president
and senior business development officer at Transamerica, he was
responsible for more than $700 million in loan
transactions. This experience, particularly with respect to
marketing and business development, has provided
Mr. Michaud with the judgment, knowledge, experience,
skills and expertise that are likely to enhance our Boards
ability to manage and direct our affairs.
Mr. Swanson is a partner in The Compass Group and currently
serves on the board of directors of three privately held
companies. With additional experience and knowledge gained from
other board positions on various committees on private portfolio
companies, he has a broad base of experience and skills to bring
to our Board. Mr. Swanson has gained extensive experience
as a partner with The Compass Group in evaluating and
structuring transactions, completing due diligence, executing
and closing on acquisitions and structuring financings of
operating companies, as well as taking privately held companies
public. Prior to The Compass Group, he gained experience in
investment banking, including capital raising and business
strategy and execution. Mr. Swanson provides our Board with
expertise in business and corporate governance matters and
assists our Board in its ability to manage and direct our
affairs.
Mr. Bottiglieri brings to our Board substantial experience
in identifying, managing and resolving accounting, tax and other
financial issues often encountered by public companies through
his positions as the chief financial officer and a director of
CODI, as well as a director for a majority of CODIs
subsidiary companies, and as the senior vice
president/controller of WebMD. In addition, as the chief
financial officer and director of a public company, CODI,
Mr. Bottiglieri has developed an extensive understanding of
the various periodic reporting requirements and corporate
governance compliance matters that assists our Board in managing
and directing our affairs. This experience, particularly with
respect to the areas of accounting and corporate governance,
provides our Board with expertise that assists our Board in its
ability to manage and direct our affairs.
Mr. Mahoney brings to our Board pertinent experience in
portfolio management, as well as in-depth knowledge of
investment advisor compliance, funds management and performance
measurement and pricing of investments. In addition, through his
past experiences he has unique knowledge of international
finance, as well as risk management strategies for foreign
exchange and property and casualty operations. This vast
experience,
79
particularly in the areas of business, risk management and
compliance matters that affect investment companies, enhances
our Boards ability to manage and direct our affairs.
Mr. Silvers is a former chief executive officer and
director of a public company and FDIC-insured bank. He brings to
our Board extensive knowledge of domestic lending to small and
midsize businesses. From his experience as the current chief
executive officer of a commercial finance company,
Mr. Silvers provides the Board with specialized expertise
in U.S. government guaranteed lending. His government and
regulatory experience, garnered through his roles as a member of
important advisory committees, councils and boards of directors
relevant to our business, complements our Boards oversight
of our Company and enhances its ability to manage and direct our
affairs.
Mr. Woodward brings to our Board a deep understanding of
corporate finance, including experience with private placements,
public offerings, venture capital investing, international
management and financial advising and restructuring.
Additionally, as a practicing CPA with a leading firm,
Mr. Woodward gained extensive accounting and audit
experience. Mr. Woodwards financial and accounting
expertise enhances the Boards oversight of our company and
its ability to manage and direct our affairs.
80
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
We have entered into the Investment Management Agreement with
the Advisor. The Advisor is registered as an investment adviser
under the Advisers Act. The investment activities are managed by
the Advisor and supervised by the Board, the majority of whom
are independent directors. Under the Investment Management
Agreement, we have agreed to pay the Advisor an annual
management fee based on its adjusted gross assets as well as an
incentive fee based on our investment performance.
Messrs. Pomeroy and Michaud control HTFM, our Advisor and
Administrator.
We have also entered into the Administration Agreement with the
Administrator. Under the Administration Agreement, we have
agreed to reimburse the Administrator for our allocable portion
of overhead and other expenses incurred by the Administrator in
performing its obligations under the Administration Agreement,
including rent and our allocable portion of the costs of
compensation and related expenses of our General Counsel and
Secretary, Chief Compliance Officer, Chief Financial Officer and
their respective staffs. In addition, pursuant to the terms of
the Administration Agreement the Administrator provides us with
the office facilities and administrative services necessary to
conduct our
day-to-day
operations.
The predecessor of the Advisor has granted the Company a
non-exclusive, royalty-free license to use the name
Horizon Technology Finance.
In October 2010, we entered into a registration rights agreement
with respect to 2,645,124 shares acquired by Compass
Horizon Partners, LP and HTF-CHF Holdings LLC in connection with
the exchange of membership interests in Compass Horizon for
shares of our common stock. As a result and subject to the terms
and conditions of the registration rights agreement, at any time
following 365 days after the completion of our IPO the
holders of a
majority-in-interest
of the shares subject to the registration rights agreement
(including permitted transferees) can require up to a maximum of
three times that we file a registration statement under the
Securities Act relating to the resale of all or a part of the
shares. In addition, the registration rights agreement also
provides for piggyback registration rights with respect to any
future registrations of the Companys equity securities and
the right to require us to register the resale of our shares on
a shelf
Form N-2
at any time following 365 days after the completion of the
Companys IPO. In connection with the IPO, Compass Horizon
Partners, LP sold 1,340,000 shares. We are registering
1,305,124 shares pursuant to our contractual obligations
under the registration rights agreement, as well as a total of
17,545 shares acquired by selling stockholders pursuant to
our dividend reinvestment plan.
We believe that we derive substantial benefits from our
relationship with our Advisor. Our Advisor may manage other
investment vehicles (Advisor Funds) with the same
investment strategy as us. The Advisor may provide us an
opportunity to co-invest with the Advisor Funds. Under the 1940
Act, absent receipt of exemptive relief from the SEC, we and our
affiliates may be precluded from co-investing in such
investments. Accordingly, we may apply for exemptive relief
which would permit us to co-invest subject to certain
conditions, including, without limitation, approval of such
investments by both a majority of our directors who have no
financial interest in such transaction and a majority of
directors who are not interested directors as defined in the
1940 Act.
81
OUR
ADVISOR
Our Advisor is located at 312 Farmington Avenue, Farmington,
Connecticut 06032 and serves as our investment advisor pursuant
to the Investment Management Agreement. Our Advisor is
registered as an investment adviser under the Advisers Act.
Subject to the overall supervision of our Board, our Advisor
manages the
day-to-day
operations of, and provides investment advisory and management
services to, us.
Portfolio
Management
The management of our investment portfolio is the responsibility
of our Advisors executive officers and its investment
committee. The investment committee currently consists of Robert
D. Pomeroy, Jr., Chief Executive Officer of our Advisor,
Gerald A. Michaud, President of our Advisor, Daniel S.
Devorsetz, Senior Vice President and Chief Credit Officer of our
Advisor, and Kevin T. Walsh, Vice President and Senior Credit
Officer of our Advisor. For more information regarding the
business experiences of Messrs. Pomeroy, Michaud and
Devorsetz, see Management Biographical
Information Interested Directors and
Management Biographical
Information Executive Officers who are not
Directors.
Below is the biography for the portfolio manager whose biography
has not been included elsewhere in this prospectus.
Kevin T. Walsh, Vice President, Senior Credit Officer of Our
Advisor. Mr. Walsh has been the Senior
Credit Officer of our Advisor since joining our Advisor in March
2006. Mr. Walsh is responsible for the underwriting of
initial investments and the ongoing review of the portfolio
accounts. Mr. Walsh has over 16 years of experience
working with early stage, venture backed technology and life
science companies. Prior to joining our Advisor in March 2006,
Mr. Walsh was a Senior Vice President and Market Manager
for Bridge Banks Technology Banking and Capital Finance
Divisions from September 2004 to March 2006 where he was
responsible for new business generation as well as risk
management activities within the Banks asset-based lending
sector. Prior to Bridge Bank, Mr. Walsh was a Vice
President and Relationship Manager for Silicon Valley Bank in
the Communication & Electronics Practice from
September 1994 to June 2004. Mr. Walsh is a graduate of the
California State University at Hayward, where he earned a
Bachelor of Science degree in Business Administration.
The compensation of the members of the senior management
committee of our Advisor are paid by our Advisor and includes an
annual base salary, in certain cases an annual bonus based on an
assessment of short-term and long-term performance and a portion
of the incentive fee, if any, paid to our Advisor. In addition,
Mr. Pomeroy and Mr. Michaud have equity interests in
our Advisor and may receive distributions of profits in respect
of those interests. See Control Persons and Principal
Stockholders for information on ownership by portfolio
managers of our securities.
82
INVESTMENT
MANAGEMENT AND ADMINISTRATION AGREEMENTS
Our Advisor serves as our investment advisor and is registered
as such under the Advisers Act. Our Advisor manages our
day-to-day
operations and also provides all administrative services
necessary for us to operate.
Investment
Management Agreement
Under the terms of the Investment Management Agreement, our
Advisor:
|
|
|
|
|
determines the composition of our portfolio, the nature and
timing of the changes to our portfolio and the manner of
implementing such changes;
|
|
|
|
identifies, evaluates and negotiates the structure of the
investments we make (including performing due diligence on our
prospective portfolio companies); and
|
|
|
|
closes, monitors and administers the investments we make,
including the exercise of any voting or consent rights.
|
Our Advisors services under the Investment Management
Agreement are not exclusive, and it is free to furnish similar
services to other entities so long as its services to us are not
impaired.
Management
Fee
Pursuant to the Investment Management Agreement, we pay our
Advisor a fee for investment advisory and management services
consisting of a base management fee and an incentive fee.
Base Management Fee. The base management fee
is calculated at an annual rate of 2.00% of our gross assets,
payable monthly in arrears. For purposes of calculating the base
management fee, the term gross assets includes any
assets acquired with the proceeds of leverage.
Incentive Fee. The incentive fee has two
parts, as follows:
The first part is calculated and payable quarterly in arrears
based on our Pre-Incentive Fee Net Investment Income for the
immediately preceding calendar quarter. For this purpose,
Pre-Incentive Fee Net Investment Income means interest income,
dividend income and any other income (including any other fees
(other than fees for providing managerial assistance), such as
commitment, origination, structuring, diligence and consulting
fees and fees for providing significant managerial assistance or
other fees that we receive from portfolio companies) accrued
during the calendar quarter, minus our operating expenses for
the quarter (including the base management fee, expenses payable
under the Administration Agreement, and any interest expense and
any dividends paid on any issued and outstanding preferred
stock, but excluding the incentive fee). Pre-Incentive Fee Net
Investment Income includes, in the case of investments with a
deferred interest feature (such as original issue discount, debt
instruments with
payment-in-kind
interest and zero coupon securities), accrued income that we
have not yet received in cash. The incentive fee with respect to
our Pre-Incentive Fee Net Investment Income is 20.00% of the
amount, if any, by which our Pre-Incentive Fee Net Investment
Income for the immediately preceding calendar quarter exceeds a
1.75% (which is 7.00% annualized) hurdle rate and a
catch-up
provision measured as of the end of each calendar quarter. Under
this provision, in any calendar quarter, our Advisor receives no
incentive fee until our net investment income equals the hurdle
rate of 1.75%, but then receives, as a
catch-up,
100.00% of our Pre-Incentive Fee Net Investment income with
respect to that portion of such Pre-Incentive Fee Net Investment
Income, if any, that exceeds the hurdle rate but is less than
2.1875%. The effect of this provision is that, if Pre-Incentive
Fee Net Investment Income exceeds 2.1875% in any calendar
quarter, our Advisor receives 20.00% of our Pre-Incentive Fee
Net Investment Income as if a hurdle rate did not apply.
Pre-Incentive Fee Net Investment Income does not include any
realized capital gains, realized capital losses or unrealized
capital appreciation or depreciation. Because of the structure
of the incentive fee, it is possible that we may pay an
incentive fee in a quarter where we incur a loss. For example,
if we receive Pre-Incentive Fee Net Investment Income in excess
of the quarterly minimum hurdle rate, we pay the applicable
incentive fee even if we have incurred a loss in that quarter
due to realized and unrealized capital losses. Our net
investment income used to calculate this part of the incentive
fee is also included in the amount of our gross assets used to
calculate the 2.00%
83
base management fee. These calculations are appropriately pro
rated for any period of less than three months and adjusted for
any share issuances or repurchases during the quarter for which
the calculations are made.
The following is a graphical representation of the calculation
of the income-related portion of the incentive fee:
Quarterly
Incentive Fee Based on Net Investment Income
Pre-Incentive
Fee Net Investment Income (expressed as a percentage of the
value of net assets)
Percentage
of Pre-Incentive Fee Net Investment Income allocated to first
part of incentive fee
The second part of the incentive fee is determined and payable
in arrears as of the end of each calendar year (or upon
termination of the Investment Management Agreement, as of the
termination date), commencing on December 31, 2010, and
equals 20% of our realized capital gains, if any, on a
cumulative basis from the date of our election to be a BDC
through the end of each calendar year, computed net of all
realized capital losses and unrealized capital depreciation on a
cumulative basis, less all previous amounts paid in respect of
the capital gain incentive fee provided that the incentive fee
determined as of December 31, 2010 was calculated for a
period of shorter than twelve calendar months in order to take
into account the realized capital gains computed net of all
realized capital losses and unrealized capital depreciation for
the period beginning on the date of our election to be a BDC and
ending December 31, 2010.
Examples
of Incentive Fee Calculation
Example
1: Income Related Portion of Incentive Fee for Each Fiscal
Quarter
Alternative
1
Assumptions:
Investment income (including interest, dividends, fees, etc.) =
1.25%
Hurdle
rate(1) =
1.75%
Management
fee(2)=
0.50%
Other expenses (legal, accounting, custodian, transfer agent,
etc.)(3)=
0.20%
Pre-Incentive Fee Net Investment Income
(investment income − (management fee + other
expenses)) = 0.55%
Pre-Incentive Fee Net Investment Income does not exceed hurdle
rate; therefore, there is no income-related incentive fee.
Alternative
2
Assumptions:
Investment income (including interest, dividends, fees, etc.) =
2.80%
Hurdle
rate(1) =
1.75%
Management
fee(2) =
0.50%
Other expenses (legal, accounting, custodian, transfer agent,
etc.)(3)
= 0.20%
Pre-Incentive Fee Net Investment Income
(investment income − (management fee + other expenses)) =
2.10%
Incentive fee = 100.00% × Pre-Incentive Fee Net Investment
Income (subject to
catch-up)(4)
= 100.00% × (2.10% − 1.75%)
= 0.35%
84
Pre-Incentive Fee Net Investment Income exceeds the hurdle rate,
but does not fully satisfy the
catch-up
provision; therefore, the income related portion of the
incentive fee is 0.35%.
Alternative
3
Assumptions:
Investment income (including interest, dividends, fees, etc.) =
3.00%
Hurdle
rate(1) =
1.75%
Management
fee(2) =
0.50%
Other expenses (legal, accounting, custodian, transfer agent,
etc.)(3)
= 0.20%
Pre-Incentive Fee Net Investment Income
(investment income − (management fee + other expenses)) =
2.30%
Incentive fee = 100.00% × Pre-Incentive Fee Net Investment
Income (subject to
catch-up)(4)
Incentive fee = 100.00% ×
catch-up
+ (20.00% × (Pre-Incentive Fee Net Investment Income
− 2.1875%))
Catch up = 2.1875% − 1.75%
= 0.4375%
Incentive fee = (100.00% × 0.4375%) + (20.00% × (2.30%
− 2.1875%))
= 0.4375% + (20.00% × 0.1125%)
= 0.4375% + 0.0225%
= 0.46%
Pre-Incentive Fee Net Investment Income exceeds the hurdle rate,
and fully satisfies the
catch-up
provision; therefore, the income related portion of the
incentive fee is 0.46%.
|
|
|
(1)
|
|
Represents 7.00% annualized hurdle
rate.
|
(2)
|
|
Represents 2.00% annualized base
management fee.
|
(3)
|
|
Excludes organizational and
offering expenses.
|
(4)
|
|
The
catch-up
provision is intended to provide our Advisor with an incentive
fee of 20.00% on all Pre-Incentive Fee Net Investment Income as
if a hurdle rate did not apply when our net investment income
exceeds 2.1875% in any fiscal quarter.
|
Example
2: Capital Gains Portion of Incentive Fee
Alternative
1
Assumptions:
Year 1: $20 million investment made in Company A
(Investment A), and $30 million investment made
in Company B (Investment B)
Year 2: Investment A sold for $50 million and fair market
value (FMV) of Investment B determined to be
$32 million
Year 3: FMV of Investment B determined to be $25 million
Year 4: Investment B sold for $31 million
The capital gains portion of the incentive fee, if any, would be:
Year 1: None (No sales transaction)
Year 2: Capital gains incentive fee of $6 million
($30 million realized capital gains on sale of Investment A
multiplied by 20%)
Year 3: None; $5 million ((20% multiplied by
($30 million cumulative capital gains less $5 million
cumulative capital depreciation)) less $6 million (previous
capital gains fee paid in Year 2))
Year 4: Capital gains incentive fee of $200,000;
$6.2 million (($31 million cumulative realized capital
gains multiplied by 20%) less $6 million (capital gains
incentive fee taken in Year 2))
85
Alternative
2
Assumptions:
Year 1: $20 million investment made in Company A
(Investment A), $30 million investment made in
Company B (Investment B) and $25 million
investment made in Company C (Investment C)
Year 2: Investment A sold for $50 million, FMV of
Investment B determined to be $25 million and FMV of
Investment C determined to be $25 million
Year 3: FMV of Investment B determined to be $27 million
and Investment C sold for $30 million
Year 4: FMV of Investment B determined to be $35 million
Year 5: Investment B sold for $20 million
The capital gains incentive fee, if any, would be:
Year 1: None (no sales transaction)
Year 2: $5 million capital gains incentive fee (20%
multiplied by $25 million ($30 million realized
capital gains on Investment A less unrealized capital
depreciation on Investment B))
Year 3: $1.4 million capital gains incentive
fee(1)
($6.4 million (20% multiplied by $32 million
($35 million cumulative realized capital gains less
$3 million unrealized capital depreciation)) less
$5 million capital gains incentive fee received in Year 2
Year 4: None (no sales transaction)
Year 5: None ($5 million (20% multiplied by
$25 million (cumulative realized capital gains of
$35 million less realized capital losses of
$10 million)) less $6.4 million cumulative capital
gains incentive fee paid in Year 2 and Year
3(2)
The hypothetical amounts of returns shown are based on a
percentage of our total net assets and assume no leverage. There
is no guarantee that positive returns will be realized and
actual returns may vary from those shown in this example.
|
|
|
(1)
|
|
As illustrated in Year 3 of
Alternative 1 above, if we were to be wound up on a date other
than our fiscal year end of any year, we may have paid aggregate
capital gains incentive fees that are more than the amount of
such fees that would be payable if we had been wound up on its
fiscal year end of such year.
|
(2)
|
|
As noted above, it is possible that
the cumulative aggregate capital gains fee received by the
Investment Manager ($6.4 million) is effectively greater
than $5 million (20.00% of cumulative aggregate realized
capital gains less net realized capital losses or net unrealized
depreciation ($25 million)).
|
Payment
of our expenses
All investment professionals and staff of our Advisor, when and
to the extent engaged in providing investment advisory and
management services, and the compensation and routine overhead
expenses of its personnel allocable to such services, are
provided and paid for by our Advisor. We bear all other costs
and expenses of our operations and transactions, including,
without limitation, those relating to:
|
|
|
|
|
our organization;
|
|
|
|
calculating our net asset value (including the cost and expenses
of any independent valuation firms);
|
|
|
|
expenses, including travel expense, incurred by our Advisor or
payable to third parties performing due diligence on prospective
portfolio companies, monitoring our investments and, if
necessary, enforcing our rights;
|
|
|
|
interest payable on debt, if any, incurred to finance our
investments;
|
|
|
|
the costs of all future offerings of our common stock and other
securities, if any;
|
|
|
|
the base management fee and any incentive management fee;
|
86
|
|
|
|
|
distributions on our shares;
|
|
|
|
administration fees payable under the Administration Agreement;
|
|
|
|
the allocated costs incurred by Advisor as our Administrator in
providing managerial assistance to those portfolio companies
that request it;
|
|
|
|
amounts payable to third parties relating to, or associated
with, making investments;
|
|
|
|
transfer agent and custodial fees;
|
|
|
|
registration fees;
|
|
|
|
listing fees;
|
|
|
|
fees and expenses associated with marketing efforts;
|
|
|
|
taxes;
|
|
|
|
independent director fees and expenses;
|
|
|
|
brokerage commissions;
|
|
|
|
costs of preparing and filing reports or other documents with
the SEC;
|
|
|
|
the costs of any reports, proxy statements or other notices to
our stockholders, including printing costs;
|
|
|
|
our allocable portion of the fidelity bond;
|
|
|
|
directors and officers/errors and omissions liability insurance,
and any other insurance premiums;
|
|
|
|
indemnification payments;
|
|
|
|
direct costs and expenses of administration, including audit and
legal costs; and
|
|
|
|
all other expenses incurred by us or the Administrator in
connection with administering our business, such as the
allocable portion of overhead under the Administration
Agreement, including rent, the fees and expenses associated with
performing compliance functions and our allocable portion of the
costs of compensation and related expenses of our Chief
Compliance Officer and our Chief Financial Officer and their
respective staffs.
|
We reimburse our Advisor for costs and expenses incurred by our
Advisor for office space rental, office equipment and utilities
allocable to the performance by our Advisor of its duties under
the Investment Management Agreement, as well as any costs and
expenses incurred by our Advisor relating to any non-investment
advisory, administrative or operating services provided by our
Advisor to us or in the form of managerial assistance to
portfolio companies that request it.
From time to time, our Advisor may pay amounts owed by us to
third party providers of goods or services. We subsequently
reimburse our Advisor for such amounts paid on our behalf.
Generally, our expenses are expensed as incurred in accordance
with GAAP. To the extent we incur costs that should be
capitalized and amortized into expense we also do so in
accordance with GAAP, which may include amortizing such amount
on a straight line basis over the life of the asset or the life
of the services or product being performed or provided.
Limitation
of liability and indemnification
The Investment Management Agreement provides that our Advisor
and its officers, managers, partners, agents, employees,
controlling persons and any other person or entity affiliated
with our Advisor are not be liable to us for any act or omission
by it in the supervision or management of our investment
activities or for any loss sustained by us except for acts or
omissions constituting willful misfeasance, bad faith, gross
negligence or reckless disregard of its obligations under the
Investment Management Agreement. The Investment Management
Agreement also provides for indemnification by us of our Advisor
and its officers, managers, partners, agents, employees,
controlling persons and any other person or entity affiliated
with our Advisor for liabilities incurred by them
87
in connection with their services to us (including any
liabilities associated with an action or suit by or in the right
of us or our stockholders), but excluding liabilities for acts
or omissions constituting willful misfeasance, bad faith or
gross negligence or reckless disregard of their duties under the
Investment Management Agreement subject to certain conditions.
Board
approval of the Investment Management Agreement
Our Board held an in-person meeting on August 3, 2011, and
considered and approved the Investment Management Agreement for
another twelve month period. In its consideration of the
Investment Management Agreement, our Board focused on
information it had received relating to, among other things:
(a) the nature, quality and extent of the advisory and
other services to be provided to us by our Advisor;
(b) comparative data with respect to advisory fees or
similar expenses paid by other BDCs with similar investment
objectives; (c) our projected operating expenses and
expense ratio compared to BDCs with similar investment
objectives; (d) any existing and potential sources of
indirect income to our Advisor or the Administrator from their
relationships with us and the profitability of those
relationships; (e) information about the services to be
performed and the personnel performing such services under the
Investment Management Agreement; (f) the organizational
capability and financial condition of our Advisor and its
affiliates; (g) our Advisors practices regarding the
selection and compensation of brokers that may execute our
portfolio transactions and the brokers provision of
brokerage and research services to our Advisor; and (h) the
possibility of obtaining similar services from other third party
service providers or through an internally managed structure.
Based on the information reviewed and the discussions related
thereto, our Board, including a majority of the non-interested
directors, concluded that the investment management fee rates
are reasonable in relation to the services to be provided.
Duration
and termination
The Investment Management Agreement was approved by our Board on
October 25, 2010 and August 3, 2011. Unless terminated
earlier as described below, it will continue in effect for a
period of two years from its effective date. It will remain in
effect from year to year thereafter if approved annually by our
Board or by the affirmative vote of the holders of a majority of
our outstanding voting securities, including, in either case,
approval by a majority of our directors who are not interested
persons. The Investment Management Agreement will automatically
terminate in the event of its assignment. The Investment
Management Agreement may be terminated by either party without
penalty by delivering notice of termination upon not more than
60 days written notice to the other. See Risk
Factors Risks Related to our Business and
Structure Our Advisor can resign on
60 days notice, and we may not be able to find a
suitable replacement within that time, resulting in a disruption
in our operations that could adversely affect our business,
results of operations or financial condition. We are
dependent upon senior management personnel of our Advisor for
our future success, and if our Advisor is unable to hire and
retain qualified personnel or if our Advisor loses any member of
its senior management team, our ability to achieve our
investment objective could be significantly harmed.
Administration
Agreement
We have entered into an Administration Agreement with the
Administrator, to provide administrative services to us. For
providing these services, facilities and personnel, we reimburse
the Administrator for our allocable portion of overhead and
other expenses incurred by the Administrator in performing its
obligations under the Administration Agreement, including rent,
the fees and expenses associated with performing compliance
functions and our allocable portion of the costs of compensation
and related expenses of our Chief Compliance Officer and our
Chief Financial Officer and their respective staffs.
From time to time, the Administrator may pay amounts owed by us
to third-party providers of goods or services. We subsequently
reimburse the Administrator for such amounts paid on our behalf.
88
License
Agreement
We have entered into a license agreement with Horizon Technology
Finance, LLC pursuant to which we were granted a non-exclusive,
royalty-free right and license to use the service mark
Horizon Technology Finance. Under this agreement, we
have a right to use the Horizon Technology Finance
service mark for so long as the Investment Management Agreement
with our Advisor is in effect. Other than with respect to this
limited license, we have no legal right to the Horizon
Technology Finance service mark.
89
CONTROL
PERSONS AND PRINCIPAL STOCKHOLDERS
No person is deemed to control us, as such term is defined in
the 1940 Act.
The following table sets forth certain information with respect
to the beneficial and record ownership of our common stock as of
February 3, 2012 by:
|
|
|
|
|
each person known to us to own beneficially and of record more
than 5% of the outstanding shares of our common stock;
|
|
|
|
each of our directors and each of our executive
officers; and
|
|
|
|
all of our directors and executive officers as a group.
|
The percentage of common stock outstanding is based on
7,636,532 shares of common stock outstanding as of
February 3, 2012.
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage of
|
|
|
Shares
|
|
Common Stock
|
Name of Beneficial
Owner
|
|
Owned
|
|
Outstanding
|
|
Principal Stockholders
|
|
|
|
|
|
|
|
|
Compass Horizon Partners,
LP(1)(3)
|
|
|
1,271,414
|
|
|
|
16.6
|
%
|
HTF-CHF Holdings
LLC(2)(3)
|
|
|
51,255
|
|
|
|
|
*%
|
Brown Advisory Holdings
Incorporated(4)
|
|
|
491,981
|
|
|
|
6.4
|
%
|
Silver Capital
Management(5)
|
|
|
453,757
|
|
|
|
5.9
|
%
|
Directors and Executive Officers
|
|
|
|
|
|
|
|
|
Robert D. Pomeroy,
Jr.(2)(6)
|
|
|
2,804
|
|
|
|
|
*%
|
Gerald A.
Michaud(2)(6)
|
|
|
1,576
|
|
|
|
|
*%
|
David P.
Swanson(6)
|
|
|
|
|
|
|
|
%
|
James J.
Bottiglieri(6)
|
|
|
3,166
|
|
|
|
|
*%
|
Edmund V.
Mahoney(6)
|
|
|
|
|
|
|
|
%
|
Brett N.
Silvers(6)
|
|
|
|
|
|
|
|
%
|
Christopher B.
Woodward(6)
|
|
|
2,732
|
|
|
|
|
*%
|
Christopher M.
Mathieu(2)(6)
|
|
|
1,055
|
|
|
|
|
*%
|
John C.
Bombara(2)(6)
|
|
|
|
|
|
|
|
*%
|
Daniel S.
Devorsetz(2)(6)
|
|
|
|
|
|
|
|
*%
|
All officers and directors as a group (10 persons)
|
|
|
62,588
|
|
|
|
|
*%
|
|
|
|
*
|
|
Less than 1%
|
(1)
|
|
Compass Horizon Partners, LP is the
beneficial and record owner of 1,271,414 shares. Concorde
Horizon Holdings LP is the limited partner of Compass Horizon
Partners, LP and Navco Management, Ltd. is the general partner.
Concorde Horizon Holdings LP and Navco Management, Ltd. are
controlled by The Kattegat Trust, a Bermudian charitable trust,
the trustee of which is Kattegat Private Trustees (Bermuda)
Limited, a Bermudian trust company with its principal offices at
2 Reid Street, Hamilton HM 11, Bermuda.
|
(2)
|
|
HTF-CHF Holdings LLC is the record
owner of 51,255 shares. Messrs. Pomeroy, Michaud,
Mathieu, Bombara and Devorsetz own 33%, 33%, 15.5%, 9.3% and
6.2% of HTF-CHF Holdings LLC, respectively, each disclaiming
beneficial ownership except to the extent of his pecuniary
interest therein. The address for HTF-CHF Holdings LLC is 312
Farmington Avenue, Farmington, Connecticut 06032.
|
(3)
|
|
Compass Horizon Partners, LP and
HTF-CHF Holdings LLC are also selling stockholders under this
registration statement.
|
|
|
|
(4)
|
|
Based upon information contained in
the Schedule 13G/A filed February 2, 2012. Pursuant to
the Schedule 13G/A, Brown Advisory Holdings Incorporated is
the beneficial owner of the common stock, such shares being
owned by investment companies and other managed accounts of
direct/indirect subsidiaries of Brown Advisory Holdings
Incorporated. The address for Brown Advisory Holdings
Incorporated is 901 South Bond Street, Ste. 400, Baltimore,
Maryland, 21321.
|
|
|
|
(5)
|
|
Based upon information contained in
the Schedule 13G/A filed February 14, 2011. Pursuant
to the Schedule 13G/A, such securities are held by certain
private funds managed by Silver Capital Management LLC. The
address for Silver Capital Management LLC is 767 Third Avenue,
32nd Floor, New York, New York 10017.
|
90
|
|
|
(6)
|
|
The address for each executive
officer and director is
c/o Horizon
Technology Finance Corporation, 312 Farmington Avenue,
Farmington, Connecticut 06032. Each executive officer and
director is the beneficial owner of the shares listed.
|
The following table sets forth the dollar range of our
securities beneficially owned by our directors and employees
primarily responsible for the
day-to-day
management of our investment portfolio as of February 3,
2012.
|
|
|
|
|
|
|
|
|
Aggregate Dollar Range of
|
|
|
|
|
Equity Securities in all
|
|
|
|
|
Registered Investment
|
|
|
|
|
Companies Overseen by
|
|
|
Dollar Range of Equity
|
|
Director in Family of
|
Name
|
|
Securities in the
Company(1)(2)
|
|
Investment Companies
|
|
Independent Directors
|
|
|
|
|
James J. Bottiglieri
|
|
$50,001-$100,000
|
|
$50,001-$100,000
|
Edmund V. Mahoney
|
|
None
|
|
None
|
Brett N. Silvers
|
|
None
|
|
None
|
Christopher B. Woodward
|
|
$10,001-$50,000
|
|
$10,001-$50,000
|
Interested Directors
|
|
|
|
|
Robert D. Pomeroy, Jr.
|
|
Over $100,000
|
|
Over $100,000
|
Gerald A. Michaud
|
|
Over $100,000
|
|
Over $100,000
|
David P. Swanson
|
|
None
|
|
None
|
Portfolio Management Employees
|
|
|
|
|
Christopher M. Mathieu
|
|
Over $100,000
|
|
Over $100,000
|
John C. Bombara
|
|
$50,001-$100,000
|
|
$50,001-$100,000
|
Daniel S. Devorsetz
|
|
$50,001-$100,000
|
|
$50,001-$100,000
|
Kevin T. Walsh
|
|
None
|
|
None
|
|
|
|
(1)
|
|
Dollar ranges are as follows: None,
$1-$10,000, $10,001-$50,000, $50,001-$100,000, or over $100,000.
|
|
|
|
(2)
|
|
The dollar range of equity
securities beneficially owned in us is based on the closing
price for our common stock of $16.66 on February 3, 2012,
on the NASDAQ. Beneficial ownership has been determined in
accordance with
Rule 16a-1(a)(2)
of the Exchange Act.
|
91
DETERMINATION
OF NET ASSET VALUE
The net asset value per share of our outstanding shares of
common stock is determined quarterly by dividing the value of
total assets minus liabilities by the total number of shares of
common stock outstanding at the date as of which the
determination is made. We conduct the valuation of our assets,
pursuant to which our net asset value is determined, at all
times consistent with GAAP and the 1940 Act.
In calculating the fair value of our total assets, investments
for which market quotations are readily available are valued at
such market quotations, which are generally obtained from an
independent pricing service or one or more broker-dealers or
market makers. However, debt investments with remaining
maturities within 60 days that are not credit impaired are
valued at cost plus accreted discount, or minus amortized
premium, which approximates fair value.
We value our investments at fair value which is the market value
of our investments. There is no readily available market value
for many of our portfolio investments, and we value those debt
and equity securities that are not publicly traded or whose
market value is not ascertainable at fair value as determined in
good faith by our Board in accordance with our valuation policy.
Our Board employs an independent third party valuation firm to
assist in determining fair value.
The types of factors that our Board may take into account in
determining fair value include: comparisons of financial ratios
of the portfolio companies that issued such private equity
securities to peer companies that are public, the nature and
realizable value of any collateral, the portfolio companys
ability to make payments and its earnings and discounted cash
flow, the markets in which the portfolio company does business
and other relevant factors. When an external event such as a
purchase transaction, public offering or subsequent equity sale
occurs, the Company considers the pricing indicated by the
external event to corroborate the private equity valuation.
With respect to investments for which market quotations are not
readily available or for which no indicative prices from pricing
services or brokers or dealers have been received, our Board
undertakes a multi-step valuation process each quarter, as
described below:
|
|
|
|
|
the quarterly valuation process begins with each portfolio
company or investment being initially valued by our
Advisors investment professionals responsible for
monitoring the investment;
|
|
|
|
preliminary valuation conclusions are then documented and
discussed with our Advisors senior management;
|
|
|
|
a third-party valuation firm is engaged by, or on behalf of, our
Board to conduct independent appraisals of all investments at
least once annually after reviewing our Advisors
preliminary valuations; and
|
|
|
|
our Board then discusses the valuations and determines in good
faith the fair value of each investment in the portfolio based
on the analysis and recommendations of our Advisor and, when
determined by our Board, an independent valuation firm.
|
Due to the inherent uncertainty in determining the fair value of
investments that do not have a readily observable fair value,
and the subjective judgments and estimates involved in those
determinations, the fair value determinations by our Board, even
though determined in good faith, may differ significantly from
the values that would have been used had a readily available
market value existed for such investments, and the differences
could be material.
Determinations
in connection with offerings
In connection with offerings of shares of our common stock, our
Board or one of its committees is required to make the
determination that we are not selling shares of our common stock
at a price below the then current net asset value of our common
stock at the time at which the sale is made, unless we have
stockholder approval to sell our common stock at an offering
price per share less any underwriting commissions or discounts
below the net asset
92
value per share of our common stock at such time. Our Board or
an applicable committee of our Board considers the following
factors, among others, in making such determination:
|
|
|
|
|
the net asset value of our common stock most recently disclosed
by us in the most recent periodic report that we filed with the
SEC;
|
|
|
|
our managements assessment of whether any material change
in the net asset value of our common stock has occurred
(including through the realization of gains on the sale of our
portfolio securities) during the period beginning on the date of
the most recently disclosed net asset value of our common stock
and ending two days prior to the date of the sale of our common
stock; and
|
|
|
|
the magnitude of the difference between (i) the net asset
value of our common stock most recently disclosed by us and our
managements assessment of any material change in the net
asset value of our common stock since that determination and
(ii) the offering price of the shares of our common stock
in the proposed offering.
|
This determination does not require that we calculate the net
asset value of our common stock in connection with each offering
of shares of our common stock, but instead it involves the
determination by our Board or a committee thereof that we are
not selling shares of our common stock at a price below the then
current net asset value of our common stock at the time at which
the sale is made or otherwise in violation of the 1940 Act.
Moreover, to the extent that there is even a remote possibility
that we may (i) issue shares of our common stock at a price
below the then current net asset value of our common stock at
the time at which the sale is made or (ii) trigger the
undertaking (which we provide in certain registration statements
we file with the SEC) to suspend the offering of shares of our
common stock pursuant to this prospectus if the net asset value
of our common stock fluctuates by certain amounts in certain
circumstances until the prospectus is amended, our Board will
elect, in the case of clause (i) above, either to postpone
the offering until such time that there is no longer the
possibility of the occurrence of such event or to undertake to
determine the net asset value of our common stock within two
days prior to any such sale to ensure that such sale will not be
below our then current net asset value, and, in the case of
clause (ii) above, to comply with such undertaking or to
undertake to determine the net asset value of our common stock
to ensure that such undertaking has not been triggered.
These processes and procedures are part of our compliance
policies and procedures. Records will be made contemporaneously
with all determinations of our Board described in this section,
and we will maintain these records with other records that we
are required to maintain under the 1940 Act.
93
DIVIDEND
REINVESTMENT PLAN
We have adopted a dividend reinvestment plan that provides for
reinvestment of our cash distributions and other distributions
on behalf of our stockholders, unless a stockholder elects to
receive cash as provided below. As a result, if our Board
authorizes, and we declare, a cash distribution, then our
stockholders who have not opted out of our dividend
reinvestment plan have their cash distribution automatically
reinvested in additional shares of our common stock, rather than
receiving the cash distribution.
No action is required on the part of a registered stockholder to
have their cash distribution reinvested in shares of our common
stock. A registered stockholder may elect to receive an entire
distribution in cash by notifying The Bank of New York Mellon,
the plan administrator and our transfer agent and registrar, in
writing so that such notice is received by the plan
administrator no later than 10 days prior to the record
date for distributions to stockholders. The plan administrator
sets up an account for shares acquired through the plan for each
stockholder who has not elected to receive dividends or other
distributions in cash and holds such shares in non-certificated
form. Upon request by a stockholder participating in the plan,
received in writing not less than 10 days prior to the
record date, the plan administrator will, instead of crediting
shares to the participants account, issue a certificate
registered in the participants name for the number of
whole shares of our common stock and a check for any fractional
share.
Those stockholders whose shares are held by a broker or other
financial intermediary may receive distributions in cash by
notifying their broker or other financial intermediary of their
election.
We intend to use primarily newly issued shares to implement the
plan, whether our shares are trading at a premium or at a
discount to net asset value. However, we reserve the right to
purchase shares in the open market in connection with our
implementation of the plan. The number of shares to be issued to
a stockholder is determined by dividing the total dollar amount
of the dividend payable to such stockholder by the market price
per share of our common stock at the close of regular trading on
NASDAQ on the valuation date, which date shall be as close as
practicable to the dividend payment date for such dividend.
Market price per share on that date will be the closing price
for such shares on NASDAQ or, if no sale is reported for such
day, at the average of their reported bid and asked prices. The
number of shares of our common stock to be outstanding after
giving effect to payment of the dividend cannot be established
until the value per share at which additional shares will be
issued has been determined and elections of our stockholders
have been tabulated. Stockholders who do not elect to receive
distributions in shares of common stock may experience accretion
to the net asset value of their shares if our shares are trading
at a premium at the time we issue new shares under the plan and
dilution if our shares are trading at a discount. The level of
accretion or discount would depend on various factors, including
the proportion of our stockholders who participate in the plan,
the level of premium or discount at which our shares are trading
and the amount of the dividend payable to a stockholder.
There are no brokerage charges or other charges to stockholders
who participate in the plan. The plan administrators fees
under the plan are paid by us. If a participant elects by
written notice to the plan administrator to have the plan
administrator sell part or all of the shares held by the plan
administrator in the participants account and remit the
proceeds to the participant, the plan administrator is
authorized to deduct a $15.00 transaction fee plus a $0.10 per
share trading fee from the proceeds.
Stockholders who receive distributions in the form of stock are
subject to the same federal, state and local tax consequences as
are stockholders who elect to receive their dividends in cash. A
stockholders basis for determining gain or loss upon the
sale of stock received in a dividend from us is equal to the
total dollar amount of the dividend payable to the stockholder.
Any stock received in a dividend has a new holding period for
tax purposes commencing on the day following the day on which
the shares are credited to the U.S. stockholders
account. See Material U.S. Federal Income Tax
Considerations.
Participants may terminate their accounts under the plan by
notifying the plan agent via its website at
www.bnymellon.com/shareowner/isd, by filling out the transaction
request form located at bottom of their statement and sending it
to the plan agent at
c/o Computershare
Shareowner Services LLC, P.O. Box 358035, Pittsburgh,
Pennsylvania
15252-8035
or by calling the plan administrator at
877-296-3711.
94
The plan may be terminated by us upon notice in writing mailed
to each participant. All correspondence concerning the plan
should be directed to the plan administrator by mail at Plan
Administrator
c/o Computershare
Shareowner Services LLC, P.O. Box 358035, Pittsburgh,
Pennsylvania
15252-8035.
If you withdraw or the plan is terminated, the plan
administrator will continue to hold your shares in book-entry
form unless you request that such shares be sold or issued. Upon
receipt of your instructions, a certificate for each whole share
in your account under the plan will be issued and you will
receive a cash payment for any fraction of a share in your
account.
If you hold your common stock with a brokerage firm that does
not participate in the plan, you are not able to participate in
the plan and any dividend reinvestment may be effected on
different terms than those described above. Consult your
financial advisor for more information.
95
DESCRIPTION
OF SECURITIES THAT WE MAY ISSUE
This prospectus contains a summary of the common stock,
preferred stock, subscription rights, debt securities and
warrants that we may issue. These summaries are not meant to be
a complete description of each security. However, this
prospectus and the accompanying prospectus supplement will
contain the material terms and conditions for each security.
Set forth below is a chart describing the shares of our capital
stock authorized and outstanding as of February 3, 2012:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount Outstanding
|
|
|
|
|
|
|
Exclusive of Amount
|
|
|
|
|
Amount Held by Us
|
|
Held by Us or for
|
Title of Class
|
|
Amount Authorized
|
|
or for Our Account
|
|
Our Account
|
|
Common Stock
|
|
|
100,000,000
|
|
|
|
|
|
|
|
7,636,532
|
|
Preferred Stock
|
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
96
DESCRIPTION
OF COMMON STOCK THAT WE MAY ISSUE
General
The following description does not purport to be complete and
is subject to the provisions of our certificate of incorporation
and bylaws, each of which are filed as exhibits to this
registration statement. The description is qualified in its
entirety by reference to our certificate of incorporation and
bylaws and to applicable law.
Under the terms of our certificate of incorporation, our
authorized common stock consists solely of
100,000,000 shares, par value $0.001 per share, of which
7,636,532 shares were outstanding as of February 3,
2012. Our common stock is traded on NASDAQ under the symbol
HRZN. There are no outstanding options or warrants
to purchase our stock. No stock has been authorized for issuance
under any equity compensation plans. Our Board is authorized to
classify and reclassify any unissued shares of stock into other
classes or series of stock without obtaining stockholder
approval. As permitted by the DGCL, our Board may, without any
action by our stockholders, amend our certificate of
incorporation from time to time to increase or decrease the
aggregate number of shares of stock or the number of shares of
stock of any class or series that we have authority to issue.
Under the DGCL, our stockholders generally are not personally
liable for our debts or obligations.
Under the terms of our certificate of incorporation, all shares
of our common stock have equal rights as to earnings, assets,
dividends and voting. When they are issued, shares of our common
stock will be duly authorized, validly issued, fully paid and
non-assessable. Distributions may be paid to the holders of our
common stock if, as and when declared by our Board out of assets
legally available therefor, subject to any preferential dividend
rights of outstanding preferred stock. Holders of common stock
are entitled to one vote for each share held on all matters
submitted to a vote of stockholders, including the election of
directors, and do not have cumulative voting rights.
Accordingly, holders of a majority of the shares of common stock
entitled to vote in any election of directors may elect all of
the directors standing for election. Upon our liquidation,
dissolution or winding up, the holders of common stock are
entitled to receive ratably our net assets available after the
payment of all debts and other liabilities and subject to the
prior rights of any outstanding preferred stock. Holders of
common stock have no preemptive, subscription, redemption or
conversion rights. The rights, preferences and privileges of
holders of common stock are subject to the rights of the holders
of any series of preferred stock which we may designate and
issue in the future. In addition, holders of our common stock
may participate in our dividend reinvestment plan.
Anti-takeover
Effects of Provisions of Our Certificate of Incorporation,
Bylaws, the DGCL and Other Arrangements
Certain provisions of our certificate of incorporation and
bylaws, applicable provisions of the DGCL and certain other
agreements to which we are a party may make it more difficult
for or prevent an unsolicited third party from acquiring control
of us or changing our Board and management. These provisions may
have the effect of deterring hostile takeovers or delaying
changes in our control or in our management. These provisions
are intended to enhance the likelihood of continued stability in
the composition of our Board and in the policies furnished by
them and to discourage certain types of transactions that may
involve an actual or threatened change in our control. The
provisions also are intended to discourage certain tactics that
may be used in proxy fights. These provisions, however, could
have the effect of discouraging others from making tender offers
for our shares and, as a consequence, they also may inhibit
fluctuations in the market price of our shares that could result
from actual or rumored takeover attempts.
Election of Directors. Our certificate of
incorporation and bylaws provide that the affirmative vote of a
plurality of all votes cast at a meeting of stockholders duly
called at which a quorum is present shall be sufficient to elect
a director. Under our certificate of incorporation, our Board
may amend the bylaws to alter the vote required to elect
directors.
Classified Board of Directors. The
classification of our Board and the limitations on removal of
directors and filling of vacancies could have the effect of
making it more difficult for a third party to acquire us, or of
discouraging a third party from acquiring us. Our Board is
divided into three classes, with the term of one class expiring
at each annual meeting of stockholders. At each annual meeting,
one class of directors is elected to a three-year term. This
provision could delay for up to two years the replacement of a
majority of our Board.
97
Number of Directors; Vacancies; Removal. Our
certificate of incorporation provides that, by amendment to our
bylaws, our Board is authorized to change the number of
directors without the consent of stockholders to any number
between three and nine.
Our certificate of incorporation provides that, subject to the
rights of any holders of preferred stock, any vacancy on our
Board, however the vacancy occurs, including a vacancy due to an
enlargement of our Board, may only be filled by vote of a
majority of the directors then in office.
Subject to the rights of any holders of preferred stock, a
director may be removed at any time at a meeting called for that
purpose, but only for cause and only by the affirmative vote of
the holders of at least 75% of the shares then entitled to vote
for the election of the respective director.
The limitations on the ability of our stockholders to remove
directors and fill vacancies could make it more difficult for a
third party to acquire, or discourage a third party from seeking
to acquire, control of us.
Action by Stockholders. Under our certificate
of incorporation and bylaws, stockholder action can only be
taken at an annual meeting or special meeting and not by written
action in lieu of a meeting. This may have the effect of
delaying consideration of a stockholder proposal until the next
annual meeting.
Advance Notice Requirements for Stockholder Proposals and
Director Nominations. Our bylaws provide that
with respect to an annual meeting of stockholders, nominations
of persons for election to our Board and the proposal of
business to be considered by stockholders may be made only
(1) by or at the direction of our Board, (2) pursuant
to our notice of meeting or (3) by a stockholder who is
entitled to vote at the meeting and who has complied with the
advance notice procedures of the bylaws. Nominations of persons
for election to our Board at a special meeting may be made only
(1) by or at the direction of our Board, or
(2) provided that our Board has determined that directors
will be elected at the meeting, by a stockholder who is entitled
to vote at the meeting and who has complied with the advance
notice provisions of the bylaws. The purpose of requiring
stockholders to give us advance notice of nominations and other
business is to afford our Board a meaningful opportunity to
consider the qualifications of the proposed nominees and the
advisability of any other proposed business and, to the extent
deemed necessary or desirable by our Board, to inform our
stockholders and make recommendations about such qualifications
or business, as well as to provide a more orderly procedure for
conducting meetings of stockholders. Although our bylaws do not
give our Board any power to disapprove stockholder nominations
for the election of directors or proposals recommending certain
action, they may have the effect of precluding a contest for the
election of directors or the consideration of stockholder
proposals if proper procedures are not followed and of
discouraging or deterring a third party from conducting a
solicitation of proxies to elect its own slate of directors or
to approve its own proposal without regard to whether
consideration of such nominees or proposals might be harmful or
beneficial to us and our stockholders.
Amendments to Certificate of Incorporation and
Bylaws. The DGCL provides generally that the
affirmative vote of a majority of the shares entitled to vote on
any matter is required to amend a corporations certificate
of incorporation or bylaws, unless a corporations
certificate of incorporation or bylaws requires a greater
percentage. Our certificate of incorporation provides that the
affirmative vote of 75% of the then outstanding shares entitled
to vote generally in the election of directors voting together
as a single class is required to amend provisions of our
certificate of incorporation relating to the classification,
size and vacancies of our Board, as well as the removal of
directors. However, if
66 2/3%
of the continuing directors have approved such amendment or
repeal, the affirmative vote for such amendment or repeal shall
be a majority of such shares. The affirmative vote of 75% of the
then outstanding shares voting together as a single class is
required to amend provisions of our certificate of incorporation
relating to the calling of a special meeting of stockholders or
the ability to amend or repeal the bylaws. Our certificate of
incorporation permits our Board to amend or repeal our bylaws,
provided that any amendment or repeal shall require the approval
of at least
66 2/3%
of the continuing directors. The stockholders do not have the
right to adopt or repeal the bylaws.
Stockholder Meetings. Our certificate of
incorporation and bylaws provide that any action required or
permitted to be taken by stockholders at an annual meeting may
only be taken if it is properly brought before such meeting. For
business to be properly brought before an annual meeting by a
stockholder, the stockholder must provide timely notice to our
Secretary. Notice is timely if it is delivered by a nationally
recognized courier service or
98
mailed by first class United States mail and received not
earlier than 90 days nor more than 120 days in advance
of the anniversary of the date our proxy statement was released
to stockholders in connection with the previous years
annual meeting. Action taken at a special meeting of
stockholders is limited to the purposes stated in the properly
provided notice of meeting. These provisions could have the
effect of delaying until the next stockholder meeting actions
that are favored by the holders of a majority of our outstanding
voting securities.
Calling of Special Meetings by
Stockholders. Our certificate of incorporation
and bylaws provide that special meetings of the stockholders may
only be called by our Board, Chairman, Chief Executive Officer
or President.
Section 203 of the DGCL. We are subject
to the provisions of Section 203 of the DGCL. In general,
these provisions prohibit a Delaware corporation from engaging
in any business combination with any interested stockholder for
a period of three years following the date that the stockholder
became an interested stockholder, unless:
|
|
|
|
|
prior to such time, the board of directors approved either the
business combination or the transaction which resulted in the
stockholder becoming an interested stockholder;
|
|
|
|
upon consummation of the transaction that resulted in the
stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the
corporation outstanding at the time the transaction
commenced; or
|
|
|
|
on or after the date the business combination is approved by the
board of directors and authorized at a meeting of stockholders,
by at least two-thirds of the outstanding voting stock that is
not owned by the interested stockholder.
|
Section 203 defines business combination to
include the following:
|
|
|
|
|
any merger or consolidation involving the corporation and the
interested stockholder;
|
|
|
|
any sale, transfer, pledge or other disposition (in one
transaction or a series of transactions) of 10% or more of
either the aggregate market value of all the assets of the
corporation or the aggregate market value of all the outstanding
stock of the corporation involving the interested stockholder;
|
|
|
|
subject to certain exceptions, any transaction that results in
the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder;
|
|
|
|
any transaction involving the corporation that has the effect of
increasing the proportionate share of the stock of any class or
series of the corporation owned by the interested
stockholder; or
|
|
|
|
the receipt by the interested stockholder of the benefit of any
loans, advances, guarantees, pledges or other financial benefits
provided by or through the corporation.
|
In general, Section 203 defines an interested stockholder
as any entity or person beneficially owning 15% or more of the
outstanding voting stock of the corporation and any entity or
person affiliated with or controlling or controlled by any of
these entities or persons.
The statute could prohibit or delay mergers or other takeover or
change in control attempts and, accordingly, may discourage
attempts to acquire us.
Conflict with 1940 Act. Our bylaws provide
that, if and to the extent that any provision of the DGCL or our
bylaws conflict with any provision of the 1940 Act, the
applicable provision of the 1940 Act will control.
Approval of Certain Transactions. To convert
us to an open-end investment company, to merge or consolidate us
with any entity in a transaction as a result of which the
governing documents of the surviving entity do not contain
substantially the same anti-takeover provisions as are provided
in our certificate of incorporation, to liquidate and dissolve
us, or to amend any of the anti-takeover provisions discussed
herein, our certificate of incorporation requires the
affirmative vote of a majority of our continuing directors
followed by the favorable vote of the holders of at least 75% of
each affected class or series of our shares, voting separately
as a class or series, unless such amendment has been approved by
the holders of at least 80% of the then outstanding shares of
our capital stock, voting together as a single class. If
approved in the foregoing manner, our conversion to an open-end
99
investment company could not occur until 90 days after the
stockholders meeting at which such conversion was approved and
would also require at least 30 days prior notice to all
stockholders. As part of any such conversion to an open-end
investment company, substantially all of our investment policies
and strategies and portfolio would have to be modified to assure
the degree of portfolio liquidity required for open-end
investment companies. In the event of conversion, the common
shares would cease to be listed on any national securities
exchange or market system. Stockholders of an open-end
investment company may require the company to redeem their
shares at any time, except in certain circumstances as
authorized by or under the 1940 Act, at their net asset value,
less such redemption charge, if any, as might be in effect at
the time of a redemption. You should assume that it is not
likely that our Board would vote to convert us to an open-end
fund.
The 1940 Act defines a majority of the outstanding voting
securities as the lesser of a majority of the outstanding
shares and 67% of a quorum of a majority of the outstanding
shares. For the purposes of calculating a majority of the
outstanding voting securities under our certificate of
incorporation, each class and series of our shares vote together
as a single class, except to the extent required by the 1940 Act
or our certificate of incorporation, with respect to any class
or series of shares. If a separate class vote is required, the
applicable proportion of shares of the class or series, voting
as a separate class or series, also will be required.
Our Board has determined that provisions with respect to our
Board and the stockholder voting requirements described above,
which voting requirements are greater than the minimum
requirements under the DGCL or the 1940 Act, are in the best
interest of stockholders generally.
Our WestLB Facility also contains a covenant that prohibits us
from merging or consolidating with any other person or selling
all or substantially all of our assets without the prior written
consent of WestLB. If we were to engage in such a transaction
without such consent, WestLB could accelerate our repayment
obligations under,
and/or
terminate, our WestLB Facility. In addition, it is a default
under our Wells Facility if (i) a person or group of
persons (within the meaning of the Exchange Act) acquires
beneficial ownership of 20% or more of our issued and
outstanding stock or (ii) during any twelve month period
individuals who at the beginning of such period constituted our
Board cease for any reason, other than death or disability, to
constitute a majority of the directors in office. If either
event were to occur, Wells could accelerate our repayment
obligations under,
and/or
terminate, our Wells Facility. See Managements
Discussion and Analysis of Financial Condition and Results of
Operations Liquidity and Capital
Resources Current Borrowings.
Limitations
of liability and indemnification
The indemnification of our officers and directors is governed by
Section 145 of the DGCL, and our certificate of
incorporation and bylaws. Subsection (a) of the DGCL
Section 145 empowers a corporation to indemnify any person
who was or is a party or is threatened to be made a party to any
threatened, pending or completed action, suit or proceeding,
whether civil, criminal, administrative or investigative (other
than an action by or in the right of the corporation) by reason
of the fact that the person is or was a director, officer,
employee or agent of the corporation, or is or was serving at
the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture,
trust or other enterprise, against expenses (including
attorneys fees), judgments, fines and amounts paid in
settlement actually and reasonably incurred by the person in
connection with such action, suit or proceeding if (1) such
person acted in good faith, (2) in a manner such person
reasonably believed to be in or not opposed to the best
interests of the corporation and (3) with respect to any
criminal action or proceeding, such person had no reasonable
cause to believe the persons conduct was unlawful.
Subsection (b) of the DGCL Section 145 empowers a
corporation to indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation
to procure a judgment in its favor by reason of the fact that
the person is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other
enterprise against expenses (including attorneys fees)
actually and reasonably incurred by such person in connection
with the defense or settlement of such action or suit if such
person acted in good faith and in a manner the person reasonably
believed to be in, or not opposed to, the best interests of the
corporation, and except that no indemnification may be made in
respect of any claim, issue or matter as to which such person
has been adjudged to be liable to the corporation unless
100
and only to the extent that the Delaware Court of Chancery or
the court in which such action or suit was brought determines
upon application that, despite the adjudication of liability but
in view of all the circumstances of the case, such person is
fairly and reasonably entitled to indemnity for such expenses
which the Delaware Court of Chancery or such other court deems
proper.
The DGCL Section 145 further provides that to the extent
that a present or former director or officer is successful, on
the merits or otherwise, in the defense of any action, suit or
proceeding referred to in subsections (a) and (b) of
Section 145, or in defense of any claim, issue or matter
therein, such person will be indemnified against expenses
(including attorneys fees) actually and reasonably
incurred by such person in connection with such action, suit or
proceeding. In all cases in which indemnification is permitted
under subsections (a) and (b) of Section 145
(unless ordered by a court), it will be made by the corporation
only as authorized in the specific case upon a determination
that indemnification of the present or former director, officer,
employee or agent is proper in the circumstances because the
applicable standard of conduct has been met by the party to be
indemnified. Such determination must be made, with respect to a
person who is a director or officer at the time of such
determination, (1) by a majority vote of the directors who
are not parties to such action, suit or proceeding, even though
less than a quorum, (2) by a committee of such directors
designated by majority vote of such directors, even though less
than a quorum, (3) if there are no such directors, or if
such directors so direct, by independent legal counsel in a
written opinion or (4) by the stockholders. The statute
authorizes the corporation to pay expenses incurred by an
officer or director in advance of the final disposition of a
proceeding upon receipt of an undertaking by or on behalf of the
person to whom the advance will be made, to repay the advances
if it is ultimately determined that he or she was not entitled
to indemnification. The DGCL Section 145 also provides that
indemnification and advancement of expenses permitted under such
Section are not to be exclusive of any other rights to which
those seeking indemnification or advancement of expenses may be
entitled under any bylaw, agreement, vote of stockholders or
disinterested directors, or otherwise. The DGCL Section 145
also authorizes the corporation to purchase and maintain
liability insurance on behalf of its directors, officers,
employees and agents regardless of whether the corporation would
have the statutory power to indemnify such persons against the
liabilities insured.
Our certificate of incorporation provides that our directors
will not be liable to us or our stockholders for monetary
damages for breach of fiduciary duty as a director to the
fullest extent permitted by the DGCL. The DGCL
Section 102(b)(7) provides that the personal liability of a
director to a corporation or its stockholders for breach of
fiduciary duty as a director may be eliminated except for
liability (1) for any breach of the directors duty of
loyalty to the corporation or its stockholders, (2) for
acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law, (3) under
Section 174 of the DGCL, relating to unlawful payment of
dividends or unlawful stock purchases or redemption of stock or
(4) for any transaction from which the director derives an
improper personal benefit.
Under our certificate of incorporation, we fully indemnify any
person who was or is involved in any actual or threatened
action, suit or proceeding by reason of the fact that such
person is or was one of our directors or officers. So long as we
are regulated under the 1940 Act, the above indemnification and
limitation of liability is limited by the 1940 Act or by any
valid rule, regulation or order of the SEC thereunder. The 1940
Act provides, among other things, that a company may not
indemnify any director or officer against liability to it or its
security holders to which he or she might otherwise be subject
by reason of his or her willful misfeasance, bad faith, gross
negligence or reckless disregard of the duties involved in the
conduct of his or her office unless a determination is made by
final decision of a court, by vote of a majority of a quorum of
directors who are disinterested, non-party directors or by
independent legal counsel that the liability for which
indemnification is sought did not arise out of the foregoing
conduct.
We have obtained liability insurance for our directors and
officers. In addition, we have entered into indemnification
agreements with each of our directors and officers in order to
effect the foregoing except to the extent that such
indemnification would exceed the limitations on indemnification
under Section 17(h) of the 1940 Act.
101
DESCRIPTION
OF PREFERRED STOCK THAT WE MAY ISSUE
Under the terms of our certificate of incorporation, our
authorized preferred stock consists of 1,000,000 shares,
par value $0.001 per share, of which no shares were outstanding
as of February 3, 2012, and our Board is authorized to
issue shares of preferred stock in one or more series without
stockholder approval. Particular terms of any preferred stock we
offer will be described in the prospectus supplement relating to
such preferred stock shares.
Our Board has discretion to determine the rights, preferences,
privileges and restrictions, including voting rights, dividend
rights, conversion rights, redemption privileges and liquidation
preferences of each series of preferred stock. Every issuance of
preferred stock will be required to comply with the requirements
of the 1940 Act. The 1940 Act limits our flexibility as to
certain rights and preferences of the preferred stock that our
certificate of incorporation may provide and requires, among
other things, that (1) immediately after issuance and
before any distribution is made with respect to our common
stock, and before any purchase of common stock is made, such
preferred stock together with all other senior securities must
not exceed an amount equal to 50% of our total assets after
deducting the amount of such dividend, distribution or purchase
price, as the case may be, (2) the holders of shares of
preferred stock, if any are issued, must be entitled as a class
to elect two directors at all times and to elect a majority of
the directors if and for so long as dividends on the preferred
stock are in arrears by two years or more and (3) such
shares be cumulative as to dividends and have a complete
preference over our common stock to payment of their liquidation
preference in the event of a dissolution. Certain matters under
the 1940 Act require the separate vote of the holders of any
issued and outstanding preferred stock. For example, holders of
preferred stock would vote separately from the holders of common
stock on a proposal to cease operations as a BDC. The features
of the preferred stock will be further limited by the
requirements applicable to RICs under the Code. The purpose of
authorizing our Board to issue preferred stock and determine its
rights and preferences is to eliminate delays associated with a
stockholder vote on specific issuances. The issuance of
preferred stock, while providing desirable flexibility in
connection with providing leverage for our investment program,
possible acquisitions and other corporate purposes, could make
it more difficult for a third party to acquire, or could
discourage a third party from acquiring, a majority of our
outstanding voting stock.
For any series of preferred stock that we may issue, our Board
will determine, and the prospectus supplement relating to such
series will describe:
|
|
|
|
|
the designation and number of shares of such series;
|
|
|
|
the rate and time at which, and the preferences and conditions
under which, any dividends will be paid on shares of such
series, as well as whether such dividends are participating or
non-participating;
|
|
|
|
any provisions relating to convertibility or exchangeability of
the shares of such series;
|
|
|
|
the rights and preferences, if any, of holders of shares of such
series upon our liquidation, dissolution or winding up of our
affairs;
|
|
|
|
the voting powers, if any, of the holders of shares of such
series;
|
|
|
|
any provisions relating to the redemption of the shares of such
series;
|
|
|
|
any limitations on our ability to pay dividends or make
distributions on, or acquire or redeem, other securities while
shares of such series are outstanding;
|
|
|
|
any conditions or restrictions on our ability to issue
additional shares of such series or other securities;
|
|
|
|
if applicable, a discussion of certain U.S. federal income
tax considerations; and
|
|
|
|
any other relative power, preferences and participating,
optional or special rights of shares of such series, and the
qualifications, limitations or restrictions thereof.
|
The preferred stock may be either fixed rate preferred stock or
variable rate preferred stock, which is sometimes referred to as
auction rate preferred stock. All shares of
preferred stock that we may issue will be identical and of equal
rank except as to the particular terms thereof that may be fixed
by our Board, and all shares of each series of preferred stock
will be identical and of equal rank except as to the dates from
which cumulative dividends, if any, thereon will be cumulative.
If we issue shares of preferred stock, holders of such preferred
stock will be entitled to receive cash dividends at an annual
rate that will be fixed or will vary for the successive dividend
periods for each series. In general, the dividend periods for
fixed rate preferred stock can range from quarterly to weekly
and are subject to extension.
102
DESCRIPTION
OF SUBSCRIPTION RIGHTS THAT WE MAY ISSUE
We may issue subscription rights to purchase common stock.
Subscription rights may be issued independently or together with
any other offered security and may or may not be transferable by
the person purchasing or receiving the subscription rights. In
connection with any subscription rights offering to our
stockholders, we may enter into a standby underwriting or other
arrangement with one or more underwriters or other persons
pursuant to which such underwriters or other persons would
purchase any offered securities remaining unsubscribed for after
such subscription rights offering. We will not offer
transferable subscription rights to our stockholders at a price
equivalent to less than the then current net asset value per
share of common stock, excluding underwriting commissions,
unless we first file a post-effective amendment that is declared
effective by the SEC with respect to such issuance and the
common stock to be purchased in connection with the rights
represents no more than one-third of our outstanding common
stock at the time such rights are issued. In connection with a
subscription rights offering to our stockholders, we would
distribute certificates evidencing the subscription rights and a
prospectus supplement to our stockholders on the record date
that we set for receiving subscription rights in such
subscription rights offering. Our common stockholders will
indirectly bear the expenses of such subscription rights
offerings, regardless of whether our common stockholders
exercise any subscription rights.
The applicable prospectus supplement would describe the
following terms of subscription rights in respect of which this
prospectus is being delivered:
|
|
|
|
|
the title of such subscription rights;
|
|
|
|
the exercise price or a formula for the determination of the
exercise price for such subscription rights;
|
|
|
|
the number or a formula for the determination of the number of
such subscription rights issued to each stockholder;
|
|
|
|
the extent to which such subscription rights are transferable;
|
|
|
|
if applicable, a discussion of the material U.S. federal
income tax considerations applicable to the issuance or exercise
of such subscription rights;
|
|
|
|
the date on which the right to exercise such subscription rights
would commence, and the date on which such rights shall expire
(subject to any extension);
|
|
|
|
the extent to which such subscription rights include an
over-subscription privilege with respect to unsubscribed
securities;
|
|
|
|
if applicable, the material terms of any standby underwriting or
other purchase arrangement that we may enter into in connection
with the subscription rights offering; and
|
|
|
|
any other terms of such subscription rights, including terms,
procedures and limitations relating to the exchange and exercise
of such subscription rights.
|
Exercise
of Subscription Rights
Each subscription right would entitle the holder of the
subscription right to purchase for cash such amount of shares of
common stock at such exercise price as shall in each case be set
forth in, or be determinable as set forth in, the prospectus
supplement relating to the subscription rights offered thereby
or another report filed with the SEC. Subscription rights may be
exercised at any time up to the close of business on the
expiration date for such subscription rights set forth in the
applicable prospectus supplement. After the close of business on
the expiration date, all unexercised subscription rights would
become void.
Subscription rights may be exercised as set forth in the
prospectus supplement relating to the subscription rights
offered thereby. Upon receipt of payment and the subscription
rights certificate properly completed and duly executed at the
corporate trust office of the subscription rights agent or any
other office indicated in the prospectus supplement, we will
forward, as soon as practicable, the shares of common stock
purchasable upon such exercise. We may determine to offer any
unsubscribed offered shares of common stock directly to
stockholders, persons other than stockholders, to or through
agents, underwriters or dealers or through a combination of such
methods, including pursuant to standby underwriting or other
arrangements, as set forth in the applicable prospectus
supplement. We have not previously completed such an offering of
subscription rights.
103
DESCRIPTION
OF DEBT SECURITIES THAT WE MAY ISSUE
We may issue debt securities in one or more series in the future
that, if publically offered, will be under an indenture to be
entered into between the Company and a trustee. The specific
terms of each series of debt securities we publically offer will
be described in the particular prospectus supplement relating to
that series. For a complete description of the terms of a
particular series of debt securities, you should read both this
prospectus and the prospectus supplement relating to that
particular series.
The prospectus supplement, which will accompany this prospectus,
will describe the particular series of debt securities being
offered by including:
|
|
|
|
|
the designation or title of the series of debt securities;
|
|
|
|
the total principal amount of the series of debt securities;
|
|
|
|
the percentage of the principal amount at which the series of
debt securities will be offered;
|
|
|
|
the date or dates on which principal will be payable;
|
|
|
|
the rate or rates (which may be either fixed or variable)
and/or the
method of determining such rate or rates of interest, if any;
|
|
|
|
the date or dates from which any interest will accrue, or the
method of determining such date or dates, and the date or dates
on which any interest will be payable;
|
|
|
|
the terms for redemption, extension or early repayment, if any;
|
|
|
|
the currencies in which the series of debt securities are issued
and payable;
|
|
|
|
whether the amount of payments of principal, premium or
interest, if any, on a series of debt securities will be
determined with reference to an index, formula or other method
(which could be based on one or more currencies, commodities,
equity indices or other indices) and how these amounts will be
determined;
|
|
|
|
the place or places of payment, transfer, conversion
and/or
exchange of the debt securities;
|
|
|
|
the denominations in which the offered debt securities will be
issued;
|
|
|
|
the provision for any sinking fund;
|
|
|
|
any restrictive covenants;
|
|
|
|
whether the series of debt securities are issuable in
certificated form;
|
|
|
|
any provisions for defeasance or covenant defeasance;
|
|
|
|
any special federal income tax implications, including, if
applicable, U.S. federal income tax considerations relating to
original issue discount;
|
|
|
|
whether and under what circumstances we will pay additional
amounts in respect of any tax, assessment or governmental charge
and, if so, whether we will have the option to redeem the debt
securities rather than pay the additional amounts (and the terms
of this option);
|
|
|
|
any provisions for convertibility or exchangeability of the debt
securities into or for any other securities;
|
|
|
|
whether the debt securities are subject to subordination and the
terms of such subordination; and
|
|
|
|
any other material terms.
|
Any debt securities we issue may be secured or unsecured
obligations. Under the provisions of the 1940 Act, we are
permitted, as a BDC, to issue debt only in amounts such that our
asset coverage, as defined in the 1940 Act, equals at least 200%
after each issuance of debt. Unless the prospectus supplement
states otherwise, principal (and premium, if any) and interest,
if any, will be paid by us in immediately available funds. In
addition, while any indebtedness and other senior securities
remain outstanding, we must make provisions to prohibit any
distribution to our stockholders or the repurchase of such
securities or shares unless we meet the applicable asset
coverage ratios at the time of the distribution or repurchase.
We may also borrow amounts up to 5% of the value of our total
assets for temporary or emergency purposes without regard to
asset coverage. For a discussion of the risks associated with
leverage, see Risk Factors Risks Relating to
Our Business and Structure Regulations governing our
operation as a BDC may limit our ability to, and the way in
which we, raise additional capital, which may expose us to
additional risks.
104
DESCRIPTION
OF WARRANTS THAT WE MAY ISSUE
The following is a general description of the terms of the
warrants we may issue from time to time. Particular terms of any
warrants we offer will be described in the prospectus supplement
relating to such warrants.
We may issue warrants to purchase shares of our common stock,
preferred stock or debt securities. Such warrants may be issued
independently or together with shares of common or preferred
stock or a specified principal amount of debt securities and may
be attached or separate from such securities. We will issue each
series of warrants under a separate warrant agreement to be
entered into between us and a warrant agent. The warrant agent
will act solely as our agent and will not assume any obligation
or relationship of agency for or with holders or beneficial
owners of warrants.
A prospectus supplement will describe the particular terms of
any series of warrants we may issue, including the following:
|
|
|
|
|
the title of such warrants;
|
|
|
|
the aggregate number of such warrants;
|
|
|
|
the price or prices at which such warrants will be issued;
|
|
|
|
the currency or currencies, including composite currencies, in
which the price of such warrants may be payable;
|
|
|
|
if applicable, the designation and terms of the securities with
which the warrants are issued and the number of warrants issued
with each such security or each principal amount of such
security;
|
|
|
|
in the case of warrants to purchase debt securities, the
principal amount of debt securities purchasable upon exercise of
one warrant and the price at which and the currency or
currencies, including composite currencies, in which this
principal amount of debt securities may be purchased upon such
exercise;
|
|
|
|
in the case of warrants to purchase common stock or preferred
stock, the number of shares of common stock or preferred stock,
as the case may be, purchasable upon exercise of one warrant and
the price at which and the currency or currencies, including
composite currencies, in which these shares may be purchased
upon such exercise;
|
|
|
|
the date on which the right to exercise such warrants shall
commence and the date on which such right will expire;
|
|
|
|
whether such warrants will be issued in registered form or
bearer form;
|
|
|
|
if applicable, the minimum or maximum amount of such warrants
which may be exercised at any one time;
|
|
|
|
if applicable, the date on and after which such warrants and the
related securities will be separately transferable;
|
|
|
|
terms of any rights to redeem or call such warrants;
|
|
|
|
information with respect to book-entry procedures, if any;
|
|
|
|
the terms of the securities issuable upon exercise of the
warrants;
|
|
|
|
if applicable, a discussion of certain U.S. federal income
tax considerations; and
|
|
|
|
any other terms of such warrants, including terms, procedures
and limitations relating to the exchange and exercise of such
warrants.
|
We and the warrant agent may amend or supplement the warrant
agreement for a series of warrants without the consent of the
holders of the warrants issued thereunder to effect changes that
are not inconsistent with the provisions of the warrants and
that do not materially and adversely affect the interests of the
holders of the warrants.
Prior to exercising their warrants, holders of warrants will not
have any of the rights of holders of the securities purchasable
upon such exercise, including, in the case of warrants to
purchase debt securities, the right to receive
105
principal, premium, if any, or interest payments, on the debt
securities purchasable upon exercise or to enforce covenants in
the applicable indenture or, in the case of warrants to purchase
common stock or preferred stock, the right to receive dividends,
if any, or payments upon our liquidation, dissolution or winding
up or to exercise any voting rights.
Under the 1940 Act, we may generally only offer warrants
provided that (1) the warrants expire by their terms within
ten years; (2) the exercise or conversion price is not less
than the current market value at the date of issuance;
(3) our stockholders authorize the proposal to issue such
warrants, and our Board approves such issuance on the basis that
the issuance is in our best interests and the best interests of
our stockholders; and (4) if the warrants are accompanied
by other securities, the warrants are not separately
transferable unless no class of such warrants and the securities
accompanying them has been publicly distributed. The 1940 Act
also provides that the amount of our voting securities that
would result from the exercise of all outstanding warrants, as
well as options and rights, at the time of issuance may not
exceed 25% of our outstanding voting securities.
106
SHARES ELIGIBLE
FOR FUTURE SALE
Future sales of substantial amounts of our common stock in the
public market, or the perception that such sales may occur,
could adversely affect the market price of our common stock and
could impair our future ability to raise capital through the
sale of our equity securities.
As of February 3, 2012, we had 7,636,532 shares of our
common stock outstanding, 1,334,002 of which are
restricted securities within the meaning of
Rule 144 promulgated under the Securities Act and may not
be sold in the absence of registration under the Securities Act
unless an exemption from registration is available, including
under the safe harbor provisions contained in Rule 144.
Pursuant to a registration rights agreement, we have agreed to
file one or more registration statements in respect of the
shares of common stock that are restricted securities. We (and,
therefore, indirectly our stockholders) will bear customary
costs and expenses incurred in connection with the registration
of such shares, although any selling stockholders will be
responsible for underwriting discounts and selling commissions
in a demand registration and their pro rata share of the
underwriting discounts and selling commissions in a piggyback
registration. This registration statement registers
1,322,669 shares of common stock that are
restricted securities.
Rule 144
In general, a person who has beneficially owned restricted
shares of our common stock for at least six months would be
entitled to sell their securities provided that (i) such
person is not deemed to have been one of our affiliates at the
time of, or at any time during the 90 days preceding, a
sale and (ii) we are subject to the Exchange Act periodic
reporting requirements for at least 90 days before the
sale. Persons who have beneficially owned restricted shares of
our common stock for at least six months but who are our
affiliates at the time of, or any time during the 90 days
preceding, a sale, would be subject to additional restrictions
by which such person would be entitled to sell within any
three-month period only a number of securities that does not
exceed the greater of either of the following:
|
|
|
|
|
1% of the number of shares of our common stock then
outstanding; or
|
|
|
|
the average weekly trading volume of our common stock on NASDAQ
for the four calendar weeks prior to the sale.
|
Such sales must also comply with the manner of sale, current
public information and notice provisions of Rule 144.
107
SELLING
STOCKHOLDERS
Below is information with respect to the number of shares of
common stock owned by each of the selling stockholders. This
common stock is being registered pursuant to our contractual
commitment to the selling stockholders under the registration
rights agreement to permit public secondary trading of such
common stock. Selling stockholders, which term includes their
transferees, pledgees or donees or their successors, may offer
the shares of common stock indicated below for resale from time
to time.
We were formed in March 2010 to continue and expand the business
of Compass Horizon, our wholly-owned subsidiary, which owned all
of the portfolio investments that we acquired upon the closing
of our IPO. Immediately prior to the completion of our IPO, the
owners of membership interests of Compass Horizon exchanged
their membership interests in Compass Horizon for
2,645,124 shares of our common stock (the Share
Exchange) and we entered into a registration rights
agreement with respect to those shares. Pursuant to the terms of
the registration rights agreement we have agreed to bear
specific expenses of the selling stockholders in connection with
the registration and sale of such shares. In addition, all
contractual lock-ups and other restrictions applicable to sales
by insiders have expired. Concurrent with the IPO, Compass
Horizon Partners LP sold 1,340,000 shares of our common
stock, which it received in the Share Exchange. After the
completion of the IPO, Compass Horizon Partners, LP owned
1,258,249 shares of our common stock, or 16.7% of the total
then outstanding shares of our common stock. Upon completion of
the Share Exchange and the IPO, HTF-CHF Holdings LLC owned
46,875 shares of our common stock, or 0.6% of the total
then outstanding shares of our common stock. We are registering
a total of 1,322,669 shares of common stock that may be
offered by the selling stockholders, of which a total of
1,305,124 shares of common stock may be offered as a result
of our contractual commitment to the selling stockholders
pursuant to the registration rights agreement we entered into in
connection with the Share Exchange and a total of
17,545 shares of common stock may be offered by the selling
stockholders which were obtained by them pursuant to our
dividend reinvestment plan. HTF-CHF Holdings LLC does not
currently intend to sell its shares within one year of the
effective date of this registration statement.
The following table sets forth, as of February 3, 2012:
|
|
|
|
|
The name of each selling stockholder;
|
|
|
|
The number of shares of common stock and the percentage of the
total shares of common stock outstanding that each selling
stockholder beneficially owned (prior to any offering under this
registration statement);
|
|
|
|
The number of shares of common stock beneficially owned by each
selling stockholder that may be offered under this registration
statement, some or all of which shares may be sold pursuant to
this prospectus and any prospectus supplement; and
|
|
|
|
The number of shares of common stock and the percentage of total
shares of common stock outstanding to be beneficially owned by
each selling stockholder following an offering under this
registration statement, assuming the sale pursuant to such
offering of all shares that are beneficially owned by such
selling stockholder and registered under this registration
statement.
|
The information included in the table under
Shares Beneficially Owned After an Offering
assumes that each stockholder below will elect to sell all of
the shares set forth under Number of Shares That May
be Sold in an Offering. The selling stockholders may sell
all, some or none of their shares in an offering pursuant to the
registration statement, of which this prospectus forms a part.
See Plan of Distribution. The information regarding
the identity of each of the selling stockholders and their
affiliations, including their beneficial ownership of shares of
our common stock, is based solely on information provided by or
on behalf of such selling stockholder.
108
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Beneficially Owned
|
|
|
|
|
|
|
|
|
|
Prior to an
|
|
|
Shares Beneficially Owned
|
|
|
|
Offering(1)
|
|
|
After an
|
|
|
|
|
|
|
|
|
|
Number of Shares
|
|
|
Offering(2)(3)
|
|
|
|
Number of
|
|
|
Percent of
|
|
|
That May be Sold in
|
|
|
Number of
|
|
|
Percent of
|
|
Name of Selling Stockholder
|
|
Shares
|
|
|
Class
|
|
|
an Offering
|
|
|
Shares
|
|
|
Class
|
|
|
Compass Horizon Partners,
LP(4)
|
|
|
1,271,414
|
|
|
|
16.6
|
%
|
|
|
1,271,414
|
|
|
|
0
|
|
|
|
0
|
|
HTF-CHF Holdings
LLC(5)
|
|
|
51,255
|
|
|
|
0.7
|
%
|
|
|
51,255
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL for Selling Stockholders
|
|
|
1,322,669
|
|
|
|
17.3
|
%
|
|
|
1,322,669
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Beneficial ownership has been
determined in accordance with
Rule 13d-3
under the Exchange Act. In accordance with such rule, a person
shall be deemed to be the beneficial owner of a security if that
person has the right to acquire such security within
60 days of February 3, 2012.
|
|
|
|
(2)
|
|
Assumes the sale of all shares
eligible for sale in this prospectus and no other purchases or
sales of our common stock. This assumption has been made under
the rules and regulations of the SEC and does not reflect any
knowledge that we have with respect to the present intent of
persons listed as selling stockholders.
|
|
|
|
(3)
|
|
Applicable percentage of ownership
is based upon 7,636,532 shares of our common stock
outstanding on February 3, 2012.
|
|
|
|
(4)
|
|
Concorde Horizon Holdings LP is the
limited partner of Compass Horizon Partners, LP and Navco
Management, Ltd. is the general partner. Concorde Horizon
Holdings LP and Navco Management, Ltd. are controlled by The
Kattegat Trust, a Bermudian charitable trust, the trustee of
which is Kattegat Private Trustees (Bermuda) Limited, a
Bermudian trust company with its principal offices at 2 Reid
Street, Hamilton HM 11, Bermuda.
|
(5)
|
|
Messrs. Pomeroy, Michaud,
Mathieu, Bombara and Devorsetz each own 33%, 33%, 15.5%, 9.3%
and 6.2% of HTF-CHF Holdings LLC, respectively. The address for
HTF-CHF Holdings LLC is 312 Farmington Avenue, Farmington,
Connecticut 06032.
|
Shares of our common stock sold by the selling stockholders will
generally be freely tradable. Sales of substantial amounts of
our common stock, including by the selling stockholders, or the
availability of such common stock for sale, whether or not sold,
could adversely affect the prevailing market prices for our
common stock.
109
REGULATION
We have elected to be regulated as a BDC under the 1940 Act and
elected to be treated as a RIC under Subchapter M of the Code.
As with other companies regulated by the 1940 Act, a BDC must
adhere to certain substantive regulatory requirements. The 1940
Act contains prohibitions and restrictions relating to
transactions between BDCs and their affiliates (including any
investment advisers or
sub-advisers),
principal underwriters and affiliates of those affiliates or
underwriters and requires that a majority of the directors be
persons other than interested persons, as that term
is defined in the 1940 Act. In addition, the 1940 Act provides
that we may not change the nature of our business so as to cease
to be, or to withdraw our election as, a BDC unless approved by
a majority of our outstanding voting securities as
defined in the 1940 Act. A majority of the outstanding voting
securities of a company is defined under the 1940 Act as the
lesser of: (i) 67% or more of such companys shares
present at a meeting if more than 50% of the outstanding shares
of such company are present and represented by proxy or
(ii) more than 50% of the outstanding shares of such
company. Our bylaws provide for the calling of a special meeting
of stockholders at which such action could be considered upon
written notice of not less than ten or more than sixty days
before the date of such meeting.
We may invest up to 100% of our assets in securities acquired
directly from issuers in privately negotiated transactions. With
respect to such securities, we may, for the purpose of public
resale, be deemed an underwriter as that term is
defined in the Securities Act. We also do not intend to acquire
securities issued by any investment company that exceed the
limits imposed by the 1940 Act. Under these limits, except for
registered money market funds, we generally cannot acquire more
than 3% of the voting stock of any investment company, invest
more than 5% of the value of our total assets in the securities
of one investment company or invest more than 10% of the value
of our total assets in the securities of more than one
investment company. With regard to that portion of our portfolio
invested in securities issued by investment companies, it should
be noted that such investments might subject our stockholders to
additional expenses. None of our investment policies are
fundamental and any may be changed without stockholder approval.
We may also be prohibited under the 1940 Act from knowingly
participating in certain transactions with our affiliates
without the prior approval of our Board who are not interested
persons and, in some cases, prior approval by the SEC. For
example, under the 1940 Act, absent receipt of exemptive relief
from the SEC, we and our affiliates may be precluded from
co-investing in private placements of securities. As a result of
one or more of these situations, we may not be able to invest as
much as we otherwise would in certain investments or may not be
able to liquidate a position as quickly.
We expect to be periodically examined by the SEC for compliance
with the 1940 Act.
We are required to provide and maintain a bond issued by a
reputable fidelity insurance company to protect us against
larceny and embezzlement. Furthermore, as a BDC, we are
prohibited from protecting any director or officer against any
liability to us or our stockholders arising from willful
misfeasance, bad faith, gross negligence or reckless disregard
of the duties involved in the conduct of such persons
office.
We and our Advisor have adopted and implemented written policies
and procedures reasonably designed to prevent violation of the
federal securities laws and review these policies and procedures
annually for their adequacy and the effectiveness of their
implementation. We and our Advisor have designated a chief
compliance officer to be responsible for administering the
policies and procedures.
Qualifying
Assets
Under the 1940 Act, a BDC may not acquire any asset other than
assets of the type listed in section 55(a) of the 1940 Act,
which are referred to as qualifying assets, unless, at the time
the acquisition is made, qualifying assets represent at least
70% of the companys total assets. The principal categories
of qualifying assets relevant to our proposed business are the
following:
|
|
|
|
|
Securities purchased in transactions not involving any public
offering from the issuer of such securities, which issuer
(subject to certain limited exceptions) is an eligible portfolio
company, or from any person who is, or has been during the
preceding 13 months, an affiliated person of an eligible
portfolio company, or from
|
110
|
|
|
|
|
any other person, subject to such rules as may be prescribed by
the SEC. An eligible portfolio company is defined in the 1940
Act as any issuer which:
|
|
|
|
|
|
is organized under the laws of, and has its principal place of
business in, the United States;
|
|
|
|
is not an investment company (other than a SBIC wholly owned by
the BDC) or a company that would be an investment company but
for certain exclusions under the 1940 Act; and
|
|
|
|
satisfies any of the following:
|
|
|
|
|
|
has a market capitalization of less than $250 million or
does not have any class of securities listed on a national
securities exchange;
|
|
|
|
is controlled by a BDC or a group of companies including a BDC,
the BDC actually exercises a controlling influence over the
management or policies of the eligible portfolio company and, as
a result thereof, the BDC has an affiliated person who is a
director of the eligible portfolio company; or
|
|
|
|
is a small and solvent company having total assets of not more
than $4 million and capital and surplus of not less than
$2 million.
|
|
|
|
|
|
Securities of any eligible portfolio company which we control.
|
|
|
|
Securities purchased in a private transaction from a
U.S. issuer that is not an investment company or from an
affiliated person of the issuer, or in transactions incident
thereto, if the issuer is in bankruptcy and subject to
reorganization or if the issuer, immediately prior to the
purchase of its securities was unable to meet its obligations as
they came due without material assistance other than
conventional lending or financing arrangements.
|
|
|
|
Securities of an eligible portfolio company purchased from any
person in a private transaction if there is no ready market for
such securities and we already own 60% of the outstanding equity
of the eligible portfolio company.
|
|
|
|
Securities received in exchange for or distributed on or with
respect to securities described above, or pursuant to the
exercise of warrants or rights relating to such securities.
|
|
|
|
Cash, cash equivalents, U.S. Government securities or
high-quality debt securities maturing in one year or less from
the time of investment.
|
The regulations defining qualifying assets may change over time.
We may adjust our investment focus as needed to comply with
and/or take
advantage of any regulatory, legislative, administrative or
judicial actions in this area.
Managerial
Assistance to Portfolio Companies
A BDC must have been organized and have its principal place of
business in the United States and must be operated for the
purpose of making investments in the types of securities
described in Qualifying Assets.
However, in order to count portfolio securities as qualifying
assets for the purpose of the 70% test, the BDC must either
control the issuer of the securities or must offer to make
available to the issuer of the securities (other than small and
solvent companies described above) significant managerial
assistance. Where the BDC purchases such securities in
conjunction with one or more other persons acting together, the
BDC will satisfy this test if one of the other persons in the
group makes available such managerial assistance. Making
available managerial assistance means, among other things, any
arrangement whereby the BDC, through its directors, officers or
employees, offers to provide, and, if accepted, does so provide,
significant guidance and counsel concerning the management,
operations or business objectives and policies of a portfolio
company.
Issuance
of Additional Shares
We are not generally able to issue and sell our common stock at
a price below net asset value per share. We may, however, issue
and sell our common stock, at a price below the current net
asset value of the common stock, or issue and sell warrants,
options or rights to acquire such common stock, at a price below
the current net asset value
111
of the common stock if our Board determines that such sale is
in our best interest and in the best interests of our
stockholders, and our stockholders have approved our policy and
practice of making such sales within the preceding
12 months. In any such case, the price at which our
securities are to be issued and sold may not be less than a
price which, in the determination of our Board, closely
approximates the market value of such securities. We intend to
seek approval from our stockholders to offer shares of our
common stock below its net asset value in the future.
Temporary
Investments
Pending investment in other types of qualifying
assets, as described above, our investments may consist of
cash, cash equivalents, U.S. Government securities or
high-quality debt securities maturing in one year or less from
the time of investment, which we refer to, collectively, as
temporary investments, so that 70% of our assets are qualifying
assets. Typically, we invest in highly rated commercial paper,
U.S. Government agency notes, U.S. Treasury bills or
in repurchase agreements relating to such securities that are
fully collateralized by cash or securities issued by the
U.S. Government or its agencies. A repurchase agreement
involves the purchase by an investor, such as us, of a specified
security and the simultaneous agreement by the seller to
repurchase it at an
agreed-upon
future date and at a price which is greater than the purchase
price by an amount that reflects an
agreed-upon
interest rate. There is no percentage restriction on the
proportion of our assets that may be invested in such repurchase
agreements. However, subject to certain exceptions, if more than
25% of our total assets constitute repurchase agreements from a
single counterparty, we would not meet the diversification tests
in order to qualify as a RIC for federal income tax purposes.
Thus, we do not intend to enter into repurchase agreements with
a single counterparty in excess of this limit. Our Advisor
monitors the creditworthiness of the counterparties with which
we enter into repurchase agreement transactions.
Senior
Securities; Derivative Securities
We are permitted, under specified conditions, to issue multiple
classes of indebtedness and one class of stock senior to our
common stock if our asset coverage, as defined in the 1940 Act,
is at least equal to 200% immediately after each such issuance.
In addition, while any senior securities are outstanding, we
must make provisions to prohibit any distribution to our
stockholders or the repurchase of such securities or shares
unless we meet the applicable asset coverage ratios at the time
of the distribution or repurchase. We may also borrow amounts up
to 5% of the value of our total assets for temporary or
emergency purposes without regard to asset coverage. For a
discussion of the risks associated with leverage, see Risk
Factors Risks Related to our Business and
Structure We borrow money, which magnifies the
potential for gain or loss on amounts invested and may increase
the risk of investing in us.
The 1940 Act also limits the amount of warrants, options and
rights to common stock that we may issue and the terms of such
securities.
Code of
Ethics
We and our Advisor have each adopted a code of ethics pursuant
to
Rule 17j-1
under the 1940 Act and
Rule 204A-1
under the Advisers Act, respectively, that establishes
procedures for personal investments and restricts certain
personal securities transactions. Personnel subject to each code
may invest in securities for their personal investment accounts,
including securities that may be purchased or held by us, so
long as such investments are made in accordance with the
codes requirements. You may read and copy the code of
ethics at the SECs Public Reference Room in
Washington, D.C. You may obtain information on the
operation of the Public Reference Room by calling the SEC at
(202) 942-8090.
In addition, each code of ethics is attached as an exhibit to
our registration statement on
Form N-2
(File
No. 333-165570
filed with the SEC on July 19, 2010 as Exhibits (r)(1) and
(r)(2)), which is available on the SECs Internet site at
www.sec.gov. You may also obtain copies of the code of
ethics, after paying a duplicating fee, by electronic request at
the following
e-mail
address: publicinfo@sec.gov, or by writing the SECs
Public Reference Section, Washington, D.C.
20549-0102.
Proxy
Voting Policies and Procedures
We have delegated our proxy voting responsibility to our
Advisor. The proxy voting policies and procedures of our Advisor
are set forth below. The guidelines are reviewed periodically by
our Advisor and our independent directors and, accordingly, are
subject to change.
112
Introduction
Our Advisor is registered with the SEC as an investment adviser
under the Advisers Act. As an investment adviser registered
under the Advisers Act, our Advisor has fiduciary duties to us.
As part of this duty, our Advisor recognizes that it must vote
client securities in a timely manner free of conflicts of
interest and in our best interests and the best interests of our
stockholders. Our Advisors proxy voting policies and
procedures have been formulated to ensure decision-making is
consistent with these fiduciary duties.
These policies and procedures for voting proxies are intended to
comply with Section 206 of, and
Rule 206(4)-6
under, the Advisers Act.
Proxy
policies
Our Advisor votes proxies relating to our portfolio securities
in what our Advisor perceives to be the best interest of our
stockholders. Our Advisor reviews on a
case-by-case
basis each proposal submitted to a stockholder vote to determine
its effect on the portfolio securities held by us. Although our
Advisor generally votes against proposals that may have a
negative effect on our portfolio securities, our Advisor may
vote for such a proposal if there exist compelling long-term
reasons to do so.
Our Advisors proxy voting decisions are made by those
senior officers who are responsible for monitoring each of our
investments. To ensure that a vote is not the product of a
conflict of interest, our Advisor requires that (1) anyone
involved in the decision-making process disclose to our Chief
Compliance Officer any potential conflict that he or she is
aware of and any contact that he or she has had with any
interested party regarding a proxy vote and (2) employees
involved in the decision-making process or vote administration
are prohibited from revealing how we intend to vote on a
proposal in order to reduce any attempted influence from
interested parties.
Proxy
Voting Records
You may obtain information about how we voted proxies by making
a written request for proxy voting information to: Chief
Compliance Officer, Horizon Technology Finance Corporation, 312
Farmington Avenue, Farmington, Connecticut 06032 or by calling
(860) 676-8654.
Sarbanes-Oxley
Act of 2002
The Sarbanes-Oxley Act imposes a wide variety of regulatory
requirements on publicly-held companies and their insiders. Many
of these requirements affect us. For example:
|
|
|
|
|
pursuant to
Rule 13a-14
under the Exchange Act, our principal executive officer and
principal financial officer must certify the accuracy of the
financial statements contained in our periodic reports;
|
|
|
|
pursuant to Item 307 under
Regulation S-K,
our periodic reports must disclose our conclusions about the
effectiveness of our disclosure controls and procedures;
|
|
|
|
pursuant to
Rule 13a-15
under the Exchange Act, our management must prepare an annual
report regarding its assessment of our internal control over
financial reporting, which must be audited by our independent
registered public accounting firm; and
|
|
|
|
pursuant to Item 308 of
Regulation S-K
and
Rule 13a-15
under the Exchange Act, our periodic reports must disclose
whether there were significant changes in our internal controls
over financial reporting or in other factors that could
significantly affect these controls subsequent to the date of
their evaluation, including any corrective actions with regard
to significant deficiencies and material weaknesses.
|
The Sarbanes-Oxley Act requires us to review our current
policies and procedures to determine whether we comply with the
Sarbanes-Oxley Act and the regulations promulgated thereunder.
We continue to monitor our compliance with all regulations that
are adopted under the Sarbanes-Oxley Act and will take actions
necessary to ensure that we are in compliance therewith.
113
NASDAQ
Global Select Market Corporate Governance Regulations
NASDAQ has adopted corporate governance regulations that listed
companies must comply with. We intend to be in compliance with
these corporate governance listing standards. We intend to
monitor our compliance with all future listing standards and to
take all necessary actions to ensure that we are in compliance
therewith.
Privacy
Principles
We are committed to maintaining the privacy of stockholders and
to safeguarding our nonpublic personal information. The
following information is provided to help you understand what
personal information we collect, how we protect that information
and why, in certain cases, we may share information with select
other parties.
Generally, we do not receive any nonpublic personal information
relating to our stockholders, although certain nonpublic
personal information of our stockholders may become available to
us. We do not disclose any nonpublic personal information about
our stockholders or former stockholders to anyone, except as
permitted by law or as is necessary in order to service
stockholder accounts (for example, to a transfer agent or third
party administrator).
We restrict access to nonpublic personal information about our
stockholders to our Advisors employees with a legitimate
business need for the information. We maintain physical,
electronic and procedural safeguards designed to protect the
nonpublic personal information of our stockholders.
114
BROKERAGE
ALLOCATIONS AND OTHER PRACTICES
Since we generally acquire and dispose of our investments in
privately negotiated transactions, we infrequently use brokers
in the normal course of our business. Subject to policies
established by our Board, our Advisor is primarily responsible
for the execution of the publicly-traded securities portion of
our portfolio transactions and the allocation of brokerage
commissions. Our Advisor does not execute transactions through
any particular broker or dealer, but seeks to obtain the best
net results for us, taking into account such factors as price
(including the applicable brokerage commission or dealer
spread), size of order, difficulty of execution, and operational
facilities of the firm and the firms risk and skill in
positioning blocks of securities. While our Advisor generally
seeks reasonably competitive trade execution costs, we do not
necessarily pay the lowest spread or commission available.
Subject to applicable legal requirements, our Advisor may select
a broker based partly upon brokerage or research services
provided to it and us and any other clients. In return for such
services, we may pay a higher commission than other brokers
would charge if our Advisor determines in good faith that such
commission is reasonable in relation to the services provided.
115
PLAN OF
DISTRIBUTION
We may offer, from time to time, in one or more underwritten
public offerings,
at-the-market
offerings, negotiated transactions, block trades, best efforts
or a combination of these methods, up to $250,000,000 of our
common stock, preferred stock, subscription rights, debt
securities, warrants representing rights to purchase shares of
our common stock, preferred stock or debt securities on the
terms to be determined at the time of an offering. The selling
stockholders may sell from time to time 1,322,669 shares of
common stock beneficially owned by them, held for their own
account or the shares may be sold by donees, transferees,
pledgees or other successors in interest that receive such
shares from the selling stockholders as a gift or other non-sale
related transfer (collectively, the Selling Stockholder
Shares). The debt securities, preferred stock, warrants
and subscription rights offered by means of this prospectus may
be convertible or exchangeable into shares of our common stock.
We may sell the securities through underwriters or dealers,
directly to one or more purchasers, including existing
stockholders in a rights offering, through agents or through a
combination of any such methods of sale and the selling
stockholders may sell the Selling Stockholder Shares owned by
them and offered hereby directly or through one or more
underwriters, broker-dealers or agents or through a combination
of any such methods of sale. In the case of a rights offering,
the applicable prospectus supplement will set forth the number
of shares of our common stock issuable upon the exercise of each
right and the other terms of such rights offering. Any
underwriter or agent involved in the offer and sale of the
securities by us
and/or the
Selling Stockholder Shares by the selling stockholders will be
named in the applicable prospectus supplement, such prospectus
supplement to also set forth the name or names of any
underwriters, dealers or agents and the amounts of securities
underwritten or purchased by each of them, the offering price of
the securities and the proceeds to us
and/or the
selling stockholders and any discounts, commissions or
concessions allowed or reallowed or paid to dealers, and any
securities exchanges on which the securities
and/or the
Selling Stockholder Shares may be listed. Only underwriters
named in the prospectus supplement will be underwriters of the
securities offered by the prospectus supplement.
The distribution of the securities may be effected from time to
time in one or more transactions at a fixed price or prices,
which may be changed, at prevailing market prices at the time of
sale, at prices related to such prevailing market prices, or at
negotiated prices; provided, however, that the offering price
per share of our common stock, less any underwriting commissions
or discounts, must equal or exceed the net asset value per share
of our common stock at the time of the offering except
(i) in connection with a rights offering to our existing
stockholders, (ii) with the consent of the majority of our
common stockholders or (iii) under such circumstances as
the SEC may permit. The selling stockholders are not restricted
in their ability to sell their shares at a price per share below
net asset value per share.
In connection with the sale of the securities and the Selling
Stockholder Shares, underwriters or agents may receive
compensation from us
and/or the
selling stockholders or from purchasers of the securities, for
whom they may act as agents, in the form of discounts,
concessions or commissions. Underwriters may sell the securities
and the Selling Stockholder Shares to or through dealers and
such dealers may receive compensation in the form of discounts,
concessions or commissions from the underwriters
and/or
commissions from the purchasers for whom they may act as agents.
Underwriters, dealers and agents that participate in the
distribution of the securities and the Selling Stockholder
Shares may be deemed to be underwriters under the Securities
Act, and any discounts and commissions they receive from us
and/or the
selling stockholders and any profit realized by them on the
resale of the securities may be deemed to be underwriting
discounts and commissions under the Securities Act. Any such
underwriter or agent will be identified and any such
compensation received from us
and/or the
selling stockholders will be described in the applicable
prospectus supplement. The maximum commission or discount to be
received by any member of the Financial Industry Regulatory
Authority or independent broker-dealer will not be greater than
8% for the sale of any securities
and/or
Selling Stockholder Shares being registered. We may also
reimburse the underwriter or agent for certain fees and legal
expenses incurred by it.
If underwriters are used in the sale of any securities
and/or the
Selling Stockholder Shares, the securities
and/or
Selling Stockholder Shares will be acquired by the underwriters
for their own accounts and may be resold from time to time in
one or more transactions, including negotiated transactions, at
a fixed public offering price or at varying prices determined at
the time of sale. The securities
and/or
Selling Stockholder Shares may be either offered to the public
through underwriting syndicates represented by managing
underwriters, or directly by underwriters.
116
Generally, the underwriters obligations to purchase the
securities
and/or
Selling Stockholder Shares will be subject to certain conditions
precedent.
We and/or
the selling stockholders may sell the securities through agents
from time to time. The prospectus supplement will name any agent
involved in the offer or sale of the securities and any
commissions we
and/or the
selling stockholders pay to them. Generally, any agent will be
acting on a best efforts basis for the period of its appointment.
In connection with sales of the shares of common stock or
otherwise, we
and/or the
selling stockholders may enter into hedging transactions with
broker-dealers, which may in turn engage in short sales of the
shares of common stock in the course of hedging in positions
they assume. We
and/or the
selling stockholders may also sell shares of common stock short
and deliver shares of common stock covered by this prospectus to
close out short positions and to return borrowed shares in
connection with such short sales. We
and/or the
selling stockholders may also loan or pledge shares of common
stock to broker-dealers that in turn may sell such shares.
We, the selling stockholders and any other person participating
in such distribution will be subject to applicable provisions of
the Exchange Act, and the rules and regulations thereunder,
including, without limitation, Regulation M of the Exchange
Act, which may limit the timing of purchases and sales of any of
the shares of common stock by us, the selling stockholders and
any other participating person. Regulation M may also
restrict the ability of any person engaged in the distribution
of the shares of common stock to engage in market-making
activities with respect to the shares of common stock. All of
the foregoing may affect the marketability of the shares of
common stock and the ability of any person or entity to engage
in market-making activities with respect to the shares of common
stock.
We may offer shares of common stock in a public offering
at-the-market
to a select group of investors, in which case you may not be
able to participate in such offering and you will experience
dilution unless you purchase additional shares of our common
stock in the secondary market at the same or lower price.
Any common stock
and/or
Selling Stockholder Shares sold pursuant to a prospectus
supplement may be traded on NASDAQ, or another exchange on which
the common stock, including Selling Stockholder Shares, are
traded. The other offered securities may or may not be listed on
a securities exchange and we cannot assure you that there will
be a liquid trading market for certain of the securities.
Under agreements that we
and/or the
selling stockholders may enter into, underwriters, dealers and
agents who participate in the distribution of shares of our
securities
and/or the
Selling Stockholder Shares may be entitled to indemnification by
us and/or
the selling stockholders against certain liabilities, including
liabilities under the Securities Act. Underwriters, dealers and
agents may engage in transactions with, or perform services for,
us and/or
the selling stockholders in the ordinary course of business.
If so indicated in the applicable prospectus supplement, we
and/or the
selling stockholders will authorize underwriters or other
persons acting as our
and/or the
selling stockholders agents to solicit offers by certain
institutions to purchase shares of our securities from us or the
Selling Stockholder Shares from the selling stockholders
pursuant to contracts providing for payment and delivery on a
future date. Institutions with which such contracts may be made
include commercial and savings banks, insurance companies,
pension funds, investment companies, educational and charitable
institutions and others, but in all cases such institutions must
be approved by us
and/or the
selling stockholders. The obligations of any purchaser under any
such contract will be subject to the condition that the purchase
of our securities
and/or the
Selling Stockholder Shares shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which such
purchaser is subject. The underwriters and such other agents
will not have any responsibility in respect of the validity or
performance of such contracts. Such contracts will be subject
only to those conditions set forth in the prospectus supplement,
and the prospectus supplement will set forth the commission
payable for solicitation of such contracts.
We and/or
the selling stockholders may enter into derivative transactions
with third parties, or sell securities not covered by this
prospectus to third parties in privately negotiated
transactions. If the applicable prospectus supplement indicates,
in connection with those derivatives, the third parties may sell
securities covered by this prospectus and the applicable
prospectus supplement, including in short sale transactions. If
so, the third party may use securities pledged by us
and/or the
selling stockholders or borrowed from us, the selling
stockholders or others
117
to settle those sales or to close out any related open
borrowings of stock, and may use securities received from us
and/or the
selling stockholders in settlement of those derivatives to close
out any related open borrowings of stock. The third parties in
such sale transactions will be underwriters and, if not
identified in this prospectus, will be identified in the
applicable prospectus supplement. We, one of our affiliates
and/or the
selling stockholders may loan or pledge securities to a
financial institution or other third party that in turn may sell
the securities or Selling Stockholder Shares using this
prospectus. Such financial institution or third party may
transfer its short position to investors in our securities or
the Selling Stockholder Shares or in connection with a
simultaneous offering of other securities offered by this
prospectus or otherwise.
In order to comply with the securities laws of certain states,
if applicable, our securities and the Selling Stockholder Shares
will be sold in such jurisdictions only through registered or
licensed brokers or dealers. In addition, in certain states, our
securities
and/or the
Selling Stockholder Shares may not be sold unless they have been
registered or qualified for sale in the applicable state or an
exemption from the registration or qualification requirement is
available and is complied with.
We will pay customary costs and expenses of the registration of
the shares of common stock pursuant to the registration rights
agreement, including, without limitation, SEC filing fees and
expenses of compliance with state securities or blue
sky laws; provided, however, that each selling stockholder
will pay all underwriting discounts and selling commissions, if
any. We will indemnify the selling stockholders against
liabilities, including some liabilities under the Securities
Act, in accordance with the registration rights agreement, or
the selling stockholders will be entitled to contribution.
We may be indemnified by the selling stockholders against civil
liabilities, including liabilities under the Securities Act,
that may arise from any written information furnished to us by
the selling stockholder specifically for use in this prospectus,
in accordance with the related registration rights agreement, or
we may be entitled to contribution.
There can be no assurance that any selling stockholder will sell
any or all of the Selling Stockholder Shares registered pursuant
to the registration statement, of which this prospectus forms a
part. Once sold under the registration statement, of which this
prospectus forms a part, the Selling Stockholder Shares will be
freely tradable in the hands of persons other than our
affiliates.
118
MATERIAL
U.S. FEDERAL INCOME TAX CONSIDERATIONS
The following discussion is a general summary of the material
U.S. federal income tax considerations applicable to us and
to an investment in shares of our common stock. This discussion
is based on the provisions of the Code and the regulations of
the U.S. Department of Treasury promulgated thereunder
(Treasury regulations) each as in effect as of the
date of this prospectus. These provisions are subject to
differing interpretations and change by legislative or
administrative action, and any change may be retroactive. This
discussion does not constitute a detailed explanation of all
U.S. federal income tax aspects affecting us and our
stockholders and does not purport to deal with the
U.S. federal income tax consequences that may be important
to particular stockholders in light of their individual
investment circumstances or to some types of stockholders
subject to special tax rules, such as financial institutions,
broker-dealers, insurance companies, tax-exempt organizations,
partnerships or other pass-through entities, persons holding our
common stock in connection with a hedging, straddle, conversion
or other integrated transaction,
non-U.S. stockholders
(as defined below) engaged in a trade or business in the United
States or persons who have ceased to be U.S. citizens or to
be taxed as resident aliens. This discussion also does not
address any aspects of U.S. estate or gift tax or foreign,
state or local tax. This discussion assumes that our
stockholders hold their shares of our common stock as capital
assets for U.S. federal income tax purposes (generally,
assets held for investment). No ruling has been or will be
sought from the IRS regarding any matter discussed herein.
For purposes of this discussion:
|
|
|
|
|
a U.S. stockholder means a beneficial owner of
shares of our common stock that is, for U.S. federal income
tax purposes: (1) a person who is a citizen or individual
resident of the United States; (2) a domestic corporation
(or other domestic entity taxable as a corporation for
U.S. federal income tax purposes); (3) an estate whose
income is subject to U.S. federal income tax regardless of
its source; or (4) a trust if (a) a U.S. court is
able to exercise primary supervision over the trusts
administration and one or more U.S. persons are authorized
to control all substantial decisions of the trust or
(b) the trust has in effect a valid election to be treated
as a domestic trust for U.S. federal income tax
purposes; and
|
|
|
|
a
non-U.S. stockholder
means a beneficial owner of shares of our common stock that is
not a U.S. stockholder or a partnership (or an entity or
arrangement treated as a partnership) for U.S. federal
income tax purposes.
|
If a partnership or other entity classified as a partnership for
U.S. federal income tax purposes holds our shares, the
U.S. tax treatment of the partnership and each partner
generally will depend on the status of the partner, the
activities of the partnership and certain determinations made at
the partner level. A stockholder that is a partnership holding
shares of our common stock, and each partner in such a
partnership, should consult their own tax advisers with respect
to the purchase, ownership and disposition of shares of our
common stock.
Tax matters are very complicated and the tax consequences to
each stockholder of an investment in our securities will depend
on the facts of its particular situation. Stockholders are urged
to consult their own tax advisers to determine the
U.S. federal, state, local and foreign tax consequences to
them of an investment in our securities, including applicable
tax reporting requirements, the applicability of
U.S. federal, state, local and foreign tax laws,
eligibility for the benefits of any applicable tax treaty, and
the effect of any possible changes in the tax laws.
Taxation
of the company
As a BDC, we have elected to be treated, and qualified, as a RIC
under Subchapter M of the Code commencing with our taxable year
ending on December 31, 2010. As a RIC, we generally do not
pay corporate-level federal income taxes on any ordinary income
or capital gains that we timely distribute to our stockholders
as dividends.
To continue to qualify as a RIC, we must, among other things,
(a) derive in each taxable year at least 90% of our gross
income from dividends, interest (including tax-exempt interest),
payments with respect to certain securities loans, gains from
the sale or other disposition of stock, securities or foreign
currencies, other income (including but not limited to gain from
options, futures or forward contracts) derived with respect to
our business of investing in stock, securities or currencies, or
net income derived from an interest in a qualified
publicly traded partnership (a QPTP) (the
90% Gross Income Test); and (b) diversify our
holdings so that, at the end of each quarter of each
119
taxable year (i) at least 50% of the market value of our
total assets is represented by cash and cash items,
U.S. Government securities, the securities of other RICs
and other securities, with other securities limited, in respect
of any one issuer, to an amount not greater than 5% of the value
of our total assets and not more than 10% of the outstanding
voting securities of such issuer (subject to the exception
described below), and (ii) not more than 25% of the market
value of our total assets is invested in the securities of any
issuer (other than U.S. Government securities and the
securities of other regulated investment companies), the
securities of any two or more issuers that we control and that
are determined to be engaged in the same business or similar or
related trades or businesses, or the securities of one or more
QPTPs (the Diversification Tests). In the case of a
RIC that furnishes capital to development corporations, there is
an exception relating to the Diversification Tests described
above. This exception is available only to RICs which the SEC
determines to be principally engaged in the furnishing of
capital to other corporations which are principally engaged in
the development or exploitation of inventions, technological
improvements, new processes, or products not previously
generally available, which we refer to as SEC
Certification. We have not sought SEC Certification, but
it is possible that we will seek SEC Certification in future
years. If we receive SEC Certification, we generally will be
entitled to include, in the computation of the 50% value of our
assets (described in (b)(i) above), the value of any securities
of an issuer, whether or not we own more than 10% of the
outstanding voting securities of the issuer, if the basis of the
securities, when added to our basis of any other securities of
the issuer that we own, does not exceed 5% of the value of our
total assets.
As a RIC, in any fiscal year with respect to which we distribute
an amount equal to at least 90% of the sum of our
(i) investment company taxable income (which includes,
among other items, dividends, interest and the excess of any net
realized short-term capital gains over net realized long-term
capital losses and other taxable income (other than any net
capital gain), reduced by deductible expenses) determined
without regard to the deduction for dividends and distributions
paid and (ii) net tax-exempt interest income (which is the
excess of our gross tax-exempt interest income over certain
disallowed deductions) (the Annual Distribution
Requirement), we (but not our stockholders) generally are
not subject to U.S. federal income tax on investment
company taxable income and net capital gains that we distribute
to our stockholders. We intend to distribute annually all or
substantially all of such income. To the extent that we retain
our net capital gains for investment or any investment company
taxable income, we are subject to U.S. federal income tax.
We may choose to retain our net capital gains for investment or
any investment company taxable income, and pay the associated
federal corporate income tax, including the 4% U.S. federal
excise tax described below.
We are subject to a nondeductible 4% U.S. federal excise
tax on certain of our undistributed income, unless we timely
distribute (or are deemed to have timely distributed) an amount
equal to the sum of:
|
|
|
|
|
at least 98% of our ordinary income (not taking into account any
capital gains or losses) for the calendar year;
|
|
|
|
at least 98% (or, for our taxable years beginning in 2011,
98.2%) of the amount by which our capital gains exceed our
capital losses (adjusted for certain ordinary losses) for a
one-year period generally ending on October 31 of the calendar
year (unless an election is made by us to use our taxable
year); and
|
|
|
|
certain undistributed amounts from previous years on which we
paid no U.S. federal income tax.
|
While we intend to distribute any income and capital gains in
order to avoid imposition of this 4% U.S. federal excise
tax, we may not be successful in avoiding entirely the
imposition of this tax. In that case, we will be liable for the
tax only on the amount by which we do not meet the foregoing
distribution requirement.
If we borrow money, we may be prevented by loan covenants from
declaring and paying dividends in certain circumstances. Limits
on our payment of dividends may prevent us from satisfying
distribution requirements, and may, therefore, jeopardize our
qualification for taxation as a RIC, or subject us to the 4%
U.S. federal excise tax.
Although we do not presently expect to do so, we are authorized
to borrow funds and to sell assets in order to satisfy
distribution requirements. However, under the 1940 Act, we are
not permitted to make distributions to our stockholders while
any senior securities are outstanding unless we meet the
applicable asset coverage ratios. See
Regulation Senior Securities; Derivative
Securities. Moreover, our ability to dispose of assets to
meet our distribution requirements may be limited by
(1) the illiquid nature of our portfolio
and/or
(2) other requirements relating to our status as a RIC,
including the Diversification Tests. If we dispose of assets in
order to meet the Annual
120
Distribution Requirement or to avoid the 4% U.S. federal
excise tax, we may make such dispositions at times that, from an
investment standpoint, are not advantageous.
A RIC is limited in its ability to deduct expenses in excess of
its investment company taxable income (which is,
generally, ordinary income plus the excess of net short-term
capital gains over net long-term capital losses). If our
expenses in a given year exceed investment company taxable
income, we would experience a net operating loss for that year.
However, a RIC is not permitted to carry forward net operating
losses to subsequent years. In addition, expenses can be used
only to offset investment company taxable income, not net
capital gain. Due to these limits on the deductibility of
expenses, we may for tax purposes have aggregate taxable income
for several years that we are required to distribute and that is
taxable to our stockholders even if such income is greater than
the aggregate net income we actually earned during those years.
Such required distributions may be made from our cash assets or
by liquidation of investments, if necessary. We may realize
gains or losses from such liquidations. In the event we realize
net capital gains from such transactions, you may receive a
larger capital gain distribution than you would have received in
the absence of such transactions.
Failure
to qualify as a RIC
If we were unable to qualify for treatment as a RIC, and if
certain cure provisions described below are not available, we
would be subject to tax on all of our taxable income (including
our net capital gains) at regular corporate rates. We would not
be able to deduct distributions to stockholders, nor would they
be required to be made. Distributions, including distributions
of net long-term capital gain, would generally be taxable to our
stockholders as ordinary dividend income to the extent of our
current and accumulated earnings and profits. Subject to certain
limitations under the Code, corporate stockholders would be
eligible to claim a dividends received deduction with respect to
such dividends, and for tax years beginning before 2013,
non-corporate stockholders would generally be able to treat such
dividends as qualified dividend income, which is
subject to reduced rates of U.S. federal income tax.
Distributions in excess of our current and accumulated earnings
and profits would be treated first as a return of capital to the
extent of the stockholders tax basis, and any remaining
distributions would be treated as a capital gain. If we fail to
qualify as a RIC for a period greater than two taxable years, to
qualify as a RIC in a subsequent year we may be subject to
regular corporate tax on any net built-in gains with respect to
certain of our assets (i.e., the excess of the aggregate
gains, including items of income, over aggregate losses that
would have been realized with respect to such assets if we had
been liquidated) that we elect to recognize on requalification
or when recognized over the next ten years.
We may decide to be taxed as a regular corporation even if we
would otherwise qualify as a RIC if we determine that treatment
as a corporation for a particular year would be in our best
interests.
Company
investments
Certain of our investment practices are subject to special and
complex U.S. federal income tax provisions that may, among
other things, (i) disallow, suspend or otherwise limit the
allowance of certain losses or deductions, including the
dividends received deduction, (ii) convert lower taxed
long-term capital gains and qualified dividend income into
higher taxed short-term capital gains or ordinary income,
(iii) convert ordinary loss or a deduction into capital
loss (the deductibility of which is more limited),
(iv) cause us to recognize income or gain without a
corresponding receipt of cash, (v) adversely affect the
time as to when a purchase or sale of stock or securities is
deemed to occur, (vi) adversely alter the characterization
of certain complex financial transactions and (vii) produce
income that will not qualify as good income for purposes of the
90% Gross Income Test. We monitor our transactions and may make
certain tax elections and may be required to borrow money or
dispose of securities to mitigate the effect of these rules and
to prevent disqualification of us as a RIC but there can be no
assurance that we will be successful in this regard.
We may be required to recognize taxable income in circumstances
in which we do not receive cash. For example, if we hold debt
instruments that are treated under applicable tax rules as
having original issue discount (such as debt instruments with
payment-in-kind
interest or, in certain cases, increasing interest rates or
issued with warrants), we must include in taxable income each
year a portion of the original issue discount that accrues over
the life of the obligation, regardless of whether cash
representing such income is received by us in the same taxable
121
year. Since in certain cases we may recognize taxable income
before or without receiving cash representing such income, we
may have difficulty meeting the Annual Distribution Requirement.
Accordingly, we may need to sell some of our assets at times
that we would not consider advantageous, raise additional debt
or equity capital or forego new investment opportunities or
otherwise take actions that are disadvantageous to our business
(or be unable to take action that are advantageous) in order to
satisfy the Annual Distribution Requirement. If we are unable to
obtain cash from other sources to satisfy the Annual
Distribution Requirement, we may fail to qualify for the federal
income tax benefits allowable to RICs and, thus, become subject
to a corporate-level federal income tax on all our income.
Warrants. Gain or loss realized by us from the
sale or exchange of warrants acquired by us as well as any loss
attributable to the lapse of such warrants generally are treated
as capital gain or loss. The treatment of such gain or loss as
long-term or short-term depends on how long we held a particular
warrant. Upon the exercise of a warrant acquired by us, our tax
basis in the stock purchased under the warrant equals the sum of
the amount paid for the warrant plus the strike price paid on
the exercise of the warrant.
Foreign Investments. In the event we invest in
foreign securities, we may be subject to withholding and other
foreign taxes with respect to those securities. We do not expect
to satisfy the requirement to pass through to our stockholders
their share of the foreign taxes paid by us.
Passive Foreign Investment Companies. We may
invest in the stock of a foreign corporation which is classified
as a passive foreign investment company (within the
meaning of Section 1297 of the Code) (PFIC). In
general, if a special tax election has not been made, we are
required to pay tax at ordinary income rates on any gains and
excess distributions with respect to PFIC stock as
if such items had been realized ratably over the period during
which we held the PFIC stock, plus an interest charge. Any
adverse tax consequences of a PFIC investment may be limited if
we are eligible to elect alternative tax treatment with respect
to such investment. No assurances can be given that any such
election will be available or that, if available, we will make
such an election.
Foreign Currency Transactions. Under the Code,
gains or losses attributable to fluctuations in exchange rates
which occur between the time we accrue income or other
receivables or accrue expenses or other liabilities denominated
in a foreign currency and the time we actually collect such
receivables or pay such liabilities generally are treated as
ordinary income or loss. Similarly, on disposition of debt
instruments and certain other instruments denominated in a
foreign currency, gains or losses attributable to fluctuations
in the value of the foreign currency between the date of
acquisition of the instrument and the date of disposition also
are treated as ordinary gain or loss. These gains and losses,
referred to under the Code as section 988 gains
or losses, may increase or decrease the amount of our investment
company taxable income to be distributed to our stockholders as
ordinary income.
The remainder of this discussion assumes that we qualify as a
RIC for each taxable year.
Taxation
of U.S. stockholders
Distributions by us generally are taxable to
U.S. stockholders as ordinary income or capital gains.
Distributions of our investment company taxable
income (which is, generally, our net ordinary income plus
net short-term capital gains in excess of net long-term capital
losses) will be taxable as ordinary income to
U.S. stockholders to the extent of our current or
accumulated earnings and profits, whether paid in cash or
reinvested in additional shares of our common stock. For the tax
years beginning on or before December 31, 2012, to the
extent such distributions paid by us to non-corporate
stockholders (including individuals) are attributable to
dividends from U.S. corporations and certain qualified
foreign corporations and if certain holding period requirements
are met, such distributions generally will be treated as
qualified dividend income and eligible for a maximum
U.S. federal tax rate of 15%. In this regard, it is
anticipated that distributions paid by us will generally not be
attributable to dividends and, therefore, generally will not
qualify for the 15% maximum U.S. federal tax rate.
Distributions of our net capital gains (which is generally our
realized net long-term capital gains in excess of realized net
short-term capital losses) properly designated by us as
capital gain dividends will be taxable to a
U.S. stockholder as long-term capital gains (currently at a
maximum U.S. federal tax rate of 15% through 2012) in
the case of individuals, trusts or estates, regardless of the
U.S. stockholders holding period for his, her or its
common stock and regardless of whether paid in cash or
reinvested in additional common stock. Distributions in
122
excess of our earnings and profits first will reduce a
U.S. stockholders adjusted tax basis in such
stockholders common stock and, after the adjusted basis is
reduced to zero, will constitute capital gains to such
U.S. stockholder. Stockholders receiving dividends or
distributions in the form of additional shares of our common
stock purchased in the market should be treated for
U.S. federal income tax purposes as receiving a
distribution in an amount equal to the amount of money that the
stockholders receiving cash dividends or distributions will
receive, and should have a cost basis in the shares received
equal to such amount. Stockholders receiving dividends in newly
issued shares of our common stock will be treated as receiving a
distribution equal to the value of the shares received, and
should have a cost basis of such amount.
Although we currently intend to distribute any net long-term
capital gains at least annually, we may in the future decide to
retain some or all of our net long-term capital gains but
designate the retained amount as a deemed
distribution. In that case, among other consequences, we
will pay tax on the retained amount, each U.S. stockholder
will be required to include their share of the deemed
distribution in income as if it had been distributed to the
U.S. stockholder, and the U.S. stockholder will be
entitled to claim a credit equal their allocable share of the
tax paid on the deemed distribution by us. The amount of the
deemed distribution net of such tax will be added to the
U.S. stockholders tax basis for their common stock.
Since we expect to pay tax on any retained capital gains at our
regular corporate tax rate, and since that rate is in excess of
the maximum rate currently payable by individuals on long-term
capital gains, the amount of tax that individual stockholders
will be treated as having paid and for which they will receive a
credit will exceed the tax they owe on the retained net capital
gain. Such excess generally may be claimed as a credit against
the U.S. stockholders other U.S. federal income
tax obligations or may be refunded to the extent it exceeds a
stockholders liability for U.S. federal income tax. A
stockholder that is not subject to U.S. federal income tax
or otherwise required to file a U.S. federal income tax
return would be required to file a U.S. federal income tax
return on the appropriate form in order to claim a refund for
the taxes we paid. In order to utilize the deemed distribution
approach, we must provide written notice to our stockholders
prior to the expiration of 60 days after the close of the
relevant taxable year. We cannot treat any of our investment
company taxable income as a deemed distribution.
Generally, you will be provided with a written notice
designating the amount of any (i) ordinary income dividends
no later than 30 days after the close of the taxable year,
and (ii) capital gain dividends or other distributions no
later than 60 days after the close of the taxable year.
For purposes of determining (1) whether the Annual
Distribution Requirement is satisfied for any year and
(2) the amount of capital gain dividends paid for that
year, we may, under certain circumstances, elect to treat a
dividend that is paid during the following taxable year as if it
had been paid during the taxable year in question. If we make
such an election, the U.S. stockholder will still be
treated as receiving the dividend in the taxable year in which
the distribution is made. However, if we pay you a dividend in
January which was declared in the previous October, November or
December to stockholders of record on a specified date in one of
these months, then the dividend will be treated for tax purposes
as being paid by us and received by you on December 31 of the
year in which the dividend was declared.
If an investor purchases shares of our stock shortly before the
record date of a distribution, the price of the shares will
include the value of the distribution and the investor will be
subject to tax on the distribution even though it represents a
return of its investment.
Alternative Minimum Tax. As a RIC, we are
subject to alternative minimum tax, also referred to as
AMT, but any items that are treated differently for
AMT purposes must be apportioned between us and our
U.S. stockholders and this may affect the
U.S. stockholders AMT liabilities. Although
regulations explaining the precise method of apportionment have
not yet been issued, such items will generally be apportioned in
the same proportion that dividends paid to each
U.S. stockholder bear to our taxable income (determined
without regard to the dividends paid deduction), unless a
different method for particular item is warranted under the
circumstances.
Dividend Reinvestment Plan. Under the dividend
reinvestment plan, if a U.S. stockholder owns shares of
common stock registered in its own name, the
U.S. stockholder will have all cash distributions
automatically reinvested in additional shares of common stock
unless the U.S. stockholder opts out of our dividend
reinvestment plan by delivering a written notice to our dividend
paying agent prior to the record date of the next dividend or
distribution. See Dividend Reinvestment Plan. Any
distributions reinvested under the plan will nevertheless
123
remain taxable to the U.S. stockholder. The
U.S. stockholder will have an adjusted basis in the
additional common shares purchased through the plan equal to the
amount of the reinvested distribution. The additional shares
will have a new holding period commencing on the day following
the day on which the shares are credited to the
U.S. stockholders account.
Dispositions. A U.S. stockholder will
recognize gain or loss on the sale, exchange or other taxable
disposition of shares of our common stock in an amount equal to
the difference between the U.S. stockholders adjusted
basis in the shares disposed of and the amount realized on their
disposition. Generally, gain recognized by a
U.S. stockholder on the disposition of shares of our common
stock will result in capital gain or loss to a
U.S. stockholder, and will be a long-term capital gain or
loss if the shares have been held for more than one year at the
time of sale. Any loss recognized by a U.S. stockholder
upon the disposition of shares of our common stock held for six
months or less will be treated as a long-term capital loss to
the extent of any capital gain dividends received (including
amounts credited as an undistributed capital gain dividend) by
the U.S. stockholder. A loss recognized by a
U.S. stockholder on a disposition of shares of our common
stock will be disallowed as a deduction if the
U.S. stockholder acquires additional shares of our common
stock (whether through the automatic reinvestment of dividends
or otherwise) within a
61-day
period beginning 30 days before and ending 30 days
after the date that the shares are disposed of. In this case,
the basis of the shares acquired will be adjusted to reflect the
disallowed loss. Present U.S. law taxes both long-term and
short-term capital gains of corporations at the rates applicable
to ordinary income. Non-corporate U.S. stockholders with
net capital losses for a year (i.e., capital losses in excess of
capital gains) generally may deduct up to $3,000 of such losses
against their ordinary income each year; any net capital losses
of a non-corporate U.S. stockholder in excess of $3,000
generally may be carried forward and used in subsequent years as
provided in the Code. Corporate U.S. stockholders generally
may not deduct any net capital losses for a year, but may carry
back such losses for three years or carry forward such losses
for five years.
Tax Shelter Reporting Regulations. Under
applicable Treasury regulations, if a U.S. stockholder
recognizes a loss with respect to shares of $2 million or
more for a non-corporate U.S. stockholder or
$10 million or more for a corporate U.S. stockholder
in any single taxable year (or a greater loss over a combination
of years), the U.S. stockholder must file with the IRS a
disclosure statement on Form 8886. Direct
U.S. stockholders of portfolio securities are in many cases
excepted from this reporting requirement, but under current
guidance, U.S. stockholders of a RIC are not excepted.
Future guidance may extend the current exception from this
reporting requirement to U.S. stockholders of most or all
RICs. The fact that a loss is reportable under these regulations
does not affect the legal determination of whether the
taxpayers treatment of the loss is proper.
U.S. stockholders should consult their own tax advisers to
determine the applicability of these regulations in light of
their individual circumstances.
Backup Withholding. We are required in certain
circumstances to backup withhold on taxable dividends or
distributions paid to non-corporate U.S. stockholders who
do not furnish us with their correct taxpayer identification
number (in the case of individuals, their social security
number) and certain certifications, or who are otherwise subject
to backup withholding. Backup withholding is not an additional
tax. Any amounts withheld from payments made to you may be
refunded or credited against your U.S. federal income tax
liability, if any, provided that the required information is
timely furnished to the IRS.
U.S. stockholders should consult their own tax advisers
with respect to the U.S. federal income tax and withholding
tax, and state, local and foreign tax consequences of an
investment in shares of our common stock. Additionally,
U.S. stockholders should be aware of recently enacted
legislation that generally imposes, effective for payments made
after December 31, 2012, a 30% federal withholding tax on
dividends and proceeds from the sale of our common stock held by
or through foreign entities, as described below in
Recently Enacted Legislation.
Taxation
of non-U.S.
stockholders
The following discussion only applies to
non-U.S. stockholders.
Whether an investment in shares of our common stock is
appropriate for a
non-U.S. stockholder
will depend upon that persons particular circumstances. An
investment in shares of our common stock by a
non-U.S. stockholder
may have adverse tax consequences.
Non-U.S. stockholders
should consult their own tax advisers before investing in shares
of our common stock.
124
Actual and Deemed Distributions;
Dispositions. Distributions of ordinary income
dividends to
non-U.S. stockholders,
subject to the discussion below, will generally be subject to
withholding of U.S. federal tax at a 30% rate (or lower
rate provided by an applicable treaty) to the extent of our
current or accumulated earnings and profits even if they are
funded by income or gains (such as portfolio interest,
short-term capital gains, or foreign-source dividend and
interest income) that, if paid to a
non-U.S. stockholder
directly, would not be subject to withholding. Different tax
consequences may result if the
non-U.S. stockholder
is engaged in a trade or business in the United States or, in
the case of an individual, is present in the United States for
183 days or more during a taxable year and certain other
conditions are satisfied. Special certification requirements
apply to a
non-U.S. stockholder
that is a foreign partnership or a foreign trust, and such
entities are urged to consult their own tax advisers.
Under a provision that is scheduled to expire for taxable years
beginning after December 31, 2011, properly designated
dividends received by a
non-U.S. stockholder
generally are exempt from U.S. federal withholding tax when
they (1) are paid in respect of our qualified net
interest income (generally, our U.S. source interest
income, other than certain contingent interest and interest from
obligations of a corporation or partnership in which we are at
least a 10% stockholder, reduced by expenses that are allocable
to such income), or (2) were paid in connection with our
qualified short-term capital gains (generally, the
excess of our net short-term capital gain over our long-term
capital loss for such taxable year). Depending on the
circumstances, we may designate all, some or none of our
potentially eligible dividends as such qualified net interest
income or as qualified short-term capital gains, or treat such
dividends, in whole or in part, as ineligible for this exemption
from withholding. In order to qualify for this exemption from
withholding, a
non-U.S. stockholder
must comply with applicable certification requirements relating
to its
non-U.S. status
(including, in general, furnishing an IRS
Form W-8BEN
or an acceptable substitute or successor form). In the case of
shares held through an intermediary, the intermediary could
withhold even if we designate the payment as qualified net
interest income or qualified short-term capital gain.
Non-U.S. stockholders
should contact their intermediaries with respect to the
application of these rules to their accounts.
Actual or deemed distributions of our net capital gains to a
non-U.S. stockholder,
and gains recognized by a
non-U.S. stockholder
upon the sale of our common stock, generally will not be subject
to federal withholding tax and will not be subject to federal
income tax unless (i) the distributions or gains, as the
case may be, are effectively connected with a U.S. trade or
business of the
non-U.S. stockholder
and, if required by an applicable income tax treaty, are
attributable to a permanent establishment maintained by the
non-U.S. stockholder
in the United States or (ii) in the case of an individual,
the
non-U.S. stockholder
is present in the United States for 183 days or more during
a taxable year and certain other conditions are satisfied.
If we distribute our net capital gains in the form of deemed
rather than actual distributions (which we may do in the
future), a
non-U.S. stockholder
will be entitled to a federal income tax credit or tax refund
equal to the stockholders allocable share of the tax we
pay on the capital gains deemed to have been distributed. In
order to obtain the refund, the
non-U.S. stockholder
must obtain a U.S. taxpayer identification number and file
a federal income tax return even if the
non-U.S. stockholder
is not otherwise required to obtain a U.S. taxpayer
identification number or file a federal income tax return.
For a corporate
non-U.S. stockholder,
distributions (both actual and deemed), and gains realized upon
the sale of our common stock that are effectively connected with
a U.S. trade or business may, under certain circumstances,
be subject to an additional branch profits tax at a
30% rate (or at a lower rate if provided for by an applicable
tax treaty). Accordingly, investment in shares of our common
stock may not be appropriate for certain
non-U.S. stockholders.
Dividend Reinvestment Plan. Under our dividend
reinvestment plan, if a
non-U.S. stockholder
owns shares of common stock registered in its own name, the
non-U.S. stockholder
will have all cash distributions automatically reinvested in
additional shares of common stock unless it opts out of our
dividend reinvestment plan by delivering a written notice to our
dividend paying agent prior to the record date of the next
dividend or distribution. See Dividend Reinvestment
Plan. If the distribution is a distribution of our
investment company taxable income, is not designated by us as a
short-term capital gains dividend or interest-related dividend
and it is not effectively connected with a U.S. trade or
business of the
non-U.S. stockholder
(or, if required by an applicable income tax treaty, is not
attributable to a U.S. permanent establishment of the
non-U.S. stockholder),
the amount distributed (to the extent of our current or
accumulated earnings and profits) will be subject to withholding
of U.S. federal income
125
tax at a 30% rate (or lower rate provided by an applicable
treaty) and only the net after-tax amount will be reinvested in
common shares. If the distribution is effectively connected with
a U.S. trade or business of the
non-U.S. stockholder,
generally the full amount of the distribution will be reinvested
in the plan and will nevertheless be subject to
U.S. federal income tax at the ordinary income rates
applicable to U.S. persons. The
non-U.S. stockholder
will have an adjusted basis in the additional common shares
purchased through the plan equal to the amount reinvested. The
additional shares will have a new holding period commencing on
the day following the day on which the shares are credited to
the
non-U.S. stockholders
account.
Backup Withholding. A
non-U.S. stockholder
who is a non-resident alien individual, and who is otherwise
subject to withholding of federal income tax, may be subject to
information reporting and backup withholding of federal income
tax on taxable dividends or distributions unless the
non-U.S. stockholder
provides us or the dividend paying agent with an IRS
Form W-8BEN
(or an acceptable substitute form) or otherwise meets
documentary evidence requirements for establishing that it is a
non-U.S. stockholder
or otherwise establishes an exemption from backup withholding.
Backup withholding is not an additional tax. Any amounts
withheld from payments made to you may be refunded or credited
against your U.S. federal income tax liability, if any,
provided that the required information is furnished to the IRS.
Non-U.S. stockholders
should consult their own tax advisers with respect to the
U.S. federal income tax and withholding tax, and state,
local and foreign tax consequences of an investment in our
shares. Additionally,
non-U.S. stockholders
should be aware of recently enacted legislation that generally
imposes, effective for payments made after December 31,
2012, a 30% federal withholding tax on dividends and proceeds
from the sale of our common stock held by or through foreign
entities, as described below in Recently
Enacted Legislation.
Recently
Enacted Legislation
President Obama recently signed into law H.R. 2847 (the
Recently Enacted Legislation), which will generally
impose a federal withholding tax of 30% on dividends and the
gross proceeds of a disposition of our common stock paid after
December 31, 2012 to a foreign financial institution unless
such institution enters into an agreement with the
U.S. government to withhold on certain payments and to
collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such
institution (which includes certain equity and debt holders of
such institution, as well as certain account holders that are
foreign entities with U.S. owners). The Recently Enacted
Legislation will also generally impose a federal withholding tax
of 30% on dividends and the gross proceeds of a disposition of
our common stock paid after December 31, 2012 to a
non-financial foreign entity unless such entity provides the
withholding agent with a certification identifying the direct
and indirect U.S. owners of the entity. Under certain
circumstances, a
non-U.S. stockholder
might be eligible for refunds or credits of such taxes.
Stockholders are encouraged to consult with their own tax
advisors regarding the possible implications of the Recently
Enacted Legislation on their investment in our common stock.
Recently, Congress enacted the Regulated Investment Company
Modernization Act of 2010 (Modernization Act) which
generally applies to taxable years of a RIC beginning on or
after December 22, 2010. In general, and among other
things, the Modernization Act (i) eliminates the
preferential dividend rule, which under current law
may disallow certain RIC distributions for purposes of the
Annual Distribution Requirement, (ii) allows a RIC to carry
forward capital losses, arising after the effective date,
indefinitely, and (iii) provides certain mitigation
exceptions for certain failures to satisfy the 90% Income Test
and the Diversification Tests.
126
CUSTODIAN,
TRANSFER AGENT, DIVIDEND PAYING AGENT AND REGISTRAR
Our securities are held by Bank of America, N.A. pursuant to a
custodian services agreement. The principal business address of
Bank of America, N.A. is 135 South LaSalle Street, Chicago,
Illinois 60603. Securities held through Credit I and
Credit II are held under custodial agreements with
U.S. Bank National Association, which acts as custodian for
West LB pursuant to the WestLB Facility and as custodian for
Wells pursuant to the Wells Facility. The principal address for
U.S. Bank National Association is 1133 Rankin Street, St.
Paul, Minnesota 55116. Computershare Shareowner Services LLC
(formerly known as BNY Mellon Shareowner Services) acts as our
transfer agent, dividend paying agent and registrar pursuant to
a transfer agency agreement. The principal business address of
Computershare Shareowner Services LLC is 480 Washington Blvd.,
Jersey City, New Jersey 07310.
LEGAL
MATTERS
Certain legal matters in connection with the securities offered
by this prospectus will be passed upon for us by Squire, Sanders
(US) LLP and certain legal matters will be passed upon for
underwriters or dealer managers, if any, by the counsel named in
the prospectus supplement.
INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
Our consolidated financial statements as of December 31,
2010 and 2009, and for the years ended December 31, 2010
and 2009, and the period from March 4, 2008 (inception)
through December 31, 2008 appearing in this prospectus and
elsewhere in the registration statement have been audited by
McGladrey & Pullen, LLP, an independent registered
public accounting firm, as stated in their report appearing
elsewhere herein, which report expresses an unqualified opinion,
and are included in reliance upon such report and upon the
authority of such firm as experts in auditing and accounting.
WHERE YOU
CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement, of which
this prospectus forms a part, on
Form N-2,
together with all amendments and related exhibits, under the
Securities Act, with respect to the securities offered by this
prospectus. The registration statement contains additional
information about us and the securities being offered by this
prospectus.
As a public company, we file with or submit to the SEC annual,
quarterly and current periodic reports, proxy statements and
other information meeting the informational requirements of the
Exchange Act. You may inspect and copy these reports, proxy
statements and other information, as well as the registration
statement and related exhibits and schedules, at the Public
Reference Room of the SEC at 100 F Street, N.E.,
Washington, D.C. 20549. You may obtain information on the
operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330.
The SEC maintains an Internet site that contains reports, proxy
and information statements and other information filed
electronically by us with the SEC which are available on the
SECs website at www.sec.gov. Copies of these
reports, proxy and information statements and other information
may be obtained, after paying a duplicating fee, by electronic
request at the following
e-mail
address: publicinfo@sec.gov, or by writing the SECs
Public Reference Section, 100 F Street, N.E.,
Washington, D.C. 20549.
127
Index to
Consolidated Financial Statements
|
|
|
|
|
|
|
Page
|
|
Unaudited Consolidated Interim Financial Information
|
|
|
|
|
Consolidated Statements of Assets and Liabilities as of
September 30, 2011 and December 31, 2010 (unaudited)
|
|
|
F-2
|
|
Consolidated Statements of Operations for the three and nine
months ended September 30, 2011 and 2010 (unaudited)
|
|
|
F-3
|
|
Consolidated Statements of Changes in Net Assets for the nine
months ended September 30, 2011 and 2010 (unaudited)
|
|
|
F-4
|
|
Consolidated Statements of Cash Flows for the nine months ended
September 30, 2011 and 2010 (unaudited)
|
|
|
F-5
|
|
Consolidated Schedules of Investments as of September 30,
2011 and December 31, 2010 (unaudited)
|
|
|
F-6
|
|
Notes to the Consolidated Financial Statements (unaudited)
|
|
|
F-12
|
|
Audited Consolidated Financial Statements
|
|
|
|
|
Report of Independent Registered Public Accounting Firm
|
|
|
F-28
|
|
Consolidated Statements of Assets and Liabilities as of
December 31, 2010 and 2009
|
|
|
F-29
|
|
Consolidated Statements of Operations for the Period from
October 29, 2010 to December 31, 2010, the Period from
January 1, 2010 to October 28, 2010, the Year Ended
December 31, 2009, and the Period from March 4, 2008
(Inception) to December 31, 2008
|
|
|
F-30
|
|
Consolidated Statements of Changes in Net Assets for the Period
from October 29, 2010 to December 31, 2010, the Period
from January 1, 2010 to October 28, 2010, and the Year
Ended December 31, 2009
|
|
|
F-31
|
|
Consolidated Statements of Cash Flows for the Period from
October 29, 2010 to December 31, 2010, the Period from
January 1, 2010 to October 28, 2010, the Year Ended
December 31, 2009, and the Period from March 4, 2008
(Inception) to December 31, 2008
|
|
|
F-32
|
|
Consolidated Schedules of Investments as of December 31,
2010 and 2009
|
|
|
F-33
|
|
Notes to the Consolidated Financial Statements
|
|
|
F-39
|
|
F-1
Horizon
Technology Finance Corporation and Subsidiaries
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
ASSETS
|
Non-affiliate investments at fair value (cost of $179,651 and
$133,494, respectively) (Note 4)
|
|
$
|
180,186
|
|
|
$
|
136,810
|
|
Cash and cash equivalents
|
|
|
32,598
|
|
|
|
76,793
|
|
Interest receivable
|
|
|
2,477
|
|
|
|
1,938
|
|
Other assets (Note 2)
|
|
|
1,610
|
|
|
|
664
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
216,871
|
|
|
$
|
216,205
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
|
Borrowings (Note 6)
|
|
$
|
81,885
|
|
|
$
|
87,425
|
|
Base management fee payable (Note 3)
|
|
|
362
|
|
|
|
360
|
|
Incentive fee payable (Note 3)
|
|
|
1,453
|
|
|
|
414
|
|
Other accrued expenses
|
|
|
792
|
|
|
|
811
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
84,492
|
|
|
|
89,010
|
|
|
|
|
|
|
|
|
|
|
Net assets
|
|
|
|
|
|
|
|
|
Common stock, par value $0.001 per share,
100,000,000 shares authorized, 7,626,718 shares
outstanding as of September 30, 2011 and
7,593,421 shares outstanding as of December 31, 2010
|
|
|
8
|
|
|
|
8
|
|
Paid-in capital in excess of par
|
|
|
124,361
|
|
|
|
123,836
|
|
Accumulated undistributed (distributions in excess of) net
investment income
|
|
|
1,507
|
|
|
|
(143
|
)
|
Net unrealized appreciation on investments
|
|
|
508
|
|
|
|
3,043
|
|
Net realized gain on investments
|
|
|
5,995
|
|
|
|
451
|
|
|
|
|
|
|
|
|
|
|
Total net assets
|
|
|
132,379
|
|
|
|
127,195
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and net assets
|
|
$
|
216,871
|
|
|
$
|
216,205
|
|
|
|
|
|
|
|
|
|
|
Net asset value per common share
|
|
$
|
17.36
|
|
|
$
|
16.75
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-2
Horizon
Technology Finance Corporation and Subsidiaries
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-IPO Prior to
|
|
|
|
|
|
Pre-IPO Prior to
|
|
|
|
Post-IPO as a
|
|
|
Becoming a
|
|
|
Post-IPO as a
|
|
|
Becoming a
|
|
|
|
Business
|
|
|
Business
|
|
|
Business
|
|
|
Business
|
|
|
|
Development
|
|
|
Development
|
|
|
Development
|
|
|
Development
|
|
|
|
Company
|
|
|
Company
|
|
|
Company
|
|
|
Company
|
|
|
|
Three Months Ended
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2011
|
|
|
September 30, 2010
|
|
|
September 30, 2011
|
|
|
September 30, 2010
|
|
|
Investment income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income on non-affiliate investments
|
|
$
|
6,129
|
|
|
$
|
4,955
|
|
|
$
|
16,911
|
|
|
$
|
12,852
|
|
Interest income on cash and cash equivalents
|
|
|
2
|
|
|
|
25
|
|
|
|
90
|
|
|
|
53
|
|
Fee income on non-affiliate investments
|
|
|
310
|
|
|
|
209
|
|
|
|
870
|
|
|
|
345
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investment income
|
|
|
6,441
|
|
|
|
5,189
|
|
|
|
17,871
|
|
|
|
13,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
725
|
|
|
|
1,189
|
|
|
|
2,093
|
|
|
|
3,282
|
|
Base management fee (Note 3)
|
|
|
1,091
|
|
|
|
675
|
|
|
|
3,229
|
|
|
|
1,816
|
|
Performance based incentive fee (Note 3)
|
|
|
561
|
|
|
|
|
|
|
|
2,701
|
|
|
|
|
|
Administrative fee (Note 3)
|
|
|
355
|
|
|
|
|
|
|
|
873
|
|
|
|
|
|
Professional fees
|
|
|
489
|
|
|
|
7
|
|
|
|
1,034
|
|
|
|
110
|
|
General and administrative
|
|
|
227
|
|
|
|
61
|
|
|
|
740
|
|
|
|
164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
3,448
|
|
|
|
1,932
|
|
|
|
10,670
|
|
|
|
5,372
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment income
|
|
|
2,993
|
|
|
|
3,257
|
|
|
|
7,201
|
|
|
|
7,878
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Credit for loan losses
|
|
|
|
|
|
|
320
|
|
|
|
|
|
|
|
739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized and unrealized gain on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized (loss) gain on investments
|
|
|
(17
|
)
|
|
|
|
|
|
|
5,544
|
|
|
|
(2
|
)
|
Net unrealized (depreciation) appreciation on investments
|
|
|
(217
|
)
|
|
|
1,711
|
|
|
|
(2,535
|
)
|
|
|
1,549
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized and unrealized (loss) gain on investments
|
|
|
(234
|
)
|
|
|
1,711
|
|
|
|
3,009
|
|
|
|
1,547
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
2,759
|
|
|
$
|
5,288
|
|
|
$
|
10,210
|
|
|
$
|
10,164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment income per common
share(1)
|
|
$
|
0.39
|
|
|
$
|
N/A
|
|
|
$
|
0.95
|
|
|
$
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in net assets per common
share(1)
|
|
$
|
0.36
|
|
|
$
|
N/A
|
|
|
$
|
1.34
|
|
|
$
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares
outstanding(1)
|
|
|
7,617,972
|
|
|
|
N/A
|
|
|
|
7,604,345
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
For the three and nine months ended September 30, 2010, the
Company did not have common shares outstanding or an equivalent
and, therefore, earnings per share and weighted average shares
outstanding information for this period is not provided. |
See Notes to Consolidated Financial Statements
F-3
Horizon
Technology Finance Corporation and Subsidiaries
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Undistributed
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(distributions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
in excess of)
|
|
|
Net Unrealized
|
|
|
Net
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
Paid-In
|
|
|
Net
|
|
|
Appreciation
|
|
|
Realized
|
|
|
|
|
|
|
Members
|
|
|
Comprehensive
|
|
|
Common Stock
|
|
|
Capital in
|
|
|
Investment
|
|
|
on
|
|
|
Gain on
|
|
|
Total
|
|
|
|
Capital
|
|
|
Loss
|
|
|
Shares
|
|
|
Amount
|
|
|
Excess of Par
|
|
|
Income
|
|
|
Investments
|
|
|
Investments
|
|
|
Net Assets
|
|
|
Balance at December 31, 2009
|
|
$
|
60,260
|
|
|
$
|
(768
|
)
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
59,492
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
10,164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,164
|
|
Unrealized loss on interest rate swaps
|
|
|
|
|
|
|
409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
409
|
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,573
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2010
|
|
$
|
70,424
|
|
|
$
|
(359
|
)
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
70,065
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
|
|
|
$
|
|
|
|
|
7,593,421
|
|
|
$
|
8
|
|
|
$
|
123,836
|
|
|
$
|
(143
|
)
|
|
$
|
3,043
|
|
|
$
|
451
|
|
|
$
|
127,195
|
|
Net increase in net assets from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,201
|
|
|
|
(2,535
|
)
|
|
|
5,544
|
|
|
|
10,210
|
|
Issuance of common stock as stock dividend
|
|
|
|
|
|
|
|
|
|
|
33,297
|
|
|
|
|
|
|
|
525
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
525
|
|
Dividends declared
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5,551
|
)
|
|
|
|
|
|
|
|
|
|
|
(5,551
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2011
|
|
$
|
|
|
|
$
|
|
|
|
|
7,626,718
|
|
|
$
|
8
|
|
|
$
|
124,361
|
|
|
$
|
1,507
|
|
|
$
|
508
|
|
|
$
|
5,995
|
|
|
$
|
132,379
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-4
Horizon
Technology Finance Corporation and Subsidiaries
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-IPO Prior to
|
|
|
|
Post-IPO as a
|
|
|
becoming a
|
|
|
|
Business
|
|
|
Business
|
|
|
|
Development
|
|
|
Development
|
|
|
|
Company
|
|
|
Company
|
|
|
|
Nine Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2011
|
|
|
2010
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
10,210
|
|
|
$
|
10,164
|
|
Adjustments to reconcile net increase in net assets resulting
from operations to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Credit for loan losses
|
|
|
|
|
|
|
(739
|
)
|
Amortization of debt issuance costs
|
|
|
227
|
|
|
|
871
|
|
Net realized (gain) loss on investments
|
|
|
(5,799
|
)
|
|
|
2
|
|
Net change in unrealized depreciation (appreciation) on
investments
|
|
|
2,535
|
|
|
|
(1,549
|
)
|
Purchase of investments
|
|
|
(78,156
|
)
|
|
|
(64,608
|
)
|
Principal payments received on investments
|
|
|
32,574
|
|
|
|
41,333
|
|
Proceeds from sale of investments
|
|
|
5,887
|
|
|
|
|
|
Stock received in settlement of fee income
|
|
|
(544
|
)
|
|
|
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
Increase in interest receivable
|
|
|
(539
|
)
|
|
|
(498
|
)
|
Decrease in unearned loan income
|
|
|
(331
|
)
|
|
|
(302
|
)
|
Decrease (increase) in other assets
|
|
|
247
|
|
|
|
(251
|
)
|
Increase in other accrued expenses
|
|
|
226
|
|
|
|
91
|
|
Increase in base management fee payable
|
|
|
2
|
|
|
|
35
|
|
Increase in incentive fee payable
|
|
|
1,039
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(32,422
|
)
|
|
|
(15,451
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Net (decrease) increase in revolving borrowings
|
|
|
(5,540
|
)
|
|
|
24,778
|
|
Dividends paid
|
|
|
(5,026
|
)
|
|
|
|
|
Capitalized debt issuance costs
|
|
|
(1,207
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by financing activities
|
|
|
(11,773
|
)
|
|
|
24,778
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(44,195
|
)
|
|
|
9,327
|
|
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
Beginning of period
|
|
|
76,793
|
|
|
|
9,892
|
|
|
|
|
|
|
|
|
|
|
End of period
|
|
$
|
32,598
|
|
|
$
|
19,219
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
1,738
|
|
|
$
|
2,366
|
|
|
|
|
|
|
|
|
|
|
Supplemental non-cash investing and financing activities:
|
|
|
|
|
|
|
|
|
Warrant investments received & recorded as unearned
loan income
|
|
$
|
1,129
|
|
|
$
|
1,212
|
|
|
|
|
|
|
|
|
|
|
Receivables resulting from sales of investments
|
|
$
|
213
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
Decrease in interest rate swap liability
|
|
$
|
(245
|
)
|
|
$
|
(409
|
)
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)
|
|
Rate(4)
|
|
|
Maturity
|
|
|
Investment(6)
|
|
|
Fair Value
|
|
|
Debt Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Life Science
41.2%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
13.10
|
%
|
|
|
12/1/2013
|
|
|
$
|
905
|
|
|
$
|
905
|
|
|
|
|
|
Term
Loan(1)
|
|
|
13.01
|
%
|
|
|
12/1/2013
|
|
|
|
905
|
|
|
|
905
|
|
|
|
|
|
Term
Loan(1)
|
|
|
13.01
|
%
|
|
|
12/1/2013
|
|
|
|
1,371
|
|
|
|
1,371
|
|
Ambit Biosciences Corporation
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.25
|
%
|
|
|
10/1/2013
|
|
|
|
5,066
|
|
|
|
5,066
|
|
Anacor Pharmaceuticals,
Inc.(5)
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
|
9.41
|
%
|
|
|
4/1/2015
|
|
|
|
3,206
|
|
|
|
3,206
|
|
GenturaDx, Inc.
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
|
11.25
|
%
|
|
|
4/1/2014
|
|
|
|
1,903
|
|
|
|
1,903
|
|
N30 Pharmaceuticals, LLC
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
11.25
|
%
|
|
|
9/1/2014
|
|
|
|
2,412
|
|
|
|
2,412
|
|
Pharmasset,
Inc.(5)
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
1/1/2012
|
|
|
|
379
|
|
|
|
379
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
10/1/2012
|
|
|
|
1,453
|
|
|
|
1,453
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Convertible
Note(1)
|
|
|
8.00
|
%
|
|
|
2/10/2013
|
|
|
|
62
|
|
|
|
62
|
|
Supernus Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
|
11.00
|
%
|
|
|
8/1/2014
|
|
|
|
2,947
|
|
|
|
2,947
|
|
Tranzyme,
Inc.(5)
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
10.75
|
%
|
|
|
1/1/2014
|
|
|
|
4,538
|
|
|
|
4,538
|
|
Xcovery Holding Company, LLC
|
|
Biotechnology
|
|
Term
Loan(2)
|
|
|
12.00
|
%
|
|
|
10/1/2013
|
|
|
|
1,494
|
|
|
|
1,494
|
|
|
|
|
|
Term
Loan(2)
|
|
|
12.00
|
%
|
|
|
7/1/2014
|
|
|
|
1,477
|
|
|
|
1,477
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
12.04
|
%
|
|
|
9/1/2013
|
|
|
|
6,676
|
|
|
|
6,676
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
11.50
|
%
|
|
|
4/1/2014
|
|
|
|
4,669
|
|
|
|
4,669
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Term
Loan(2)
|
|
|
10.75
|
%
|
|
|
11/1/2014
|
|
|
|
9,910
|
|
|
|
9,910
|
|
Tengion,
Inc.(5)
|
|
Medical Device
|
|
Term
Loan(2)
|
|
|
11.75
|
%
|
|
|
1/1/2014
|
|
|
|
4,948
|
|
|
|
4,588
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
13.55
|
%
|
|
|
11/1/2011
|
|
|
|
656
|
|
|
|
656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Life Science
|
|
|
54,977
|
|
|
|
54,617
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Technology 36.2%
|
|
|
|
|
|
|
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Term
Loan(1)
|
|
|
11.86
|
%
|
|
|
12/1/2013
|
|
|
|
6,016
|
|
|
|
5,647
|
|
Starcite, Inc.
|
|
Consumer-related Technologies
|
|
Term
Loan(1)
|
|
|
12.05
|
%
|
|
|
9/1/2012
|
|
|
|
1,604
|
|
|
|
1,604
|
|
Tagged, Inc.
|
|
Consumer-related Technologies
|
|
Term
Loan(1)
|
|
|
12.78
|
%
|
|
|
5/1/2012
|
|
|
|
671
|
|
|
|
671
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.46
|
%
|
|
|
8/1/2012
|
|
|
|
300
|
|
|
|
300
|
|
Xtera Communications, Inc.
|
|
Semiconductors
|
|
Term
Loan(2)
|
|
|
11.50
|
%
|
|
|
12/1/2014
|
|
|
|
9,739
|
|
|
|
9,739
|
|
Vette Corp.
|
|
Data Storage
|
|
Term
Loan(1)
|
|
|
11.75
|
%
|
|
|
7/1/2014
|
|
|
|
4,928
|
|
|
|
4,928
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Term
Loan(1)
|
|
|
12.43
|
%
|
|
|
4/1/2012
|
|
|
|
238
|
|
|
|
238
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.33
|
%
|
|
|
6/1/2012
|
|
|
|
315
|
|
|
|
315
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.33
|
%
|
|
|
10/1/2012
|
|
|
|
729
|
|
|
|
729
|
|
Construction Software Technologies, Inc.
|
|
Software
|
|
Term
Loan(2)
|
|
|
11.75
|
%
|
|
|
12/1/2014
|
|
|
|
3,940
|
|
|
|
3,940
|
|
|
|
|
|
Term Loan
|
|
|
11.75
|
%
|
|
|
6/1/2014
|
|
|
|
1,969
|
|
|
|
1,969
|
|
Courion Corporation
|
|
Software
|
|
Term
Loan(1)
|
|
|
11.45
|
%
|
|
|
9/1/2014
|
|
|
|
6,889
|
|
|
|
6,889
|
|
Recondo Technology, Inc.
|
|
Software
|
|
Term Loan
|
|
|
11.50
|
%
|
|
|
4/1/2015
|
|
|
|
1,923
|
|
|
|
1,923
|
|
Seapass Solutions, Inc.
|
|
Software
|
|
Term
Loan(2)
|
|
|
11.75
|
%
|
|
|
11/1/2014
|
|
|
|
4,924
|
|
|
|
4,924
|
|
StreamBase Systems, Inc.
|
|
Software
|
|
Term
Loan(1)
|
|
|
12.51
|
%
|
|
|
11/1/2013
|
|
|
|
3,115
|
|
|
|
3,115
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
6/1/2014
|
|
|
|
960
|
|
|
|
960
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Technology
|
|
|
48,260
|
|
|
|
47,891
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Cleantech 22.9%
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(5)
|
|
Waste Recycling
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
4/1/2014
|
|
|
|
2,448
|
|
|
|
2,448
|
|
|
|
Waste Recycling
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
6/1/2014
|
|
|
|
2,441
|
|
|
|
2,441
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
|
12.60
|
%
|
|
|
10/1/2013
|
|
|
|
5,697
|
|
|
|
5,697
|
|
|
|
|
|
Term Loan
|
|
|
10.75
|
%
|
|
|
4/1/2015
|
|
|
|
1,968
|
|
|
|
1,968
|
|
|
|
|
|
Term Loan
|
|
|
10.75
|
%
|
|
|
4/1/2015
|
|
|
|
2,938
|
|
|
|
2,938
|
|
Satcon Technology
Corporation(5)
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
|
12.58
|
%
|
|
|
1/1/2014
|
|
|
|
8,521
|
|
|
|
8,521
|
|
Tigo Energy, Inc.
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
|
11.00
|
%
|
|
|
8/1/2014
|
|
|
|
3,422
|
|
|
|
3,422
|
|
|
|
|
|
Revolver(2)
|
|
|
10.75
|
%
|
|
|
1/1/2014
|
|
|
|
2,933
|
|
|
|
2,933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Prime + 7.50
|
%)
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Cleantech
|
|
|
30,368
|
|
|
|
30,368
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Healthcare information and
services 31.4%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
8/1/2012
|
|
|
|
1,351
|
|
|
|
1,351
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.51
|
%
|
|
|
1/1/2014
|
|
|
|
4,941
|
|
|
|
4,941
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
10.25
|
%
|
|
|
12/1/2014
|
|
|
|
6,952
|
|
|
|
6,952
|
|
See Notes to Consolidated Financial Statements
F-6
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments (Unaudited)
September 30,
2011 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)
|
|
Rate(4)
|
|
|
Maturity
|
|
|
Investment(6)
|
|
|
Fair Value
|
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
|
12.75
|
%
|
|
|
1/1/2014
|
|
|
|
9,340
|
|
|
|
9,340
|
|
Aperio Technologies, Inc.
|
|
Other Healthcare
|
|
Term Loan
|
|
|
9.64
|
%
|
|
|
5/1/2015
|
|
|
|
4,929
|
|
|
|
4,929
|
|
Patientkeeper, Inc.
|
|
Other Healthcare
|
|
Term Loan
|
|
|
10.50
|
%
|
|
|
12/1/2014
|
|
|
|
5,222
|
|
|
|
5,222
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Term
Loan(1)
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
2,968
|
|
|
|
2,968
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
1,978
|
|
|
|
1,978
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Term
Loan(1)
|
|
|
12.10
|
%
|
|
|
12/1/2013
|
|
|
|
1,924
|
|
|
|
1,924
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.05
|
%
|
|
|
12/1/2013
|
|
|
|
1,921
|
|
|
|
1,921
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investment Healthcare information and
services
|
|
|
41,526
|
|
|
|
41,526
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments
|
|
|
175,131
|
|
|
|
174,402
|
|
|
|
|
|
|
|
|
|
|
Warrant Investments
|
|
|
|
|
|
|
|
|
Warrants Life Science 1.3%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
58
|
|
|
|
67
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
143
|
|
|
|
98
|
|
Anacor Pharmaceuticals,
Inc.(5)
|
|
Biotechnology
|
|
Common Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
22
|
|
Anesiva,
Inc.(5)
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
GenturaDx, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
63
|
|
|
|
60
|
|
N30 Pharmaceuticals, LLC
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
59
|
|
|
|
46
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
224
|
|
|
|
489
|
|
Supernus Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
15
|
|
Tranzyme,
Inc.(5)
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
84
|
|
|
|
875
|
|
EnteroMedics,
Inc.(5)
|
|
Medical Device
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
347
|
|
|
|
2
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
78
|
|
|
|
67
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
96
|
|
|
|
46
|
|
Tengion,
Inc.(5)
|
|
Medical Device
|
|
Common Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
62
|
|
|
|
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Life Science
|
|
|
1,373
|
|
|
|
1,787
|
|
|
|
|
|
|
|
|
|
|
Warrants Technology 1.5%
|
|
|
|
|
|
|
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
89
|
|
|
|
|
|
Everyday Health, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
116
|
|
SnagAJob.com, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
270
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
27
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
27
|
|
Xtera Communications, Inc.
|
|
Semiconductors
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
206
|
|
|
|
242
|
|
Vette Corp.
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
75
|
|
|
|
48
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
80
|
|
Cartera Commerce, Inc.
|
|
Internet and media
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
30
|
|
Grab Networks, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
524
|
|
Motion Computing, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
334
|
|
Impinj, Inc.
|
|
Semi-conductor
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
Clarabridge, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
24
|
|
Construction Software Technologies, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
45
|
|
|
|
44
|
|
Courion Corporation
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
85
|
|
|
|
100
|
|
DriveCam, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
7
|
|
Netuitive, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
21
|
|
Recondo Technology, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
47
|
|
|
|
47
|
|
Seapass Solutions, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(2)
|
|
|
|
|
|
|
|
|
|
|
43
|
|
|
|
42
|
|
StreamBase Systems, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
67
|
|
|
|
68
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Technology
|
|
|
1,029
|
|
|
|
2,051
|
|
|
|
|
|
|
|
|
|
|
Warrants Cleantech 0.2%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(5)
|
|
Waste Recycling
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
112
|
|
|
|
28
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
175
|
|
|
|
136
|
|
See Notes to Consolidated Financial Statements
F-7
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments (Unaudited)
September 30,
2011 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(3)
|
|
Rate(4)
|
|
|
Maturity
|
|
|
Investment(6)
|
|
|
Fair Value
|
|
|
Satcon Technology
Corporation(5)
|
|
Energy Efficiency
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
285
|
|
|
|
5
|
|
Tigo Energy, Inc.
|
|
Energy Efficiency
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
101
|
|
|
|
79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Cleantech
|
|
|
673
|
|
|
|
248
|
|
|
|
|
|
|
|
|
|
|
Warrants Healthcare information and
services 0.8%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
54
|
|
|
|
62
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
73
|
|
|
|
158
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
167
|
|
|
|
372
|
|
Aperio Technologies, Inc.
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
35
|
|
|
|
34
|
|
Patientkeeper, Inc.
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
269
|
|
|
|
266
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
40
|
|
|
|
31
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Healthcare information and services
|
|
|
738
|
|
|
|
1,005
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
3,813
|
|
|
|
5,091
|
|
|
|
|
|
|
|
|
|
|
Equity 0.5%
|
|
|
|
|
|
|
|
|
Insmed
Incorporated(5)
|
|
Biotechnology
|
|
Common
Stock(1)
|
|
|
|
|
|
|
|
|
|
|
227
|
|
|
|
169
|
|
Overture Networks Inc.
|
|
Communications
|
|
Preferred
Stock(1)
|
|
|
|
|
|
|
|
|
|
|
480
|
|
|
|
524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Equity
|
|
|
707
|
|
|
|
693
|
|
|
|
|
|
|
|
|
|
|
Total Investments Assets
|
|
$
|
179,651
|
|
|
$
|
180,186
|
|
|
|
|
|
|
|
|
|
|
Investment Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Agreement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WestLB, AG
|
|
Interest rate swap pay fixed/receive floating,
Notional Amount $10 million
|
|
|
|
|
3.58
|
%
|
|
|
10/14/2011
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Investment Liabilities
|
|
$
|
|
|
|
$
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Has been pledged as collateral under the WestLB Facility. |
|
(2) |
|
Has been pledged as collateral under the Wells Facility. |
|
(3) |
|
All investments are less than 5% ownership of the class and
ownership of the portfolio company. |
|
(4) |
|
All interest is payable in cash due monthly in arrears, unless
otherwise indicated and applies only to the Companys debt
investments. Amount is the annual interest rate on the debt
investment and does not include any additional fees related to
the investment, such as deferred interest, commitment fees or
prepayment fees. The majority of the debt investments are at
fixed rates for the term of the loan. For each debt investment,
we have provided the current interest rate in effect as of
September 30, 2011. |
|
(5) |
|
Portfolio company is a public company. |
|
(6) |
|
For debt investments, represents principal balance less unearned
income. |
See Notes to Consolidated Financial Statements
F-8
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2010
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Debt Investments
|
|
|
|
|
|
|
|
|
Debt Investments Life Science
39.3%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.10
|
%
|
|
|
6/1/2013
|
|
|
$
|
958
|
|
|
$
|
958
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.01
|
%
|
|
|
6/1/2013
|
|
|
|
957
|
|
|
|
957
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.01
|
%
|
|
|
6/1/2013
|
|
|
|
1,478
|
|
|
|
1,478
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.25
|
%
|
|
|
10/1/2013
|
|
|
|
5,898
|
|
|
|
5,898
|
|
GenturaDx, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
11.25
|
%
|
|
|
4/1/2014
|
|
|
|
1,917
|
|
|
|
1,917
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
6/1/2012
|
|
|
|
3,146
|
|
|
|
3,146
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
8/1/2011
|
|
|
|
868
|
|
|
|
868
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
1/1/2012
|
|
|
|
1,448
|
|
|
|
1,448
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
10/1/2012
|
|
|
|
2,422
|
|
|
|
2,422
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
10.50
|
%
|
|
|
12/1/2011
|
|
|
|
1,445
|
|
|
|
1,445
|
|
|
|
|
|
Term
Loan(1)
|
|
|
10.50
|
%
|
|
|
3/1/2013
|
|
|
|
3,478
|
|
|
|
3,478
|
|
Tranzyme, Inc.
|
|
Biotechnology
|
|
Term
Loan(1)
|
|
|
10.75
|
%
|
|
|
1/1/2014
|
|
|
|
4,966
|
|
|
|
4,966
|
|
Xcovery Holding Company, LLC
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
10/1/2013
|
|
|
|
1,490
|
|
|
|
1,490
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
12.04
|
%
|
|
|
9/1/2013
|
|
|
|
6,887
|
|
|
|
6,887
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
11.50
|
%
|
|
|
4/1/2014
|
|
|
|
4,887
|
|
|
|
4,887
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
13.00
|
%
|
|
|
1/1/2013
|
|
|
|
4,221
|
|
|
|
4,221
|
|
Tengion,
Inc.(4)
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
12.26
|
%
|
|
|
9/1/2011
|
|
|
|
2,740
|
|
|
|
2,740
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Term
Loan(1)
|
|
|
13.55
|
%
|
|
|
11/1/2011
|
|
|
|
885
|
|
|
|
837
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Life Science
|
|
|
50,091
|
|
|
|
50,043
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Technology 24.4%
|
|
|
|
|
|
|
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Term
Loan(1)
|
|
|
12.40
|
%
|
|
|
2/1/2011
|
|
|
|
1,042
|
|
|
|
1,042
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Term
Loan(1)
|
|
|
11.86
|
%
|
|
|
12/1/2013
|
|
|
|
6,549
|
|
|
|
6,549
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Term
Loan(1)
|
|
|
12.05
|
%
|
|
|
9/1/2012
|
|
|
|
2,679
|
|
|
|
2,679
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Term
Loan(1)
|
|
|
12.78
|
%
|
|
|
5/1/2012
|
|
|
|
1,284
|
|
|
|
1,284
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.46
|
%
|
|
|
8/1/2012
|
|
|
|
498
|
|
|
|
498
|
|
Vette Corp.
|
|
Data Storage
|
|
Term
Loan(1)
|
|
|
11.75
|
%
|
|
|
7/1/2014
|
|
|
|
4,916
|
|
|
|
4,916
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Term
Loan(1)
|
|
|
14.00
|
%
|
|
|
5/1/2012
|
|
|
|
2,997
|
|
|
|
2,997
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Term
Loan(1)
|
|
|
12.43
|
%
|
|
|
4/1/2012
|
|
|
|
515
|
|
|
|
515
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.33
|
%
|
|
|
6/1/2012
|
|
|
|
598
|
|
|
|
598
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.33
|
%
|
|
|
10/1/2012
|
|
|
|
1,171
|
|
|
|
1,171
|
|
Clarabridge, Inc.
|
|
Software
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
1/1/2013
|
|
|
|
1,166
|
|
|
|
1,166
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
6/1/2013
|
|
|
|
688
|
|
|
|
688
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
5/1/2014
|
|
|
|
743
|
|
|
|
743
|
|
Courion Corporation
|
|
Software
|
|
Term
Loan(1)
|
|
|
11.45
|
%
|
|
|
12/1/2011
|
|
|
|
1,083
|
|
|
|
1,083
|
|
Netuitive, Inc.
|
|
Software
|
|
Term
Loan(1)
|
|
|
12.90
|
%
|
|
|
4/1/2011
|
|
|
|
152
|
|
|
|
152
|
|
StreamBase Systems, Inc.
|
|
Software
|
|
Term
Loan(1)
|
|
|
12.51
|
%
|
|
|
11/1/2013
|
|
|
|
3,934
|
|
|
|
3,934
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.50
|
%
|
|
|
6/1/2014
|
|
|
|
977
|
|
|
|
977
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Technology
|
|
|
30,992
|
|
|
|
30,992
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Cleantech 14.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(4)
|
|
Waste Recycling
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
4/1/2014
|
|
|
|
2,363
|
|
|
|
2,363
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
|
12.60
|
%
|
|
|
10/1/2013
|
|
|
|
6,869
|
|
|
|
6,869
|
|
Satcon Technology
Corporation(4)
|
|
Energy Efficiency
|
|
Term
Loan(1)
|
|
|
12.58
|
%
|
|
|
1/1/2014
|
|
|
|
9,701
|
|
|
|
9,701
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Cleantech
|
|
|
18,933
|
|
|
|
18,933
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-9
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2010 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Debt Investments Healthcare information and
services 23.8%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
|
12.00
|
%
|
|
|
8/1/2012
|
|
|
$
|
2,454
|
|
|
$
|
2,454
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.51
|
%
|
|
|
1/1/2014
|
|
|
|
4,908
|
|
|
|
4,908
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
|
13.00
|
%
|
|
|
3/1/2012
|
|
|
|
3,255
|
|
|
|
3,255
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Term
Loan(1)
|
|
|
12.75
|
%
|
|
|
1/1/2014
|
|
|
|
9,855
|
|
|
|
9,855
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Term
Loan(1)
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
2,949
|
|
|
|
2,949
|
|
|
|
|
|
Term
Loan(1)
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
1,964
|
|
|
|
1,964
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Term
Loan(1)
|
|
|
12.10
|
%
|
|
|
12/1/2013
|
|
|
|
2,443
|
|
|
|
2,443
|
|
|
|
|
|
Term
Loan(1)
|
|
|
12.05
|
%
|
|
|
12/1/2013
|
|
|
|
2,438
|
|
|
|
2,438
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investment Healthcare information and
services
|
|
|
30,266
|
|
|
|
30,266
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments
|
|
|
130,282
|
|
|
|
130,234
|
|
|
|
|
|
|
|
|
|
|
Warrant Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Life Science 2.1%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
23
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
143
|
|
|
|
147
|
|
Anesiva,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
GenturaDx, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
63
|
|
|
|
63
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
126
|
|
|
|
789
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
224
|
|
|
|
121
|
|
Tranzyme, Inc.
|
|
Biotechnology
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
Advanced BioHealing, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
1,209
|
|
Calypso Medical Technologies, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
76
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
85
|
|
|
|
89
|
|
EnteroMedics,
Inc.(4)
|
|
Medical Device
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
347
|
|
|
|
18
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
78
|
|
|
|
83
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
61
|
|
|
|
61
|
|
Tengion,
Inc.(4)
|
|
Medical Device
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Life Science
|
|
|
1,292
|
|
|
|
2,680
|
|
|
|
|
|
|
|
|
|
|
Warrants Technology 1.2%
|
|
|
|
|
|
|
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
89
|
|
|
|
92
|
|
Everyday Health, Inc.
|
|
Consumer related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
137
|
|
SnagAJob.com, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
39
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
28
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
27
|
|
Vette Corp.
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
75
|
|
|
|
49
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
81
|
|
Cartera Commerce, Inc.
|
|
Internet and media
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
38
|
|
Grab Networks, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
544
|
|
Motion Computing, Inc.
|
|
Networking
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
292
|
|
Impinj, Inc.
|
|
Semi-conductor
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
Clarabridge, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
|
25
|
|
See Notes to Consolidated Financial Statements
F-10
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2010 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Courion Corporation
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
$
|
7
|
|
|
$
|
17
|
|
DriveCam, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
8
|
|
Netuitive, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
22
|
|
Plateau Systems, Ltd.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
35
|
|
StreamBase Systems, Inc.
|
|
Software
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
67
|
|
|
|
69
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Technology
|
|
|
618
|
|
|
|
1,538
|
|
|
|
|
|
|
|
|
|
|
Warrants Cleantech 1.0%
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(4)
|
|
Waste Recycling
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
112
|
|
|
|
112
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
122
|
|
|
|
122
|
|
Satcon Technology
Corporation(4)
|
|
Energy Efficiency
|
|
Common Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
286
|
|
|
|
1,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Cleantech
|
|
|
520
|
|
|
|
1,291
|
|
|
|
|
|
|
|
|
|
|
Warrants Healthcare information and
services 0.6%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
55
|
|
|
|
49
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
52
|
|
|
|
139
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
167
|
|
|
|
384
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
39
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Preferred Stock
Warrants(1)
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
105
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Healthcare information and services
|
|
|
413
|
|
|
|
716
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
2,843
|
|
|
|
6,225
|
|
|
|
|
|
|
|
|
|
|
Equity 0.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFS Technologies, Inc
|
|
|
|
Common
Stock(1)
|
|
|
|
|
|
|
|
|
|
|
142
|
|
|
|
142
|
|
Insmed
Incorporated(4)
|
|
|
|
Common Stock and Convertible Preferred
Stock(1)
|
|
|
|
|
|
|
|
|
|
|
227
|
|
|
|
209
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
369
|
|
|
|
351
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Investments Assets
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative Agreement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
WestLB, AG
|
|
Interest rate swap pay fixed/receive floating,
Notional Amount $10 million
|
|
|
|
|
3.58
|
%
|
|
|
10/14/2011
|
|
|
|
|
|
|
|
258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Investment Liabilities
|
|
$
|
|
|
|
$
|
258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Has been pledged as collateral under the WestLB Facility. |
|
(2) |
|
All investments are less than 5% ownership of the class and
ownership of the portfolio company. |
|
(3) |
|
All interest is payable in cash due monthly in arrears, unless
otherwise indicated and applies only to the Companys debt
investments. Amount is the annual interest rate on the debt
investment and does not include any additional fees related to
the investment, such as deferred interest, commitment fees or
prepayment fees. The majority of the debt investments are at
fixed rates for the term of the loan. For each debt investment,
we have provided the current interest rate in effect as of
December 31, 2010. |
|
(4) |
|
Portfolio company is a public company. |
|
(5) |
|
For debt investments, represents principal balance less unearned
income. |
See Notes to Consolidated Financial Statements
F-11
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands, except shares and per share data)
Horizon Technology Finance Corporation (the Company)
was organized as a Delaware corporation on March 16, 2010
and is an externally managed, non-diversified, closed end
investment company. The Company has elected to be regulated as a
business development company (BDC) under the
Investment Company Act of 1940, as amended (1940
Act). In addition, for tax purposes, the Company has
elected to be treated as a regulated investment company
(RIC) as defined in Subtitle A, Chapter 1,
under Subchapter M of the Internal Revenue Code of 1986, as
amended (the Code). As a RIC, the Company will not
be subject to federal income tax on the portion of its taxable
income and capital gains the Company distributes to the
stockholders. The Company primarily makes secured loans to
development-stage companies in the technology, life science,
healthcare information and services and cleantech industries.
On October 28, 2010 the Company completed an initial public
offering (IPO) and its common stock trades on the
NASDAQ Global Market under the symbol HRZN. The
Company was formed to continue and expand the business of
Compass Horizon Funding Company LLC (CHF), a
Delaware limited liability company, which commenced operations
in March 2008 and became the Companys wholly owned
subsidiary with the completion of the IPO.
Horizon Credit I LLC (Credit I) was formed as a
Delaware limited liability company on January 23, 2008,
with CHF as the sole equity member. Credit I is a special
purpose bankruptcy remote entity and is reported herein as a
wholly owned subsidiary of the Company. CHF sold certain
portfolio transactions to Credit I (Purchased
Assets). Credit I is a separate legal entity from CHF and
the Purchased Assets conveyed to Credit I are not available to
creditors of the Company or any other entity other than Credit
Is lenders.
Horizon Credit II LLC (Credit II) was formed as
a Delaware limited liability company on June 28, 2011, with
the Company as the sole equity member. Credit II is a
special purpose bankruptcy remote entity and is a separate legal
entity from the Company. Any assets conveyed to Credit II
will not be available to creditors of the Company or any other
entity other than Credit IIs lenders.
Longview SBIC GP LLC and Longview SBIC LP (collectively,
Horizon SBIC) were formed as a Delaware limited
liability company and Delaware limited partnership, respectively
on February 11, 2011. Horizon SBIC are wholly owned
subsidiaries of the Company and were formed in anticipation of
receiving a license to operate a small business investment
company (SBIC) from the U.S. Small Business
Administration (SBA). There has been no activity in
Horizon SBIC since its inception.
The Companys investment strategy is to maximize the
investment portfolios return by generating current income
from the loans made and the capital appreciation from the
warrants received when making such loans. The Company has
entered into an investment management agreement (the
Investment Management Agreement) with Horizon
Technology Finance Management LLC (HTFM or the
Advisor), under which the Advisor will manage the
day-to-day
operations of, and provide investment advisory services to, the
Company.
|
|
Note 2.
|
Basis of
Presentation and Significant Accounting Policies
|
Election
to become a Business Development Company and Basis of Financial
Statement Presentation
The results of operations for the three and nine months ended
September 30, 2011 reflect the Companys results as a
BDC under the 1940 Act, whereas the operating results for the
three and nine months ended September 30, 2010 reflect the
Companys results prior to operating as a BDC under the
1940 Act. Accounting principles used in the preparation of these
two periods are different and, therefore, the financial position
and results of operations of these periods are not directly
comparable. The primary differences in accounting principles
relate to the carrying value of debt investments and
classification of hedging activity see corresponding
sections below for further discussion.
F-12
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
The consolidated financial statements of the Company have been
prepared in accordance with U.S. generally accepted
accounting principles (GAAP) and pursuant to the
requirements for reporting on
Form 10-Q
and Articles 6 or 10 of
Regulation S-X.
In the opinion of management, the consolidated financial
statements reflect all adjustments and reclassifications that
are necessary for the fair presentation of financial results as
of and for the periods presented. All intercompany balances and
transactions have been eliminated. Certain prior period amounts
have been reclassified to conform to the current period
presentation.
Principles
of Consolidation
As permitted under
Regulation S-X
and the AICPA Audit and Accounting Guide for Investment
Companies, the Company will generally not consolidate its
investment in a company other than an investment company
subsidiary or a controlled operating company whose business
consists of providing services to the Company. Accordingly, the
Company consolidated the results of the Companys
subsidiaries in its consolidated financial statements.
Use of
Estimates
In preparing the consolidated financial statements in accordance
with GAAP, management is required to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, and disclosures of contingent assets and
liabilities, as of the date of the balance sheet and income and
expenses for the period. Actual results could differ from those
estimates. Material estimates that are particularly susceptible
to significant change in the near term relate to the valuation
of loans, equity investments and warrants.
Fair
Value
The Company applies fair value to substantially all of its
investments in accordance with relevant GAAP, which establishes
a framework used to measure fair value and requires disclosures
for fair value measurements. The Company has categorized its
investments carried at fair value, based on the priority of the
valuation technique, into a three-level fair value hierarchy as
more fully described in Note 5. Fair value is a
market-based measure considered from the perspective of the
market participant who holds the financial instrument rather
than an entity specific measure. Therefore, when market
assumptions are not readily available, the Companys own
assumptions are set to reflect those that management believes
market participants would use in pricing the financial
instrument at the measurement date.
The availability of observable inputs can vary depending on the
financial instrument and is affected by a wide variety of
factors, including, for example, the type of product, whether
the product is new, whether the product is traded on an active
exchange or in the secondary market and the current market
conditions. To the extent that the valuation is based on models
or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment.
Accordingly, the degree of judgment exercised by the Company in
determining fair value is greatest for financial instruments
classified as Level 3.
In May 2011, the FASB issued Accounting Standards Update (ASU)
2011-04,
Amendments to Achieve Common Fair Value Measurements and
Disclosure Requirements in U.S. GAAP and IFRs, (ASU
2011-04).
ASU 2011-04
converges the fair value measurement guidance in U.S. GAAP
and International Financial Reporting Standards (IFRSs). Some of
the amendments clarify the application of existing fair value
measurement requirements, while other amendments change a
particular principle in existing guidance. In addition, ASU
2011-04
requires additional fair value disclosures. The amendments are
to be applied prospectively and are effective for interim and
annual periods beginning after December 15, 2011.
Management is currently evaluating the effect that the
provisions of ASU
2011-04 will
have on the Companys financial statements.
See Note 5 for additional information regarding fair value.
F-13
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
Segments
The Company has determined that it has a single reporting
segment and operating unit structure. The Company lends to and
invests in portfolio companies in various technology, life
science, healthcare information and services and cleantech
industries. The Company separately evaluates the performance of
each of its lending and investment relationships. However,
because each of these loan and investment relationships has
similar business and economic characteristics, they have been
aggregated into a single lending and investment segment.
Cash
and Cash Equivalents
Cash and cash equivalents as presented in the consolidated
balance sheets and the consolidated statements of cash flows
include bank checking accounts and money market funds with an
original maturity of less than 90 days.
Investments
Investments are recorded at fair value. The Companys board
of directors (Board) determines the fair value of
its portfolio investments. Prior to the Companys election
to become a BDC, debt investments were stated at current unpaid
principal balances adjusted for the allowance for loan losses,
unearned income and any unamortized deferred fees or costs.
The Company has the intent to hold its loans for the foreseeable
future or until maturity or payoff.
Interest on debt investments is accrued and included in income
based on contractual rates applied to principal amounts
outstanding. Interest income is determined using a method that
results in a level rate of return on principal amounts
outstanding. When a loan becomes 90 days or more past due,
or if the Company otherwise does not expect to receive interest
and principal repayments, the loan is placed on non-accrual
status and the recognition of interest income is discontinued.
Interest payments received on loans that are on non-accrual
status are treated as reductions of principal until the
principal is repaid. No loans were on non-accrual status as of
September 30, 2011 and December 31, 2010.
The Company receives a variety of fees from borrowers in the
ordinary course of conducting its business, including advisory
fees, commitment fees, amendment fees, non-utilization fees and
prepayment fees. In a limited number of cases, the Company may
also receive a non-refundable deposit earned upon the
termination of a transaction. Loan origination fees, net of
certain direct origination costs, are deferred, and, along with
unearned income, are amortized as a level yield adjustment over
the respective term of the loan. Fees for counterparty loan
commitments with multiple loans are allocated to each loan based
upon each loans relative fair value. When a loan is placed
on non-accrual status, the amortization of the related fees and
unearned income is discontinued until the loan is returned to
accrual status.
Certain loan agreements also require the borrower to make an
end-of-term
payment that is accrued into income over the life of the loan to
the extent such amounts are expected to be collected. The
Company will generally cease accruing the income if there is
insufficient value to support the accrual or the Company does
not expect the borrower to be able to pay all principal and
interest due.
In connection with substantially all lending arrangements, the
Company receives warrants to purchase shares of stock from the
borrower. The warrants are recorded as assets at estimated fair
value on the grant date using the Black-Scholes valuation model.
The warrants are considered loan fees and are also recorded as
unearned loan income on the grant date. The unearned income is
recognized as interest income over the contractual life of the
related loan in accordance with the Companys income
recognition policy. Subsequent to loan origination, the warrants
are also measured at fair value using the Black-Scholes
valuation model. Any adjustment to fair value is recorded
through earnings as net unrealized gain or loss on investments.
Gains from the disposition of the warrants or stock acquired
from the exercise of warrants are recognized as realized gain on
investments.
F-14
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
See Note 5 for additional information regarding fair value.
Allowance
for Loan Losses
Prior to the Companys election to become a BDC, the
allowance for loan losses represented managements estimate
of probable loan losses inherent in the loan portfolio as of the
balance sheet date. The estimation of the allowance was based on
a variety of factors, including past loan loss experience, the
current credit profile of the Companys borrowers, adverse
situations that had occurred that may affect individual
borrowers ability to repay, the estimated value of
underlying collateral and general economic conditions. The loan
portfolio is comprised of large balance loans that are evaluated
individually for impairment and are risk-rated based upon a
borrowers individual situation, current economic
conditions, collateral and industry-specific information that
management believes is relevant in determining the potential
occurrence of a loss event and in measuring impairment. The
allowance for loan losses was sensitive to the risk rating
assigned to each of the loans and to corresponding qualitative
loss factors that the Company used to estimate the allowance.
Those factors were applied to the outstanding loan balances in
estimating the allowance for loan losses. If necessary, based on
performance factors related to specific loans, specific
allowances for loan losses were established for individual
impaired loans. Increases or decreases to the allowance for loan
losses were charged or credited to current period earnings
through the provision (credit) for loan losses. Amounts
determined to be uncollectible were charged against the
allowance for loan losses, while amounts recovered on previously
charged-off loans increased the allowance for loan losses.
A loan was considered impaired when, based on current
information and events, it was probable that the Company was
unable to collect the scheduled payments of principal or
interest when due according to the contractual terms of the loan
agreement. Factors considered by management in determining
impairment included payment status, collateral value and the
probability of collecting scheduled principal and interest
payments when due. Loans that experienced insignificant payment
delays and payment shortfalls generally were not classified as
impaired. Management determined the significance of payment
delays and payment shortfalls on a
case-by-case
basis, taking into consideration all of the circumstances
surrounding the loan and the borrower, including the length of
the delay, the reasons for the delay, the borrowers prior
payment record and the amount of the shortfall in relation to
the principal and interest owed. Impairment was measured on a
loan by loan basis by either the present value of expected
future cash flows discounted at the loans effective
interest rate, the loans observable market price or the
fair value of the collateral, if the loan was collateral
dependent.
Impaired loans also included loans modified in troubled debt
restructurings where concessions had been granted to borrowers
experiencing financial difficulties. These concessions could
include a reduction in the interest rate on the loan, payment
extensions, forgiveness of principal, forbearance or other
actions intended to maximize collection.
Debt
Issuance Costs
Debt issuance costs are fees and other direct incremental costs
incurred by the Company in obtaining debt financing from its
lenders and are recognized as assets and are amortized as
interest expense over the term of the related credit facility.
The unamortized balance of debt issuance costs as of
September 30, 2011 and December 31, 2010, included in
other assets, was $1,174 and $194, respectively. The accumulated
amortization balances as of September 30, 2011 and
December 31, 2010 was $227 and $3,292, respectively. The
amortization expense for the nine months ended
September 30, 2011 and 2010 relating to debt issuance costs
was $227 and $871, respectively.
Income
Taxes
The Company elected to be treated as a RIC under subchapter M of
the Code and operates in a manner so as to qualify for the tax
treatment applicable to RICs. In order to qualify as a RIC,
among other things, the Company is required to meet certain
source of income and asset diversification requirements and
timely distribute to its
F-15
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
stockholders at least 90% of investment company taxable income,
as defined by the Code, for each year. The Company, among other
things, has made and intends to continue to make the requisite
distributions to its stockholders, which will generally relieve
the Company from U.S. federal income taxes.
Depending on the level of taxable income earned in a tax year,
the Company may choose to carry forward taxable income in excess
of current year dividend distributions into the next tax year
and pay a 4% excise tax on such income, as required. To the
extent that the Company determines that its estimated current
year annual taxable income will be in excess of estimated
current year dividend distributions, the Company accrues excise
tax, if any, on estimated excess taxable income as taxable
income is earned. For the nine months ended September 30,
2011, no amount was recorded for U.S. federal excise tax.
The Company evaluates tax positions taken in the course of
preparing the Companys tax returns to determine whether
the tax positions are more-likely-than-not to be
sustained by the applicable tax authority. Tax benefits of
positions not deemed to meet the more-likely-than-not threshold,
or uncertain tax positions, would be recorded as a tax expense
in the current year. It is the Companys policy to
recognize accrued interest and penalties related to uncertain
tax benefits in income tax expense. There were no material
uncertain tax positions at September 30, 2011 and
December 31, 2010. The 2008 and 2009 tax years remain
subject to examination by U.S. federal and state tax
authorities.
Prior to the Companys election to become a BDC, the
Company was a limited liability company treated as a partnership
for U.S. federal income tax purposes and, as a result, all
items of income and expense were passed through to, and are
generally reportable on, the tax returns of the respective
members of the limited liability company. Therefore, no federal
or state income tax provision has been recorded for the nine
months ended September 30, 2010.
Dividends
Dividends and distributions to common stockholders are recorded
on the declaration date. The amount to be paid out as a dividend
is determined by the Board. Net realized capital gains, if any,
are distributed at least annually, although the Company may
decide to retain such capital gains for investment.
The Company has adopted a dividend reinvestment plan
(DRIP) that provides for reinvestment of cash
distributions and other distributions on behalf of its
stockholders, unless a stockholder elects to receive cash. As a
result, if the Board authorizes, and the Company declares, a
cash dividend, then stockholders who have not opted
out of the dividend reinvestment plan will have their cash
dividends automatically reinvested in additional shares of the
Companys common stock, rather than receiving the cash
dividend. The Company may use newly issued shares to implement
the plan (especially if the Companys shares are trading at
a premium to net asset value), or the Company may purchase
shares in the open market in connection with the obligations
under the plan.
Interest
Rate Swaps and Hedging Activities
The Company entered into interest rate swap agreements to manage
interest rate risk. The Company does not hold or issue interest
rate swap agreements or other derivative financial instruments
for speculative purposes.
Subsequent to the Companys election to become a BDC, the
interest rate swaps are recorded at fair value with changes in
fair value reflected in net unrealized appreciation or
depreciation of investments during the reporting period. The
Company records the accrual of periodic interest settlements of
interest rate swap agreements in net unrealized appreciation or
depreciation of investments and subsequently records the amount
as a net realized gain or loss on investments on the interest
settlement date. Cash payments received or paid for the
termination of an interest rate swap agreement would be recorded
as a realized gain or loss upon termination in the consolidated
statements of operations.
F-16
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
Prior to the Companys election to become a BDC, the
Company recognized its interest rate swap derivatives on the
balance sheet as either an asset or liability measured at fair
value. Changes in the derivatives fair value were
recognized in income unless specific hedge accounting criteria
were met. Special accounting for qualifying hedges allows a
derivatives gains and losses to offset related results on
the hedged item in the statement of operations and required the
Company to formally document, designate and assess effectiveness
of transactions that receive hedge accounting. Derivatives that
are not hedges are adjusted to fair value through earnings. If
the derivative qualifies as a hedge, depending on the nature of
the hedge, changes in the fair value of derivatives are either
offset against the change in fair value of hedged assets,
liabilities or firm commitments through earnings, or recognized
in other comprehensive income until the hedged item is
recognized in earnings. The ineffective portion of a
derivatives change in fair value, if any, would have been
recognized as interest expense.
Transfers
of Financial Assets
Transfers of financial assets are accounted for as sales, when
control over the assets has been surrendered. Control over
transferred assets is deemed to be surrendered when (1) the
assets have been isolated from the Company put
presumptively beyond the reach of the transferor and its
creditors, even in bankruptcy or other receivership,
(2) the transferee obtains the right (free of conditions
that constrain it from taking advantage of that right) to pledge
or exchange the transferred assets and (3) the transferor
does not maintain effective control over the transferred assets
through either (a) an agreement that both entitles and
obligates the transferor to repurchase or redeem the assets
before maturity or (b) the ability to unilaterally cause
the holder to return specific assets, other than through a
cleanup call.
|
|
Note 3.
|
Related
Party Transactions
|
Investment
Management Agreement
On October 28, 2010, the Company entered into the
Investment Management Agreement with the Advisor, under which
the Advisor manages the
day-to-day
operations of, and provides investment advisory services to, the
Company. Under the terms of the Investment Management Agreement,
the Advisor determines the composition of the Companys
investment portfolio, the nature and timing of the changes to
the investment portfolio and the manner of implementing such
changes; identifies, evaluates and negotiates the structure of
the investments the Company makes (including performing due
diligence on the Companys prospective portfolio
companies); and closes, monitors and administers the investments
the Company makes, including the exercise of any voting or
consent rights.
The Advisors services under the Investment Management
Agreement are not exclusive to the Company, and the Advisor is
free to furnish similar services to other entities so long as
its services to the Company are not impaired. The Advisor is a
registered investment advisor with the SEC. The Advisor receives
fees for providing services, consisting of two components, a
base management fee and an incentive fee.
The base management fee is calculated at an annual rate of 2.00%
of the Companys gross assets, payable monthly in arrears.
For purposes of calculating the base management fee, the term
gross assets includes any assets acquired with the
proceeds of leverage. The base management fee expense was $1,091
and $3,229 for the three and nine months ended
September 30, 2011, respectively. The accrued management
fee as of September 30, 2011 and December 31, 2010 was
$362 and $360, respectively.
The incentive fee has two parts, as follows:
The first part is calculated and payable quarterly in arrears
based on the Companys pre-incentive fee net investment
income for the immediately preceding calendar quarter. For this
purpose, pre-incentive fee net investment income means interest
income, dividend income and any other income (including any
other fees (other than fees for providing managerial
assistance), such as commitment, origination, structuring,
diligence
F-17
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
and consulting fees or other fees received from portfolio
companies) accrued during the calendar quarter, minus operating
expenses for the quarter (including the base management fee,
expenses payable under the Administration Agreement (as defined
below) and any interest expense and any dividends paid on any
issued and outstanding preferred stock, but excluding the
incentive fee). Pre-incentive fee net investment income
includes, in the case of investments with a deferred interest
feature (such as original issue discount, debt instruments with
payment-in-kind
interest and zero coupon securities), accrued income that we
have not yet received in cash. The incentive fee with respect to
the pre-incentive fee net income is 20.00% of the amount, if
any, by which the pre-incentive fee net investment income for
the immediately preceding calendar quarter exceeds a 1.75%
(which is 7.00% annualized) hurdle rate and a
catch-up
provision measured as of the end of each calendar quarter. Under
this provision, in any calendar quarter, the Advisor receives no
incentive fee until the net investment income equals the hurdle
rate of 1.75%, but then receives, as a
catch-up,
100.00% of the pre-incentive fee net investment income with
respect to that portion of such pre-incentive fee net investment
income, if any, that exceeds the hurdle rate but is less than
2.1875%. The effect of this provision is that, if pre-incentive
fee net investment income exceeds 2.1875% in any calendar
quarter, the Advisor will receive 20.00% of the pre-incentive
fee net investment income as if a hurdle rate did not apply.
Pre-incentive fee net investment income does not include any
realized capital gains, realized capital losses or unrealized
capital appreciation or depreciation. Because of the structure
of the incentive fee, it is possible that the Company may pay an
incentive fee in a quarter in which the Company incurs a loss.
For example, if the Company receives pre-incentive fee net
investment income in excess of the quarterly minimum hurdle
rate, the Company will pay the applicable incentive fee even if
the Company has incurred a loss in that quarter due to realized
and unrealized capital losses. The Companys net investment
income used to calculate this part of the incentive fee is also
included in the amount of the Companys gross assets used
to calculate the 2.00% base management fee. These calculations
are appropriately prorated for any period of less than three
months and adjusted for any share issuances or repurchases
during the current quarter.
The second part of the incentive fee is determined and payable
in arrears as of the end of each calendar year (or upon
termination of the Investment Management Agreement, as of the
termination date), and equals 20.00% of the Companys
aggregate realized capital gains, if any, on a cumulative basis
from the date of the election to be a BDC through the end of
each calendar year, computed net of all realized capital losses
and unrealized capital depreciation through the end of such
year, less all previous amounts paid in respect of the capital
gain incentive fee.
The total performance based incentive fee expense was $561 and
$2,701 for the three and nine months ended September 30,
2011, respectively. The incentive fee payable as of
September 30, 2011 and December 31, 2010 was $1,453
and $414, respectively. The incentive fee payable as of
September 30, 2011 includes $711 for part one and $742 for
part two of the incentive fee, respectively.
Prior to the Companys election to become a BDC, the
Advisor served as the Advisor for CHF under a Management and
Services Agreement which provided for management fees to be paid
monthly at a rate of 2.00% per annum of the gross investment
assets of CHF. Total management fee expense under this agreement
was $675 and $1,816 for the three and nine months ended
September 30, 2010, respectively.
Administration
Agreement
The Company entered into an Administration Agreement with the
Advisor to provide administrative services to the Company. For
providing these services, facilities and personnel, the Company
will reimburse the Advisor for the Companys allocable
portion of overhead and other expenses incurred by the Advisor
in performing its obligations under the Administration
Agreement, including rent, the fees and expenses associated with
performing compliance functions and the Companys allocable
portion of the costs of compensation and related expenses of the
Companys chief compliance officer and chief financial
officer and their respective staffs. For the three and nine
F-18
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
months ended September 30, 2011, $355 and $873,
respectively, was charged to operations under this
Administration Agreement.
From time to time, the Advisor may pay amounts owed by the
Company to third-party providers of goods or services. The
Company will subsequently reimburse the Advisor for such amounts
paid on the Companys behalf.
Investments, all of which are with portfolio companies in the
United States, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Debt
|
|
$
|
175,131
|
|
|
$
|
174,402
|
|
|
$
|
130,282
|
|
|
$
|
130,234
|
|
Warrants
|
|
|
3,813
|
|
|
|
5,091
|
|
|
|
2,843
|
|
|
|
6,225
|
|
Equity
|
|
|
707
|
|
|
|
693
|
|
|
|
369
|
|
|
|
351
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
179,651
|
|
|
$
|
180,186
|
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table shows the Companys investments by
industry sector.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
December 31, 2010
|
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Life Science
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$
|
29,038
|
|
|
$
|
29,084
|
|
|
$
|
31,138
|
|
|
$
|
31,614
|
|
Medical Device
|
|
|
27,539
|
|
|
|
27,489
|
|
|
|
20,472
|
|
|
|
21,317
|
|
Technology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer-related Technologies
|
|
|
2,705
|
|
|
|
3,014
|
|
|
|
4,592
|
|
|
|
4,692
|
|
Networking
|
|
|
1,402
|
|
|
|
2,140
|
|
|
|
2,405
|
|
|
|
3,120
|
|
Software
|
|
|
24,080
|
|
|
|
24,073
|
|
|
|
9,042
|
|
|
|
9,062
|
|
Data Storage
|
|
|
5,042
|
|
|
|
5,086
|
|
|
|
8,010
|
|
|
|
8,042
|
|
Internet and Media
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
38
|
|
Communications
|
|
|
6,588
|
|
|
|
6,173
|
|
|
|
7,681
|
|
|
|
7,719
|
|
Semiconductors
|
|
|
9,952
|
|
|
|
9,980
|
|
|
|
7
|
|
|
|
|
|
Healthcare Information and Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
22,879
|
|
|
|
23,177
|
|
|
|
20,745
|
|
|
|
21,044
|
|
Other Healthcare Related Services and Technologies
|
|
|
19,385
|
|
|
|
19,354
|
|
|
|
9,934
|
|
|
|
9,938
|
|
Cleantech
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Energy Efficiency
|
|
|
26,039
|
|
|
|
25,699
|
|
|
|
16,977
|
|
|
|
17,749
|
|
Waste Recycling
|
|
|
5,002
|
|
|
|
4,917
|
|
|
|
2,475
|
|
|
|
2,475
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
179,651
|
|
|
$
|
180,186
|
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company uses fair value measurements to record fair value
adjustments to certain assets and liabilities and to determine
fair value disclosures. Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the
measurement date. Fair value is best determined based upon
quoted market prices. However, in certain instances, there are
no quoted market prices
F-19
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
for certain assets or liabilities. In cases where quoted market
prices are not available, fair values are based on estimates
using present value or other valuation techniques. Those
techniques are significantly affected by the assumptions used,
including the discount rate and estimates of future cash flows.
Accordingly, the fair value estimates may not be realized in an
immediate settlement of the asset or liability.
Fair value measurements focus on exit prices in an orderly
transaction (that is, not a forced liquidation or distressed
sale) between market participants at the measurement date under
current market conditions. If there has been a significant
decrease in the volume and level of activity for the asset or
liability, a change in valuation technique or the use of
multiple valuation techniques may be appropriate. In such
instances, determining the price at which willing market
participants would transact at the measurement date under
current market conditions depends on the facts and circumstances
and requires the use of significant judgment.
The Companys fair value measurements are classified into a
fair value hierarchy based on the markets in which the assets
and liabilities are traded and the reliability of the
assumptions used to determine fair value. The three categories
within the hierarchy are as follows:
|
|
|
|
Level 1
|
Quoted prices in active markets for identical assets and
liabilities.
|
|
|
Level 2
|
Observable inputs other than Level 1 prices such as quoted
prices for similar assets or liabilities in active markets,
quoted prices in markets that are not active and model-based
valuation techniques for which all significant inputs are
observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
|
|
|
Level 3
|
Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the
assets or liabilities. Level 3 assets and liabilities
include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies or similar
techniques, as well as instruments for which the determination
of fair value requires significant management judgment or
estimation.
|
Cash and cash equivalents and interest
receivable: The carrying amount is a reasonable
estimate of fair value. These financial instruments are not
recorded at fair value on a recurring basis.
Loans: For variable rate loans that re-price
frequently and have no significant change in credit risk,
carrying values are a reasonable estimate of fair values,
adjusted for credit losses inherent in the portfolio. The fair
value of fixed rate loans is estimated by discounting the future
cash flows using the year end rates at which similar loans would
be made to borrowers with similar credit ratings and for the
same remaining maturities, adjusted for credit losses inherent
in the portfolio. Therefore, the Company has categorized loan
investments as Level 3 within the fair value hierarchy
described above. These financial instruments are recorded at
fair value on a recurring basis.
Warrants: The Company primarily values its
warrants using the Black-Scholes valuation model incorporating
the following material assumptions:
|
|
|
|
|
Underlying asset value of the issuer is estimated based on
information available, including any information regarding the
most recent rounds of borrower funding.
|
|
|
|
Volatility, or the amount of uncertainty or risk about the size
of the changes in the warrant price, is based on guideline
publicly traded companies within indices similar in nature to
the underlying company issuing the warrant. A total of seven
such indices were used. The weighted average volatility
assumptions used for the warrant valuation at September 30,
2011 and December 31, 2010 was 30%.
|
|
|
|
The risk-free interest rates are derived from the
U.S. Treasury yield curve. The risk-free interest rates are
calculated based on a weighted average of the risk-free interest
rates that correspond closest to the expected remaining life of
the warrant.
|
F-20
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
|
|
|
|
|
Other adjustments, including a marketability discount on private
company warrants, are estimated based on managements
judgment about the general industry environment. The
marketability discount used for the warrant valuation at
September 30, 2011 and December 31, 2010 was 20%.
|
Under certain circumstances the company may use an alternative
technique to value warrants that better reflects the warrants
fair value, such as an expected settlement of a warrant in the
near term or a model that incorporates a put feature associated
with the warrant. The fair value may be determined based on the
expected proceeds to be received from such settlement or based
on the net present value of the expected proceeds from the put
option. Prior to September 30, 2011, there were no warrants
that required valuation under an alternate technique.
The fair value of the Companys warrants held in publicly
traded companies is determined based on inputs that are readily
available in public markets or can be derived from information
available in public markets. Therefore, the Company has
categorized these warrants as Level 2 within the fair value
hierarchy described in Note 2. The fair value of the
Companys warrants held in private companies is determined
using both observable and unobservable inputs and represents
managements best estimate of what market participants
would use in pricing the warrants at the measurement date.
Therefore, the Company has categorized these warrants as
Level 3 within the fair value hierarchy described above.
These financial instruments are recorded at fair value on a
recurring basis.
Equities: The fair value of an equity
investment in a privately held company is initially the face
value of the amount invested. The Company adjusts the fair value
of equity investments in private companies upon the completion
of a new third-party round of equity financing. The Company may
make adjustments to fair value, absent a new equity financing
event, based upon positive or negative changes in a portfolio
companys financial or operational performance. The fair
value of an equity investment in a publicly traded company is
based upon the closing public share price on the date of
measurement.
Borrowings: The carrying amount of borrowings
under the revolving credit facilities approximates its fair
value due to the variable interest rate of these borrowings.
Additionally, the Company considers its creditworthiness in
determining the fair value of such borrowings. These financial
instruments are not recorded at fair value on a recurring basis.
Interest rate swap derivatives: The fair value
of the Companys interest rate swap derivative instruments
is estimated as the amount the Company would pay to terminate
its swaps at the balance sheet date, taking into account current
interest rates and the creditworthiness of the counterparty for
assets and the creditworthiness of the Company for liabilities.
The Company has categorized these derivative instruments as
Level 2 within the fair value hierarchy described above.
These financial instruments are recorded at fair value on a
recurring basis.
Off-balance-sheet instruments: Fair values for
off-balance-sheet lending commitments are based on fees
currently charged to enter into similar agreements, taking into
account the remaining terms of the agreements and the
counterparties credit standings. Off-balance-sheet
instruments are not recorded at fair value on a recurring basis.
F-21
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
The following tables detail the financial instruments that are
carried at fair value and measured at fair value on a recurring
basis as of September 30, 2011 and December 31, 2010,
and indicate the fair value hierarchy of the valuation
techniques utilized by the Company to determine the fair value:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Loan investments
|
|
$
|
174,402
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
174,402
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant investments
|
|
$
|
5,091
|
|
|
$
|
|
|
|
$
|
56
|
|
|
$
|
5,035
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity investments
|
|
$
|
693
|
|
|
$
|
169
|
|
|
$
|
|
|
|
$
|
524
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swap liability
|
|
$
|
13
|
|
|
$
|
|
|
|
$
|
13
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Loan investments
|
|
$
|
130,234
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
130,234
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant investments
|
|
$
|
6,225
|
|
|
$
|
|
|
|
$
|
1,976
|
|
|
$
|
4,249
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity investments
|
|
$
|
351
|
|
|
$
|
209
|
|
|
$
|
|
|
|
$
|
142
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swap liability
|
|
$
|
258
|
|
|
$
|
|
|
|
$
|
258
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following tables show a reconciliation of the beginning and
ending balances for Level 3 assets for the three months
ended September 30, 2011 and 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2011
|
|
|
|
Loan
|
|
|
Warrant
|
|
|
Equity
|
|
|
|
|
|
|
Investments
|
|
|
Investments
|
|
|
Investments
|
|
|
Total
|
|
|
Level 3 assets, beginning of period
|
|
$
|
180,110
|
|
|
$
|
4,360
|
|
|
$
|
668
|
|
|
$
|
185,138
|
|
Purchase of investments
|
|
|
7,000
|
|
|
|
|
|
|
|
|
|
|
|
7,000
|
|
Warrants and equity received and classified as Level 3
|
|
|
|
|
|
|
47
|
|
|
|
|
|
|
|
47
|
|
Principal payments received on investments
|
|
|
(12,874
|
)
|
|
|
|
|
|
|
|
|
|
|
(12,874
|
)
|
Unrealized (depreciation) appreciation included in earnings
|
|
|
(282
|
)
|
|
|
703
|
|
|
|
|
|
|
|
421
|
|
Other
|
|
|
448
|
|
|
|
(75
|
)
|
|
|
(144
|
)
|
|
|
229
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
174,402
|
|
|
$
|
5,035
|
|
|
$
|
524
|
|
|
$
|
179,961
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-22
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, 2010
|
|
|
|
Loan
|
|
|
Warrant
|
|
|
Equity
|
|
|
|
|
|
|
Investments
|
|
|
Investments
|
|
|
Investments
|
|
|
Total
|
|
|
Level 3 assets, beginning of period
|
|
$
|
|
|
|
$
|
2,343
|
|
|
$
|
|
|
|
$
|
2,343
|
|
Purchase of investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants and equity received and classified as Level 3
|
|
|
|
|
|
|
104
|
|
|
|
|
|
|
|
104
|
|
Principal payments received on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized appreciation included in earnings
|
|
|
|
|
|
|
1,268
|
|
|
|
|
|
|
|
1,268
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
|
|
|
$
|
3,715
|
|
|
$
|
|
|
|
$
|
3,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following tables show a reconciliation of the beginning and
ending balances for Level 3 assets for the nine months
ended September 30, 2011 and 2010:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2011
|
|
|
|
Loan
|
|
|
Warrant
|
|
|
Equity
|
|
|
|
|
|
|
Investments
|
|
|
Investments
|
|
|
Investments
|
|
|
Total
|
|
|
Level 3 assets, beginning of period
|
|
$
|
130,234
|
|
|
$
|
4,249
|
|
|
$
|
142
|
|
|
$
|
134,625
|
|
Purchase of investments
|
|
|
78,156
|
|
|
|
|
|
|
|
|
|
|
|
78,156
|
|
Warrants and equity received and classified as Level 3
|
|
|
|
|
|
|
1,040
|
|
|
|
482
|
|
|
|
1,522
|
|
Principal payments received on investments
|
|
|
(32,574
|
)
|
|
|
|
|
|
|
|
|
|
|
(32,574
|
)
|
Unrealized (depreciation) appreciation included in earnings
|
|
|
(681
|
)
|
|
|
(163
|
)
|
|
|
44
|
|
|
|
(800
|
)
|
Other
|
|
|
(733
|
)
|
|
|
(91
|
)
|
|
|
(144
|
)
|
|
|
(968
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
174,402
|
|
|
$
|
5,035
|
|
|
$
|
524
|
|
|
$
|
179,961
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, 2010
|
|
|
|
Loan
|
|
|
Warrant
|
|
|
Equity
|
|
|
|
|
|
|
Investments
|
|
|
Investments
|
|
|
Investments
|
|
|
Total
|
|
|
Level 3 assets, beginning of period
|
|
$
|
|
|
|
$
|
2,010
|
|
|
$
|
|
|
|
$
|
2,010
|
|
Purchase of investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants and equity received and classified as Level 3
|
|
|
|
|
|
|
927
|
|
|
|
|
|
|
|
927
|
|
Principal payments received on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unrealized appreciation included in earnings
|
|
|
|
|
|
|
780
|
|
|
|
|
|
|
|
780
|
|
Other
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
|
|
|
$
|
3,715
|
|
|
$
|
|
|
|
$
|
3,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The total change in unrealized appreciation and depreciation
included in the consolidated statement of operations
attributable to Level 3 investments still held at
September 30, 2011 includes $681 depreciation on loans,
$2,142 appreciation on warrants and $44 appreciation on equity
investments.
The Company discloses fair value information about financial
instruments, whether or not recognized in the statement of
assets and liabilities, for which it is practicable to estimate
that value. Certain financial instruments are
F-23
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
excluded from the disclosure requirements. Accordingly, the
aggregate fair value amounts presented do not represent the
underlying value of the Company.
The fair value amounts have been measured as of the reporting
date, and have not been reevaluated or updated for purposes of
these financial statements subsequent to that date. As such, the
fair values of these financial instruments subsequent to the
reporting date may be different than amounts reported at
year-end.
As of September 30, 2011 and December 31, 2010, the
recorded book balances and fair values of the Companys
financial instruments were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2011
|
|
December 31, 2010
|
|
|
Recorded
|
|
|
|
Recorded
|
|
|
|
|
Book
|
|
|
|
Book
|
|
|
|
|
Balance
|
|
Fair Value
|
|
Balance
|
|
Fair Value
|
|
Financial assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash & cash equivalents
|
|
$
|
32,598
|
|
|
$
|
32,598
|
|
|
$
|
76,793
|
|
|
$
|
76,793
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt
|
|
$
|
174,402
|
|
|
$
|
174,402
|
|
|
$
|
130,234
|
|
|
$
|
130,234
|
|
Warrants
|
|
$
|
5,091
|
|
|
$
|
5,091
|
|
|
$
|
6,225
|
|
|
$
|
6,225
|
|
Equity
|
|
$
|
693
|
|
|
$
|
693
|
|
|
$
|
351
|
|
|
$
|
351
|
|
Interest receivable
|
|
$
|
2,477
|
|
|
$
|
2,477
|
|
|
$
|
1,938
|
|
|
$
|
1,938
|
|
Financial liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings
|
|
$
|
81,885
|
|
|
$
|
81,885
|
|
|
$
|
87,425
|
|
|
$
|
87,425
|
|
Interest rate swap liability
|
|
$
|
13
|
|
|
$
|
13
|
|
|
$
|
258
|
|
|
$
|
258
|
|
Off-balance-sheet
instruments
The Company assumes interest rate risk (the risk that general
interest rate levels will change) as a result of its normal
operations. As a result, the fair values of the Companys
financial instruments will change when interest rate levels
change and that change may be either favorable or unfavorable to
the Company. Management attempts to match maturities of assets
and liabilities to the extent believed necessary to minimize
interest rate risk. Management monitors rates and maturities of
assets and liabilities and attempts to minimize interest rate
risk by adjusting terms of new loans and by investing in
securities with terms that mitigate the Companys overall
interest rate risk.
In accordance with the 1940 Act, with certain limited
exceptions, the Company is only allowed to borrow amounts such
that the asset coverage, as defined in the 1940 Act, is at least
200% after such borrowings. As of September 30, 2011, the
asset coverage for borrowed amounts was 257%.
The Company entered into a revolving credit facility (the
WestLB Facility) with WestLB, AG, New York Branch
(WestLB) effective March 4, 2008. The WestLB
Facility had a three year initial revolving term and on
March 3, 2011, the revolving term ended. The outstanding
principal balance of the WestLB Facility is amortizing based on
loan investment payments received through March 3, 2015.
The interest rate is based upon the one-month LIBOR (0.24% as of
September 30, 2011 and 0.26% as of December 31,
2010) plus a spread of 2.50%. The rates at
September 30, 2011 and December 31, 2010 were 2.74%
and 2.76%, respectively, and the average rates for the nine
months ended September 30, 2011 and 2010 were 2.78%, and
2.79%, respectively.
The WestLB Facility is collateralized by all loans and warrants
held by Credit I and permits an advance rate of up to 75% of
eligible loans held by Credit I. The WestLB Facility contains
covenants that, among other things, require the Company to
maintain a minimum net worth and to restrict the loans securing
the WestLB Facility to
F-24
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
certain criteria for qualified loans, and includes portfolio
company concentration limits as defined in the related loan
agreement. The average amounts of borrowings were approximately
$78,100 and $78,200 for the nine months ended September 30,
2011 and 2010, respectively. At September 30, 2011 and
December 31, 2010, the Company had borrowings outstanding
of $66,049 and $87,425, respectively, on the WestLB Facility.
The Company entered into a revolving credit facility (the
Wells Facility) with Wells Fargo Capital Finance,
LLC (Wells) effective July 14, 2011. The Wells
Facility has an accordion feature which allows for an increase
in the total loan commitment to $150 million from the
current $75 million commitment provided by Wells. The Wells
Facility has a three year revolving term followed by a three
year amortization period and matures on July 14, 2017. The
interest rate is based upon the one-month LIBOR plus a spread of
4.00%, with a LIBOR floor of 1.00%. The rate at
September 30, 2011 was 5.0%, and the average rate for the
three months ended September 30, 2011 was 5.0%.
The Wells Facility is collateralized by all loans and warrants
held by Credit II and permits an advance rate of up to 50%
of eligible loans held by Credit II. The Wells Facility contains
covenants that, among other things, require the Company to
maintain a minimum net worth and to restrict the loans securing
the Wells Facility to certain criteria for qualified loans and
includes portfolio company concentration limits as defined in
the related loan agreement. The average amount of borrowings was
approximately $15,100 for the three months ended
September 30, 2011. At September 30, 2011, the Company
had borrowings outstanding of $15,836 on the Wells Facility.
|
|
Note 7.
|
Financial
Instruments with Off-Balance-Sheet Risk
|
In the normal course of business, the Company is party to
financial instruments with off-balance-sheet risk to meet the
financing needs of its borrowers. These financial instruments
include commitments to extend credit and involve, to varying
degrees, elements of credit risk in excess of the amount
recognized in the consolidated balance sheet. The Company
attempts to limit its credit risk by conducting extensive due
diligence and obtaining collateral where appropriate.
The balance of unfunded commitments to extend credit was
approximately $18,667 and $26,500 as of September 30, 2011
and December 31, 2010, respectively. Commitments to extend
credit consist principally of the unused portions of commitments
that obligate the Company to extend credit. Commitments may also
include a financial or non-financial milestone that has to be
achieved before the commitment can be drawn. Commitments
generally have fixed expiration dates or other termination
clauses. Since commitments may expire without being drawn upon,
the total commitment amounts do not necessarily represent future
cash requirements.
|
|
Note 8.
|
Concentrations
of Credit Risk
|
The Companys loan portfolio consists primarily of loans to
development-stage companies at various stages of development in
the technology, life science, healthcare information and
services and cleantech industries. Many of these companies may
have relatively limited operating histories and also may
experience variation in operating results. Many of these
companies conduct business in regulated industries and could be
affected by changes in government regulations. Most of the
Companys borrowers will need additional capital to satisfy
their continuing working capital needs and other requirements,
and in many instances, to service the interest and principal
payments on the loans.
The largest loans may vary from year to year as new loans are
recorded and repaid. The aggregate outstanding principal balance
of the Companys five largest loans represented
approximately 27% and 31% of the aggregate outstanding principal
balance of all loans outstanding as of September 30, 2011
and December 31, 2010, respectively. No single loan
represents more than 10% of the total loans as of
September 30, 2011 and December 31, 2010. Loan income,
consisting of interest and fees, can fluctuate significantly
upon repayment of large loans.
F-25
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
Interest income from the five largest loans accounted for
approximately 25% and 19% of total loan interest and fee income
for the nine months ended September 30, 2011 and 2010,
respectively.
|
|
Note 9:
|
Interest
Rate Swaps and Hedging Activities
|
On October 14, 2008, the Company entered into two interest
rate swap agreements (collectively, the Swap) with
WestLB, fixing the rate of $10 million at 3.58% and
$15 million at 3.20% on the first advances of a like amount
of variable rate WestLB Facility borrowings. The
$15 million interest rate swap expired in October 2010 and
the $10 million interest rate swap will expire in October
2011. The objective of the Swap was to hedge the risk of changes
in cash flows associated with the future interest payments on
the first $25 million of the variable rate WestLB Facility
debt with a combined notional amount of $25 million.
During the nine months ended September 30, 2011,
approximately $245 of net unrealized appreciation from the Swap
was recorded in the statement of operations, and approximately
$255 of net realized losses from the Swap was recorded in the
consolidated statement of operations.
Prior to the Companys election to become a BDC, the Swap
was designated as a hedging instrument and the Company applied
cash flow hedge accounting. The Swap was recorded in the
consolidated statement of assets and liabilities at fair value,
and any related increases or decreases in the fair value were
recognized within accumulated other comprehensive income.
Prior to the Companys election to become a BDC, the
Company assessed the effectiveness of the Swap on a quarterly
basis. The Company had considered the impact of the then current
credit crisis in the United States in assessing the risk of
counterparty default. As most of the critical terms of the
hedging instruments and hedged items matched, the hedging
relationship was considered to be highly effective. No
ineffectiveness on the Swap was recognized during the nine
months ended September 30, 2010.
|
|
Note 10:
|
Dividends
and Distributions
|
The Companys dividends and distributions are recorded on
the record date. The following table summarizes the
Companys dividend declaration and distribution activity
during the nine months ended September 30, 2011.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date
|
|
Record
|
|
Payment
|
|
Amount
|
|
Cash
|
|
DRIP Shares
|
|
DRIP Share
|
Declared
|
|
Date
|
|
Date
|
|
Per Share
|
|
Distribution
|
|
Issued
|
|
Value
|
|
5/10/11
|
|
5/19/11
|
|
5/26/11
|
|
$
|
0.33
|
|
|
$
|
2,190
|
|
|
|
20,104
|
|
|
$
|
316
|
|
8/9/11
|
|
8/23/11
|
|
8/30/11
|
|
$
|
0.40
|
|
|
$
|
2,836
|
|
|
|
13,193
|
|
|
$
|
209
|
|
On November 8, 2011, the Company declared a third quarter
dividend of $0.45 per share, payable on November 30, 2011
to stockholders of record on November 23, 2011.
F-26
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial Statements
(Unaudited) (Continued)
(In thousands, except shares and per share data)
|
|
Note 11:
|
Financial
Highlights
|
The financial highlights for the Company are as
follows:(1)
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Nine Months Ended
|
|
|
|
September 30, 2011
|
|
|
September 30, 2011
|
|
|
Per share data:
|
|
|
|
|
|
|
|
|
Net asset value at beginning of period
|
|
$
|
17.40
|
|
|
$
|
16.75
|
|
Dividends declared and paid
|
|
|
(0.40
|
)
|
|
|
(0.73
|
)
|
Net investment income
|
|
|
0.39
|
|
|
|
0.95
|
|
Realized gain on investments
|
|
|
0.00
|
|
|
|
0.73
|
|
Net change in unrealized depreciation on investments
|
|
|
(0.03
|
)
|
|
|
(0.34
|
)
|
|
|
|
|
|
|
|
|
|
Net asset value at end of period
|
|
$
|
17.36
|
|
|
$
|
17.36
|
|
|
|
|
|
|
|
|
|
|
Per share market value, end of period
|
|
$
|
14.66
|
|
|
$
|
14.66
|
|
Total return based on average net asset value
|
|
|
8.3
|
%
|
|
|
10.5
|
%
|
Shares outstanding at end of period
|
|
|
7,626,718
|
|
|
|
7,626,718
|
|
Ratios to average net assets:
|
|
|
|
|
|
|
|
|
Expenses without incentive fees
|
|
|
8.7
|
%(2)
|
|
|
8.2
|
%(2)
|
Incentive fees
|
|
|
1.7
|
%(2)
|
|
|
2.8
|
%(2)
|
Total expenses
|
|
|
10.4
|
%(2)
|
|
|
11.1
|
%(2)
|
Net investment income without incentive fees
|
|
|
10.7
|
%(2)
|
|
|
10.2
|
%(2)
|
Average net asset value
|
|
$
|
132,417
|
|
|
$
|
129,786
|
|
|
|
|
(1) |
|
Periods prior to becoming a public company are not presented in
the financial highlights because the Company did not record
assets at fair value, therefore the information would not be
meaningful. |
(2) |
|
Annualized. |
F-27
Report of
Independent Registered Public Accounting Firm
To the Board of Directors and Stockholders
Horizon Technology Finance Corporation
We have audited the accompanying consolidated statements of
assets and liabilities, including the consolidated schedules of
investments, of Horizon Technology Finance Corporation and
Subsidiary (the Company) as of December 31,
2010 and 2009, and the related consolidated statements of
operations, changes in net assets, and cash flows for the period
from October 29, 2010 to December 31, 2010, the period
from January 1, 2010 to October 28, 2010, the year
ended December 31, 2009, and the period from March 4,
2008 (inception) to December 31, 2008. These financial
statements are the responsibility of the Companys
management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The Company is not required to
have, nor were we engaged to perform an audit of its internal
control over financial reporting. Our audit included
consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion
on the effectiveness of the Companys internal control over
financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that
our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial
position of Horizon Technology Finance Corporation and
Subsidiary as of December 31, 2010 and 2009, and the
results of their operations and their cash flows for the period
from October 29, 2010 to December 31, 2010, the period
from January 1, 2010 to October 28, 2010, the year
ended December 31, 2009, and for the period from
March 4, 2008 (inception) to December 31, 2008, in
conformity with U.S. generally accepted accounting
principles.
/s/ McGladrey &
Pullen, LLP
New Haven, Connecticut
March 16, 2011
F-28
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
ASSETS
|
Non-affiliate investments at fair value at December 31,
2010 (cost of $133,494), at cost net of allowance for loan
losses of $1,924 at December 31, 2009 (Note 4)
|
|
$
|
136,810
|
|
|
$
|
111,954
|
|
Cash and cash equivalents
|
|
|
76,793
|
|
|
|
9,892
|
|
Interest receivable
|
|
|
1,938
|
|
|
|
1,452
|
|
Debt issuance costs (net of accumulated amortization of:
|
|
|
|
|
|
|
|
|
December 31, 2010 $3,292 and December 31, 2009 $2,130)
|
|
|
194
|
|
|
|
1,355
|
|
Other assets
|
|
|
470
|
|
|
|
215
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
216,205
|
|
|
$
|
124,868
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES
|
Borrowings (Note 6)
|
|
$
|
87,425
|
|
|
$
|
64,166
|
|
Base management fee payable (Note 3)
|
|
|
360
|
|
|
|
182
|
|
Incentive fee payable (Note 3)
|
|
|
414
|
|
|
|
|
|
Interest rate swap liability (Note 10)
|
|
|
258
|
|
|
|
768
|
|
Other accrued expenses
|
|
|
553
|
|
|
|
259
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
89,010
|
|
|
|
65,375
|
|
|
|
|
|
|
|
|
|
|
Net assets/members capital
|
|
|
|
|
|
|
|
|
Members capital
|
|
$
|
|
|
|
$
|
60,261
|
|
Accumulated other comprehensive loss Unrealized loss
on interest rate swaps
|
|
|
|
|
|
|
(768
|
)
|
Common Stock, par value $0.001 per share,
100,000,000 shares authorized, 7,593,422 shares
outstanding as of December 31, 2010
|
|
|
8
|
|
|
|
|
|
Paid-in capital in excess of par
|
|
|
123,836
|
|
|
|
|
|
Distributions in excess of net investment income
|
|
|
(143
|
)
|
|
|
|
|
Net unrealized appreciation on investments
|
|
|
3,043
|
|
|
|
|
|
Net realized gains on investments
|
|
|
451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net assets/members capital
|
|
|
127,195
|
|
|
|
59,493
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and net assets/members capital
|
|
$
|
216,205
|
|
|
$
|
124,868
|
|
|
|
|
|
|
|
|
|
|
Net asset value per common share
|
|
$
|
16.75
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-29
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-IPO as a
|
|
|
|
|
|
|
Business
|
|
|
|
|
|
|
Development
|
|
|
Pre-IPO Prior to becoming a
|
|
|
|
Company
|
|
|
Business Development Company
|
|
|
|
|
|
|
|
|
|
|
|
|
March 4, 2008
|
|
|
|
|
|
|
January 1,
|
|
|
|
|
|
(Inception)
|
|
|
|
October 29, 2010
|
|
|
2010 to
|
|
|
Year Ended
|
|
|
through
|
|
|
|
to December 31,
|
|
|
October 28,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Investment income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income on non-affiliate investments
|
|
$
|
2,993
|
|
|
$
|
14,373
|
|
|
$
|
14,987
|
|
|
$
|
6,530
|
|
Interest income on cash and cash equivalents
|
|
|
10
|
|
|
|
60
|
|
|
|
67
|
|
|
|
359
|
|
Fee income on non-affiliate investments
|
|
|
248
|
|
|
|
523
|
|
|
|
272
|
|
|
|
132
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investment income
|
|
|
3,251
|
|
|
|
14,956
|
|
|
|
15,326
|
|
|
|
7,021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
508
|
|
|
|
3,622
|
|
|
|
4,246
|
|
|
|
2,748
|
|
Base management fee (Note 3)
|
|
|
668
|
|
|
|
2,019
|
|
|
|
2,202
|
|
|
|
1,073
|
|
Performance based incentive fee (Note 3)
|
|
|
414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Administrative fee (Note 3)
|
|
|
88
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Professional fees
|
|
|
92
|
|
|
|
112
|
|
|
|
131
|
|
|
|
60
|
|
General and administrative
|
|
|
122
|
|
|
|
178
|
|
|
|
190
|
|
|
|
150
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
1,892
|
|
|
|
5,931
|
|
|
|
6,769
|
|
|
|
4,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment income
|
|
|
1,359
|
|
|
|
9,025
|
|
|
|
8,557
|
|
|
|
2,990
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Credit (provision) for loan losses
|
|
|
|
|
|
|
739
|
|
|
|
(274
|
)
|
|
|
(1,650
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized and unrealized gain (loss) on investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized gain on investments
|
|
|
611
|
|
|
|
69
|
|
|
|
138
|
|
|
|
22
|
|
Net unrealized appreciation (depreciation) on investments
|
|
|
1,449
|
|
|
|
1,481
|
|
|
|
892
|
|
|
|
(73
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net realized and unrealized gain (loss) on investments
|
|
|
2,060
|
|
|
|
1,550
|
|
|
|
1,030
|
|
|
|
(51
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
3,419
|
|
|
$
|
11,314
|
|
|
$
|
9,313
|
|
|
$
|
1,289
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net investment income per common share
|
|
$
|
0.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in net assets per common share
|
|
$
|
0.45
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding
|
|
|
7,555,722
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-30
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
|
|
|
Net
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
in Excess of
|
|
|
Unrealized
|
|
|
Net
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
Paid-In
|
|
|
Net
|
|
|
Appreciation
|
|
|
Realized
|
|
|
|
|
|
|
Members
|
|
|
Comprehensive
|
|
|
Common Stock
|
|
|
Capital in
|
|
|
Investment
|
|
|
on
|
|
|
Gains on
|
|
|
Total
|
|
|
|
Capital
|
|
|
Loss
|
|
|
Shares
|
|
|
Amount
|
|
|
Excess of Par
|
|
|
Income
|
|
|
Investments
|
|
|
Investments
|
|
|
Net Assets
|
|
|
March 4, 2008
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
1,289
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,289
|
|
Unrealized loss on interest rate swaps
|
|
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
126
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital contribution, net of costs
|
|
|
49,659
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,659
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2008
|
|
|
50,948
|
|
|
|
(1,163
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,785
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
9,313
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,313
|
|
Unrealized gain on interest rate swaps
|
|
|
|
|
|
|
395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
395
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,708
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009
|
|
|
60,261
|
|
|
|
(768
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
59,493
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
11,314
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,314
|
|
Unrealized gain on interest rate swaps
|
|
|
|
|
|
|
409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
409
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,723
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash distribution
|
|
|
(18,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(18,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at October 28, 2010
|
|
|
53,575
|
|
|
|
(359
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53,216
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Election to business development
company(1)
|
|
|
(53,575
|
)
|
|
|
359
|
|
|
|
2,645,124
|
|
|
|
3
|
|
|
|
52,456
|
|
|
|
|
|
|
|
1,594
|
|
|
|
|
|
|
|
837
|
|
Issuance of common stock, net of offering
costs(2)
|
|
|
|
|
|
|
|
|
|
|
4,910,000
|
|
|
|
5
|
|
|
|
70,815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
70,820
|
|
Net increase in net assets from operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,359
|
|
|
|
1,449
|
|
|
|
611
|
|
|
|
3,419
|
|
Issuance of common stock as stock
dividend(3)
|
|
|
|
|
|
|
|
|
|
|
38,298
|
|
|
|
|
|
|
|
565
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
565
|
|
Dividends declared
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,502
|
)
|
|
|
|
|
|
|
(160
|
)
|
|
|
(1,662
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2010
|
|
$
|
|
|
|
$
|
|
|
|
|
7,593,422
|
|
|
$
|
8
|
|
|
$
|
123,836
|
|
|
$
|
(143
|
)
|
|
$
|
3,043
|
|
|
$
|
451
|
|
|
$
|
127,195
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reclassification from members capital to net assets and
net unrealized appreciation on investments upon election.
Immediately prior to the initial public offering
(IPO), the members of Compass Horizon Funding
Company LLC (CHF) exchanged their membership
interests for 2,645,124 shares of common stock of the
Company and CHF became a wholly owned subsidiary of the Company.
Concurrent with the IPO Compass Horizon Partners, LP, one of
CHFs owners, sold 1,340,000 shares. |
|
(2) |
|
On October 28, 2010, the Company priced its IPO, offering
6,250,000 shares of its common stock at a public offering
price of $16.00 per share. Of the 6,250,000 shares offered,
4,910,000 shares were sold by the Company and
1,340,000 shares were sold by Compass Horizon Partners, LP,
one of CHFs owners. Total offering costs were $7,740. |
|
(3) |
|
The Company declared a fourth quarter dividend of $0.22 per
share, payable on December 31, 2010 to stockholders of
record on December 28, 2010. The Companys dividend
reinvestment plan provides for reinvestment of dividends, unless
a stockholder elects to receive cash. Dividends were reinvested
at $14.75 per share resulting in 38,298 additional shares. |
See Notes to Consolidated Financial Statements
F-31
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-IPO as a
|
|
|
|
|
|
|
Business
|
|
|
|
|
|
|
Development
|
|
|
Pre-IPO Prior to becoming a
|
|
|
|
Company
|
|
|
Business Development Company
|
|
|
|
|
|
|
|
|
|
|
|
|
March 4,
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
|
October 29,
|
|
|
January 1,
|
|
|
|
|
|
(Inception)
|
|
|
|
2010 to
|
|
|
2010 to
|
|
|
Year Ended
|
|
|
through
|
|
|
|
December 31,
|
|
|
October 28,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
3,419
|
|
|
$
|
11,314
|
|
|
$
|
9,313
|
|
|
$
|
1,289
|
|
Adjustments to reconcile net increase in net assets resulting
from operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Credit) provision for loan losses
|
|
|
|
|
|
|
(739
|
)
|
|
|
274
|
|
|
|
1,650
|
|
Amortization of debt issuance costs
|
|
|
200
|
|
|
|
962
|
|
|
|
1,123
|
|
|
|
953
|
|
Net realized gain on investments
|
|
|
(611
|
)
|
|
|
(69
|
)
|
|
|
(138
|
)
|
|
|
(22
|
)
|
Net unrealized (appreciation) depreciation on investments
|
|
|
(1,449
|
)
|
|
|
(1,481
|
)
|
|
|
(892
|
)
|
|
|
73
|
|
Purchase of investments
|
|
|
(19,316
|
)
|
|
|
(65,357
|
)
|
|
|
(49,936
|
)
|
|
|
(112,178
|
)
|
Principal payments received on investments
|
|
|
14,273
|
|
|
|
50,325
|
|
|
|
31,190
|
|
|
|
18,154
|
|
Proceeds from sale of investments
|
|
|
874
|
|
|
|
135
|
|
|
|
142
|
|
|
|
32
|
|
Changes in assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease (increase) in interest receivable
|
|
|
675
|
|
|
|
(1,162
|
)
|
|
|
(949
|
)
|
|
|
(503
|
)
|
(Decrease) increase in unearned loan income
|
|
|
(63
|
)
|
|
|
(500
|
)
|
|
|
(618
|
)
|
|
|
117
|
|
(Increase) decrease in other assets
|
|
|
(151
|
)
|
|
|
(246
|
)
|
|
|
19
|
|
|
|
(35
|
)
|
Increase (decrease) in other accrued expenses
|
|
|
220
|
|
|
|
74
|
|
|
|
(175
|
)
|
|
|
435
|
|
Increase in base management fee payable
|
|
|
157
|
|
|
|
21
|
|
|
|
22
|
|
|
|
159
|
|
Increase in incentive fee payable
|
|
|
414
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(1,358
|
)
|
|
|
(6,723
|
)
|
|
|
(10,625
|
)
|
|
|
(89,876
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from shares sold, net of offering costs
|
|
|
70,820
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital contributions, net of offering costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
49,659
|
|
Dividends and distributions paid
|
|
|
(1,097
|
)
|
|
|
(18,000
|
)
|
|
|
|
|
|
|
|
|
Net (decrease) increase in revolving borrowings
|
|
|
(3,748
|
)
|
|
|
27,007
|
|
|
|
493
|
|
|
|
63,673
|
|
Debt issuance costs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3,432
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
65,975
|
|
|
|
9,007
|
|
|
|
493
|
|
|
|
109,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
64,617
|
|
|
|
2,284
|
|
|
|
(10,132
|
)
|
|
|
20,024
|
|
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beginning of period
|
|
|
12,176
|
|
|
|
9,892
|
|
|
|
20,024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
End of period
|
|
$
|
76,793
|
|
|
$
|
12,176
|
|
|
$
|
9,892
|
|
|
$
|
20,024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
393
|
|
|
$
|
2,655
|
|
|
$
|
3,096
|
|
|
$
|
1,535
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental non-cash investing and financing activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant investments received & recorded as unearned
loan income
|
|
$
|
304
|
|
|
$
|
1,212
|
|
|
$
|
876
|
|
|
$
|
776
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock received in settlement of investments
|
|
$
|
209
|
|
|
$
|
|
|
|
$
|
198
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Decrease) increase in interest rate swap liability
|
|
$
|
|
|
|
$
|
(409
|
)
|
|
$
|
(395
|
)
|
|
$
|
1,163
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Type of
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Debt
Investments(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Life Science
39.3%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.10
|
%
|
|
|
6/1/2013
|
|
|
$
|
958
|
|
|
$
|
958
|
|
|
|
|
|
Term Loan
|
|
|
12.01
|
%
|
|
|
6/1/2013
|
|
|
|
957
|
|
|
|
957
|
|
|
|
|
|
Term Loan
|
|
|
12.01
|
%
|
|
|
6/1/2013
|
|
|
|
1,478
|
|
|
|
1,478
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.25
|
%
|
|
|
10/1/2013
|
|
|
|
5,898
|
|
|
|
5,898
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
12.04
|
%
|
|
|
9/1/2013
|
|
|
|
6,887
|
|
|
|
6,887
|
|
GenturaDX, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
11.25
|
%
|
|
|
4/1/2014
|
|
|
|
1,917
|
|
|
|
1,917
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
6/1/2012
|
|
|
|
3,146
|
|
|
|
3,146
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
11.50
|
%
|
|
|
4/1/2014
|
|
|
|
4,887
|
|
|
|
4,887
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
8/1/2011
|
|
|
|
868
|
|
|
|
868
|
|
|
|
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
1/1/2012
|
|
|
|
1,448
|
|
|
|
1,448
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
10/1/2012
|
|
|
|
2,422
|
|
|
|
2,422
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
1/1/2013
|
|
|
|
4,221
|
|
|
|
4,221
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
10.50
|
%
|
|
|
12/1/2011
|
|
|
|
1,445
|
|
|
|
1,445
|
|
|
|
|
|
Term Loan
|
|
|
10.50
|
%
|
|
|
3/1/2013
|
|
|
|
3,478
|
|
|
|
3,478
|
|
Tengion,
Inc.(4)
|
|
Medical Device
|
|
Term Loan
|
|
|
12.26
|
%
|
|
|
9/1/2011
|
|
|
|
2,740
|
|
|
|
2,740
|
|
Tranzyme, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
10.75
|
%
|
|
|
1/1/2014
|
|
|
|
4,966
|
|
|
|
4,966
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
13.55
|
%
|
|
|
11/1/2011
|
|
|
|
885
|
|
|
|
837
|
|
Xcovery Holding Company, LLC
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
10/1/2013
|
|
|
|
1,490
|
|
|
|
1,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Life Science
|
|
|
50,091
|
|
|
|
50,043
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Technology 24.4%
|
|
|
|
|
|
|
|
|
Clarabridge, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
1/1/2013
|
|
|
|
1,166
|
|
|
|
1,166
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
6/1/2013
|
|
|
|
688
|
|
|
|
688
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
5/1/2014
|
|
|
|
743
|
|
|
|
743
|
|
Courion Corporation
|
|
Software
|
|
Term Loan
|
|
|
11.45
|
%
|
|
|
12/1/2011
|
|
|
|
1,083
|
|
|
|
1,083
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Term Loan
|
|
|
12.40
|
%
|
|
|
2/1/2011
|
|
|
|
1,042
|
|
|
|
1,042
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Term Loan
|
|
|
12.43
|
%
|
|
|
4/1/2012
|
|
|
|
515
|
|
|
|
515
|
|
|
|
|
|
Term Loan
|
|
|
12.33
|
%
|
|
|
6/1/2012
|
|
|
|
598
|
|
|
|
598
|
|
|
|
|
|
Term Loan
|
|
|
12.33
|
%
|
|
|
10/1/2012
|
|
|
|
1,171
|
|
|
|
1,171
|
|
Netuitive, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.90
|
%
|
|
|
4/1/2011
|
|
|
|
152
|
|
|
|
152
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Term Loan
|
|
|
11.86
|
%
|
|
|
12/1/2013
|
|
|
|
6,549
|
|
|
|
6,549
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
12.05
|
%
|
|
|
9/1/2012
|
|
|
|
2,679
|
|
|
|
2,679
|
|
StreamBase Systems, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.51
|
%
|
|
|
11/1/2013
|
|
|
|
3,934
|
|
|
|
3,934
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
6/1/2014
|
|
|
|
977
|
|
|
|
977
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
12.78
|
%
|
|
|
5/1/2012
|
|
|
|
1,284
|
|
|
|
1,284
|
|
|
|
|
|
Term Loan
|
|
|
11.46
|
%
|
|
|
8/1/2012
|
|
|
|
498
|
|
|
|
498
|
|
Vette Corp.
|
|
Data Storage
|
|
Term Loan
|
|
|
11.75
|
%
|
|
|
7/1/2014
|
|
|
|
4,916
|
|
|
|
4,916
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Term Loan
|
|
|
14.00
|
%
|
|
|
5/1/2012
|
|
|
|
2,997
|
|
|
|
2,997
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Technology
|
|
|
30,992
|
|
|
|
30,992
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Cleantech 14.9%
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(4)
|
|
Waste Removal
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
4/1/2014
|
|
|
|
2,363
|
|
|
|
2,363
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Term Loan
|
|
|
12.60
|
%
|
|
|
10/1/2013
|
|
|
|
6,869
|
|
|
|
6,869
|
|
Satcon Technology
Corporation(4)
|
|
Energy Efficiency
|
|
Term Loan
|
|
|
12.58
|
%
|
|
|
1/1/2014
|
|
|
|
9,701
|
|
|
|
9,701
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Cleantech
|
|
|
18,933
|
|
|
|
18,933
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Healthcare information and
services 23.8%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
8/1/2012
|
|
|
|
2,454
|
|
|
|
2,454
|
|
|
|
|
|
Term Loan
|
|
|
11.51
|
%
|
|
|
1/1/2014
|
|
|
|
4,908
|
|
|
|
4,908
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
3/1/2012
|
|
|
|
3,255
|
|
|
|
3,255
|
|
See Notes to Consolidated Financial Statements
F-33
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2010 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Type of
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
12.75
|
%
|
|
|
1/1/2014
|
|
|
|
9,855
|
|
|
|
9,855
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Term Loan
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
2,949
|
|
|
|
2,949
|
|
|
|
|
|
Term Loan
|
|
|
11.00
|
%
|
|
|
3/1/2014
|
|
|
|
1,964
|
|
|
|
1,964
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Term Loan
|
|
|
12.10
|
%
|
|
|
12/1/2013
|
|
|
|
2,443
|
|
|
|
2,443
|
|
|
|
|
|
Term Loan
|
|
|
12.05
|
%
|
|
|
12/1/2013
|
|
|
|
2,438
|
|
|
|
2,438
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investment Healthcare information and
services
|
|
|
30,266
|
|
|
|
30,266
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments
|
|
|
130,282
|
|
|
|
130,234
|
|
|
|
|
|
|
|
|
|
|
Warrant
Investments(1)
|
|
|
|
|
|
|
|
|
Warrants Life Science 2.1%
|
|
|
|
|
|
|
|
|
ACT Biotech, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
23
|
|
Advanced BioHealing, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
1,209
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
143
|
|
|
|
147
|
|
Anesiva,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
Calypso Medical Technologies, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
76
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
85
|
|
|
|
89
|
|
EnteroMedics,
Inc.(4)
|
|
Medical Device
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
347
|
|
|
|
18
|
|
GenturaDX, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
63
|
|
|
|
63
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
|
|
OraMetrix, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
78
|
|
|
|
83
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
126
|
|
|
|
789
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
61
|
|
|
|
61
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
224
|
|
|
|
121
|
|
Tengion,
Inc.(4)
|
|
Medical Device
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
|
|
Tranzyme, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
1
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Life Science
|
|
|
1,292
|
|
|
|
2,680
|
|
|
|
|
|
|
|
|
|
|
Warrants Technology 1.2%
|
|
|
|
|
|
|
|
|
Cartera Commerce, Inc.
|
|
Internet and media
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
38
|
|
Clarabridge, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
|
25
|
|
Courion Corporation
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
17
|
|
DriveCam, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
8
|
|
Everyday Health, Inc.
|
|
Consumer related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
137
|
|
Grab Networks, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35
|
|
Impinj, Inc.
|
|
Semi-conductor
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
544
|
|
Motion Computing, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
292
|
|
Netuitive, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
22
|
|
OpenPeak, Inc.
|
|
Communications
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
89
|
|
|
|
92
|
|
Plateau Systems, Ltd.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
35
|
|
SnagAJob.com, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
39
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
28
|
|
StreamBase Systems, Inc.
|
|
Technology-Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
67
|
|
|
|
69
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
27
|
|
Vette Corp.
|
|
Data Storage
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
75
|
|
|
|
49
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Technology
|
|
|
618
|
|
|
|
1,538
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-34
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2010 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Type of
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Warrants Cleantech 1.0%
|
|
|
|
|
|
|
|
|
Cereplast,
Inc.(4)
|
|
Waste Removal
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
112
|
|
|
|
112
|
|
Enphase Energy, Inc.
|
|
Energy Efficiency
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
122
|
|
|
|
122
|
|
Satcon Technology
Corporation(4)
|
|
Energy Efficiency
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
286
|
|
|
|
1,057
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Cleantech
|
|
|
520
|
|
|
|
1,291
|
|
|
|
|
|
|
|
|
|
|
Warrants Healthcare information and
services 0.6%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
55
|
|
|
|
49
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
52
|
|
|
|
139
|
|
Radisphere National Radiology Group, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
167
|
|
|
|
384
|
|
Singulex, Inc.
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
39
|
|
Talyst, Inc.
|
|
Other Healthcare
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
100
|
|
|
|
105
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Healthcare information and services
|
|
|
413
|
|
|
|
716
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
2,843
|
|
|
|
6,225
|
|
|
|
|
|
|
|
|
|
|
Equity 0.3%
|
|
|
|
|
|
|
|
|
AFS Technologies, Inc.
|
|
|
|
Common Stock
|
|
|
|
|
|
|
|
|
|
|
142
|
|
|
|
142
|
|
Insmed
Incorporated(4)
|
|
|
|
Common Stock and
Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
|
|
227
|
|
|
|
209
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity
|
|
|
369
|
|
|
|
351
|
|
|
|
|
|
|
|
|
|
|
Total investments assets
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
|
|
|
|
|
|
|
|
Investment Liabilities
|
|
|
|
|
|
|
|
|
Derivative Agreement
|
|
|
|
|
|
|
|
|
WestLB, AG
|
|
Interest rate swap pay fixed/receive floating,
Notional Amount $10 million
|
|
3.58%
|
|
|
10/14/2011
|
|
|
|
|
|
|
|
|
|
|
|
258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total investment liabilities
|
|
$
|
|
|
|
$
|
258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Substantially all debt and warrant investments have been pledged
as collateral under the Credit Facility. |
|
(2) |
|
All investments are less than 5% ownership of the class and
ownership of the portfolio company. |
|
(3) |
|
All interest is payable in cash due monthly in arrears, unless
otherwise indicated and applies only to the Companys debt
investments. Amount is the annual interest rate on the debt
investment and does not include any additional fees related to
the investment such as commitment fees or prepayment fees. The
majority of the debt investments are at fixed rates for the term
of the loan. For each debt investment we have provided the
current interest rate in effect as of December 31, 2010. |
|
(4) |
|
Portfolio company is a public company. |
|
(5) |
|
For debt investments, represents principal balance. |
See Notes to Consolidated Financial Statements
F-35
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated Schedule of Investments
December 31, 2009
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Debt
Investments(1)
|
|
|
|
|
|
|
|
|
Debt Investments Life Science
29.6%
|
|
|
|
|
|
|
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.15
|
%
|
|
|
6/1/2011
|
|
|
$
|
1,272
|
|
|
$
|
1,272
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Revolving Loan
|
|
|
Prime + 3.25
|
%
|
|
|
7/1/2010
|
|
|
|
3,333
|
|
|
|
3,333
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
6/1/2012
|
|
|
|
4,770
|
|
|
|
4,770
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
8/1/2011
|
|
|
|
2,201
|
|
|
|
2,201
|
|
|
|
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
1/1/2012
|
|
|
|
2,704
|
|
|
|
2,704
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
10/1/2012
|
|
|
|
3,284
|
|
|
|
3,284
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
1/1/2013
|
|
|
|
4,889
|
|
|
|
4,889
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
10.50
|
%
|
|
|
12/1/2011
|
|
|
|
2,705
|
|
|
|
2,705
|
|
Tengion, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
12.26
|
%
|
|
|
9/1/2011
|
|
|
|
5,753
|
|
|
|
5,753
|
|
Transave, Inc.
|
|
Biotechnology
|
|
Term Loan
|
|
|
11.75
|
%
|
|
|
2/29/2012
|
|
|
|
2,730
|
|
|
|
2,730
|
|
|
|
|
|
Term Loan
|
|
|
11.75
|
%
|
|
|
7/1/2012
|
|
|
|
1,992
|
|
|
|
1,992
|
|
|
|
|
|
Convertible Note
|
|
|
10.00
|
%
|
|
|
6/30/2010
|
|
|
|
102
|
|
|
|
102
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Term Loan
|
|
|
13.55
|
%
|
|
|
11/1/2011
|
|
|
|
1,727
|
|
|
|
1,626
|
|
Xoft, Inc.
|
|
Medical Device
|
|
Revolving Loan
|
|
|
Prime + 4.25
|
%
|
|
|
11/15/2010
|
|
|
|
331
|
|
|
|
331
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt investments Life Science
|
|
|
37,793
|
|
|
|
37,692
|
|
|
|
|
|
|
|
|
|
|
Debt Investments Technology 44.9%
|
|
|
|
|
|
|
|
|
Cartera Commerce, Inc.
|
|
Internet and media
|
|
Term Loan
|
|
|
11.75
|
%
|
|
|
6/1/2012
|
|
|
|
2,483
|
|
|
|
2,483
|
|
Clarabridge, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
1/1/2013
|
|
|
|
1,467
|
|
|
|
1,467
|
|
|
|
|
|
Term Loan
|
|
|
12.50
|
%
|
|
|
6/1/2013
|
|
|
|
743
|
|
|
|
743
|
|
Courion Corporation
|
|
Software
|
|
Term Loan
|
|
|
11.45
|
%
|
|
|
12/1/2011
|
|
|
|
2,044
|
|
|
|
2,044
|
|
Genesis Networks, Inc.
|
|
Networking
|
|
Term Loan
|
|
|
11.80
|
%
|
|
|
8/1/2012
|
|
|
|
3,955
|
|
|
|
3,555
|
|
Grab Networks, Inc.
|
|
Networking
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
4/1/2012
|
|
|
|
3,579
|
|
|
|
3,579
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Term Loan
|
|
|
12.40
|
%
|
|
|
2/1/2011
|
|
|
|
2,457
|
|
|
|
2,457
|
|
Impinj, Inc.
|
|
Semi-conductor
|
|
Term Loan
|
|
|
Prime + 4.25
|
%
|
|
|
1/1/2011
|
|
|
|
866
|
|
|
|
866
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Term Loan
|
|
|
12.43
|
%
|
|
|
4/1/2012
|
|
|
|
836
|
|
|
|
836
|
|
|
|
|
|
Term Loan
|
|
|
12.33
|
%
|
|
|
6/1/2012
|
|
|
|
933
|
|
|
|
933
|
|
|
|
|
|
Term Loan
|
|
|
12.33
|
%
|
|
|
10/1/2012
|
|
|
|
1,692
|
|
|
|
1,692
|
|
iSkoot, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.75
|
%
|
|
|
5/1/2013
|
|
|
|
3,917
|
|
|
|
3,917
|
|
Motion Computing, Inc.
|
|
Networking
|
|
Term Loan
|
|
|
12.25
|
%
|
|
|
4/1/2011
|
|
|
|
1,431
|
|
|
|
1,431
|
|
|
|
|
|
Term Loan
|
|
|
12.25
|
%
|
|
|
1/1/2012
|
|
|
|
2,136
|
|
|
|
2,136
|
|
Netuitive, Inc.
|
|
Software
|
|
Term Loan
|
|
|
12.90
|
%
|
|
|
4/1/2011
|
|
|
|
569
|
|
|
|
569
|
|
NewRiver, Inc.
|
|
Software
|
|
Term Loan
|
|
|
11.60
|
%
|
|
|
1/1/2012
|
|
|
|
3,403
|
|
|
|
3,403
|
|
Plateau Systems, Ltd.
|
|
Software
|
|
Term Loan
|
|
|
12.40
|
%
|
|
|
9/1/2010
|
|
|
|
744
|
|
|
|
744
|
|
SnagAJob.com, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
11.50
|
%
|
|
|
6/1/2012
|
|
|
|
3,477
|
|
|
|
3,477
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
12.05
|
%
|
|
|
9/1/2012
|
|
|
|
3,960
|
|
|
|
3,960
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
12.78
|
%
|
|
|
5/1/2012
|
|
|
|
2,108
|
|
|
|
2,108
|
|
|
|
|
|
Term Loan
|
|
|
11.46
|
%
|
|
|
8/1/2012
|
|
|
|
746
|
|
|
|
746
|
|
Vette Corp.
|
|
Data Storage
|
|
Term Loan
|
|
|
11.85
|
%
|
|
|
3/1/2012
|
|
|
|
4,530
|
|
|
|
4,530
|
|
Waterfront Media, Inc.
|
|
Consumer-related technologies
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
5/1/2013
|
|
|
|
4,890
|
|
|
|
4,890
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Term Loan
|
|
|
14.00
|
%
|
|
|
5/1/2012
|
|
|
|
4,494
|
|
|
|
4,494
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total debt investment Technology
|
|
|
57,460
|
|
|
|
57,060
|
|
|
|
|
|
|
|
|
|
|
Healthcare information and services 12.5%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
12.00
|
%
|
|
|
8/1/2012
|
|
|
|
3,774
|
|
|
|
3,509
|
|
F & S Health Care Services, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
11.80
|
%
|
|
|
12/1/2012
|
|
|
|
7,457
|
|
|
|
7,457
|
|
See Notes to Consolidated Financial Statements
F-36
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2009 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Term Loan
|
|
|
13.00
|
%
|
|
|
3/1/2012
|
|
|
|
4,936
|
|
|
|
4,936
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments Healthcare information and
services
|
|
|
16,167
|
|
|
|
15,902
|
|
|
|
|
|
|
|
|
|
|
Total Debt Investments
|
|
|
111,420
|
|
|
|
110,654
|
|
|
|
|
|
|
|
|
|
|
Warrant
Investments(1)
|
|
|
|
|
|
|
|
|
Warrants Life Science 0.8%
|
|
|
|
|
|
|
|
|
Advanced BioHealing, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
42
|
|
Ambit Biosciences, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
55
|
|
Anesiva,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
18
|
|
|
|
|
|
Calypso Medical Technologies, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
75
|
|
Concentric Medical, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
11
|
|
EnteroMedics,
Inc.(4)
|
|
Medical Device
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
347
|
|
|
|
10
|
|
Novalar Pharmaceuticals, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
79
|
|
Pharmasset,
Inc.(4)
|
|
Biotechnology
|
|
Common Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
251
|
|
|
|
437
|
|
PixelOptics, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
61
|
|
|
|
61
|
|
Revance Therapeutics, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
156
|
|
|
|
49
|
|
Tengion, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
15
|
|
|
|
50
|
|
Transave, Inc.
|
|
Biotechnology
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
12
|
|
|
|
45
|
|
ViOptix, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
21
|
|
Xoft, Inc.
|
|
Medical Device
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
51
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Life Science
|
|
|
1,008
|
|
|
|
986
|
|
|
|
|
|
|
|
|
|
|
Warrants Technology 1.0%
|
|
|
|
|
|
|
|
|
Arcot Systems, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
5
|
|
|
|
57
|
|
Cartera Commerce, Inc.
|
|
Internet and media
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
35
|
|
Clarabridge, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
28
|
|
|
|
31
|
|
Courion Corporation
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
16
|
|
DriveCam, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
20
|
|
|
|
15
|
|
Genesis Networks, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
53
|
|
|
|
|
|
Grab Networks, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
74
|
|
|
|
84
|
|
Hatteras Networks, Inc.
|
|
Communications
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35
|
|
Impinj, Inc.
|
|
Semi-conductor
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
34
|
|
IntelePeer, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
52
|
|
iSkoot, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
59
|
|
|
|
59
|
|
Motion Computing, Inc.
|
|
Networking
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
9
|
|
|
|
465
|
|
Netuitive, Inc.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
43
|
|
Plateau Systems, Ltd.
|
|
Software
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
7
|
|
|
|
34
|
|
SnagAJob.com, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
23
|
|
|
|
38
|
|
Starcite, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
24
|
|
|
|
28
|
|
Tagged, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
17
|
|
|
|
28
|
|
Vette Corp.
|
|
Data Storage
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
27
|
|
|
|
69
|
|
Waterfront Media, Inc.
|
|
Consumer-related technologies
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
69
|
|
|
|
69
|
|
XIOtech, Inc.
|
|
Data Storage
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
22
|
|
|
|
81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Warrants Technology
|
|
|
533
|
|
|
|
1,273
|
|
|
|
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-37
Horizon
Technology Finance Corporation and Subsidiaries
Consolidated
Schedule of Investments
December 31,
2009 (Continued)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
|
|
|
|
|
|
Cost of
|
|
|
|
|
Portfolio Company
|
|
Sector
|
|
Type of
Investment(2)
|
|
Rate(3)
|
|
|
Maturity
|
|
|
Investment(5)
|
|
|
Fair Value
|
|
|
Warrants Healthcare information and
services 0.2%
|
|
|
|
|
|
|
|
|
BioScale, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
13
|
|
|
|
33
|
|
F & S Health Care Services, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
32
|
|
|
|
105
|
|
Precision Therapeutics, Inc.
|
|
Diagnostics
|
|
Preferred Stock Warrants
|
|
|
|
|
|
|
|
|
|
|
52
|
|
|
|
61
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants Healthcare information and services
|
|
|
97
|
|
|
|
199
|
|
|
|
|
|
|
|
|
|
|
Total Warrants
|
|
|
1,638
|
|
|
|
2,458
|
|
|
|
|
|
|
|
|
|
|
Total investment
assets(6)
|
|
$
|
113,058
|
|
|
$
|
113,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Substantially all debt and warrant investments have been pledged
as collateral under the Credit Facility. |
|
(2) |
|
All investments are less than 5% ownership of the class and
ownership of the portfolio company. |
|
(3) |
|
All interest is payable in cash due monthly in arrears, unless
otherwise indicated and applies only to the Companys debt
investments. Amount is the annual interest rate on the debt
investment and does not include any additional fees related to
the investment such as commitment fees or prepayment fees. The
majority of the debt investments are at fixed rates for the term
of the loan. For each debt investment we have provided the
current interest rate in effect as of December 31, 2009.
For variable rate debt investments we have also provided the
reference index plus the applicable spread which resets monthly. |
|
(4) |
|
Portfolio company is a public company. |
|
(5) |
|
For debt investments, represents principal balance. |
|
(6) |
|
Total investment assets in 2009 were recorded at book value net
of allowance for loan losses as follows: |
|
|
|
|
|
Book value of debt investments (at cost)
|
|
$
|
112,572
|
|
Book value of warrants investments (at fair value)
|
|
|
2,458
|
|
Unearned income
|
|
|
(1,152
|
)
|
Allowance for loan losses
|
|
|
(1,924
|
)
|
|
|
|
|
|
Net investments at book value
|
|
$
|
111,954
|
|
|
|
|
|
|
See Notes to Consolidated Financial Statements
F-38
Horizon
Technology Finance Corporation and Subsidiaries
(In
thousands, except shares and per share data)
Horizon Technology Finance Corporation (the Company)
was organized as a Delaware corporation on March 16, 2010
and is an externally managed non-diversified closed end
investment company. The Company has elected to be regulated as a
business development company (BDC) under the
Investment Company Act of 1940, as amended (1940
Act). In addition, for tax purposes, the Company will
elect to be treated as a regulated investment company
(RIC) as defined in Subtitle A, Chapter 1,
under Subchapter M of the Internal Revenue Code of 1986, as
amended (the Code). As a RIC, the Company will not
be subject to federal income tax on the portion of its taxable
income and capital gains the Company distributes to the
stockholders. The Company primarily makes secured loans to
development-stage companies in the technology, life science,
healthcare information and services and cleantech industries.
On October 28, 2010 the Company completed an initial public
offering (IPO) and its common stock trades on the
NASDAQ Global Market under the symbol HRZN. The
Company was formed to continue and expand the business of
Compass Horizon Funding Company LLC (CHF), a
Delaware limited liability company, which commenced operations
in March 2008 and became the Companys wholly owned
subsidiary with the completion of the IPO.
Horizon Credit I LLC (Credit I) was formed as a
Delaware limited liability company on January 23, 2008,
with CHF as the sole equity member. Credit I is a special
purpose bankruptcy remote entity and is reported herein as a
wholly owned subsidiary of the Company. CHF sells certain
portfolio transactions to Credit I (Purchased
Assets). Credit I is a separate legal entity from CHF and
the Purchased Assets have been conveyed to Credit I and are not
available for creditors of CHF or any other entity other than
its lenders.
The Companys investment strategy is to maximize the
investment portfolios return by generating current income
from the loans made and the capital appreciation from the
warrants received when making such loans. The Company has
entered into an investment management agreement (the
Investment Management Agreement) with Horizon
Technology Finance Management LLC (HTFM or the
Advisor), under which the Advisor will manage the
day-to-day
operations of, and provide investment advisory services to the
Company.
|
|
Note 2.
|
Basis of
Presentation and Significant Accounting Policies
|
Election
to become a Business Development Company and Basis of Financial
Statement Presentation
The results of operations for 2010 are divided into two periods.
The period from January 1, 2010 through October 28,
2010, reflects the Companys results prior to operating as
a BDC under the 1940 Act. The period from October 29, 2010
through December 31, 2010, reflects the Companys
results as a BDC under the 1940 Act. Accounting principles used
in the preparation of the consolidated financial statements
beginning October 29, 2010 are different than those of
prior periods and, therefore, the financial position and results
of operations of these periods are not directly comparable. The
primary differences in accounting principles relate to the
carrying value of loan investments and classification of hedging
activity see corresponding sections below for
further discussion.
Cumulative
Effect of Business Development Company Election
|
|
|
|
|
Effect of recording loans at fair value
|
|
$
|
(348
|
)
|
Elimination of allowance for loan losses
|
|
|
1,185
|
|
|
|
|
|
|
Total cumulative effect of BDC election
|
|
$
|
837
|
|
|
|
|
|
|
In addition, the balance of the unrealized loss on interest rate
swaps included in accumulated other comprehensive loss at
October 28, 2010 of $359 was reclassified to Paid-In
Capital in Excess of Par and subsequent to October 28,
2010, changes in the fair value of the interest rate swaps are
recorded in operations.
F-39
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
The consolidated financial statements of the Company have been
prepared in accordance with U.S. generally accepted
accounting principles (GAAP) and pursuant to the
requirements for reporting on
Form 10-K
and Article 6 or 10 of
Regulation S-X.
In the opinion of management, the consolidated financial
statements reflect all adjustments and reclassifications that
are necessary for the fair presentation of financial results as
of and for the periods presented. All intercompany balances and
transactions have been eliminated. Certain prior period amounts
have been reclassified to conform to the current period
presentation.
Principles
of Consolidation
As permitted under
Regulation S-X
and the AICPA Audit and Accounting Guide for Investment
Companies, the Company will generally not consolidate its
investment in a company other than an investment company
subsidiary or a controlled operating company whose business
consists of providing services to the Company. Accordingly, the
Company consolidated the results of the Companys
subsidiaries in its consolidated financial statements.
Use of
Estimates
In preparing the consolidated financial statements in accordance
with GAAP, management is required to make estimates and
assumptions that affect the reported amounts of assets and
liabilities, and disclosures of contingent assets and
liabilities, as of the date of the balance sheet and income and
expenses for the period. Actual results could differ from those
estimates. Material estimates that are particularly susceptible
to significant change in the near term relate to the valuation
of loans and warrants.
Fair
Value
The Company applies fair value to substantially all of its
investments in accordance with relevant GAAP, which establishes
a framework used to measure fair value and requires disclosures
for fair value measurements. The Company has categorized its
investments carried at fair value, based on the priority of the
valuation technique, into a three-level fair value hierarchy.
Fair value is a market-based measure considered from the
perspective of the market participant who holds the financial
instrument rather than an entity specific measure. Therefore,
when market assumptions are not readily available, the
Companys own assumptions are set to reflect those that
management believes market participants would use in pricing the
financial instrument at the measurement date.
The availability of observable inputs can vary depending on the
financial instrument and is affected by a wide variety of
factors, including, for example, the type of product, whether
the product is new, whether the product is traded on an active
exchange or in the secondary market and the current market
conditions. To the extent that the valuation is based on models
or inputs that are less observable or unobservable in the
market, the determination of fair value requires more judgment.
Accordingly, the degree of judgment exercised by the Company in
determining fair value is greatest for financial instruments
classified as Level 3.
In January 2010, the FASB issued Accounting Standards Update
2010-06,
Fair Value Measurements and Disclosure Improving
Disclosures about Fair Value Measurements, which amends the
existing guidance related to fair value measurements and
disclosures. The amendments require the following new fair value
disclosures:
|
|
|
|
|
Separate disclosure of the significant transfers in and out of
Level 1 and Level 2 fair value measurements, and a
description of the reasons for the transfers.
|
|
|
|
In the roll forward of activity for Level 3 fair value
measurements (significant unobservable inputs), purchases,
sales, issuances, and settlements should be presented separately
(on a gross basis rather than as one net number).
|
F-40
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
In addition, the amendments clarify existing disclosure
requirements, as follows:
|
|
|
|
|
Fair value measurements and disclosures should be presented for
each class of assets and liabilities within a line item in the
balance sheet.
|
|
|
|
Reporting entities should provide disclosures about the
valuation techniques and inputs used to measure fair value for
both recurring and nonrecurring fair value measurements that
fall in either Level 2 or Level 3.
|
The new disclosures and clarifications of existing disclosures
were effective for the Companys interim and annual
reporting periods beginning after December 15, 2009, except
for the disclosures included in the roll forward of activity for
Level 3 fair value measurements, for which the effective
date is for fiscal years beginning after December 15, 2010,
and for interim periods within those fiscal years.
See Note 5 for additional information regarding fair value.
Segments
The Company has determined that it has a single reporting
segment and operating unit structure. The Company lends to and
invests in portfolio companies in various technology, life
science, healthcare information and services and cleantech
industries. The Company separately evaluates the performance of
each of its lending and investment relationships. However,
because each of these loan and investment relationships has
similar business and economic characteristics, they have been
aggregated into a single lending and investment segment.
Cash
and Cash Equivalents
Cash and cash equivalents as presented in the consolidated
balance sheets and the consolidated statements of cash flows
include bank checking accounts and money market funds with an
original maturity of less than 90 days.
Investments
Investments are recorded at fair value. The Companys board
of directors (Board) determines the fair value of
its portfolio investments. Prior to the Companys election
to become a BDC, loan investments were stated at current unpaid
principal balances adjusted for the allowance for loan losses,
unearned income and any unamortized deferred fees or costs.
The Company has the intent to hold its loans for the foreseeable
future or until maturity or payoff.
Interest on loan investments is accrued and included in income
based on contractual rates applied to principal amounts
outstanding. Interest income is determined using a method that
results in a level rate of return on principal amounts
outstanding. When a loan becomes 90 days or more past due,
or if the Company otherwise does not expect to receive interest
and principal repayments, the loan is placed on non-accrual
status and the recognition of interest income is discontinued.
Interest payments received on loans that are on non-accrual
status are treated as reductions of principal until the
principal is repaid. No loans were on non-accrual status as of
December 31, 2010 and 2009.
The Company receives a variety of fees from borrowers in the
ordinary course of conducting its business, including advisory
fees, commitment fees, amendment fees, non-utilization fees and
prepayment fees (collectively, the Fees). In a
limited number of cases, the Company may also receive a
non-refundable deposit earned upon the termination of a
transaction. Loan origination fees, net of certain direct
origination costs, are deferred, and along with unearned income,
are amortized as a level yield adjustment over the respective
term of the loan. Fees for counterparty loan commitments with
multiple loans are allocated to each loan based upon each
loans relative fair value. When a loan is placed on
non-accrual status, the amortization of the related fees and
unearned income is discontinued until the loan is returned to
accrual status.
F-41
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Certain loan agreements also require the borrower to make an
end-of-term
payment that is accrued into income over the life of the loan to
the extent such amounts are expected to be collected. The
Company will generally cease accruing the income if there is
insufficient value to support the accrual or the Company does
not expect the borrower to be able to pay all principal and
interest due.
In connection with substantially all lending arrangements, the
Company receives warrants to purchase shares of stock from the
borrower. The warrants are recorded as assets at estimated fair
value on the grant date using the Black-Scholes valuation model.
The warrants are considered loan fees and are also recorded as
unearned loan income on the grant date. The unearned income is
recognized as interest income over the contractual life of the
related loan in accordance with the Companys income
recognition policy. Subsequent to loan origination, the warrants
are also measured at fair value using the Black-Scholes
valuation model. Any adjustment to fair value is recorded
through earnings as net unrealized gain or loss on investments.
Gains from the disposition of the warrants or stock acquired
from the exercise of warrants are recognized as realized gains
on investments.
See Note 5 for additional information regarding fair value.
Allowance
for Loan Losses
Prior to the Companys election to become a BDC, the
allowance for loan losses represented managements estimate
of probable loan losses inherent in the loan portfolio as of the
balance sheet date. The estimation of the allowance was based on
a variety of factors, including past loan loss experience, the
current credit profile of the Companys borrowers, adverse
situations that had occurred that may affect individual
borrowers ability to repay, the estimated value of
underlying collateral and general economic conditions. The loan
portfolio is comprised of large balance loans that are evaluated
individually for impairment and are risk-rated based upon a
borrowers individual situation, current economic
conditions, collateral and industry-specific information that
management believes is relevant in determining the potential
occurrence of a loss event and in measuring impairment. The
allowance for loan losses was sensitive to the risk rating
assigned to each of the loans and to corresponding qualitative
loss factors that the Company used to estimate the allowance.
Those factors were applied to the outstanding loan balances in
estimating the allowance for loan losses. If necessary, based on
performance factors related to specific loans, specific
allowances for loan losses were established for individual
impaired loans. Increases or decreases to the allowance for loan
losses were charged or credited to current period earnings
through the provision (credit) for loan losses. Amounts
determined to be uncollectible were charged against the
allowance for loan losses, while amounts recovered on previously
charged-off loans increased the allowance for loan losses.
A loan was considered impaired when, based on current
information and events, it was probable that the Company was
unable to collect the scheduled payments of principal or
interest when due according to the contractual terms of the loan
agreement. Factors considered by management in determining
impairment included payment status, collateral value, and the
probability of collecting scheduled principal and interest
payments when due. Loans that experienced insignificant payment
delays and payment shortfalls generally were not classified as
impaired. Management determined the significance of payment
delays and payment shortfalls on a
case-by-case
basis, taking into consideration all of the circumstances
surrounding the loan and the borrower, including the length of
the delay, the reasons for the delay, the borrowers prior
payment record, and the amount of the shortfall in relation to
the principal and interest owed. Impairment was measured on a
loan by loan basis by either the present value of expected
future cash flows discounted at the loans effective
interest rate, the loans observable market price or the
fair value of the collateral, if the loan was collateral
dependent.
Impaired loans also included loans modified in troubled debt
restructurings where concessions had been granted to borrowers
experiencing financial difficulties. These concessions could
include a reduction in the interest rate on the loan, payment
extensions, forgiveness of principal, forbearance or other
actions intended to maximize collection. There were no impaired
loans or troubled debt restructured loans at December 31,
2009.
F-42
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Debt
Issuance Costs
Debt issuance costs are fees and other direct incremental costs
incurred by the Company in obtaining debt financing from its
lender and are recognized as assets and are amortized as
interest expense over the term of the related Credit Facility.
The unamortized balance of debt issuance costs as of
December 31, 2010 and 2009 was $194 and $1,355,
respectively. The amortization expense for the period from
October 29, 2010 to December 31, 2010, the period from
January 1, 2010 to October 28, 2010 and the years
ended December 31, 2009 and 2008 relating to debt issuance
costs was $200, $962, $1,123 and $953, respectively.
Income
Taxes
The Company intends to elect to be treated as a RIC under
subchapter M of the Code and operates in a manner so as to
qualify for the tax treatment applicable to RICs. In order to
qualify as a RIC, among other things, the Company is required to
meet certain source of income and asset diversification
requirements and timely distribute to its stockholders at least
90% of investment company taxable income, as defined by the
Code, for each year. The Company, among other things, has made
and intends to continue to make the requisite distributions to
its stockholders, which will generally relieve the Company from
U.S. federal income taxes.
Depending on the level of taxable income earned in a tax year,
the Company may choose to carry forward taxable income in excess
of current year dividend distributions into the next tax year
and pay a 4% excise tax on such income, as required. To the
extent that the Company determines that its estimated current
year annual taxable income will be in excess of estimated
current year dividend distributions, the Company accrues excise
tax, if any, on estimated excess taxable income as taxable
income is earned. For the period from October 29, 2010 to
December 31, 2010 no amount was recorded for
U.S. federal excise tax.
The Company evaluates tax positions taken in the course of
preparing the Companys tax returns to determine whether
the tax positions are more-likely-than-not to be
sustained by the applicable tax authority. Tax benefits of
positions not deemed to meet the more-likely-than-not threshold,
or uncertain tax positions, would be recorded as a tax expense
in the current year. It is the Companys policy to
recognize accrued interest and penalties related to uncertain
tax benefits in income tax expense. There were no material
uncertain tax positions at December 31, 2010 and 2009. The
2008 and 2009 tax years remain subject to examination by
U.S. federal and state tax authorities.
Prior to the Companys election to become a BDC, the
Company was a limited liability company treated as a partnership
for U.S. federal income tax purposes and, as a result, all
items of income and expense were passed through to, and are
generally reportable on, the tax returns of the respective
members of the limited liability company. Therefore, no federal
or state income tax provision has been recorded for the period
from January 1, 2010 to October 28, 2010 and the years
ended December 31, 2009 and 2008.
Dividends
Dividends and distributions to common stockholders are recorded
on the declaration date. The amount to be paid out as a dividend
is determined by the Board. Net realized capital gains, if any,
are distributed at least annually, although the Company may
decide to retain such capital gains for investment.
The Company has adopted a dividend reinvestment plan that
provides for reinvestment of cash distributions and other
distributions on behalf of its stockholders, unless a
stockholder elects to receive cash. As a result, if the Board
authorizes, and the Company declares, a cash dividend, then
stockholders who have not opted out of the dividend
reinvestment plan will have their cash dividends automatically
reinvested in additional shares of the Companys common
stock, rather than receiving the cash dividend. The Company may
use newly issued shares to implement the plan (especially if the
Companys shares are trading at a premium to net asset
value), or the Company may purchase shares in the open market in
connection with the obligations under the plan.
F-43
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Interest
Rate Swaps and Hedging Activities
The Company entered into interest rate swap agreements to manage
interest rate risk. The Company does not hold or issue interest
rate swap agreements or other derivative financial instruments
for speculative purposes.
Subsequent to the Companys election to become a BDC, the
interest rate swaps are recorded at fair value with changes in
fair value reflected in net unrealized appreciation or
depreciation of investments during the reporting period. The
Company records the accrual of periodic interest settlements of
interest rate swap agreements in net unrealized appreciation or
depreciation of investments and subsequently records the amount
as a net realized gain or loss on investments on the interest
settlement date. Cash payments received or paid for the
termination of an interest rate swap agreement would be recorded
as a realized gain or loss upon termination in the consolidated
statements of operations.
Prior to the Companys election to become a BDC, the
Company recognized its interest rate swap derivatives on the
balance sheet as either an asset or liability measured at fair
value. Changes in the derivatives fair value were
recognized in income unless specific hedge accounting criteria
were met. Special accounting for qualifying hedges allows a
derivatives gains and losses to offset related results on
the hedged item in the statement of operations and required the
Company to formally document, designate and assess effectiveness
of transactions that receive hedge accounting. Derivatives that
are not hedges are adjusted to fair value through earnings. If
the derivative qualifies as a hedge, depending on the nature of
the hedge, changes in the fair value of derivatives are either
offset against the change in fair value of hedged assets,
liabilities or firm commitments through earnings, or recognized
in other comprehensive income until the hedged item is
recognized in earnings. The ineffective portion of a
derivatives change in fair value, if any, would have been
recognized as interest expense.
Transfers
of Financial Assets
Transfers of financial assets are accounted for as sales, when
control over the assets has been surrendered. Control over
transferred assets is deemed to be surrendered when (1) the
assets have been isolated from the Company put
presumptively beyond the reach of the transferor and its
creditors, even in bankruptcy or other receivership,
(2) the transferee obtains the right (free of conditions
that constrain it from taking advantage of that right) to pledge
or exchange the transferred assets and (3) the transferor
does not maintain effective control over the transferred assets
through either (a) an agreement that both entitles and
obligates the transferor to repurchase or redeem the assets
before maturity or (b) the ability to unilaterally cause
the holder to return specific assets, other than through a
cleanup call.
In June 2009, the Financial Accounting Standards Board (the
FASB) issued guidance which modified certain
guidance relating to transfers and servicing of financial
assets. This guidance eliminates the concept of qualifying
special purpose entities, provides guidance as to when a portion
of a transferred financial asset can be evaluated for sale
accounting, provides additional guidance with regard to
accounting for transfers of financial assets and requires
additional disclosures. This guidance was effective for the
Company as of January 1, 2010, with adoption applied
prospectively for transfers that occurred on and after the
effective date. The adoption of this guidance did not have an
impact on the Companys financial statements.
|
|
Note 3.
|
Related
Party Transactions
|
Investment
Management Agreement
On October 28, 2010 the Company entered into the Investment
Management Agreement with the Advisor, under which the Advisor
manages the
day-to-day
operations of, and provides investment advisory services, to the
Company. Under the terms of the Investment Management Agreement,
the Advisor determines the composition of the Companys
investment portfolio, the nature and timing of the changes to
the investment portfolio and the manner of implementing such
changes; identifies, evaluates and negotiates the structure of
the investments the
F-44
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Company makes (including performing due diligence on the
Companys prospective portfolio companies) and closes,
monitors and administers the investments the Company makes,
including the exercise of any voting or consent rights.
The Advisors services under the Investment Management
Agreement are not exclusive to the Company, and the Advisor is
free to furnish similar services to other entities so long as
its services to the Company are not impaired. The Advisor is a
registered investment advisor with the SEC. The Advisor receives
fees for providing services, consisting of two components, a
base management fee and an incentive fee.
The base management fee is calculated at an annual rate of 2.00%
of the Companys gross assets, payable monthly in arrears.
For purposes of calculating the base management fee, the term
gross assets includes any assets acquired with the
proceeds of leverage.
The incentive fee has two parts, as follows:
The first part is calculated and payable quarterly in arrears
based on the Companys pre-incentive fee net investment
income for the immediately preceding calendar quarter. For this
purpose, pre-incentive fee net investment income means interest
income, dividend income and any other income (including any
other fees (other than fees for providing managerial
assistance), such as commitment, origination, structuring,
diligence and consulting fees or other fees received from
portfolio companies) accrued during the calendar quarter, minus
operating expenses for the quarter (including the base
management fee, expenses payable under the administration
agreement (as defined below), and any interest expense and any
dividends paid on any issued and outstanding preferred stock,
but excluding the incentive fee). Pre-incentive fee net
investment income includes, in the case of investments with a
deferred interest feature (such as original issue discount, debt
instruments with
payment-in-kind
interest and zero coupon securities), accrued income that we
have not yet received in cash. The incentive fee with respect to
the pre-incentive fee net income is 20.00% of the amount, if
any, by which the pre-incentive fee net investment income for
the immediately preceding calendar quarter exceeds a 1.75%
(which is 7.00% annualized) hurdle rate and a
catch-up
provision measured as of the end of each calendar quarter. Under
this provision, in any calendar quarter, the Advisor receives no
incentive fee until the net investment income equals the hurdle
rate of 1.75%, but then receives, as a
catch-up,
100.00% of the pre-incentive fee net investment income with
respect to that portion of such pre-incentive fee net investment
income, if any, that exceeds the hurdle rate but is less than
2.1875%. The effect of this provision is that, if pre-incentive
fee net investment income exceeds 2.1875% in any calendar
quarter, the Advisor will receive 20.00% of the pre-incentive
fee net investment income as if a hurdle rate did not apply.
Pre-incentive fee net investment income does not include any
realized capital gains, realized capital losses or unrealized
capital appreciation or depreciation. Because of the structure
of the incentive fee, it is possible that the Company may pay an
incentive fee in a quarter in which the Company incurs a loss.
For example, if the Company receives pre-incentive fee net
investment income in excess of the quarterly minimum hurdle
rate, the Company will pay the applicable incentive fee even if
the Company has incurred a loss in that quarter due to realized
and unrealized capital losses. The Companys net investment
income used to calculate this part of the incentive fee is also
included in the amount of the Companys gross assets used
to calculate the 2.00% base management fee. These calculations
are appropriately prorated for any period of less than three
months and adjusted for any share issuances or repurchases
during the current quarter. The base management fee expense was
$668 for the period from October 29, 2010 through
December 31, 2010 and the accrued management fee was $360
as of December 31, 2010.
The second part of the incentive fee is determined and payable
in arrears as of the end of each calendar year (or upon
termination of the investment management agreement, as of the
termination date), commencing on December 31, 2010, and
equals 20.00% of the Companys aggregate realized capital
gains, if any, on a cumulative basis from the date of the
election to be a BDC through the end of each calendar year,
computed net
F-45
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
of all realized capital losses and unrealized capital
depreciation through the end of such year, less all previous
amounts paid in respect of the capital gain incentive fee;
provided that the incentive fee determined as of
December 31, 2010 is calculated for a period of shorter
than twelve calendar months to take into account any realized
capital gains computed net of all realized capital losses and
unrealized capital depreciation for the period beginning on the
date of the Companys election to be a BDC and ending
December 31, 2010. The incentive fee expense was $414 for
the period from October 29, 2010 through December 31,
2010 and the incentive fee payable was $414 as of
December 31, 2010.
Prior to the Companys election to become a BDC, the
Advisor served as the Advisor for CHF under a Management and
Services Agreement which provided for management fees to be paid
monthly at a rate of 2.00% per annum of the gross investment
assets of CHF. Total management fee expense was $2,019 for the
period from January 1, 2010 to October 28, 2010, and
$2,202 and $1,073 for the years ended December 31, 2009 and
2008, respectively.
Administration
Agreement
The Company entered into an administration agreement with the
Advisor to provide administrative services to the Company. For
providing these services, facilities and personnel, the Company
will reimburse the Advisor for the Companys allocable
portion of overhead and other expenses incurred by the Advisor
in performing its obligations under the administration
agreement, including rent, the fees and expenses associated with
performing compliance functions, and the Companys
allocable portion of the costs of compensation and related
expenses of the Companys chief compliance officer and
chief financial officer and their respective staffs. During the
period from October 29, 2010 to December 31, 2010, $88
was charged to operations under this agreement.
From time to time, the Advisor may pay amounts owed by the
Company to third-party providers of goods or services. The
Company will subsequently reimburse the Advisor for such amounts
paid on the Companys behalf.
Investments, all of which are with portfolio companies in the
United States, consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
December 31, 2009
|
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Book Value
|
|
|
Fair Value
|
|
|
Debt
|
|
$
|
130,282
|
|
|
$
|
130,234
|
|
|
$
|
109,496
|
|
|
$
|
110,654
|
|
Warrants
|
|
|
2,843
|
|
|
|
6,225
|
|
|
|
2,458
|
|
|
|
2,458
|
|
Equity
|
|
|
369
|
|
|
|
351
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
$
|
111,954
|
|
|
$
|
113,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-46
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
The following table shows the Companys investments by
industry sector. The book value as of December 31, 2009
excludes the effect of the allowance for loan loss of $1,924.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
December 31, 2009
|
|
|
|
Cost
|
|
|
Fair Value
|
|
|
Book Value
|
|
|
Fair Value
|
|
|
Life Science
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$
|
31,138
|
|
|
$
|
31,614
|
|
|
$
|
22,426
|
|
|
$
|
22,426
|
|
Medical Device
|
|
|
20,472
|
|
|
|
21,317
|
|
|
|
16,355
|
|
|
|
16,255
|
|
Technology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer-related Technologies
|
|
|
4,592
|
|
|
|
4,692
|
|
|
|
15,342
|
|
|
|
15,342
|
|
Networking
|
|
|
2,405
|
|
|
|
3,120
|
|
|
|
15,162
|
|
|
|
14,762
|
|
Software
|
|
|
9,042
|
|
|
|
9,062
|
|
|
|
13,143
|
|
|
|
13,143
|
|
Data Storage
|
|
|
8,010
|
|
|
|
8,042
|
|
|
|
9,174
|
|
|
|
9,174
|
|
Internet and Media
|
|
|
16
|
|
|
|
38
|
|
|
|
2,518
|
|
|
|
2,518
|
|
Communications
|
|
|
7,681
|
|
|
|
7,719
|
|
|
|
2,492
|
|
|
|
2,492
|
|
Semiconductors
|
|
|
7
|
|
|
|
|
|
|
|
900
|
|
|
|
900
|
|
Healthcare Information and Services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
20,745
|
|
|
|
21,044
|
|
|
|
16,366
|
|
|
|
16,100
|
|
Other healthcare related services
|
|
|
9,934
|
|
|
|
9,938
|
|
|
|
|
|
|
|
|
|
Cleantech
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Energy efficiency
|
|
|
16,977
|
|
|
|
17,749
|
|
|
|
|
|
|
|
|
|
Waste recycling
|
|
|
2, 475
|
|
|
|
2,475
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
133,494
|
|
|
$
|
136,810
|
|
|
$
|
113,878
|
|
|
$
|
113,112
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company uses fair value measurements to record fair value
adjustments to certain assets and liabilities and to determine
fair value disclosures. Fair value is the price that would be
received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the
measurement date. Fair value is best determined based upon
quoted market prices. However, in certain instances, there are
no quoted market prices for certain assets or liabilities. In
cases where quoted market prices are not available, fair values
are based on estimates using present value or other valuation
techniques. Those techniques are significantly affected by the
assumptions used, including the discount rate and estimates of
future cash flows. Accordingly, the fair value estimates may not
be realized in an immediate settlement of the asset or liability.
Fair value measurements focus on exit prices in an orderly
transaction (that is, not a forced liquidation or distressed
sale) between market participants at the measurement date under
current market conditions. If there has been a significant
decrease in the volume and level of activity for the asset or
liability, a change in valuation technique or the use of
multiple valuation techniques may be appropriate. In such
instances, determining the price at which willing market
participants would transact at the measurement date under
current market conditions depends on the facts and circumstances
and requires the use of significant judgment.
The Companys fair value measurements are classified into a
fair value hierarchy based on the markets in which the assets
and liabilities are traded and the reliability of the
assumptions used to determine fair value. The three categories
within the hierarchy are as follows:
|
|
|
|
Level 1
|
Quoted prices in active markets for identical assets and
liabilities.
|
F-47
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
|
|
|
|
Level 2
|
Observable inputs other than Level 1 prices such as quoted
prices for similar assets or liabilities in active markets,
quoted prices in markets that are not active, and model-based
valuation techniques for which all significant inputs are
observable or can be corroborated by observable market data for
substantially the full term of the assets or liabilities.
|
|
|
Level 3
|
Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the
assets or liabilities. Level 3 assets and liabilities
include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar
techniques as well as instruments for which the determination of
fair value requires significant management judgment or
estimation.
|
Cash and cash equivalents and interest
receivable: The carrying amount is a reasonable
estimate of fair value. These financial instruments are not
recorded at fair value on a recurring basis.
Loans: For variable rate loans which re-price
frequently and have no significant change in credit risk,
carrying values are a reasonable estimate of fair values,
adjusted for credit losses inherent in the portfolio. The fair
value of fixed rate loans is estimated by discounting the future
cash flows using the year end rates at which similar loans would
be made to borrowers with similar credit ratings and for the
same remaining maturities, adjusted for credit losses inherent
in the portfolio. Therefore, the Company has categorized loan
investments as Level 3 within the fair value hierarchy
described above. Upon the Companys election to become a
BDC, these financial instruments are recorded at fair value on a
recurring basis.
Warrants: The Company values its warrants
using the Black-Scholes valuation model incorporating the
following material assumptions:
|
|
|
|
|
Underlying asset value of the issuer is estimated based on
information available, including any information regarding the
most recent rounds of borrower funding.
|
|
|
|
Volatility, or the amount of uncertainty or risk about the size
of the changes in the warrant price, is based on guideline
publicly traded companies within indices similar in nature to
the underlying company issuing the warrant. A total of seven
such indices were used. The weighted average volatility
assumptions used for the warrant valuation at December 31,
2010, 2009 and 2008 were 30%, 29% and 25%, respectively.
|
|
|
|
The risk-free interest rates are derived from the
U.S. Treasury yield curve. The risk-free interest rates are
calculated based on a weighted average of the risk-free interest
rates that correspond closest to the expected remaining life of
the warrant.
|
|
|
|
Other adjustments, including a marketability discount on private
company warrants, are estimated based on managements
judgment about the general industry environment. The
marketability discount used for the warrant valuation at
December 31, 2010, 2009 and 2008 was 20%.
|
The fair value of the Companys warrants held in publicly
traded companies is determined based on inputs that are readily
available in public markets or can be derived from information
available in public markets. Therefore, the Company has
categorized these warrants as Level 2 within the fair value
hierarchy described in Note 2. The fair value of the
Companys warrants held in private companies is determined
using both observable and unobservable inputs and represents
managements best estimate of what market participants
would use in pricing the warrants at the measurement date.
Therefore, the Company has categorized these warrants as
Level 3 within the fair value hierarchy described above.
These financial instruments are recorded at fair value on a
recurring basis.
Borrowings: The carrying amount of borrowings
under the revolving credit facility approximates its fair value
due to the short duration and variable interest rate of this
debt. Additionally, the Company considers its creditworthiness
in determining the fair value of such borrowings. These
financial instruments are not recorded at fair value on a
recurring basis.
F-48
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Interest rate swap derivatives: The fair value
of the Companys interest rate swap derivative instruments
is estimated as the amount the Company would pay to terminate
its swaps at the balance sheet date, taking into account current
interest rates and the creditworthiness of the counterparty for
assets and the creditworthiness of the Company for liabilities.
The Company has categorized these derivative instruments as
Level 2 within the fair value hierarchy described above.
These financial instruments are recorded at fair value on a
recurring basis.
Off-balance-sheet instruments: Fair values for
off-balance-sheet lending commitments are based on fees
currently charged to enter into similar agreements, taking into
account the remaining terms of the agreements and the
counterparties credit standings. Off-balance-sheet
instruments are not recorded at fair value on a recurring basis.
The following tables detail the financial instruments that are
carried at fair value and measured at fair value on a recurring
basis as of December 31, 2010 and 2009, and indicate the
fair value hierarchy of the valuation techniques utilized by the
Company to determine the fair value:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Loan investments
|
|
$
|
130,234
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
130,234
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity investments
|
|
$
|
351
|
|
|
$
|
209
|
|
|
$
|
|
|
|
$
|
142
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant investments
|
|
$
|
6,225
|
|
|
$
|
|
|
|
$
|
1,976
|
|
|
$
|
4,249
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swap liability
|
|
$
|
258
|
|
|
$
|
|
|
|
$
|
258
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2009
|
|
|
|
Total
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Warrant assets
|
|
$
|
2,458
|
|
|
$
|
|
|
|
$
|
448
|
|
|
$
|
2,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swap liability
|
|
$
|
768
|
|
|
$
|
|
|
|
$
|
768
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table shows a reconciliation of the beginning and
ending balances for Level 3 assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Post-IPO as a BDC
|
|
|
|
October 29, 2010 to December 31, 2010
|
|
|
|
Loan
|
|
|
Warrant
|
|
|
Equity
|
|
|
|
|
|
|
Investments
|
|
|
Investments
|
|
|
Investments
|
|
|
Total
|
|
|
Level 3 assets, beginning of period
|
|
$
|
|
|
|
$
|
3,715
|
|
|
$
|
|
|
|
$
|
3,715
|
|
Transfers into Level 3 upon election to BDC
|
|
|
125,741
|
|
|
|
|
|
|
|
142
|
|
|
|
125,883
|
|
Purchase of investments
|
|
|
19,316
|
|
|
|
|
|
|
|
|
|
|
|
19,316
|
|
Warrants received and classified as Level 3
|
|
|
|
|
|
|
192
|
|
|
|
|
|
|
|
192
|
|
Principal payments received on investments
|
|
|
(14,273
|
)
|
|
|
|
|
|
|
|
|
|
|
(14,273
|
)
|
Unrealized (depreciation)/ appreciation included in earnings
|
|
|
(48
|
)
|
|
|
528
|
|
|
|
|
|
|
|
480
|
|
Other
|
|
|
(502
|
)
|
|
|
(186
|
)
|
|
|
|
|
|
|
(688
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
130,234
|
|
|
$
|
4,249
|
|
|
$
|
142
|
|
|
$
|
134,625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-49
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pre-IPO Prior to becoming a BDC
|
|
|
|
January 1,
|
|
|
|
|
|
March 4,
|
|
|
|
2010
|
|
|
|
|
|
2008
|
|
|
|
through
|
|
|
Year Ended
|
|
|
through
|
|
|
|
October 28,
|
|
|
December 31,
|
|
|
December 31,
|
|
|
|
2010
|
|
|
2009
|
|
|
2008
|
|
|
Warrants
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, beginning of period
|
|
$
|
2,010
|
|
|
$
|
557
|
|
|
$
|
|
|
Warrants received and classified as Level 3
|
|
|
927
|
|
|
|
535
|
|
|
|
515
|
|
Unrealized appreciation included in earnings
|
|
|
780
|
|
|
|
918
|
|
|
|
42
|
|
Other
|
|
|
(2
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Level 3 assets, end of period
|
|
$
|
3,715
|
|
|
$
|
2,010
|
|
|
$
|
557
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The total change in unrealized appreciation
(depreciation)included in the statement of operations
attributable to Level 3 investments still held at
December 31, 2010 includes $48 depreciation on loans and
$1,505 appreciation on warrants.
The Company discloses fair value information about financial
instruments, whether or not recognized in the statement of
assets and liabilities, for which it is practicable to estimate
that value. Certain financial instruments are excluded from the
disclosure requirements. Accordingly, the aggregate fair value
amounts presented do not represent the underlying value of the
Company.
The fair value amounts for 2010 and 2009 have been measured as
of the year-end date, and have not been reevaluated or updated
for purposes of these financial statements subsequent to that
date. As such, the fair values of these financial instruments
subsequent to the reporting date may be different than amounts
reported at year-end.
As of December 31, 2010 and 2009, the recorded book
balances and fair values of the Companys financial
instruments were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2010
|
|
December 31, 2009
|
|
|
Recorded
|
|
|
|
Recorded
|
|
|
|
|
Book
|
|
|
|
Book
|
|
|
|
|
Balance
|
|
Fair Value
|
|
Balance
|
|
Fair Value
|
|
Financial Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash & cash equivalents
|
|
$
|
76,793
|
|
|
$
|
76,793
|
|
|
$
|
9,892
|
|
|
$
|
9,892
|
|
Investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt
|
|
$
|
130,234
|
|
|
$
|
130,234
|
|
|
$
|
109,496
|
|
|
$
|
110,654
|
|
Warrants
|
|
$
|
6,225
|
|
|
$
|
6,225
|
|
|
$
|
2,458
|
|
|
$
|
2,458
|
|
Equity
|
|
$
|
351
|
|
|
$
|
351
|
|
|
$
|
|
|
|
$
|
|
|
Interest receivable
|
|
$
|
1,938
|
|
|
$
|
1,938
|
|
|
$
|
1,452
|
|
|
$
|
1,452
|
|
Financial Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings
|
|
$
|
87,425
|
|
|
$
|
87,425
|
|
|
$
|
64,166
|
|
|
$
|
64,166
|
|
Interest rate swap liability
|
|
$
|
258
|
|
|
$
|
258
|
|
|
$
|
768
|
|
|
$
|
768
|
|
Off-balance-sheet
instruments
The Company assumes interest rate risk (the risk that general
interest rate levels will change) as a result of its normal
operations. As a result, the fair values of the Companys
financial instruments will change when interest rate levels
change and that change may be either favorable or unfavorable to
the Company. Management attempts to match maturities of assets
and liabilities to the extent believed necessary to minimize
interest rate risk. Management
F-50
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
monitors rates and maturities of assets and liabilities and
attempts to minimize interest rate risk by adjusting terms of
new loans and by investing in securities with terms that
mitigate the Companys overall interest rate risk.
In accordance with the 1940 Act, with certain limited
exceptions, the Company is only allowed to borrow amounts such
that the asset coverage, as defined in the 1940 Act, is at least
200% after such borrowings. As of December 31, 2010, the
asset coverage for borrowed amounts was 243%.
The Company entered into a Revolving Credit Facility (the
Credit Facility) with WestLB, AG, New York Branch
(WestLB) effective March 4, 2008. The facility
limit is $125 million at December 31, 2010.
The Credit Facility has a three year initial revolving term and
on March 3, 2011 the revolving term ended. The balance at
that time of $92,712 will be amortized based on loan investment
payments received over four years. The interest rate is based
upon the one-month LIBOR plus a spread of 2.50%. The rates at
December 31, 2010 and 2009 were 2.76% and 2.73%,
respectively, and the average rates for the years ending
December 31, 2010, 2009 and 2008 were 2.78%, 2.85%, and
5.00%, respectively.
The Credit Facility is collateralized by all loans and warrants
held by the Companys subsidiary, Credit I, and
permits an advance rate of up to 75% of eligible loans held by
the Credit I. The Credit Facility contains covenants that, among
other things, require the Company to maintain a minimum net
worth and to restrict the loans securing the Credit Facility to
certain criteria for qualified loans, and includes portfolio
company concentration limits as defined in the related loan
agreement. The average amounts of borrowings were approximately
$77,000 and $71,000 for the years ended December 31, 2010
and 2009, respectively. At December 31, 2010 the Company
had available borrowing capacity of approximately $37,500 and
had actual borrowings outstanding of $87,425 on the Credit
Facility.
|
|
Note 7.
|
Federal
Income Tax
|
The Company intends to elect to be treated as a RIC under
Subchapter M of the Code and to distribute substantially all of
its respective net taxable income. Accordingly, no provision for
federal income tax has been recorded in the financial
statements. Taxable income differs from net increase in net
assets resulting from operations primarily due to unrealized
appreciation on investments as investment gains and losses are
not included in taxable income until they are realized.
The following reconciles net increase in net assets resulting
from operations to taxable income for the period from
October 29, 2010 to December 31, 2010:
|
|
|
|
|
Net increase in net assets resulting from operations
|
|
$
|
3,419
|
|
Net unrealized appreciation on investments
|
|
|
(1,449
|
)
|
Other temporary differences
|
|
|
143
|
|
|
|
|
|
|
Taxable income before deductions for distributions
|
|
$
|
2,113
|
|
|
|
|
|
|
The tax character of distributions paid during the period from
October 29, 2010 to December 31, 2010 was as follows:
|
|
|
|
|
Ordinary income
|
|
$
|
1,502
|
|
Long-term capital gains
|
|
|
160
|
|
|
|
|
|
|
Total
|
|
$
|
1,662
|
|
|
|
|
|
|
F-51
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
As of December 31, 2010 the components of undistributed
ordinary income earnings on a tax basis were as follows:
|
|
|
|
|
Undistributed long-term gain
|
|
$
|
451
|
|
Unrealized appreciation
|
|
|
1,449
|
|
|
|
|
|
|
Total
|
|
$
|
1,900
|
|
|
|
|
|
|
|
|
Note 8.
|
Financial
Instruments with Off-Balance-Sheet Risk
|
In the normal course of business, the Company is party to
financial instruments with off-balance-sheet risk to meet the
financing needs of its borrowers. These financial instruments
include commitments to extend credit and involve, to varying
degrees, elements of credit risk in excess of the amount
recognized in the consolidated balance sheet. The Company
attempts to limit its credit risk by conducting extensive due
diligence and obtaining collateral where appropriate.
The balance of unfunded commitments to extend credit was
approximately $26,500 and $5,400 as of December 31, 2010
and 2009, respectively. Commitments to extend credit consist
principally of the unused portions of commitments that obligate
the Company to extend credit, such as revolving credit
arrangements or similar transactions. Commitments may also
include a financial or non-financial milestone that has to be
achieved before the commitment can be drawn. Commitments
generally have fixed expiration dates or other termination
clauses. Since commitments may expire without being drawn upon,
the total commitment amounts do not necessarily represent future
cash requirements.
|
|
Note 9.
|
Concentrations
of Credit Risk
|
The Companys loan portfolio consists primarily of loans to
development-stage companies at various stages of development in
the technology, life science, healthcare information and
services and cleantech industries. Many of these companies may
have relatively limited operating histories and also may
experience variation in operating results. Many of these
companies conduct business in regulated industries and could be
affected by changes in government regulations. Most of the
Companys borrowers will need additional capital to satisfy
their continuing working capital needs and other requirements,
and in many instances, to service the interest and principal
payments on the loans.
The largest loans may vary from year to year as new loans are
recorded and repaid. The Companys five largest loans
represented approximately 31% and 28% of total loans outstanding
as of December 31, 2010 and 2009, respectively. No single
loan represents more than 10% of the total loans as of
December 31, 2010 and 2009. Loan income, consisting of
interest and fees, can fluctuate significantly upon repayment of
large loans. Interest income from the five largest loans
accounted for approximately 22%, 23% and 21% of total loan
interest and fee income for the years ended December 31,
2010, 2009 and 2008, respectively.
|
|
Note 10:
|
Interest
Rate Swaps and Hedging Activities
|
On October 14, 2008, the Company entered into two interest
rate swap agreements (collectively, the Swap) with
WestLB, fixing the rate of $10 million at 3.58% and
$15 million at 3.20% on the first advances of a like amount
of variable rate Credit Facility borrowings. The
$15 million interest rate swap expired in October 2010 and
the $10 million will expire in October 2011. The objective
of the Swap was to hedge the risk of changes in cash flows
associated with the future interest payments on the first
$25 million of the variable rate Credit Facility debt with
a combined notional amount of $25 million.
During the period from October 29, 2010 to
December 31, 2010, approximately $85 of net unrealized
appreciation from the Swap was recorded in the statement of
operations, and approximately $42 of net realized losses from
the Swap was recorded in the statement of operations.
F-52
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
Prior to the Companys election to become a BDC, the Swap
was designated as a hedging instrument and the Company applied
cash flow hedge accounting. The Swap was recorded in the
statement of assets and liabilities at fair value, and any
related increases or decreases in the fair value were recognized
within accumulated other comprehensive income.
The Company assessed the effectiveness of the Swap on a
quarterly basis. The Company had considered the impact of the
current credit crisis in the United States in assessing the risk
of counterparty default. As most of the critical terms of the
hedging instruments and hedged items matched, the hedging
relationship was considered to be highly effective. No
ineffectiveness on the Swap was recognized during the period
from January 1, 2010 to October 28, 2010, and the
years ended December 31, 2009 and 2008, respectively.
|
|
Note 11:
|
Subsequent
Events
|
On February 11, 2011, the Company formed, as wholly owned
subsidiaries, Longview SBIC GP LLC and Longview SBIC LP
(collectively, Horizon SBIC) in anticipation of
receiving a license to operate a small business investment
company (SBIC) from the Small Business
Administration (SBA). When licensed, Longview SBIC
LP will issue SBA-guaranteed debentures at long-term fixed
rates. On March 1, 2011, the Company applied for exemptive
relief from the Securities and Exchange Commission to permit the
Company to exclude the debt of the Longview SBIC LP from the
consolidated asset coverage ratio.
|
|
Note 12:
|
Financial
Highlights
|
The financial highlights for the Company are as
follows:(1)
|
|
|
|
|
|
|
Post-IPO as a
|
|
|
Business
|
|
|
Development
|
|
|
Company
|
|
|
October 29, 2010 to
|
|
|
December 31, 2010
|
|
Per share data:
|
|
|
|
|
Net asset value at beginning of period
|
|
|
N/A
|
(2)
|
Issuance of common stock and capital contributions
|
|
|
N/A
|
(2)
|
Dividend declared and distributions to members
|
|
|
N/A
|
(2)
|
Offering costs
|
|
|
N/A
|
(2)
|
Net investment income
|
|
|
N/A
|
(2)
|
Realized gain (loss) on investments
|
|
|
N/A
|
(2)
|
Unrealized appreciation (depreciation) on investments
|
|
|
N/A
|
(2)
|
Net asset value at end of period
|
|
$
|
16.75
|
|
Per share market value, end of period
|
|
$
|
14.44
|
|
Total return based on a market value
|
|
|
22.7
|
%(3)
|
Shares outstanding at end of period
|
|
|
7,593,422
|
|
Ratios to average net assets:
|
|
|
|
|
Expenses without incentive fees
|
|
|
9.8
|
%(3)
|
Incentive fees
|
|
|
2.8
|
%(3)
|
Total expenses
|
|
|
12.6
|
%(3)
|
Net investment income without incentive fees
|
|
|
11.8
|
%(3)
|
Average net asset value
|
|
$
|
90,205
|
|
|
|
|
(1) |
|
Years prior to becoming a public company are not presented in
the financial highlights because the Company did not record
assets at fair value, therefore the information would not be
meaningful. |
|
(2) |
|
Per share data is not provided as the Company did not have
shares of common stock outstanding or an equivalent prior to the
October 28, 2010 IPO. |
|
(3) |
|
Annualized. |
F-53
Horizon
Technology Finance Corporation and Subsidiaries
Notes to
Consolidated Financial
Statements (Continued)
(In
thousands, except shares and per share data)
|
|
Note 13:
|
Selected
Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
September 30,
|
|
June 30,
|
|
March 31,
|
|
|
2010
|
|
2010
|
|
2010
|
|
2010
|
|
Total investment income
|
|
$
|
4,956
|
|
|
$
|
5,189
|
|
|
$
|
4,270
|
|
|
$
|
3,793
|
|
Net investment income
|
|
|
2,507
|
|
|
|
3,256
|
|
|
|
2,508
|
|
|
|
2,113
|
|
Net realized and unrealized gain (loss)
|
|
|
2,063
|
|
|
|
1,711
|
|
|
|
(366
|
)
|
|
|
202
|
|
Net increase in net asset resulting from operations
|
|
|
4,570
|
|
|
|
5,287
|
|
|
|
2,259
|
|
|
|
2,617
|
|
Earnings per share
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Net asset value per share at period end
|
|
$
|
16.75
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
September 30,
|
|
June 30,
|
|
March 31,
|
|
|
2009
|
|
2009
|
|
2009
|
|
2009
|
|
Total investment income
|
|
$
|
4,155
|
|
|
$
|
4,169
|
|
|
$
|
3,746
|
|
|
$
|
3,256
|
|
Net investment income
|
|
|
2,492
|
|
|
|
2,393
|
|
|
|
1,998
|
|
|
|
1,673
|
|
Net realized and unrealized gain (loss)
|
|
|
498
|
|
|
|
(55
|
)
|
|
|
143
|
|
|
|
445
|
|
Net increase in net asset resulting from operations
|
|
|
3,343
|
|
|
|
2,004
|
|
|
|
1,884
|
|
|
|
2,083
|
|
Earnings per share
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Net asset value per share at period end
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
F-54
$250,000,000
Horizon Technology Finance
Corporation
Common Stock
Preferred Stock
Subscription Rights
Debt Securities
Warrants
And
1,322,669 Shares of Common
Stock
Offered by the Selling Stockholders
PRELIMINARY
PROSPECTUS
Part C
OTHER
INFORMATION
|
|
Item 25.
|
Financial
Statements and Exhibits
|
1. Financial
Statements
The following financial statements of Horizon Technology Finance
Corporation (the Registrant or the
Company) are included in Part A of this
registration statement (this Registration Statement):
|
|
|
|
|
|
|
Page
|
|
UNAUDITED FINANCIAL STATEMENTS
|
|
|
|
|
Consolidated Statements of Assets and Liabilities as of
September 30, 2011 and December 31, 2010 (unaudited)
|
|
|
F-2
|
|
Consolidated Statements of Operations for the three and nine
months ended September 30, 2011 and 2010 (unaudited)
|
|
|
F-3
|
|
Consolidated Statements of Changes in Net Assets for the nine
months ended September 30, 2011 and 2010 (unaudited)
|
|
|
F-4
|
|
Consolidated Statements of Cash Flows for the nine months ended
September 30, 2011 and 2010 (unaudited)
|
|
|
F-5
|
|
Consolidated Schedules of Investments as of September 30,
2011 and December 31, 2010 (unaudited)
|
|
|
F-6
|
|
Notes to the Consolidated Financial Statements (unaudited)
|
|
|
F-12
|
|
AUDITED FINANCIAL STATEMENTS
|
|
|
|
|
Report of Independent Registered Public Accounting Firm
|
|
|
F-28
|
|
Consolidated Statements of Assets and Liabilities as of
December 31, 2010 and 2009
|
|
|
F-29
|
|
Consolidated Statements of Operations for the Period from
October 29, 2010 to December 31, 2010, the Period from
January 1, 2010 to October 28, 2010, the Year Ended
December 31, 2009, and the Period from March 4, 2008
(Inception) to December 31, 2008
|
|
|
F-30
|
|
Consolidated Statements of Changes in Net Assets for the Period
from October 29, 2010 to December 31, 2010, the Period
from January 1, 2010 to October 28, 2010, the Year
Ended December 31, 2009, and the Period from March 4,
2008 (Inception) to December 31, 2008
|
|
|
F-31
|
|
Consolidated Statements of Cash Flows for the Period from
October 29, 2010 to December 31, 2010, the Period from
January 1, 2010 to October 28, 2010, the Year Ended
December 31, 2009, and the Period from March 4, 2008
(Inception) to December 31, 2008
|
|
|
F-32
|
|
Consolidated Schedules of Investments as of December 31,
2010 and 2009
|
|
|
F-33
|
|
Notes to the Consolidated Financial Statements
|
|
|
F-39
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
(a)
|
|
Amended and Restated Certificate of Incorporation (Incorporated
by reference to Exhibit(a) of the Companys
Pre-Effective Amendment No. 2 to the Registration Statement
on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(b)
|
|
Amended and Restated Bylaws (Incorporated by reference to
Exhibit(b) of the Companys Pre-Effective Amendment
No. 2 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(d)(1)
|
|
Form of Stock Certificate (Incorporated by reference to
Exhibit(d) of the Companys Pre-Effective Amendment
No. 3 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 19, 2010)
|
(d)(2)
|
|
Form of Certificate of Designation for Preferred Stock*
|
(d)(3)
|
|
Form of Subscription Certificate*
|
C-1
|
|
|
Exhibit No.
|
|
Description
|
|
(d)(4)
|
|
Form of Indenture*
|
(d)(5)
|
|
Form of Subscription Agent Agreement*
|
(d)(6)
|
|
Form of Warrant Agreement*
|
(e)
|
|
Form of Dividend Reinvestment Plan (Incorporated by reference to
Exhibit(e) of the Companys Pre-Effective Amendment
No. 2 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(f)(1)
|
|
Credit and Security Agreement by and among Horizon Credit I LLC,
WestLB AG, New York Branch, U.S. Bank National Association, as
custodian and paying agent, and WestLB AG, New York Branch, as
agent, dated as of March 4, 2008 (Incorporated by reference
to Exhibit(f)(1) of the Companys Pre-Effective Amendment
No. 1 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on June 4, 2010)
|
(f)(2)
|
|
First Amendment of Transaction Documents by and among Horizon
Credit I LLC, WestLB AG, New York Branch, U.S. Bank National
Association, as custodian and paying agent, WestLB AG, New York
Branch, as agent, Horizon Technology Finance Management LLC, and
Lyon Financial Services, Inc., dated as of September 30,
2008 (Incorporated by reference to Exhibit(f)(2) of the
Companys Pre-Effective Amendment No. 1 to the
Registration Statement on
Form N-2,
File
No. 333-165570,
filed on June 4, 2010)
|
(f)(3)
|
|
Second Amendment of Transaction Documents by and among Horizon
Credit I LLC, WestLB AG, New York Branch, as the lender and
agent, and U.S. Bank National Association, as custodian, dated
as of October 7, 2008 (Incorporated by reference to
Exhibit(f)(3) of the Companys Pre-Effective Amendment
No. 1 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on June 4, 2010)
|
(f)(4)
|
|
Third Amendment of Transaction Documents by and among Horizon
Credit I LLC, Compass Horizon Funding Company LLC, WestLB AG,
New York Branch, as the lender and agent, and U.S. Bank National
Association, as custodian, dated as of June 25, 2010
(Incorporated by reference to Exhibit(f)(4) of the
Companys Pre-Effective Amendment No. 2 to the
Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(f)(5)
|
|
Sale and Contribution Agreement by and between Compass Horizon
Funding Company LLC and Horizon Credit I LLC, dated as of
March 4, 2008 (Incorporated by reference to Exhibit(f)(5)
of the Companys Pre-Effective Amendment No. 2 to the
Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(f)(6)
|
|
Loan and Security Agreement by and among Horizon Credit II
LLC and Wells Fargo Capital Finance, LLC, as arranger and
administrative agent, dated as of July 14, 2011
(Incorporated by reference to Exhibit 10.1 of the
Companys Current Report on
Form 8-K
filed on July 18, 2011)
|
(f)(7)
|
|
Sale and Servicing Agreement by and among Horizon Credit II
LLC, Horizon Technology Finance Management LLC, U.S. Bank
National Association, Wells Fargo Capital Finance, LLC and the
Company dated as of July 14, 2011 (Incorporated by
reference to Exhibit 10.2 of the Companys Current
Report on
Form 8-K
filed on July 18, 2011)
|
(g)
|
|
Form of Investment Management Agreement (Incorporated by
reference to Exhibit(g) of the Companys Pre-Effective
Amendment No. 2 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(h)(1)
|
|
Form of Underwriting Agreement for equity securities*
|
(h)(2)
|
|
Form of Underwriting Agreement for debt securities*
|
(j)
|
|
Form of Custody Agreement (Incorporated by reference to
Exhibit(j) of the Companys Pre-Effective Amendment
No. 3 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 19, 2010)
|
(k)(1)
|
|
Form of Administration Agreement (Incorporated by reference to
Exhibit(k)(1) of the Companys Pre-Effective Amendment
No. 2 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
(k)(2)
|
|
Form of Trademark License Agreement by and between the Company
and Horizon Technology Finance, LLC (Incorporated by reference
to Exhibit(k)(2) of the Companys Pre-Effective Amendment
No. 2 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 2, 2010)
|
C-2
|
|
|
Exhibit No.
|
|
Description
|
|
(k)(3)
|
|
Form of Registration Rights Agreement among Compass Horizon
Partners, LP, HTF-CHF Holdings LLC and the Company (Incorporated
by reference to Exhibit(k)(3) of the Companys
Pre-Effective Amendment No. 2 to the Registration Statement
on
Form N-2,
File
No. 3330-165570,
filed on July 2, 2010)
|
(k)(4)
|
|
Form of Exchange Agreement by and among Compass Horizon
Partners, LP, HTF-CHF Holdings LLC, Compass Horizon Funding
Company LLC and the Company (Incorporated by reference to
Exhibit(k)(4) of the Companys Pre-Effective Amendment
No. 3 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed July 19, 2010)
|
(l)
|
|
Opinion and Consent of Squire Sanders (US) LLP, counsel to the
Company*
|
(n)
|
|
Consent of Independent Registered Public Accounting Firm**
|
(r)(1)
|
|
Code of Ethics of the Company (Incorporated by reference to
Exhibit(r)(1) of the Companys Pre-Effective Amendment
No. 3 to the Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 19, 2010)
|
(r)(2)
|
|
Code of Ethics and Personal Trading Policy of the Advisor
(Incorporated by reference to Exhibit(r)(2) of the
Companys Pre-Effective Amendment No. 3 to the
Registration Statement on
Form N-2,
File
No. 333-165570,
filed on July 19, 2010)
|
(s)(1)
|
|
Form of prospectus supplement for Common Stock Offerings**
|
(s)(2)
|
|
Form of prospectus supplement for Preferred Stock Offerings*
|
(s)(3)
|
|
Form of prospectus supplement for Subscription Rights Offerings**
|
(s)(4)
|
|
Form of prospectus supplement for Debt Securities Offerings*
|
(s)(5)
|
|
Form of prospectus supplement for Warrant Offerings**
|
|
|
|
* |
|
Previously filed. |
** |
|
Filed herewith. |
|
|
Item 26.
|
Marketing
Arrangements
|
The information contained under the heading Plan of
Distribution in this Registration Statement is
incorporated herein by reference.
|
|
Item 27.
|
Other
Expenses of Issuance and Distribution
|
The following table sets forth the estimated expenses to be
incurred in connection with the offering described in this
Registration Statement:
|
|
|
|
|
SEC registration fee
|
|
$
|
31,076
|
|
FINRA filing fee
|
|
$
|
27,616
|
|
NASDAQ listing fee
|
|
$
|
130,000
|
*
|
Printing expenses
|
|
$
|
215,000
|
*
|
Accounting fees and expenses
|
|
$
|
200,000
|
*
|
Legal fees and expenses
|
|
$
|
500,000
|
*
|
Miscellaneous fees and expenses
|
|
|
10,000
|
*
|
|
|
|
|
|
Total
|
|
$
|
1,113,692
|
*
|
|
|
|
|
|
|
|
|
* |
|
Estimated for filing purposes. |
All of the expenses set forth above shall be borne by the
Registrant. However, underwriting discounts and commissions with
respect to the Selling Stockholder Shares will be borne by any
selling stockholders.
C-3
|
|
Item 28.
|
Persons
Controlled by or Under Common Control
|
|
|
|
|
|
Compass Horizon Funding Company LLC, a Delaware limited
liability company and wholly-owned subsidiary of the Registrant
|
|
|
|
Horizon Credit I LLC, a Delaware limited liability company and
wholly-owned subsidiary of Compass Horizon Funding Company LLC,
which is a wholly-owned subsidiary of the Registrant
|
|
|
|
Horizon Credit II LLC, a Delaware limited liability company
and wholly-owned subsidiary of the Registrant
|
|
|
|
Longview SBIC GP LLC, a Delaware limited liability company and
wholly-owned subsidiary of the Registrant
|
|
|
|
Longview SBIC LP, a Delaware limited partnership and
wholly-owned subsidiary of the Registrant
|
All subsidiaries listed above are included in the
Registrants consolidated financial statements as of
September 30, 2011 and December 31, 2010.
|
|
Item 29.
|
Number
of Holders of Securities
|
The following table sets forth the approximate number of record
holders of the Companys common stock as of
February 3, 2012:
|
|
|
|
|
Title of Class
|
|
Number of Record
Holders
|
|
|
Common Stock, $0.001 par value
|
|
|
4
|
|
The information contained under the heading Description of
Common Stock That We May Issue Limitations of
liability and indemnification is incorporated herein by
reference.
Insofar as indemnification for liabilities arising under the
Securities Act of 1933, as amended (the Securities
Act) may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that
in the opinion of the Securities and Exchange Commission (the
SEC) such indemnification is against public policy
as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer
or controlling person of the Registrant in the successful
defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the
securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is
again public policy as expressed in the Securities Act and will
be governed by the final adjudication of such issue.
The investment management agreement (the Investment
Management Agreement) provides that, absent willful
misfeasance, bad faith or gross negligence in the performance of
its duties or by reason of the reckless disregard of its duties
and obligations, Horizon Technology Finance Management LLC (the
Advisor) and its officers, managers, partners,
agents, employees, controlling persons, members and any other
person or entity affiliated with it are entitled to
indemnification from the Registrant for any damages,
liabilities, costs and expenses (including reasonable
attorneys fees and amounts reasonably paid in settlement)
arising from the rendering of the Advisors services under
the Investment Management Agreement or otherwise as an
investment adviser of the Registrant.
The administration agreement (the Administration
Agreement) provides that, absent willful misfeasance, bad
faith or negligence in the performance of its duties or by
reason of the reckless disregard of its duties and obligations,
Horizon Technology Finance Management LLC (in such capacity, the
Administrator) and its officers, managers, partners,
agents, employees, controlling persons, members and any other
person or entity affiliated with it are entitled to
indemnification from the Registrant for any damages,
liabilities, costs and expenses (including reasonable
attorneys fees and amounts reasonably paid in settlement)
arising from the rendering of the Administrators services
under the Administration Agreement or otherwise as administrator
for the Registrant.
C-4
Each of the underwriting agreement relating to equity securities
and the underwriting agreement relating to debt securities
(each, an Underwriting Agreement) provides that each
of the Registrant, the Advisor and the Administrator jointly and
severally agrees to indemnify and hold harmless the underwriters
listed on Schedule A to the applicable Underwriting
Agreement (each an Underwriter), its affiliates, as
such term is defined in Rule 501(b) under the Securities
Act, its selling agents and each person, if any, who controls
any Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), against
specified liabilities for actions taken in their capacity as
such, including liabilities under the Securities Act. The
Underwriting Agreement also provides that each Underwriter
severally agrees to indemnify and hold harmless the Registrant,
its directors, its officers, each person, if any, who controls
the Registrant, the Advisor or the Administrator within the
meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act, the Advisor and the
Administrator against specified liabilities for actions taken in
their capacity as such.
The Registrant carries liability insurance for the benefit of
its directors and officers (other than with respect to claims
resulting from the willful misfeasance, bad faith, gross
negligence or reckless disregard of the duties involved in the
conduct of his or her office) on a claims-made basis.
|
|
Item 31.
|
Business
and Other Connections of Investment Advisor
|
A description of any other business, profession, vocation or
employment of a substantial nature in which our Advisor and each
managing director, director or executive officer of our Advisor,
is or has been during the past two fiscal years, engaged in for
his or her own account or in the capacity of director, officer,
employee, partner or trustee, is set forth in Part A of
this Registration Statement in the sections entitled
Management and Our Advisor. Additional
information regarding our Advisor and its executive officers and
directors is set forth in its Form ADV, as filed with the
SEC (SEC File
No. 801-71141),
and is incorporated herein by reference.
|
|
Item 32.
|
Location
of Accounts and Records
|
All accounts, books and other documents required to be
maintained by Section 31(a) of the Investment Company Act
of 1940 and the rules thereunder are maintained at the offices
of:
|
|
(1)
|
the Registrant, Horizon Technology Finance Corporation, 312
Farmington Avenue, Farmington, Connecticut 06032;
|
|
(2)
|
the Transfer Agent, BNY Mellon Shareowner Services, Newport
Office Center VII, 480 Washington Boulevard, Jersey City, New
Jersey 07310;
|
|
(3)
|
the Custodian, Bank of America, N.A., 100 West
33rd Street, New York, New York 1001; and
|
|
(4)
|
the Advisor, Horizon Technology Finance Management LLC, 312
Farmington Avenue, Farmington, Connecticut 06032.
|
|
|
Item 33.
|
Management
Services
|
Not applicable.
|
|
(1) |
The Registrant hereby undertakes to suspend the offering of its
common stock until it amends its prospectus if
(a) subsequent to the effective date of its Registration
Statement, the net asset value declines more than 10% from its
net asset value as of the effective date of the Registration
Statement or (b) the net asset value increases to an amount
greater than its net proceeds as stated in the prospectus.
|
(2) Not applicable.
|
|
(3) |
The Registrant hereby undertakes, in the event that the
securities being registered are to be offered to existing
stockholders pursuant to warrants or rights, and any securities
not taken by stockholders are to be reoffered to the public, to
supplement the prospectus, after the expiration of the
subscription period, to set forth the results of
|
C-5
|
|
|
the subscription offer, the transactions by underwriters during
the subscription period, the amount of unsubscribed securities
to be purchased by underwriters, and the terms of any subsequent
reoffering thereof; and further, if any public offering by the
underwriters of the securities being registered is to be made on
terms differing from those set forth on the cover page of the
prospectus, to file a post-effective amendment to set forth the
terms of such offering.
|
(4) The Registrant hereby undertakes:
|
|
|
|
(a)
|
to file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3)
of the Securities Act; (ii) to reflect in the prospectus
any facts or events after the effective date of this
Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in
this Registration Statement; and (iii) to include any
material information with respect to the plan of distribution
not previously disclosed in this Registration Statement or any
material change to such information in this Registration
Statement;
|
|
|
|
|
(b)
|
to file, in connection with any offering of securities, a
post-effective amendment to the registration statement under
Rule 462(d) to include as an exhibit a legal opinion
regarding the valid issuance of any shares of common stock being
sold.
|
|
|
|
|
(c)
|
that, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the
securities offered herein, and the offering of those securities
at that time shall be deemed to be the initial bona fide
offering thereof;
|
|
|
|
|
(d)
|
to remove from registration by means of a post-effective
amendment any of the securities being registered which remain
unsold at the termination of the offering;
|
|
|
|
|
(e)
|
that, for the purpose of determining liability under the
Securities Act to any purchaser, if the Registrant is subject to
Rule 430C: Each prospectus filed pursuant to
Rule 497(b), (c), (d) or (e) under the Securities
Act as part of a registration statement relating to an offering,
other than prospectuses filed in reliance on Rule 430A
under the Securities Act, shall be deemed to be part of and
included in this Registration Statement as of the date it is
first used after effectiveness; provided, however, that no
statement made in a registration statement or prospectus that is
part of this Registration Statement or made in a document
incorporated or deemed incorporated by reference into this
Registration Statement or prospectus that is part of this
Registration Statement will, as to a purchaser with a time of
contract of sale prior to such first use, supersede or modify
any statement that was made in this Registration Statement or
prospectus that was part of this Registration Statement or made
in any such document immediately prior to such date of first
use; and
|
|
|
|
|
(f)
|
that, for the purpose of determining liability of the Registrant
under the Securities Act to any purchaser in the initial
distribution of securities, the undersigned Registrant
undertakes that in a primary offering of securities of the
undersigned Registrant pursuant to this Registration Statement,
regardless of the underwriting method used to sell the
securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following
communications, the undersigned Registrant will be a seller to
the purchaser and will be considered to offer or sell such
securities to the purchaser: (i) any preliminary prospectus
or prospectus of the undersigned Registrant relating to the
offering required to be filed pursuant to Rule 497 under
the Securities Act; (ii) the portion of any advertisement
pursuant to Rule 482 under the Securities Act relating to
the offering containing material information about the
undersigned Registrant or its securities provided by or on
behalf of the undersigned Registrant; and (iii) any other
communication that is an offer in the offering made by the
undersigned Registrant to the purchaser.
|
|
|
|
|
(g)
|
to file a post-effective amendment to the registration
statement, and to suspend any offers or sales pursuant to the
registration statement until such post-effective amendment has
been declared effective under the 1933 Act, in the event the
shares of the Registrant are trading below its net asset value
and either (a) the Registrant receives, or has been advised
by its independent registered accounting firm that it will
receive, an audit report reflecting substantial doubt regarding
the Registrants ability to continue as a going concern or
(b) the Registrant has concluded that a material adverse
change has occurred in its financial position or
|
C-6
results of operations that has caused the financial statements
and other disclosures on the basis of which the offering would
be made to be materially misleading.
(5) The Registrant hereby undertakes:
|
|
|
|
(a)
|
for the purposes of determining any liability under the
Securities Act, the information omitted from the form of
prospectus filed as part of this Registration Statement in
reliance upon Rule 430A and contained in a form of
prospectus filed by the Registrant under Rule 497(h) under
the Securities Act shall be deemed to be part of this
Registration Statement as of the time it was declared
effective; and
|
|
|
|
|
(b)
|
for the purpose of determining any liability under the
Securities Act, each post-effective amendment that contains a
form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the
offering of the securities at that time shall be deemed to be
the initial bona fide offering thereof.
|
(6) Not applicable.
C-7
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant has duly caused this Registration Statement to be
signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Farmington, and State of Connecticut,
on the 6th day of February, 2012.
Horizon Technology
Finance Corporation
|
|
|
|
By:
|
/s/ Robert
D. Pomeroy, Jr.
Name: Robert
D. Pomeroy, Jr.
|
|
|
|
|
Title:
|
Chief Executive Officer
|
(Principal Executive Officer)
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons
in the capacities set forth below on February 6, 2012. This
document may be executed by the signatories hereto on any number
of counterparts, all of which constitute one and the same
instrument.
|
|
|
|
|
Name
|
|
Title
|
|
|
|
|
/s/ Robert
D. Pomeroy, Jr.
Robert
D. Pomeroy, Jr.
|
|
Chief Executive Officer and
Chairman of the Board of Directors
(Principal Executive Officer)
|
|
|
|
/s/ Christopher
M. Mathieu
Christopher
M. Mathieu
|
|
Senior Vice President and Chief Financial Officer
(Principal Financial Officer and Principal
Accounting Officer)
|
|
|
|
*
Gerald
A. Michaud
|
|
President and Director
|
|
|
|
*
David
P. Swanson
|
|
Director
|
|
|
|
*
James
J. Bottiglieri
|
|
Director
|
|
|
|
*
Edmund
V. Mahoney
|
|
Director
|
|
|
|
*
Brett
N. Silvers
|
|
Director
|
|
|
|
*
Christopher
B. Woodward
|
|
Director
|
|
|
|
|
|
*By:
|
|
/s/ Robert
D. Pomeroy, Jr.
Attorney-in-fact
|
|
|